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Abstract 
Author: Ana María Barbería 
Title: A retrospective study exploring clinical, biological and behavioural 
factors contributing to changes in body weight following early breast cancer 
diagnosis. 
 
Background  
Changes in body weight and adiposity levels can follow breast cancer (BC) 
diagnosis and treatment, which could result in poor long-term BC outcomes. The 
factors associated with these changes and the biological mechanisms underlying 
them remain unclear.  
  
Aims, methods, sample and data analysis  
A longitudinal retrospective study was conducted to explore weight change post-
diagnosis and its association with BC treatment, disease characteristics and 
biological and behavioural factors. A second aim was to examine factors associated 
with adiposity and metabolic parameters measured at the end of the follow up. 239 
women diagnosed with BC one to seven years prior to study entry attending a 
specialist BC centre were recruited. Weight from BC diagnosis to the study entry, 
BC treatments received, disease characteristics, menopausal status, smoking status 
and age were collected from medical notes. Genetic profile (FTO, Mc4R), body fat 
and fat free mass, waist circumference and fasting glucose and insulin levels were 
measured once, at study entry only. Associations were examined using t-tests, 
correlations, regression and multilevel modelling. 
 
Results 
Participants were followed for a mean of 47.46 months (SD: 20.45).  
Average weight change across the sample from diagnosis to 12, 24, 36 and 48 
months post-diagnosis was + 1.30 kg, + 0.85 kg, + 1.59 kg and + 0.42 kg 
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respectively (increased mean weight). At 12 months, 61% gained weight, 32% lost 
weight and 7% remained the same. Nearly all participants had weight changes at 24, 
36 and 48 months post-diagnosis. Based on evidence, large weight changes (over 
10% of weight at diagnosis) were considered clinically relevant. At 24 months post-
diagnosis, 6% of participants had an important decrease of weight, 8% had an 
important weight gain and 86% of participants had no potentially relevant weight 
change (less than 10% weight change).  Notably, 62.9% of the sample was 
overweight or obese (BMI larger than 25 kg/m
2
) at the time of diagnosis.   
Chemotherapy was not associated with statistically significant weight change post-
diagnosis. Tamoxifen contributed significantly to weight change at 24 and 36 
months, whereas smoking status and weight at diagnosis were significant predictors 
of weight change in the first 12 months of diagnosis. Time-invariant multilevel 
models fitted showed differences in rate of weight change across women. The 
differences were predicted by tamoxifen used. Moreover, time-varying models 
indicated that weight post-diagnosis was larger among tamoxifen users compared to 
non-users (estimated magnitude of the difference 1.09 kg, 95% CI: -1.63 to -0.56, 
p<0.01) and among anastrozole users (difference 0.85 kg, 95% CI: -1.48 to -0.21, 
p<0.01). 
Body adiposity parameters were significantly associated with larger body weight and 
older age at the time of diagnosis (both p<0.01), whereas glucose and insulin levels 
were predicted by higher weight at diagnosis (p=0.05 and p<0.01) and the presence 
of the risky A-allele of the FTO gene (p=0.03 and p=0.01 respectively). 
 
Conclusions 
Findings confirmed that on average weight increased post BC diagnosis. The 
magnitude of the changes in body weight and the levels of body fat and waist 
circumference found among participants could compromise their BC prognosis and 
increase risk of obesity-related diseases, such as type-two diabetes. Understanding 
the factors associated with weight changes or adiposity and metabolic levels can help 
health professionals to identify patients at risk. The study has found that hormone 
therapy contributed to differences in weight and rate of weight change post-diagnosis 
and that weight at the time of BC diagnosis was a predictor of body adiposity and 
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metabolic parameters at the end of the follow up. Nonetheless the effects of other 
variables (i.e. smoking status, genetic profile and other variables not included in this 
study) cannot be ruled out. Because of the potential negative effects that large body 
weight at diagnosis, weight changes post diagnosis, excessive adiposity and high 
insulin levels have, it is imperative to assess those parameters following BC 
diagnosis and to implement care plans to control them and help newly diagnosed BC 
patients to achieve optimal weight, body adiposity parameters and a healthy 
metabolic status.    
6 
 
List of Contents 
Copyright Statement .................................................................................................... 2 
Abstract ........................................................................................................................ 3 
List of Contents ............................................................................................................ 6 
List of Tables.............................................................................................................. 14 
List of Figures ............................................................................................................ 22 
Acknowledgement...................................................................................................... 23 
Abbreviation List ....................................................................................................... 24 
CHAPTER 1: INTRODUCTION TO BREAST CANCER AND WEIGHT 
CHANGE ................................................................................................................... 29 
1 Introduction ................................................................................................ 29 
1.1 Breast cancer epidemiology ............................................................... 29 
1.2 Types of breast disorders and diagnostic tests ................................... 30 
1.3 Breast cancer treatments .................................................................... 32 
1.4 Problem: weight change after breast cancer diagnosis ...................... 34 
1.4.1 Magnitude of weight change after breast cancer diagnosis ........... 35 
1.4.2 Frequency of weight change after breast cancer diagnosis ............ 35 
1.4.3 Trajectory of weight change after breast cancer diagnosis ............ 37 
1.4.4 Changes in body adiposity after breast cancer diagnosis ............... 39 
1.4.5 Metabolic status after breast cancer diagnosis ............................... 40 
1.5 The negative effects of weight change, high adiposity levels and 
abnormal metabolic status after breast cancer diagnosis ............................... 41 
1.6 Potential mechanisms explaining the association between weight 
change, obesity and insulin with breast cancer outcomes .............................. 44 
7 
 
1.7 Conclusions ........................................................................................ 45 
CHAPTER 2: LITERATURE REVIEW ON WEIGHT CHANGE AFTER BREAST 
CANCER DIAGNOSIS ............................................................................................. 47 
2 Introduction ................................................................................................ 47 
2.1 Body weight regulation ...................................................................... 47 
2.2 Factors related to weight change after breast cancer diagnosis ......... 51 
2.2.1 Breast cancer treatments and their association with weight change 
after breast cancer diagnosis ...................................................................... 52 
2.2.1.1 Hormone therapy and weight change post diagnosis .............. 52 
2.2.1.2 Chemotherapy and weight change post-diagnosis .................. 56 
2.2.1.3 Potential mechanisms accounting for suspected treatment 
effects on weight change ........................................................................ 57 
2.2.2 Genes associated with common forms of obesity and their effect on 
weight change after breast cancer diagnosis .............................................. 62 
2.3 Summary and aims of the study ......................................................... 63 
CHAPTER 3: RESEARCH METHODS ................................................................... 66 
3 Introduction ................................................................................................ 66 
3.1 Study design, its advantages and limitations ..................................... 66 
3.1.1 Retrospective cohort study ............................................................. 67 
3.1.2 Cross-sectional data nested within the study ................................. 69 
3.2 Target population ............................................................................... 70 
3.3 Sample size......................................................................................... 71 
3.4 Research procedures........................................................................... 74 
3.4.1 Protocol amendments ..................................................................... 74 
3.4.2 Participants‘ recruitment ................................................................ 75 
3.4.3 Data collection: variables, procedures and instruments ................. 76 
8 
 
3.4.3.1 Outcome variables ................................................................... 76 
3.4.3.2 Independent variables .............................................................. 77 
3.4.3.3 Procedures and instruments of data collection ........................ 78 
3.5 Definition of the variables .................................................................. 80 
3.6 Features of the dataset ........................................................................ 82 
3.6.1 Outcome, metric of time and predictors ......................................... 83 
3.6.2 Follow up ....................................................................................... 83 
3.6.3 Waves of data collection and timing of weight measurement ....... 83 
3.6.4 Missing data ................................................................................... 84 
3.6.4.1 Are there missing data? Reasons for missing data .................. 85 
3.6.4.2 Missingness mechanisms ........................................................ 85 
3.6.4.3 Dealing with missing data ....................................................... 86 
3.7 Data analysis ...................................................................................... 87 
3.7.1 Exploring the magnitude and frequency of weight change after 
breast cancer diagnosis ............................................................................... 88 
3.7.1.1 Analysis on the magnitude of weight change at 12, 24, 36 and 
48 months post breast cancer diagnosis and factors related to it ........... 89 
3.7.1.2 Analysis of the frequency of weight change at 12, 24, 36 and 
48 months post breast cancer diagnosis ................................................. 93 
3.7.2 Multilevel modelling for weight change after breast cancer 
diagnosis ..................................................................................................... 94 
3.7.2.1 Multilevel model for change: descriptive analysis .................. 95 
3.7.2.2 Multilevel model for change: model fitting ............................ 95 
3.7.3 Adipose and metabolic parameters at the end of the follow up ... 102 
3.8 Ethical considerations ...................................................................... 104 
CHAPTER 4: RESULTS ......................................................................................... 106 
4 Introduction .............................................................................................. 106 
9 
 
4.1 Baseline characteristics of participants ............................................ 106 
4.1.1 General biological characteristics ................................................ 106 
4.1.2 Breast cancer treatment received ................................................. 107 
4.2 Number of participants with available weight data.......................... 108 
4.3 Magnitude and frequency of weight change after breast cancer 
diagnosis ....................................................................................................... 109 
4.4 Factors associated with weight change post-diagnosis .................... 111 
4.4.1 Univariable analysis of weight change ........................................ 111 
4.4.1.1 Breast cancer treatment ......................................................... 111 
4.4.1.2 Menopausal status ................................................................. 112 
4.4.1.3 Genetic profile ....................................................................... 113 
4.4.1.4 Other covariates of interest .................................................... 114 
4.4.2 Multivariable analysis of weight change...................................... 114 
4.4.2.1 Weight change at 12 months after breast cancer diagnosis ... 114 
4.4.2.2 Weight change at 24 months after breast cancer diagnosis ... 115 
4.4.2.3 Weight change at 36 months after breast cancer diagnosis ... 115 
4.4.2.4 Weight change at 48 months after breast cancer diagnosis ... 116 
4.5 Multilevel model for weight change after breast cancer diagnosis .. 117 
4.5.1 Trajectory of weight change after breast cancer diagnosis .......... 117 
4.5.2 Linear models with breast cancer treatment as time-invariant 
predictors .................................................................................................. 118 
4.5.3 Linear models with breast cancer treatments treated as time-varying 
predictors .................................................................................................. 121 
4.6 Adiposity parameters at the end of the follow up ............................ 123 
4.6.1 Univariable analysis of body adiposity parameters at the end of the 
follow up .................................................................................................. 123 
4.6.1.1 Breast cancer treatment ......................................................... 123 
10 
 
4.6.1.2 Menopausal status ................................................................. 124 
4.6.1.3 Genetic profile ....................................................................... 124 
4.6.1.4 Other covariates of interest .................................................... 124 
4.6.2 Multivariable analysis of body adiposity parameters at the end of 
the follow up ............................................................................................ 125 
4.6.2.1 Percentage of body fat ........................................................... 125 
4.6.2.2 Fat mass/fat free mass ratio ................................................... 125 
4.6.2.3 Waist circumference .............................................................. 126 
4.7 Metabolic parameters at the end of the follow up ............................ 126 
4.7.1 Univariable analysis of metabolic parameters at the end of the 
follow up .................................................................................................. 127 
4.7.2 Multivariable analysis of metabolic parameters at the end of the 
follow up .................................................................................................. 127 
4.8 Summary of the findings .................................................................. 128 
CHAPTER 5: DISCUSSION AND CONCLUSSIONS .......................................... 130 
5 Introduction .............................................................................................. 130 
5.1 The sample ....................................................................................... 130 
5.2 Weight change after breast cancer diagnosis ................................... 132 
5.2.1 Magnitude and frequency of weight change after breast cancer 
diagnosis ................................................................................................... 132 
5.2.1.1 Is the magnitude of weight change different from the healthy 
population? ........................................................................................... 134 
5.2.1.2 Potential clinical implications of the weight change found .. 135 
5.2.2 Factors associated with weight change post-diagnosis ................ 137 
5.2.2.1 Chemotherapy ....................................................................... 137 
5.2.2.2 Hormone therapy ................................................................... 138 
5.2.2.3 Menopausal status and change in menopausal status ............ 140 
11 
 
5.2.2.4 Genes ..................................................................................... 141 
5.2.2.5 Other variables of interest ..................................................... 143 
5.3 Multilevel models for weight change ............................................... 145 
5.4 Body adiposity parameters ............................................................... 145 
5.4.1 Are these adiposity parameters different from the healthy 
population? ............................................................................................... 146 
5.4.2 Potential clinical implications of the excess body fat and waist 
circumference observed ........................................................................... 147 
5.4.3 Factors associated with body adiposity parameters at the end of the 
follow up .................................................................................................. 148 
5.4.3.1 Chemotherapy ....................................................................... 148 
5.4.3.2 Hormone therapy ................................................................... 149 
5.4.3.3 Menopausal status and change in menopausal status ............ 149 
5.4.3.4 Genes ..................................................................................... 151 
5.4.3.5 Other variables of interest ..................................................... 151 
5.5 Metabolic parameters at the end of the follow up ............................ 152 
5.5.1 Potential clinical implications of the high glucose and insulin levels 
observed ................................................................................................... 153 
5.5.2 Factors associated with metabolic parameters at the end of the 
follow up .................................................................................................. 154 
5.5.2.1 Chemotherapy ....................................................................... 154 
5.5.2.2 Hormone therapy ................................................................... 155 
5.5.2.3 Other variables of interest ..................................................... 156 
5.6 Contribution to the knowledge. Implications for clinical practice and 
research ........................................................................................................ 157 
5.6.1 Assessment of body weight, body adiposity and metabolic 
parameters ................................................................................................ 159 
12 
 
5.6.2 Care plan to improve control of weight, adiposity and metabolic 
parameters ................................................................................................ 161 
5.7 Limitations of the study ................................................................... 163 
5.7.1 Representativeness of the sample................................................. 163 
5.7.2 Validity of data collected ............................................................. 163 
5.7.3 Lack of control group ................................................................... 164 
5.7.4 Lack of statistical power .............................................................. 165 
5.7.5 Unbalanced data ........................................................................... 165 
5.7.6 Causality ....................................................................................... 166 
5.7.7 Data analysis ................................................................................ 166 
5.8 Strengths of the study ....................................................................... 168 
5.8.1 Data collection ............................................................................. 168 
5.8.2 Repeated measures and long follow up ........................................ 169 
5.8.3 Data analysis ................................................................................ 169 
5.9 Conclusions ...................................................................................... 170 
REFERENCES ......................................................................................................... 172 
APPENDIX I: TABLES AND FIGURES ............................................................... 199 
Appendix I Introduction ................................................................................... 199 
APPENDIX II: EXPLORING MISSING DATA .................................................... 261 
Appendix II. Introduction ................................................................................ 261 
Appendix II.A. Number of participants with available weight records ....... 261 
Appendix II.B. Number of weights across participants according to main 
predictors ...................................................................................................... 262 
Appendix II.C. Reasons for differences in number of weight records between 
chemotherapy users and non-users. Is this missing data? ............................ 263 
13 
 
Appendix II.D. What are the reasons for differences in number of weight 
records between tamoxifen and/or aromatase inhibitors users and non-users? 
Are there missing data? ................................................................................ 264 
APPENDIX III: SENSITIVITY ANALYSIS OF WEIGHT CHANGE AFTER 
BREAST CANCER DIAGNOSIS ........................................................................... 276 
Appendix III. Introduction ............................................................................... 276 
Appendix  III.A. Similarities between participants included in, and 
participants excluded from the analysis of weight change after breast cancer 
diagnosis: Comparison of their weights at breast cancer diagnosis ............. 276 
Appendix III.B. Non-parametric approach for the analysis of weight change 
at 12, 24, 36 and 48 months post breast cancer diagnosis............................ 277 
Appendix III.C. Factors associated with weight change at 12, 24, 36 and 48 
months after breast cancer diagnosis analysed using a non-parametric 
approach ....................................................................................................... 277 
Appendix III.D. Outlier values in the analysis of weight change at 12, 24, 36 
and 48 months post breast cancer diagnosis ................................................ 279 
Appendix III.E. Multivariable analysis of factors associated with weight 
change at 12, 24, 36 and 48 months post breast cancer diagnosis. Repeated 
analysis ......................................................................................................... 280 
APPENDIX IV: SAMPLE RESIDUALS IN THE MULTILEVEL MODELS ...... 295 
APPENDIX V: SENSITIVITY ANALYSIS OF THE RESULTS OF BODY 
ADIPOSITY AND METABOLIC PARAMETERS ............................................... 297 
Appendix V. Introduction ................................................................................ 297 
Appendix V.A. Exploring insulin level as a numerical variable ................. 297 
Appendix V.B. Factors associated with body adiposity and metabolic 
parameters at the end of the follow up, using a non-parametric approach .. 298 
Appendix V.C. Outlier values in body adiposity and metabolic parameters at 
the end of the follow up.  Repeated analysis ................................................ 298 
14 
 
Appendix V.D. Multiple regression analysis of body adiposity and metabolic 
parameters at the end of the follow up.  Repeated analysis ......................... 299 
APPENDIX VI: PARTICIPANTS INFORMATION SHEET, CONSENT FORM 
AND DECLINE SLIP .............................................................................................. 324 
Appendix VI. Introduction ............................................................................... 324 
Appendix VI.A. Participants information sheet ........................................... 324 
Appendix VI.B. Consent form ..................................................................... 330 
GLOSSARY ............................................................................................................. 334 
 
List of Tables 
Table 1 Appendix I - Summary of results from previous studies on weight change 
after breast cancer diagnosis and factors associated with weight change ........ 200 
Table 2 Appendix I - Standardised effect sizes of weight change after breast cancer 
diagnosis found in previous studies in the field ............................................... 210 
Table 3 Appendix I - Number of weight records hold by participants from breast 
cancer diagnosis to the end of the follow up .................................................... 212 
Table 4 Appendix I - Number of pre, peri and postmenopausal participants at breast 
cancer diagnosis and at 12, 24, 36 and 48 months post-diagnosis ................... 214 
Table 5 Appendix I - Number of participants grouped according to genetic profile 
included in the analysis of weight change from breast cancer diagnosis to 12, 
24, 36 and 48 months post-diagnosis ............................................................... 214 
Table 6 Appendix I - Participants' biological characteristics at breast cancer 
diagnosis ........................................................................................................... 215 
15 
 
Table 7 Appendix I - Magnitude of the weight change post-diagnosis calculated in 
this study, corresponding to the conventional small, medium and large Cohen‘s 
conventional criteria ......................................................................................... 216 
Table 8 Appendix I - Participants' clinical characteristics ....................................... 217 
Table 9 Appendix I - Details of the hormone therapy used by the 205 participants 
treated with hormone therapy after breast cancer diagnosis ............................ 218 
Table 10 Appendix I - Details of chemotherapy regimens used by the 134 
participants treated with chemotherapy after breast cancer diagnosis ............. 219 
Table 11 Appendix I - Number of participants with available and missing weight 
records at diagnosis and at 12, 24, 36 and 48 months after breast cancer 
diagnosis ........................................................................................................... 221 
Table 12 Appendix I - Participants‘ body weight at, and body weight change from, 
breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis ............... 222 
Table 13 Appendix I - Frequency of weight change (larger than 0.0 kg) from breast 
cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis ......................... 224 
Table 14 Appendix I - Frequency of weight change (larger than 2.0 kg) from breast 
cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis ......................... 225 
Table 15 Appendix I - Frequency of weight change (larger to 0.0% relative to weight 
at diagnosis), from breast cancer diagnosis to 12, 24, 36 and 48 months post-
diagnosis ........................................................................................................... 226 
Table 16 Appendix I - Parametric univariable analysis on the association between 
participants‘ weight change from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis and breast cancer treatment ......................................... 227 
Table 17 Appendix I - Parametric univariable analysis on the association between 
participants‘ weight change from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis and 1) menopausal status at diagnosis and 2) change in 
16 
 
menopausal status from  diagnosis to 12, 24, 36 and 48 months post-diagnosis
 .......................................................................................................................... 230 
Table 18 Appendix I - Number of participants whose menopausal status changed 
from breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis ...... 231 
Table 19 Appendix I - Parametric univariable analysis on the association between 
participants‘ weight change from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis and genetic profile ....................................................... 232 
Table 20 Appendix I - Parametric univariable analysis on the association between 
participants‘ weight change from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis and biological, behavioural and tumour-related variables
 .......................................................................................................................... 233 
Table 21 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ weight change from breast cancer diagnosis to 12 months post-
diagnosis ........................................................................................................... 235 
Table 22 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ weight change from breast cancer diagnosis to 24 months post-
diagnosis ........................................................................................................... 235 
Table 23 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ weight change from breast cancer diagnosis to 36 months post-
diagnosis ........................................................................................................... 236 
Table 24 Appendix I - Multilevel models for linear weight change after breast cancer 
diagnosis, using breast cancer treatments as time-invariant predictors ........... 237 
Table 25 Appendix I - Final multilevel models for linear weight change after breast 
cancer diagnosis among participants, using breast cancer treatments as time-
invariant predictors .......................................................................................... 239 
Table 26 Appendix I - Multilevel models for linear weight change after breast cancer 
diagnosis among participants, using breast cancer treatments as time-varying 
predictors .......................................................................................................... 241 
17 
 
Table 27 Appendix I - Final multilevel models for linear weight change after breast 
cancer diagnosis among participants, using breast cancer treatments as time-
varying predictors ............................................................................................ 243 
Table 28 Appendix I - Estimated body weight after breast cancer diagnosis of a 
woman diagnosed with breast cancer predicted by model 4 ............................ 245 
Table 29 Appendix I - Parametric univariable analysis on the association between 
participants‘ body adiposity parameters at the end of the follow up and breast 
cancer treatment ............................................................................................... 246 
Table 30 Appendix I - Parametric univariable analysis on the association between 
participants‘ body adiposity parameters at the end of the follow up and 1) 
menopausal status at diagnosis and 2) change in menopausal status after breast 
cancer diagnosis ............................................................................................... 248 
Table 31 Appendix I - Parametric univariable analysis on the association between 
participants‘ body adiposity parameters at the end of the follow up and genetic 
profile ............................................................................................................... 249 
Table 32 Appendix I - Parametric univariable analysis on the association between 
participants‘ body adiposity parameters at the end of the follow up and 
biological, behavioural and tumour-related variables ...................................... 250 
Table 33 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ fat mass percentage at the end of the follow up .......................... 252 
Table 34 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ fat mass/fat free mass ratio at the end of the follow ................... 252 
Table 35 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ waist circumference at the end of the follow up ......................... 253 
Table 36 Appendix I - Parametric univariable analysis on the association between 
participants‘ glucose and insulin levels at the end of the follow up and breast 
cancer treatment ............................................................................................... 254 
18 
 
Table 37 Appendix I - Parametric univariable analysis on the association between 
participants‘ glucose and insulin levels at the end of the follow up and 1) 
menopausal status at diagnosis and 2) change in menopausal status after breast 
cancer diagnosis ............................................................................................... 256 
Table 38 Appendix I - Parametric univariable analysis on the association between 
participants‘ glucose and insulin levels at the end of the follow up and genetic 
profile ............................................................................................................... 257 
Table 39 Appendix I - Parametric univariable analysis on the association between 
participants‘ glucose and insulin levels at the end of the follow up and 
biological, behavioural and tumour-related variables ...................................... 258 
Table 40 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ glucose levels at the end of the follow up ................................... 260 
Table 41 Appendix I - Multiple linear regression analysis on factors associated with 
participants‘ insulin levels at the end of the follow up .................................... 260 
Table 42 Appendix II - Number of participants with weight records available at 
breast cancer diagnosis and at 12, 24, 36 and 48 months post-diagnosis, looking 
at different window periods (±0.5, ±3.0 and ±4.0 months) .............................. 265 
Table 43 Appendix II - Number of weight records hold by participants from breast 
cancer diagnosis to the end of the follow up, according to breast cancer 
treatment and menopausal status at diagnosis .................................................. 270 
Table 44 Appendix II - Number of participants with available weight records from 
breast cancer diagnosis to 1
st
, 2
nd
, 3
rd
, 4
th
, 5
th
, 6
th
and 7
th
 year post diagnosis and 
to the end of the follow up, stratified by chemotherapy use ............................ 272 
Table 45 Appendix II - Number of weight records hold by participants during the 1
st
 
and 2
nd
 year post breast cancer diagnosis stratified by tamoxifen and 
chemotherapy use ............................................................................................. 274 
19 
 
Table 46 Appendix II - Number of weight records hold by participants during the 
4th, 5th and 6th year post breast cancer diagnosis, stratified by aromatase 
inhibitors (AINs) and chemotherapy use ......................................................... 275 
Table 47 Appendix III - Differences in weight at diagnosis between participants 
included in, and those excluded from the analysis of weight change from breast 
cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis, using parametric 
and non-parametric tests .................................................................................. 281 
Table 48 Appendix III - Non-parametric univariable analysis on the association 
between participants‘ weight change from breast cancer diagnosis to 12, 24, 36 
and 48 months post-diagnosis and breast cancer treatment ............................. 284 
Table 49 Appendix III - Non-parametric univariable analysis on the association 
between weight change from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis and 1) menopausal status at diagnosis and 2) change in 
menopausal status from diagnosis to 12, 24, 36 and 48 months post-diagnosis
 .......................................................................................................................... 286 
Table 50 Appendix III - Non-parametric univariable analysis on the association 
between participants‘ weight change from breast cancer diagnosis to 12, 24, 36 
and 48 months post-diagnosis and genetic profile ........................................... 287 
Table 51 Appendix III - Non-parametric univariable analysis on the association 
between participants‘ weight change from breast cancer diagnosis to 12, 24, 36 
and 48 months post-diagnosis with biological, behavioural and tumour-related 
variables ........................................................................................................... 288 
Table 52 Appendix III - Repeated analysis of participants‘ weight change from 
breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis, after 
excluding outliers ............................................................................................. 290 
Table 53 Appendix III - Repeated multiple linear regression analysis of participants‘ 
weight change from breast cancer diagnosis to 24 months post- diagnosis, after 
excluding outliers ............................................................................................. 291 
20 
 
Table 54 Appendix III - Repeated multiple linear regression analysis of participants‘ 
weight change from breast cancer diagnosis to 36 months post- diagnosis, after 
excluding outliers ............................................................................................. 292 
Table 55 Appendix III - Multiple linear regression analysis of participants‘ weight 
change from breast cancer diagnosis to 48 months post- diagnosis, including 
outliers .............................................................................................................. 293 
Table 56 Appendix III - Repeated multiple linear regression analysis of participants‘ 
weight change from breast cancer diagnosis to 48 months post- diagnosis, after 
excluding outliers ............................................................................................. 294 
Table 57 Appendix V - Sensitivity analysis of the association between participants‘ 
insulin levels at the end of the follow up and breast cancer treatment, using 
three hypothetical values for those insulin levels whose magnitude was below 
the limit the assay could detect ........................................................................ 300 
Table 58 Appendix V - Sensitivity analysis of the association between participants‘ 
insulin levels at the end of the follow up and 1) menopausal status at diagnosis 
and 2) change in menopausal status after breast cancer diagnosis, using three 
hypothetical values for insulin levels whose magnitude was below the limit the 
assay could detect ............................................................................................. 303 
Table 59 Appendix V - Sensitivity analysis of the association between participants‘ 
insulin levels at the end of the follow up and genetic profile, using three 
hypothetical values for insulin levels whose magnitude was below the limit the 
assay could detect ............................................................................................. 304 
Table 60 Appendix V - Sensitivity analysis of the association between participants‘ 
insulin levels at the end of the follow up and biological, behavioural and 
tumour-related variables, using three hypothetical values for insulin levels 
whose magnitude was below the limit the assay could detect ......................... 305 
Table 61 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ body waist circumference at the end of the follow up and 
breast cancer treatment ..................................................................................... 309 
21 
 
Table 62 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ waist circumference at the end of the follow up and 1) 
menopausal status at diagnosis and 2) change in menopausal status after breast 
cancer diagnosis ............................................................................................... 311 
Table 63 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ waist circumference at the end of the follow up and 
genetic profile .................................................................................................. 312 
Table 64 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ waist circumference at the end of the follow up and 
biological, behavioural and tumour-related variables ...................................... 313 
Table 65 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ glucose and insulin levels at study entry, and breast 
cancer treatment ............................................................................................... 315 
Table 66 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ glucose and insulin levels at study entry and 1) 
menopausal status at diagnosis and 2) change in menopausal status after breast 
cancer diagnosis ............................................................................................... 317 
Table 67 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ glucose and insulin levels at study entry, and genetic 
profile ............................................................................................................... 318 
Table 68 Appendix V - Non-parametric univariable analysis on the association 
between participants‘ glucose and insulin levels at study entry, and biological, 
behavioural and tumour-related variables ........................................................ 319 
Table 69 Appendix V - Multiple linear regression analysis of participants‘ body fat 
percentage at the end of the follow up, after excluding an outlier ................... 321 
Table 70 Appendix V - Multiple linear regression analysis of participants‘ fat 
mass/fat free mass ratio, after excluding two outliers ...................................... 321 
22 
 
Table 71 Appendix V - Multiple linear regression analysis of participants‘ waist 
circumference at the end of the follow up, after excluding one outlier ........... 322 
Table 72 Appendix V - Multiple linear regression analysis of participants‘ glucose 
level at the end of the follow up, including outliers ......................................... 322 
Table 73 Appendix V - Multiple linear regression analysis of participants‘ glucose 
level at the end of the follow up, after excluding two outliers ......................... 323 
Table 74 Appendix V - Multiple linear regression analysis of participants‘ insulin 
level at the end of the follow up, excluding one outlier ................................... 323 
 
List of Figures 
Figure 1 Appendix I - Number of participants followed at 12, 24, 36, 48, 60, 72 and 
84 months post-diagnosis ................................................................................. 220 
Figure 2 Appendix I - Weight change from diagnosis to 12, 24, 36 and 48 months 
post BC diagnosis ............................................................................................. 223 
Figure 3 Appendix II - Histogram representing the total number of weight records 
hold by participants from breast cancer diagnosis to the end of the follow up, 
according to breast cancer treatments and menopausal status ......................... 267 
Figure 4 Appendix III - Distribution of weight change from diagnosis to 12, 24, 36 
and 48 months post-diagnosis .......................................................................... 282 
Figure 5 Appendix IV - Normal Q-Q plot and scatter/dot plot of the residuals in 
model F ............................................................................................................ 295 
Figure 6 Appendix IV - Normal Q-Q plot and scatter/dot plots of the residuals in 
model 4 ............................................................................................................. 296 
Figure 7 Appendix V - Histograms representing the distribution of waist 
circumference, glucose and insulin levels at the end of the follow up ............ 307 
23 
 
Acknowledgement 
 
Prof. David Kerr and Prof. Tamas Hickish, my sincere gratitude for your trust and 
supervision. Prof. Peter Thomas, thank you for your patience, encouragement and 
immense guidance. I could not have finished it without you. 
Prof. Tish Knobf, Prof. Samuel Porter and Dr. Zoe Sheppard, thank you for taking 
your time to examine me and for your insightful comments and suggestions.  
Mr. Skene, Mr Perry, Dr Coppini, Mrs. Evans, Mr Pain, Linda Purundae and the rest 
of your team, thank you for allowing me to join you, for all the things I learnt from 
you and for your efforts to recruit participants.  
Dr Begley, Tanya Hart, Anton Parker, thank you so much for managing and 
analysing the research blood samples and for always answering all my questions! 
Janet Beach, I trusted you the responsibility of finishing data collection when I went 
on maternity leave and then when I moved to New Zealand. You did a great job! 
This research could not have been finished without your help.  
Dee and Val, my dearest friends, how could I not thank you for all the long hours 
editing this thesis after a busy day with the kids, for your encouragement and for 
always being there for me! And Monica, we started and we will finish our PhD at the 
same time. I couldn‘t be more thankful for all the times you took me out for dinner 
and for all the times we spent together in the laboratory and in the university sharing 
our worries and our achievements!  
Khalid, you would not let me give up my study all those times I thought looking 
after our beautiful little kids, moving from one country to another and doing a PhD 
were not compatible! My friend once told me how proudly you talked about your 
wife doing a PhD. That meant a lot to me. I love you. 
The last words go to each one of you, my 239 participants in this research, you are 
awesome brave women with a big heart. 
 
24 
 
Abbreviation List  
Abbreviation Meaning 
ABCPP 
 
After Breast Cancer Pooling Project 
ABCSG-6 
 
Austrian Breast and Colorectal Cancer Study Group Trial 6   
AC 
 
Doxorubicin and Cyclophosphamide 
AINs 
 
Aromatase Inhibitors 
ANOVA 
 
Analysis of the Variance 
ARC  
 
Arcuate Nucleus 
AUC 
 
Area Under the Receiver Operating Characteristic Curve 
Β 
  
Regression beta Coefficient 
ATAC 
 
The Arimidex, Tamoxifen Alone or in Combination Trial 
BC 
 
Breast Cancer 
BRCA 
 
Tumour Suppressor Gene 
BIA  
 
Bioelectrical Impedance Analysis 
BIC  
 
Schwarz‘s Bayesian Criterion 
BMI  
 
Body Mass Index 
C 
 
Degrees Celsius 
CFA 
 
Cyclophosphamide,  5-fluorouacil and Doxorubicin 
CI  
 
Confidence Intervals 
Cm Centimetres 
  
25 
 
CT 
  
Computed Tomography 
CMF   
 
Cyclophosphamide, Methotrexate and 5-fluorouacil 
d.f. 
 
Degrees of Freedom 
DNA  
 
Deoxyribonucleic Acid 
DXA 
 
Dual Energy X-ray Absorptiometry 
EC 
 
Cyclophosphamide and Epirubicin 
ER  
 
Oestrogen Receptors 
Et al.  
 
And Others 
Etc. 
 
Et Cetera 
ERK1/2  
 
Extracellular Signal‑regulated Kinases 
F 
 
F-statistic  resulting from the F-Test ANOVA Test.  
FEC 
 
Fluorouracil, Cyclophosphamide and Epirubicin 
FM 
 
Fat Mass 
FFM 
 
Fat Free Mass 
FTO 
 
Fat Mass and Obesity-associated Gene 
HbA1c 
 
Glycated Haemoglobin 
HEAL 
 
Health, Eating, Activity and Lifestyle Study 
HER-2 
 
Human Epidermal Growth Factor Receptor-2 
HOMA  
 
Homeostasis Model Assessment 
26 
 
HOMA IS  
 
Homeostasis Model Assessment of Insulin Sensitivity 
HOMA IR  
 
Homeostasis Model Assessment of Insulin Resistance 
HR 
 
Hazard Ratio 
HRT  
 
Hormone Replacement Therapy 
IBIS 
 
International Breast Cancer Intervention Study 
IBM 
 
International Business Machines 
I.e. 
 
In Example 
IGF 
 
Insulin Growth Factor 
IR 
 
Insulin Resistance 
Kg 
 
Kilogram 
LACE 
 
Life After Cancer Epidemiology Study 
MAPKs 
 
Mitogen-activated Protein Kinase 
MAP4K4 
 
Mitogen-activated Protein Kinase Kinase Kinase Kinase Four 
MAR 
 
Missing at Random 
Mc4R  
 
Melanocortin-4 Receptor 
ML 
 
Maximum Likelihood 
Mmol/l 
 
Milimol per Litre 
MPOA 
 
Medial Preoptic Area 
NHS 
 
National Health System 
OR 
 
Odds Ratio 
PI3K/Akt Phosphatidylinosito-3-kinase 
27 
 
 
PhD  
 
Doctor of Philosophy 
Pmol/l 
 
Picomole per Litre 
PVN 
 
Paraventricular Nuclei 
Q-Q plot 
 
Quantile-quantile Plot 
r 
 
Pearson‘s Product Moment Correlation Coefficient 
R 
 
Multiple Correlation Coefficient 
R2 
 
Coefficient of Determination  
R&D 
 
Research and Development Department 
REC 
 
Research Ethics Committee 
REE 
 
Resting Energy Expenditure 
RR  
 
Risk Ratio 
SBCSS 
 
Shanghai Breast Cancer Survival Study 
SD  
 
Standard Deviation 
SE 
 
Standard Error 
SNP  
 
Single Nucleotide Polymorphism 
SPSS  
 
Statistical Package for the Social Sciences 
U 
 
Statistic resulting from the Mann-Whitney U test 
UK 
 
United Kingdom 
USA 
 
United States of America 
VMH 
 
Ventral Medial Hypothalamus 
Vs. 
 
Versus 
28 
 
WHEL  
 
Women‘s Healthy Eating and Living Trial 
WHR 
 
Waist to Hip Ratio 
χ 2 
 
Chi Squared Value for the Kruskal Wallis Test 
Z 
 
Statistic resulting from the Mann-Whitney U test 
 
29 
 
CHAPTER 1: INTRODUCTION TO BREAST CANCER 
AND WEIGHT CHANGE 
 
1 Introduction 
It is not uncommon that women diagnosed with breast cancer (BC) will experience 
changes in weight and body composition (i.e. increases in body fat). These changes 
have been reported for many years and are the focus of on-going investigations to 
understand the causes. 
The first chapter of this dissertation offers the reader a brief introduction to general 
aspects of BC, such as epidemiology, diagnosis and current treatments offered in the 
United Kingdom (UK). The attention then moves to the focus of the study: weight 
change after BC diagnosis, exploring how common it is and its magnitude.  The 
chapter concludes with an exposition of current knowledge about the impact that this 
common and undesired phenomena may have on women‘s health. In particular, its 
effects on BC recurrence and survival. This highlights the importance of 
understanding the factors associated with changes in body weight and the underlying 
mechanisms, to ultimately identify women at risk and to develop interventions to 
help them to avoid potentially harmful changes in body weight following BC 
diagnosis. 
 
1.1 Breast cancer epidemiology 
Statistics from 2012 show that BC was the most common cancer affecting women in 
the world and constituting the first cause of cancer death in women in both 
developed and in developing regions (World Cancer Research Fund International 
2014). In the UK, incidences have increased since the mid-1970s up to mid-2000s.  
In 2011, 50,285 new cases of BC were diagnosed, 99% of them in women, 
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representing a female/male ratio of 43/1; it is expected that one in eight women will 
develop BC during their lifetime (Cancer Research UK 2014b). 
The aetiology of BC is not completely understood and therefore, it is difficult to 
explain the BC incidence trends over these decades (World Health Organization 
Regional Office for the Eastern Mediterranean 2006). Biological (i.e. ageing, 
increased adiposity), behavioural [alcohol intake, use of hormone replacement 
therapy (HRT), or oral contraceptives] and genetic factors [mutations in tumour 
suppressor genes one and two (BRCA1 and BRCA2)] can increase the risk of BC 
(Cancer Research UK 2014d). Therefore, changes in incidence or prevalence of 
those factors over the past few decades might provide plausible explanations for the 
growing incidence of BC (Kumle et al. 2002). On the other hand, survival rates have 
improved dramatically, probably due to improvements in BC treatment and use of 
the BC screening programme. Currently, around 90% of women will survive for at 
least five years after diagnosis and 80% are expected to survive for more than ten 
years. Nonetheless, cancer can recur, most likely within the first two years of 
diagnosis, although it can happen even ten or 20 years after first diagnosis (Cancer 
Research UK 2014f). 
 
1.2 Types of breast disorders and diagnostic tests 
BC can be classified in non-invasive (ductal or lobular carcinoma in situ) and 
invasive carcinoma [National Health System (NHS) 2014a; Cancer Research UK 
2015].  Ductal carcinoma is the most common malignant invasive carcinoma and 
accounts for around 80% of diagnosed BCs (National Health System 2014a). Other 
less common types of BC are inflammatory BC, Paget‘s disease and finally those 
included under the broad name of ―special type of BC‖ (Cancer Research UK 2015).  
Currently, the BC diagnostic journey includes a triple assessment involving a clinical 
examination, imaging tests and a biopsy (National Institute for Health and Care 
Excellence (NICE) 2014). The results of these tests will determine how aggressive 
the cancer is (grade from 1-3) and will provide information about tumour size and 
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whether it has spread (cancer stage) (Breakthrough breast cancer 2013; NHS 2014b). 
The two methods used to describe staging are the TNM staging system, which looks 
at tumour size (T), whether the tumour has spread to the lymph nodes (N), or 
whether the tumour has metastasised (M) (Cancer Research Uk 2014). The second 
method is the number system, which classifies cancer into stages cero to four 
(Cancer Research UK 2014e). Early BC comprises stages I, II and III, whereas stage 
IV denotes advanced BC (National Collaborating Centre for Cancer 2009). In 
addition to grade and stage, clinically important subsets of BC can be identified 
according to the expression of two main types of receptors: oestrogen receptor (ER) 
and human epidermal growth factor receptor-2 (HER-2) (Burstein 2011). ER and 
HER-2 are growth factor receptors (Cancer Research UK 2014g; NHS 2014b), 
therefore, upon ligand binding they are able to transmit signals from outside the cell 
to the inside, promoting tumour cells. HER-2 is a tyrosine kinase receptor involved 
in the proliferation and survival of BC cells, via receptor activation of different 
signalling pathways, including the phosphatidylinosito-3-kinase (PI3K/Akt), or the 
mitogen-activated protein kinase (MAPKs) signalling pathways (Roy and Perez 
2009). The level of HER-2 protein present in the tumour can be graded between cero 
and three positive (Cancer Research UK 2014g), an its overexpression has been 
associated with a more adverse prognosis (Roy and Perez 2009).  
On the other hand, ER belongs to the family of nuclear receptors and mediates the 
effects of oestrogens. A tumour that has ER is classified as ER positive. ERs are   
activated upon ligand binding, leading to transcriptional activity, which can be 
promoted by coactivators, or by contrast, can be suppressed by corepressors. 
Furthermore, ERs‘ role on breast carcinogenesis and BC progression can mediated 
by the interaction with other growth factors and their downstream signalling 
proteins, as well as by the interaction between signalling pathways emerging from 
ERs and other growth factors receptor pathways (i.e. the PI3K/Akt, or the MAPKs) 
(Murphy et al. 2003). 
ERs are present in two thirds of BCs (ER-positive cancers), whereas HER-2 is found 
in about 25% of breast tumours (Cancer Research UK 2014g). The tumour 
expression of these receptors shows a differential response to different types of drugs 
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(Hsu and Hung, 2016), hence the presence of those receptors in the breast tumour 
will help doctors to determine the BC treatment for each individual. 
 
1.3 Breast cancer treatments 
BC treatment is largely determined by cancer characteristics (Cancer Research Uk 
2014), although other factors including age, menopausal status, potential benefits, 
acceptability of the diagnosis and treatment, as well as patients‘ needs and 
preferences should  also be  accounted (National Collaborating Centre for Cancer 
2009).   
The main treatments currently offered in the UK for early BC are surgery, 
radiotherapy, chemotherapy, hormone therapy and biological therapy, singularly or 
in combination (NHS 2014c). Local treatments (surgery and radiotherapy) aim to 
remove the tumour from the breast and axilla, whereas systemic treatment 
(chemotherapy, hormone therapy and biological therapy) reach the blood systems to 
prevent the growth of microscopic tumour cells that might have remained in the 
tissue or the spread of breast tumour to other parts of the body (Breakthrough breast 
cancer 2013). Mastectomy and breast conserving surgery are the two types of 
surgery used for BC (Breakthrough breast cancer 2013; Cancer Research UK 
2014g). Currently, it is recommended that further treatment with adjuvant 
chemotherapy or radiotherapy should start within 31 days of completion of surgery 
(NICE 2009), although in some cases, systemic therapy can also be offered before 
surgery (neo-adjuvant therapy) in order to reduce the size of the tumour so the 
subsequent surgery is less extensive (National Collaborating Centre for Cancer 
2009). 
Chemotherapy uses one or a combination of different cytotoxic agents that disrupt 
the growth of tumour cells, by killing dividing cells. Consequently, in addition to 
tumour cells, it also affects cells in healthy tissues where the cells are constantly 
growing and dividing, like the skin, bone marrow, hair follicles or the digestive 
system (Cancer Research UK 2014a). That explains the numerous side effects of 
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different cytotoxic agents (Breakthrough breast cancer 2013), including anaemia, 
neutropenia, fatigue, nausea and vomiting, loss of appetite, sore mouth or mouth 
ulcers (Cancer Research UK 2014a). Chemotherapy can also have endocrine effects, 
by interrupting ovarian oestrogen production, which leads to a temporary or 
permanent infertility accompanied by amenorrhea (Zhao et al. 2014) and other 
menopausal symptoms (i.e. hot flushes or sleep disturbances) (Cancer Research UK 
2014c; Zhao et al. 2014). Currently, NICE recommends taxane-based chemotherapy 
regimens that include docetaxel (NICE 2009). The lengh of treatment depends on the 
agents and the number of cycles prescribed (usually four to eight cycles), which are 
usually administered at intervals of three to four weeks (Cancer Research UK 
2014a). 
Hormone therapy aims to reduce the availability of endogenous oestrogen to tumour 
cells (Goel et al. 2009), as it is well known the ability of oestrogen to stimulate BC 
cells growth (Jonat 2001; Folkerd and Dowsett 2013). It is therefore, the mainstay 
treatment for ER positive tumours (Burstein 2011) and it is recommended for about 
five years (Cancer research uk 2014). One variant of hormone therapy acts on ER, 
aiming to block the activation of oestrogen-stimulated signalling pathways in the 
cells. Tamoxifen is a drug that does that. It competes with oestrogens and binds and 
phosphorylates ER in breast tumour cells (Burstein 2011). A second way to reduce 
oestrogen availability is by stopping oestrogen production in the tissues synthesising 
oestrogen (i.e. ovaries in premenopausal women and adipose tissue).  In 
premenopausal women, this can be achieved mainly via surgical or chemical ovarian 
ablation (Burstein 2011). Chemical agents to reduce oestrogen levels are gonadorelin 
analogues, such as goserelin, an injectable gonadotropin releasing hormone 
supeagonist (Cancer research uk 2014), which is able to suppress circulating 
oestrogen to postmenopausal levels (Jonat 2001). On the other hand, in 
postmenopausal women, oestrogen synthesis can be reduced with the use of 
aromatase inhibitors (AINs), which block the action of aromatase, a crucial enzyme 
in the process of oestrogen production in the adipose tissue, the main source of 
oestrogen in postmenopausal women. Three AINs used to treat early BC are: 
exemestane, anastrozole and letrozole (Burstein 2011). At present, AINs are used 
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singularly or in combination with tamoxifen to treat postmenopausal women with 
ER positive tumours (NICE 2009; Burstein 2011). 
Finally, biological therapy with trastuzumab is the standard treatment for patients 
with HER-2 positive invasive BC (National Collaborating Centre for Cancer 2009), 
as it targets the HER-2 signalling pathway in BC cells (Moja et al. 2012). Currently, 
it is administered every three weeks for one year or until tumour recurrence 
(European Medicines Agency 2008).  
 
1.4 Problem: weight change after breast cancer diagnosis 
Weight change, in particular weight gain, following BC diagnosis is an undesired 
phenomenon documented in several papers with large and small sample sizes and 
with short and long follow ups, from all around the world, including Australia 
(Vagenas et al. 2015), Brasil (Costa et al. 2002), Canada (Kutynec et al. 1999), 
China (Chen et al. 2011), France (Tredan et al. 2010),  Italy (Del Rio et al. 2002), the 
Netherlands (Heideman et al. 2009), UK (Lankester et al. 2002; Harvie et al. 2004; 
Sestak et al. 2012) and United States of America (USA) (Camoriano et al. 1999; 
McIness and Knobf 2001; Nissen et al. 2011; Reddy et al. 2013; Saquib et al. 2007) 
(Table 1, Appendix I).  
In the general population, changes in weight during adulthood are not unusual 
(Williamson et al. 1990) (more details in Chapter 2). Nonetheless, although weight 
change can occur in absence of BC diagnosis, the amount of weight change observed 
after BC diagnosis seems to be larger than what would be expected in the health 
population (Vance et al. 2011). This is a worrying finding because there is evidence 
of a link between weight change post BC diagnosis and poorer BC outcomes, as it is 
explained below in this chapter. 
The following lines present a summary of findings from previous studies reporting 
weight changes following BC diagnosis. Table 1 (Appendix I) contains more details 
of the characteristics of these studies (i.e. length of follow up, sample size, frequency 
and magnitude of weight change and factors related to it).   
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1.4.1 Magnitude of weight change after breast cancer diagnosis 
Most studies in the field have shown changes in weight following BC diagnosis. 
Mean weight changes from + 1.6 kilograms (kg) to + 5.0 kg have been documented 
across the samples within the first year of diagnosis (Goodwin et al. 1999; Demark-
Wahnefried et al. 2001; McInnes and Knobf 2001; Harvie et al. 2004; Kumar et al. 
2004; Makari-Judson et al. 2007; Heideman et al. 2009; Basaran et al. 2011; Chen et 
al. 2011) (Table 1, Appendix I). Post-diagnosis weight changes in the long term have 
been less frequently explored, but evidence indicates weight changes are also 
present. For  instance, mean weight changes of + 1.7 kg or even + 2.4 kg within the 
first two and three years‘ post-diagnosis have been reported (Irwin et al. 2005; 
Kroenke et al. 2005; Caan et al. 2006, 2008; Chen et al. 2011; Caan et al. 2012b).  
 
1.4.2 Frequency of weight change after breast cancer diagnosis  
Most research has reported positive weight changes following BC diagnosis. 
Nonetheless, their findings also revealed that some women maintain their pre-
diagnosis weight, or in other words, do not experience weight changes, whereas 
others lose weight post diagnosis. Caan et al. (2012b) published data from nearly 
13,000 BC survivors included in the After Breast Cancer Pooling Project (ABCPP), 
a large international collaboration of four prospective cohort studies from USA and 
from China: The Shanghai Breast Cancer Survival Study (SBCSS), the Life After 
Cancer Epidemiology (LACE), the Women‘s Healthy Eating and Living (WHEL) 
and the Nurses‘ Health Study. Findings showed that two years post-diagnosis, 34.7% 
of the participants gained weight (more than 5% of initial body weight) and 14.7% 
lost weight. The remaining participants maintained their weight (changes within 5% 
of their initial body weight) (Caan et al. 2012b). These figures are consistent with 
several studies that reported that 22% to 37.7% of all participants experienced 
weight gain and 14.96% to 27.1% participants lost weight post-diagnosis (Rock et al. 
1999; Kroenke et al. 2005; Caan et al. 2006, 2008; Gu et al. 2010; Chen et al. 2011; 
Nissen et al. 2011; Bradshaw et al. 2012; Caan et al. 2012b).  
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It is worth noting that the incidence of weight change post diagnosis depends on the 
categorization of weight change. Several studies have defined weight change as 
changes larger than 5% of baseline weight (Han et al. 2009; Nissen et al. 2011; 
Bradshaw et al. 2012, Caan et al. 2012b). Unfortunately, most of these studies did 
not report mean weight change within the ‗weight stable‘ (or not weight change) 
category and it is possible that other studies might have been identified that 
unreported magnitude of mean weight change as weight gain or weight loss, 
depending on the direction of the change. For instance, previous published data from 
the SBCSS (Gu et al. 2010; Chen et al. 2011), the Arimidex, Tamoxifen Alone or in 
Combination trial (ATAC) (Sestak et al. 2012) and the LACE (Wayne et al. 2014) 
defined weight change those changes larger than 2 kg.   
Despite the methodological differences in the definition of weight change, most 
studies showed changes in weight across their sample. Nonetheless, it has being 
acknowledged that the magnitude of weight change post BC diagnosis seems to have 
decreased since the mid 1990s (Vance et al. 2011; Makari-Judson et al. 2014). 
Unfortunately, this post-diagnosis weight change still seems to be larger than what 
would be expected in the general population in the same period of time (Vance et al. 
2011). For instance, a study demonstrated that 50% of BC patients put on weight and 
80% of them gained more weight than the average weight gain observed in a healthy 
age-matched sample (Vagenas et al. 2015). Furthermore, larger weight change (on 
average a positive weight change) was reporded in a study with women treated with 
BC compared to women at risk of BC (Sestak et al. 2012).  
As noted above, the exact magnitude of, and the frequency of weight change are 
difficult to ascertain due to differences in the way weight change was analysed (i.e. 
definition of weight change, relative and absolute terms, weight change as a 
continuous variable or as a categorical variable) and the timing of the follow up 
measurements. Furthermore, the starting point, or baseline weight, has been 
measured at different times, which ranges from one or two years before diagnosis 
(i.e. Kroenke et al. 2005; Caan et al. 2006; Bradshaw et al. 2012), to six months post 
diagnosis (Irwin et al. 2005) (Table 1, Appendix I). For instance, Bradshaw et al. 
(2012) explored weight change from one year before diagnosis to a year post 
diagnosis in a sample of 1,436 women diagnosed with early BC. Overall weight 
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change was not reported. Instead, it was categorised, and findings showed that most 
participants (60%) maintained weight (± 5% of baseline weight), whereas 26% lost 
weight (more than 5%), and 14% gained weight (more than 5%). On the other hand, 
Irwin et al (2005) investigated changes in body fat and body weight in 514 breast 
cancer survivors enrolled onto the Health, Eating, Activity and Lifestyle (HEAL) 
study, a population based prospective cohort study conducted to determine whether 
weight, physical activity, diet, sex hormones, and other exposures affect breast 
cancer prognosis. Baseline weight was recorded an average of six months from 
diagnosis. Mean weight change two years post-baseline weight measurement was + 
1.7 kg [Standard deviation (SD): 4.7 kg], with 68% of the sample gaining weight 
(mean weight gain + 3.9 kg, SD: 3.7 kg). In a previous study, Caan and colleagues 
(2006) published data from 3,215 BC survivors enrolled either in the LACE, or in 
the comparison group of the WHEL, a dietary intervention trial to prevent breast 
cancer recurrence. Similar to Bradshaw et al. (2012), baseline weight was measured 
a year before diagnosis. Overall change in body weight two years post diagnosis was 
+2.4 kg (SD: 7.5). The percentage of participants that gained weight (more than 5%), 
maintained their weight (± 5% of baseline weight), and lost weight (more than 5%), 
was 39.6%, 45.4% and 14.9% respectively. The authors noted that weight gains were 
of smaller magnitude than other studies, and discussed that participants taking part in 
the WHEL study might have already change their eating habits. As Caan and 
colleagues (2012b) note, the characteristics of the sample could influence the 
magnitude and frequency of weight changes, if for instance, the prevalence of factors 
that potentially influence weight change (i.e. eating habits, physical activity, 
chemotherapy use, or menopausal status, more detailed in Chapter 2) is larger in 
some studies compared to others.   
 
1.4.3 Trajectory of weight change after breast cancer diagnosis 
At the earlier stages of this project, most of the studies reported changes in body 
weight between two evaluation points: around diagnosis and at the end of follow up 
(Rock et al. 1999; Wayne et al. 2004; Irwin et al. 2005; Kroenke et al. 2005). This 
provided limited information on what happened in between. Only the study 
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conducted by McInness and Knob (2001) presented weight change at different points 
in between, and noted after two and three years post-diagnosis, 68% and 40% of 
those who gained weight during the first year maintained a significant weight gain. 
This finding is consistent with more recent reports which indicate that the average 
increase in weight peaks and that some breast cancer survivors are able to reverse the 
weight gained. For instance, Gu et al. (2010) found significant weight change from 
diagnosis to six months (+1.0 kg), 18 months (+2.0 kg) and 36 months (+1.0 kg). 
Makari-Judson et al. (2007) found average weight changes of +1.5 kg  and +2.7 kg 
from diagnosis to the first and second year post-diagnosis respectively, and an 
average weight increase of + 0.1 kg from the second to the third year post-diagnosis, 
suggesting that weight change stabilises three years post-diagnosis. Findings also 
revealed that 15% and 20% of those who gained weight during the first year of 
diagnosis lost it by year two and three respectively. Data from the WHEL trial study 
showed that 10% of those who gained weight returned to their pre-diagnosis weight 
nearly two years later (Saquib et al. 2007). Recently, a study reported that body 
weight of Taiwanese women diagnosed with BC experienced a cubic trajectory post-
diagnosis. Their body weight was a mean of 56.9 kg before chemotherapy, it 
increased to a mean of 59.4 kg at eight months after chemotherapy, and decreased to 
58.5 kg at 21.5 months. Finally, body weight slightly increased in the last two 
months. Interestingly, body weight never returned to the initial level (Liu et al. 
2014). 
For most women, the journey following BC diagnosis is characterized by multiple 
phases: surgery, radiotherapy, adjuvant therapy. It is possible that these therapeutic 
periods have a different impact on the factors that might contribute to weight 
changes observed post-diagnosis. For instance, the common fatigue, nausea and 
vomiting side effects accompanying chemotherapy treatment (Cancer Research UK 
2014a) could reduce physical activity and modify eating behaviours during the 
length of treatment, which could ultimately, have an impact on body weight (more 
details in Chapter 2). The emerging literature reporting fluctuations in weight change 
following diagnosis highlight the need of studies to investigate the trajectory of 
weight change in the long term and to identify factors that might contribute to 
different patterns of weight change. 
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1.4.4 Changes in body adiposity after breast cancer diagnosis 
Two large cohort studies have reported individual variations in body adiposity levels 
following BC diagnosis. Data from the HEAL study showed that in addition to the + 
1.7 kg weight increase observed across the sample (see previous paragraphs), there 
was a rise in fat mass (FM) percentage (mean + 2.1%, SD: 3.9%), which seemed to 
be negatively correlated with both body mass index (BMI) (p for trend 0.050) and 
age (p for trend: 0.060). Most participants (74%) gained FM (Irwin et al. 2005). 
Arpino et al. (2015) documented changes in waist and hip circumference (both are 
indicators of body fat) in a sample of patients receiving adjuvant therapy for BC. 
Over a median follow-up of 14 months, there were increases in weight and waist 
circumference (+ 0.72 kg/year, 95 % CI: 0.32 to 1.11 and +1.53 cm/year, 95 % CI:  
0.85 to 2.22 respectively). Hip circumference levels only increased among 
participants treated with chemotherapy (+ 3.16 cm/year, 95 % CI: 1.60 to 4.73). 
Interestingly, changes in body fat levels in the absence of weight gain among women 
treated for BC have been reported by at least two studies (Kutynec et al. 1999; 
Freedman et al. 2001). Kutynec et al. (1999) explored prospective changes in weight 
and body FM, and in non-bone fat free tissue, or fat free mass (FFM), in a sample of 
18 women treated with either chemotherapy or radiotherapy (n=10). The magnitude 
of body weight from initiation of adjuvant therapy to 12 weeks later did not change.  
Nonetheless, in both groups there were significant increases in FM percentage (mean 
+ 1.3%, p=0.04) and a significant decrease in FFM (mean -0.4kg, p=0.02).  
Freedman et al. (2001) compared weight change in a sample of 20 women receiving 
chemotherapy for BC and a group of 51 healthy controls, and could not find 
significant changes in weight, in either of the groups at the end of chemotherapy or 
six months later. Nonetheless, the group treated for BC experienced an increase in 
the percentage of FM and a reduction of FFM.  
This phenomenon of gaining FM and losing FFM is consistent with sarcopenia 
(Demark-Wahnefried et al. 2001), and has been reported by several other small 
studies (Cheney et al. 1997; Demark-Wahnefried et al. 1997a; Demark-Wahnefried 
et al. 2001; Freedman et al. 2004; Harvie et al. 2004; Nissen et al. 2011). 
Nonetheless, gains in lean body mass have also been reported (Del Rio et al. 2002; 
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Genton et al. 2006). Villasenor et al. (2012) explored the prevalence of sarcopenia, 
assessed by lean mass in arms and legs relative to height, and the association with 
overall and BC cancer-specific mortality in 471 participants in the HEAL study. 
Results indicated that 16 % of the sample were sarcopenic, and 38 % of these women 
with sarcopenia were classified as obese (total body fat percentage ≥38 %) and 62 % 
as not obese (<38 %).   
The repercussions of abnormal levels of FM or FFM are described later in the 
chapter. 
 
1.4.5 Metabolic status after breast cancer diagnosis 
Post-diagnosis changes in weight and body fat levels can predispose women to 
develop chronic illnesses commonly associated with obesity such as diabetes or 
cardiovascular disease (Vagenas et al. 2015).  
At the planning stages of this study, little data was available on the metabolic status 
of women treated for BC. In 2009, Makari-Judson et al. published data on body 
weight, waist and circumferences, insulin and glucose levels in a sample of 95 
women diagnosed with BC. Measurements were collected before adjuvant therapy, 
and at six and 12 months later. At six months, waist measurement and waist to hip 
ratio were unchanged. However, the Homeostasis Model Assessment (HOMA) of 
insulin resistance (IR) (HOMA IR) and glucose/insulin ratio tended to increase 
(p=0.06 and p=0.05 respectively) across the sample. A cross-sectional study with 
data collected a mean of 44.8 months post BC diagnosis showed that glucose, insulin 
and glycoslyated haemoglobin levels were all at the upper end of the normal range 
(Thomson et al. 2009). Worth noting, all participants (n=42) were overweight (BMI 
more than 24.9 kg/m
2
). Two further studies were also published that year looking at 
the effect of BC treatments on glucose levels and on IR. A local study carried out by 
Hickish et al. (2009) measured changes in blood glucose levels with each cycle of 
chemotherapy in 39 non-diabetic women diagnosed with BC. Glucose levels 
increased as the chemotherapy cycles progressed, and an increasing number of 
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participants developed degrees of glucose intolerance. Results from paired t-tests 
showed statistically significant increases in blood glucose levels with later cycles 
among women who received the higher dose of dexamethasone in combination with 
docetaxel (cycle 5: p < .001 and cycle 6: p =0.002). Later on, in 2012, Erickson et al. 
analysed data from the WHEL study examining the association between weight 
change (from around one year pre-diagnosis to two years post-diagnosis) and 
incident diabetes over six year follow up, in BC survivors (n =1,617). Higher BMI 
was statistically significantly associated with incident diabetes (p ≤ 0.05). Overall, 
43.8% of women had stable weight post-diagnosis (± 5% of baseline weight), 23.5% 
of the sample gained more than 10% of baseline weight, 19.1% of participants had a 
moderate weight gain, and 13.6% of participants lost more than 10% of baseline 
weight. Both weight loss and major weight gain increased the risk of incident 
diabetes compared to stable weight (p <0.05 for both). A plausible explanation for 
the association found regarding weight loss and diabetes was that participants in that 
category had the highest pre-diagnosis weight (mean BMI= 27.1, SD =5.3 kg/m
2
) 
and returned to that weight by the year six follow-up visit. Finally, in the previously 
cited cohort study published by Arpino and colleagues (2015), there were no 
statistically significant changes in glucose and insulin levels over a median follow-
up of 14 months, despite the observed increases in body weight and waist 
circumference levels described earlier on.  
 
1.5 The negative effects of weight change, high adiposity levels and 
abnormal metabolic status after breast cancer diagnosis  
Current evidence suggests that changes in body weight, or FM and FFM levels post 
BC diagnosis might not benefit women. Slight changes in weight post-diagnosis 
might not be problematic. However a large magnitude of weight change (in both 
directions) can have a negative impact on BC prognosis. For instance, each 5 kg/m
2
 
increment of BMI before 12 months post-diagnosis increased risk of all-cause 
mortality [RR: 1.08, 95% Confidence interval (CI): 1.01 to1.15] and BC specific 
mortality (RR: 1.29, 95% CI: 0.97 to 1.72) (Chan et al. 2014). Caan et al. (2012b) 
found that the risk of death was only associated with substantial weight gain (more 
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than 10% of baseline weight, mean + 10.5 kg) during the first two years of diagnosis. 
Kroenke et al. (2005) also found an adverse prognosis among non-smoking women 
who gained a mean of 6.6 lb (around 3 kg) within the first three years post-diagnosis 
[risk ratio (RR) of all cause mortality: 1.59, 95% CI: 1.07 to 2.51 and RR of BC 
recurrence: 1.53, 95% CI: 1.04 to 2.24]. Weight gains of 5% after BC diagnosis have 
also been associated with worse physical functioning (Imayama et al. 2013).  
Similarly, large weight losses (more than 10% of the baseline weight) occurring by 
two years post BC diagnosis have been associated with increased risk of all cause 
mortality among women who ever smoked [hazard ratio (HR): 1.58, 95% CI: 1.20 to 
2.09], among underweight women with no comorbidities (HR: 2.16, 95% CI: 1.25 to 
3.75), and among overweight/obese women with comorbidities (HR: 1.89, 95% CI: 
1.25 to 3.75) (Caan et al. 2012b). Weight losses of smaller magnitude might be also 
negative for health. In Caan and colleagues‘ study (2012b), a moderate weight loss 
of 5 to 10% (mean: - 4.9 kg) in normo-weight (BMI: 18.5-24.9kg/m
2
) women was 
associated with an increased risk of all cause mortality. The association was not 
found among overweight women (BMI more than 24.9 kg/m
2
). A previous study 
found that women who lost more than 1 kg by 18 months post-diagnosis had higher 
risk of all cause mortality (HR: 2.41, 95% CI: 1.62 to 3.58) and BC recurrence (HR: 
1.60, 95% CI: 1.03 to 2.48) (Chen et al. 2010). As Jackson et al. (2017) discusses, it 
is worth noting that the association between weight loss and mortality could have 
been the result of methodological limitations. Most studies did not control for 
tumour stage (so might have included participants with advanced stages of BC), nor 
for comorbidities. These might be confounding factors that could have biased the 
association found between weight loss and BC mortality. Interestingly, a further 
limitation found in most literature exploring the impact of weight changes post BC 
diagnosis is that they did not distinguish between intentional and disease-related 
(unintentional) weight loss. This is an important issue as research in non-cancer 
populations indicates that unintentional weight loss is associated with increased risk 
of mortality whereas intentional weight loss has an overall neutral effect on survival 
(Harrington et al. 2009). Moreover, weight loss in a healthy population leads to 
improvements in biomarkers that are plausibly linked with cancer-related outcomes 
(Jackson et al. 2017). Therefore, the fact that this finding contrasted with results 
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from those studies suggesting a detrimental effect of weight loss post BC diagnosis 
suggests that the weight loss observed among BC survivors in those studies was not 
intentional (Jackson et al. 2017). Consequently, more research is needed in the area. 
Although there is no agreed definition of clinically significant weight change (Paige 
et al. 2014), the figures above reported suggest that weight changes larger than 10% 
of the diagnosis weight, or weight gains of more than 3 kg could have clinical 
relevance. Nonetheless, smaller figures could also affect different subgroups of BC 
survivors (i.e. normo-weight women).  
In addition to the potentially harmful impact of large weight changes post-diagnosis, 
abundant literature has also underlined the link between high adiposity levels (as 
seen in obesity) at the time of BC diagnosis, and BC prognosis (Protani et al. 2010; 
Druesne-Pecollo et al. 2012; Niraula et al. 2012; Jain et al. 2013; Azrad and Demark-
Wahnefried 2014; Chan et al. 2014). A systematic review and meta-analysis of 82 
studies indicated that a pre-diagnosis BMI of more than 30.0 kg/m
2
 was associated 
with an increased risk of total mortality (RR: 1.41, 95% CI: 1.29 to 1.53) (Chan et al. 
2014). Nonetheless, whether obesity affects all biologic subtypes of BC, or whether 
there is a direct or indirect causal relationship between obesity and BC is unclear 
(Goodwin 2015b). 
Similarly, sarcopenia has been associated with higher risk of developing dose-
limiting toxicity in treatment of advanced BC and other cancers (Prado et al. 2009; 
Antoun et al. 2013). Data from the HEAL study revealed that sarcopenia was 
associated with an increased risk of overall mortality following BC after adjusting 
for adiposity (HR: 2.86, 95 % CI: 1.67 to 4.89), suggesting that sarcopenia could be 
an independent predictor of BC outcomes (Villasenor et al. 2012). 
Remaining weight stable post-diagnosis has been associated with the lowest risk of 
mortality, and hence, avoiding weight change appears to constitute the most 
favourable target for newly diagnosed BC patients (Caan et al. 2012b). Worth 
noting, in Caan‘s et al. (2012b) study, weight stable was defined as weight changes 
within 5% of the baseline weight. This recommendation is supported by the 
American Cancer Society, which advises patients to maintain and achieve a healthy 
44 
 
body weight during and after cancer treatment through diet and physical activity 
(Rock et al. 2012).  
The role of insulin in cancer is well documented. Being resistant to the actions of 
insulin has been described as one of the most significant metabolic disturbances in 
cancer (Hursting et al. 2007). Pre-diagnosis elevated fasting glucose has been 
associated with shorter overall survival after BC diagnosis (HR: 3.50, 95% CI: 1.87 
to 6.54) (Monzavi-Karbassi et al. 2016). Similarly, higher insulin levels and IR have 
been associated with adverse BC prognosis, even after adjusting for BMI and other 
prognosis factors (Goodwin et al. 2002; Borugian et al. 2004; Duggan et al. 2011; 
Goodwin et al. 2012). Women with fasting insulin in the highest versus (vs.) lowest 
quartile had a HR of 2.32 (95% CI, 1.39 to 3.86) for distant BC recurrence and a HR 
of 2.85 (95% CI: 1.48 to 5.50) for death after BC (Goodwin et al. 2012). And a 
systematic review and meta-analysis concluded that diabetic women diagnosed with 
BC have an increased risk of all-cause mortality post diagnosis (pooled HR: 1.49, 
95% CI: 1.35 to 1.65) (Kimberly et al. 2010). These findings suggest that insulin and 
glucose levels post BC diagnosis should be taken into consideration.  
 
1.6 Potential mechanisms explaining the association between weight change, 
obesity and insulin with breast cancer outcomes 
The link between obesity and BC outcomes might be non-causal due to numerous 
facts: First, it is possible that the diagnosis of BC occurs at more advanced stages in 
obese women. Second, less aggressive treatment might be given to obese patients. 
And third, obesity might affect the efficacy of hormone therapy (Goodwin 2015a). 
However, a biological plausible explanation might also exist. Physiological changes 
arising from a metabolically active adipose tissue can increase serum levels of 
insulin, oestrogens and other inflammatory substances both locally at the breast and 
systemically in the whole body (Goodwin 2015b). Insulin itself enhances aromatase 
activity and oestrogen production in the adipose tissue (Rose et al. 2015), and down-
regulates plasma concentrations of sex hormone binding globuline, resulting in an 
elevation of available bioactive oestrogens (Vance et al. 2011), which altogether, can 
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activate oestrogen, insulin and insulin growth factor (IGF) signalling pathways 
related to carcinogenesis, tumour progression, invasion and metastasis (Goodwin 
2015b). Supporting this plausible explanation, the previous section in this thesis has 
shown the growing body of literature providing evidence on the negative effect of 
high insulin levels on BC (Goodwin et al. 2002; Borugian et al. 2004; Duggan et al. 
2011; Goodwin et al. 2012), which is worrying as an increase in body weight and fat 
levels could rise baseline insulin levels (Makari-Judson et al. 2009).  
 
1.7 Conclusions 
BC has usually good prognosis; nonetheless, post-diagnosis weight change is a 
common phenomenon, which seems to be greater than for women in the general 
population. Changes in body weight, as well as the variations in body adiposity 
levels might be accompanied by metabolic disruptions (i.e. elevation of insulin and 
glucose levels). Increasing evidence is highlighting the fact that both positive and 
negative weight changes, as well as abnormal adiposity or high insulin and glucose 
levels could have a negative impact on BC prognosis, and could put women at risk 
of other comorbidities associated with obesity.  
Therefore, since weight change post-diagnosis remains an area of concern for 
clinicians as well as for patients, the main aim of this study is to explore the 
magnitude, the frequency and the trajectory of weight change following BC 
diagnosis. Furthermore, as the next chapter will show, there is a need to identify the 
factors involved in weight change post-diagnosis. This study will address that need 
by exploring the association between weight change and different factors that could 
potentially affect body weight. Finally, the study will also look at adiposity 
parameters and the metabolic status of participants, which is a relevant and relatively 
unexplored area.  
It is expected that the findings from this study will increase current knowledge of 
this undesirable weight change phenomena and of the metabolic status following BC 
diagnosis. Findings will also generate hypothesis to understand the biological 
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mechanisms underlying changes in body weight and in metabolic and adiposity 
parameters. Finally, the knowledge generated from this study may inform the 
development of weight management interventions that could potentially benefit 
women diagnosed with BC. 
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CHAPTER 2: LITERATURE REVIEW ON WEIGHT 
CHANGE AFTER BREAST CANCER DIAGNOSIS 
 
2 Introduction 
This chapter shows what is known and what still remains unclear about weight 
changes after BC diagnosis. It details the link between BC treatments and the 
potential mechanisms that could mediate their association with weight change post-
diagnosis. It also introduces two genes that could have an impact on body weight 
post BC diagnosis, an area that has only started to be explored. All this will precede 
the last section of the chapter: the statement of the aims of the study.   
 
2.1 Body weight regulation   
Body weight is the result of the difference between energy intake (derived from food 
intake) and energy expenditure (resulting from a combination of physical activity, 
resting metabolic rate and thermogenesis): when energy intake exceeds energy 
expenditure, fat accumulates increasing body weight. Conversely, a reduced energy 
intake accompanied by high energy expenditure would lead to weight loss (Flier and 
Maratos-Flier 2007).  
The observations that humans tend to keep a relatively constant level of body weight 
over prolonged periods of time, as well as the fact that body weight is likely to return 
to previous levels after marked increased or decreased of weight (i.e. after an illness 
or diet-induced weight loss), led to the idea that body weight is subject to regulation, 
what is known as energy homeostasis (Havel 2000). Nowadays, it is accepted that 
energy homeostasis is a complex process orchestrated by the hypothalamus and other 
parts of the brain; they process signals related to feeding, glucose and body fat status, 
and translate this information into short and long-term actions to regulate food intake 
and energy expenditure to keep body energy and fat levels within the desired range 
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(Flier and Maratos-Flier 2007). These signals emanate from organs like the adipose 
tissue, the gastro-intestinal system and the pancreas (Mayer 1955), and include 
peptides, which are released after nutrient ingestion, neuronal signals resulting from 
gastro-intestinal distension, metabolic signals reflecting the availability of glucose 
levels and fat stores, as well as adipose signals (i.e. insulin and leptin) (Schwartz et 
al. 1999; Dulloo 2005). The hypothalamus regulates anabolic pathways, which are 
activated when energy balance is negative, and as a consequence, food intake 
increases and energy expenditure decreases. It also regulates catabolic pathways, 
which are triggered when energy balance is positive, so they inhibit appetite and 
promote energy expenditure (Frank et al. 2014).   
ER-alpha are expressed in different regions of the brain involved in energy 
homeostasis, such as the ventral medial hypothalamus (VMH), the arcuate nucleus 
(ARC), the medial preoptic area (MPOA), or the paraventricular nuclei (PVN). A 
reduction in ER in the VMH can increase body weight gain and visceral fat 
deposition, and can reduce energy expenditure. Similarly, a decrease of oestrogen 
levels in the ARC can lead to an inhibition of a group of neurones that reduce food 
intake and increase energy expenditure (Frank et al. 2014). Oestrogens can also 
affect cholecystokinin receptors, a substance that increases satiation, and can also 
decrease the appetite-promoting effects of ghrelin and melanin-concentrating 
hormone. Furthermore, a reduction of oestrogen levels has been associated with an 
increase of IR (Lipscombe et al. 2012) and with a decrease sensitivity to leptin in the 
brain (Frank et al. 2014). Leptin is a substance that operates in different areas of the 
brain to regulate energy balance (Trayhurn and Beattie 2001). Alteration in leptin 
signalling can lead to leptin resistance, a primary risk factor for obesity (Su et al. 
2012). Leptin production can be also stimulated by insulin (Trayhurn and Beattie 
2001) and circulating glucose levels, increasing leptin‘s effects on appetite and 
energy expenditure (Su et al. 2012) Insulin signalling in the brain controls body 
weight and also regulates peripheral glucose and fat metabolism (Konner et al. 
2011). Insulin is therefore considered an adipose signal that promotes uptake and 
storage of glucose and lipid in the adipose tissue (Dullo 2005; Szablewsksi 2011). 
Activation of insulin receptors in the ARC, PVN and in the lateral hypothalamus 
decreases food intake and decreases body weight (Frank et al. 2014). In line with 
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that, the resistance to the actions of insulin, or IR, has been linked to weight gain, 
probably due to attenuation in the response to insulin in areas of the brain relevant to 
eating behaviours (Anthony et al. 2006). 
There are a number of factors that can also influence food intake and energy 
expenditure, and therefore, can determine body weight. These include behaviour (i.e. 
level of physical activity, diet,or smoking), psychological and socio-cultural aspects 
(i.e. availability and abundance of food, or meal patterns) (Jequier and Tappy 1999; 
Flier and Maratos-Flier 2000; Drewnowski and Bellisle 2003), as well as biological 
factors (genes, gender and age) or pharmacological agents (Institute of Medicine 
2004). Weight changes in adulthood seem to be common among the healthy 
population, and seem to be the consequence of changes in modifiable factors (i.e. 
food intake), as well as in changes in factors that individuals cannot control, for 
instance, the ageing process. The National Health and Nutrition Examination Survey 
found a gradual increase in body weight in early and middle adulthood (25 to 55 
years of age), whereas weight loses were common after that (Williamson et al. 
1990). The rationale for these weight changes is little understood, but it could 
involve reduced physical activity and a decrease in metabolically active tissues (i.e. 
skeletal muscle) (Institute of medicine 2004). Furthermore, a critical period in 
women‘s weight is the transition to menopause, which is commonly associated with 
weight gain and with a redistribution of body fat to the abdominal area, although it is 
not clear whether such changes are the result of a physiological reduction of sex 
steroids (oestrogen and progesterone), or due to the ageing process (Toth et al. 2000; 
Boonyaratanakornkit and Pateetin 2015). In addition to that, research has pointed to 
the importance of genetic and environmental factors, and their interaction, in 
determining body weight (Xi et al. 2012a). Studies conducted with pairs of 
monozygotic twins reared apart have shown that one-third of the variability in BMI 
is attributable to non-genetic factors and two-thirds to genetic factors (Galgani and 
Ravussin 2010). This indicates that some individuals have a genetic predisposition to 
obesity, which is particularly relevant in an environment where high-fat food is 
available at low cost, and where there is little need for physical activity (Galgani and 
Ravussin 2010).  
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The fat mass and obesity-associated gene (FTO) and a common polymorphism near 
the melanocortin-4 receptor (Mc4R) gene are two genes most robustly associated 
with common forms of obesity. In 2007, the FTO was identified as the first gene that 
contributes to common forms of obesity (Loos and Bouchard 2008). A study of 
38,759 Europeans identified a high-risk allele of the FTO gene. People homozygous 
for the high-risk single nucleotide polymorphism (SNP) rs9939609 A-allele of the 
FTO associated gene tended to weigh 3 kg more and had higher risk of obesity [odds 
Ratio (OR): 1.67, 95% CI: 1.47 to 1.89, p<0.001] compared to those homozygous for 
the low risk FTO T-allele (Frayling et al. 2007). Furthermore, this A-allele has also 
been associated with type-two diabetes (OR 1.13, p=4.5 × 10 (-8) (Frayling et al. 
2007; Hertel et al. 2011; Xi et al. 2012a). A year later, common genetic 
polymorphisms near the Mc4R were also associated with common forms of obesity 
(Loos et al. 2008). Each copy of the high risk rs17782313 C allele was associated 
with a difference in BMI of around 0.22 kg/m
2 
(Loos et al. 2008). A more recent 
meta-analysis confirmed the association between the rs17782313 polymorphism near 
the Mc4R gene with obesity (Xi et al. 2012a) and also with type-two diabetes (OR: 
1.10, 95% CI: 1.07 to 1.13, p=2.83 × 10 (-12) (Xi et al. 2012b).  
Little is known about the molecular bases of the relationship between these two 
genes and obesity (Olszewski et al. 2009, Xi et al. 2012a; Arrizabalaga et al. 2014). 
Nonetheless, evidence has suggested that both genes are highly expressed in the 
central nervous system which regulates the energy metabolism (Xi et al. 2012a). The 
FTO gene is expressed in hypothalamic sites related to hunger/satiation control, and 
low hypothalamic FTO levels have been associated with an increase in food intake 
but not with an increase in body weight (Olszewski et al. 2009). Consequently, FTO 
seems to control appetite and feeding behaviour, and also seems to reduce insulin 
secretion (Fan et al. 2015). In addition, evidence indicates that the FTO rs9939609 
polymorphism is associated with lower resting energy expenditure (REE), and with 
serum thyroid-stimulating hormone‘s levels, suggesting that the influence of FTO on 
the increased adiposity might be mediated by the endocrine system that depends on 
the hypothalamus, pituitary and thyroid gland (Arrizabalaga et al. 2014). On the 
other hand, the gene Mc4R seems to activate both satiety and hunger signals by 
integrating an anorexigenic (satiety) signal provided by the alpha-melanocyte-
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stimulating hormone and an orexigenic (hunger) signal provided by the agouti-
related peptide (Valette et al. 2013). The presence of the risky allele at rs17782313 
polymorphism might affect the leptin-melanocortin signalling system, whose 
downstream peptides bind to Mc4R and inhibit food intake (Valette et al. 2013). On 
the other hand, most evidence concludes that the Mc4R does not affect body 
adiposity through its effects on REE (Kring et al.2009; Arrizabalaga et al. 2014). 
Lesions in the hypothalamus can produce weight changes by disrupting the balance 
of appetite and metabolic rate (Flier and Maratos-Flier 2007). Hence, from a 
scientific point of view, it is logical to think that any interference of the neurological 
regulation of energy homeostasis or factors that produce metabolic/endocrine 
disturbances or behavioural changes could lead to weight following BC diagnosis.  
As pointed out in Chapter 1, although weight change is common among the general 
population, evidence suggests that the weight change observed among BC patients is 
larger than the weight change experienced by age-matched healthy controls. For 
instance, Gross‘ et al. (2015) study, BC survivors gained significantly more weight 
[β = + 3.06 pounds (lb), 95% CI: 0.94 to 5.17] than cancer-free women. Vagenas and 
colleagues (2015) found that 56% of BC patients gained weight (mean + 5.3 kg) 
between six and 72 months post- BC surgery, and nearly 80% of them experienced 
greater gains than the average weight gain seen in sex- and age-matched controls. 
 
2.2 Factors related to weight change after breast cancer diagnosis 
The interest in uncovering the factors that could explain weight changes after BC has 
a long history. Most of the research conducted on weight change after BC has looked 
at chemotherapy and less frequently at hormone therapy and at energy intake and 
expenditure. Only recently research has broadened its scope by looking at genes 
associated with obesity. The following lines summarise the results of these 
investigations. 
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2.2.1 Breast cancer treatments and their association with weight change after 
breast cancer diagnosis 
2.2.1.1 Hormone therapy and weight change post diagnosis 
In clinical practice, many women diagnosed with BC complain of gaining weight in 
the abdominal area, and they believe that is a consequence of using tamoxifen, a 
drug that blocks the actions of oestrogens in BC cells (Burstein 2011). This is a 
reasonable belief, as oestrogens can reduce food intake and ultimately body weight, 
possibly through its alpha receptor in the hypothalamus (Roesch 2006). 
Unfortunately, the effects of tamoxifen in the hypothalamus are still unknown 
(Aquino et al. 2016), and the biological mechanisms that could link tamoxifen with a 
potential weight changes post-diagnosis are not understood.  
Research conducted with women diagnosed with BC has provided inconsistent 
results on the association between weight change post-diagnosis and tamoxifen use. 
Several large cohort studies with long follow up have failed to provide empirical 
evidence to support the link between tamoxifen and significant weight gain post BC 
diagnosis (Rock et al. 1999; Irwin et al. 2005; Saquib et al. 2007; Gu et al. 2010; 
Chen et al. 2011; Arpino et al. 2015) (Table 1, Appendix I). For instance, the HEAL 
study did not find statistically significant associations between tamoxifen use and 
absolute changes in body fat and body weight from diagnosis to within three years 
after diagnosis, in a population of 514 breast cancer survivors (Irwin et al. 2005). 
Arguably, baseline measurements were taken within their first year after diagnosis 
(mean six months from diagnosis), and some weight change might have occurred 
prior that. Similarly, data from 2,972 BC survivors taking part in the WHEL study 
revealed that tamoxifen was not associated with significant weight gain (>5% of 
baseline weight) from a year prior BC diagnosis to two years post-diagnosis (OR= 
1.03, 95% CI: 0.71 to 1.51) and it did not modify the effect of chemotherapy use 
(OR= 1.65 vs. OR = 1.69) (Saquib et al. 2007). These findings support previous 
results from the same trial (Rock et al. 1999). On the other hand, data from a cohort 
of 445 women with newly diagnosed breast cancer showed that those who received 
tamoxifen had a mean weight change of + 1.26 kg (95% CI: 0.7 to 1.8) one year 
post-diagnosis, a magnitude larger than those who did not received adjuvant 
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treatment (+ 0.6 kg, 95% CI: 0.01 to 1.3). Nonetheless, chemotherapy users had the 
largest amount of weight change (+2.5 kg, 95% CI: 1.8 to 3.2), and multivariable 
analysis indicated that the onset of menopause and chemotherapy use, not tamoxifen, 
were independent predictors of weight change (all p<0 .05) (Goodwin et al. 1999). 
Results from the Chinese SBCSS cohort study with more than four thousand 
participants also failed to find a significant association between tamoxifen use and 
weight change (more than 2 kg weight change), from one year prior diagnosis to 18 
months post-diagnosis (Chen et al. 2011), or to six months post-diagnosis (Gu et al. 
2010). 
Conversely, findings from other studies did advocate for a possible role of hormone 
therapy in weight changes. A smaller study (n=50) conducted by McInness and 
Knobf (2001) suggested that women who took tamoxifen had a greater weight 
change than those who did not take tamoxifen from diagnosis to 12, 24 and 36 
months post-diagnosis, although the differences were not statistically significant 
(data not reported). Nonetheless, it is possible that they might have been with a 
larger sample size. A more recent study published by Heideman et al. (2009) with 
data from 271 women treated for BC followed for a median of three years post-
diagnosis showed a significant weight change, with an average change of + 2.4 kg. 
In that study, women treated with chemotherapy and hormone therapy experienced 
the greatest weight change (+ 4.7 kg, SD: 6.3 kg), whereas women who were treated 
with chemotherapy only had an overall change of +1.7 kg (SD: 5.1 kg), and those 
who received hormone therapy only (mainly tamoxifen) and those who did not 
received adjuvant treatment had a mean weight change of + 0.9 kg (SD: 5.0 kg and 
SD: 4.0 kg respectively). Combined adjuvant therapy was strongly related to larger 
weight change during longer follow up (Heideman et al. 2009). In addition, findings 
from the Nurses Health Study showed that women with the largest weight changes 
post BC diagnosis tended to be more likely to have received treatment with 
chemotherapy or tamoxifen (Kroenke et al. 2005). Similarly, Reddy and colleagues 
(2013) found larger weight change 18 months post-diagnosis among women who 
took tamoxifen, although the results were not statistically significant.  
A randomise control trial comparing women diagnosed with BC treated with 
tamoxifen with women diagnosed with BC without receiving tamoxifen could 
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provide stronger evidence on the impact of tamoxifen on weight change. 
Unfortunately, due to ethical implication of not treating BC patients with hormone 
treatment if it can benefit them makes it difficult to conduct a study with those 
characteristics. The closest data was presented by Sestak et al (2012). They reported 
data on weight change from three large clinical trials on endocrine therapy for the 
treatment of BC (ATAC study), or for the prevention of BC [International Breast 
Cancer Intervention Studies (IBIS-1 and 2)]. Participants in the ATAC were 
postmenopausal women with early BC randomly assigned to receive anastrozole 
alone (n=3092), tamoxifen alone (n=3094), or the combination (n=3097) for five 
years after surgery. The other two trials involved women without BC. In the first 
one, postmenopausal women without BC were randomly allocated to either five 
years of tamoxifen or matching placebo, and were followed up every six months 
during the five years of treatment (IBIS -1). In the second one, high risk 
postmenopausal women without BC  received either anastrozole or placebo for five 
years (IBIS-2). In the ATAC study, after 12 months of follow-up, the mean weight 
change was + 1.4 kg, and at 60 months there was a mean negative weight change (- 
0.35 kg). There were no significant changes in weight observed between 12 months 
and 60 months in either treatment arm. The IBIS-1 showed comparable weights at 
baseline, at 12 and at 60 months of follow-up between tamoxifen users and placebo 
users. In the IBIS-2 study, women in the anastrozole group had a mean weight 
change of + 0.8 kg (5.3) compared with a + 0.5 kg (7.3) weight change seen in the 
placebo group at 12 months of follow up. No statistically significant differences 
were found at any point between the groups (Sestak et al. 2012).  
The reasons for the discrepancy of the findings in the previous studies looking at 
tamoxifen are unclear. The percentage of participants that took tamoxifen in the 
studies varied considerably. For instance, in Heideman‘s et al. (2009) study and in 
McInness and Knobf‘s  (2001) study were 44.3% and 46% respectively, whereas in 
the studies conducted by Saquib et al.(2007),  and by in Goodwin‘s et al. (1999), the 
percentages were 67.3% and 82.9%. Furthermore, the approach used to analyse 
weight change in relation to tamoxifen use (and also to other factors of interest) 
might have also influenced the findings. Paige et al (2014) demonstrated that in a 
healthy sample of participants the association of weight change with different 
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variables (i.e. education, gender) varied when weight change was measured as the 
average of a continuous weight change vs. categories of weight change (weight gain, 
loss, maintenance). Moreover, the associations were also different when different 
cut-points for defining the categories of weight change were used. Therefore, Paige‘s 
and colleagues‘ (2014) findings could explain inconsistencies in the literature 
exploring the association of weight change with tamoxifen and other factors. 
Interestingly, although the studies exploring the association between tamoxifen and 
weight change present mixed results, several studies suggests that the effect of 
tamoxifen might be reflected in body adiposity. Cross-sectional data from 32 
postmenopausal women taking tamoxifen for BC for a mean of 30 months were 
compared with data from a convenience sample of 39 women without BC. Visceral 
adiposity levels measured with a computed tomography (CT) scan were statistically 
significantly higher among women taking tamoxifen (Nguyen et al. 2001). 
Nonetheless, causal relationship between tamoxifen and increased adiposity should 
not be concluded from this cross-sectional study, as it is possible that those with 
higher adiposity levels were more likely to have BC and therefore, were treated with 
tamoxifen. In fact, other observational studies did not find a similar association 
(Freedman et al. 2004; Irwin et al. 2005; Francini et al. 2006). Nonetheless, 
interventions conducted with BC survivors support a possible impact of tamoxifen 
on body fat. Nissen et al (2011) conducted a small trial to evaluate the effects of a 
physical activity intervention vs. bisphosphonate (a drug to prevent bone mass loss) 
on bone mineral density in women undergoing treatment for breast cancer. Findings 
showed that although tamoxifen use did not affect weight change, it was associated 
with higher body fat levels. Women who took tamoxifen following chemotherapy 
gained FM whereas those who took AINs or had no hormone therapy following 
chemotherapy did not. Nonetheless, the association vanished when other variables 
(i.e. BMI, age) were taken into account. Knobf et al. (2008) conducted a study to 
determine the feasibility of a one-group pre-post-test exercise intervention on bone 
mass, weight and body adiposity, in 26 midlife breast cancer survivors with early 
menopause. There were no significant changes in weight over the course of the 
intervention. However, there was an interaction effect for hormone therapy over time 
(p=0.04), and FM increased significantly more for women on tamoxifen (p=0.006) 
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and women on AINs (p=0.05) compared to women who were not on hormone 
therapy.  
Consistent with a potential role of hormone therapy, there is evidence that AINs can 
produce weight gain in mice (Kubatka et al. 2008a; Kubatka et al. 2008b; Sadlonova 
et al. 2009).  However, those findings have not been mirrored in women diagnosed 
with BC (Francini et al. 2006; Sestak et al. 2012).   
Given these inconclusive but inviting findings, it is clear that the role of hormone 
therapy deserves further investigation.  
 
2.2.1.2 Chemotherapy and weight change post-diagnosis 
Several studies have reported positive weight changes associated with chemotherapy 
use following BC diagnosis (i.e. Demark-Wahnefried et al. 1997; Aslani et al. 1999; 
Costa et al. 2002; Del Rio et al. 2002; Basaran et al. 2010). Unfortunately, they did 
not include a comparison group, making it difficult to ascertain whether other 
women who did not received adjuvant chemotherapy might have also experienced 
changes in weight. Nonetheless, data from the WHEL cohort study (Rock et al. 
1999; Saquib et al. 2007) and from other smaller studies (Demark-Wahnefried et al. 
2001; Makari-Judson et al. 2007; Heideman et al. 2009) that included a comparision 
group found a statistically significant association between chemotherapy and weight 
change. 
Weight changes have been observed during chemotherapy or in the first year of 
diagnosis (i.e. Camoriano et al. 1990; Goodwin et al. 1999; Demark-Wahnefried et 
al. 2001; Costa et al. 2002; Del Rio et al. 2002; Lankester et al. 2002), but also in the 
long term, as demonstrated for example by Caan et al. (2006), who found that almost 
two years post-diagnosis, women who received chemotherapy had an mean increase 
of 4.6% (SD: 10.0) of their initial weight, a magnitude that was higher than those 
who did not receive chemotherapy (+ 2.5%, SD: 9.5). Interestingly, data from the 
SBCSS showed that chemotherapy was associated with weight change 18 months 
post-diagnosis (Chen et al. 2011), but the association vanished in the long term (i.e. 
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36 months post-diagnosis) (Gu et al. 2011), suggesting that the effect of 
chemotherapy on body weight might not be sustained over time. Findings from a 
smaller study conducted by Makari-Judson and colleagues (2007) are in the same 
line. Chemotherapy use was associated with weight changes at 12 and 24 months 
post-diagnosis, however, chemotherapy was not a predictor of weight change from 
24 to 36 months post-diagnosis. 
Importantly, large cohort studies including the ATAC showed that chemotherapy use 
was not associated with weight changes (Irwin et al. 2005; Sestak et al. 2012; Reddy 
et al. 2013; Arpino et al. 2015). Results from the HEAL showed greater weight 
change (mean positive weight change) among women who received chemotherapy 
than women who did not receive systemic treatment. However, when adjusted for 
potential confounders (menopausal status and physical activity), average weight 
change was no longer associated with chemotherapy use (Irwin et al. 2005). It has 
been hypothesised that the lack of association in these recent studies could be due to 
the new chemotherapy regimens used, which tend to contain anthracycline agents, 
and seem to lead to lower amounts of weight gain (Rock et al. 1999; Saquib et al. 
2007; Makari-Judson et al. 2014). Arguably, other treatment characteristics (i.e. 
duration of chemotherapy treatment, or steroids use could influence the effect of 
chemotherapy on weight change, although some studies found that these factors did 
not have a significant effect (Lankester et al. 2002; Saquib et al. 2007; Makari-
Judson et al. 2014). Therefore, the effect of current chemotherapy regimens on 
weight change post-diagnosis requires further research. 
 
2.2.1.3 Potential mechanisms accounting for suspected treatment effects on 
weight change  
Potential mechanisms accountable for the hypothetical association between BC 
treatment and weight change post-diagnosis include endocrine changes due to 
treatment-induced menopause, as well as changes in energy intake (food intake) 
and/or decreases in energy expenditure (i.e. alterations in metabolic rate, 
thermogenesis or physical activity) (Demark-Wahnefried et al. 1993; Partridge et al. 
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2001; Vance et al. 2011). In addition, the liver and the muscle might be affected by 
chemotherapy drugs, leading to disruptions of glucose metabolism and IR (Makari-
Judson et al. 2014).  
 
2.2.1.3.1 Transition to menopause 
Many studies found that post-diagnosis weight gain appears to be more frequent 
among premenopausal women than among postmenopausal women (Camoriano et 
al. 1990; McInnes and Knobf 2001; Freedman et al. 2004; Caan et al. 2006, 2008; 
Heideman et al. 2009; Basaran et al. 2011; Chen et al. 2011; Caan et al. 2012b). 
Nonetheless, the opposite has also been reported (Cheney et al. 1997; Aslani et al. 
1999; Rock et al. 1999; Costa et al. 2002; Lankester et al. 2002; Megale et al. 2002; 
Irwin et al. 2005; Kroenke et al. 2005; Makari-Judson et al. 2007; Saquib et al. 2007; 
Gu et al. 2010; Tredan et al. 2010; Sestak et al. 2012; Reddy et al. 2013). 
Most premenopausal women experience chemotherapy-induced menopause (Vance 
et al. 2011). The transition to menopause is commonly associated with weight gain 
and with a body fat redistribution, possibly due to a physiological reduction of 
oestrogen and progesterone (Toth et al. 2000; Boonyaratanakornkit and Pateetin 
2015). A reduction of oestrogens can cause a decrease in insulin sensitivity and 
glucose metabolism, as well as a reduction in cellular metabolism and energy 
expenditure, which could promote weight gain (Boonyaratanakornkit and Pateetin 
2015). Nonetheless, this biological explanation has not been fully supported by 
empirical data in the context of this study. In Goodwin‘s et al. (1999) cohort study, 
535 women with BC underwent anthropometric measurements at baseline and one 
year later. Menopausal status at diagnosis (p=0.02) and change in menopausal status 
post-diagnosis (p=0.002) predicted weight change in univariable analysis. When 
other variables were included in the analysis, onset of menopause and chemotherapy 
use remained significant predictors of weight change post-diagnosis (all p<0.05). 
Nonetheless, other studies found no significant differences in the magnitude of 
weight change between those who had a treatment-induced amenorrhea and those 
who remained premenopausal (Camoriano et al. 1990; Lankester et al. 2002; Makari-
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Judson et al. 2007). Similarly, in other studies, menopausal status at the time of 
diagnosis was not associated with changes in body adiposity in women diagnosis 
with BC (Irwin et al. 2005; Arpino et al. 2005).  
Lack of consistent findings might be due to the different classification of menopausal 
status, or the different duration of transition to menopause and follow ups when 
weight changes were assessed. On the other hand, some studies have postulated that 
age, rather than menopausal status, is a more significant risk factor for weight 
change (Saquib et al. 2007; Gu et al. 2010; Sestak et al. 2012; Reddy et al. 2013; 
Makari-Judson et al. 2014). For instance, multivariable analysis from the SBCSS 
showed that menopausal status was not associated with weight change post-
diagnosis, however, age at diagnosis was associated with the positive weight change 
observed from diagnosis to 36 months post-diagnosis (all p<0.001) (Gu et al. 2010). 
Interestingly, age and menopausal status were both relevant in Irwin‘s et al. (2005) 
study: younger postmenopausal women (those aged 40-49 years) experienced the 
greatest weight changes [+5.2 kg, standard error (SE): 1.4], when compared with 
older postmenopausal women (+2.1 kg, SD: 0.4) (p for trend 0.002).                        
  
2.2.1.3.2 Insulin and glucose levels 
The role of insulin in glucose metabolism and body weight regulation has been 
described earlier. Alterations in insulin and glucose levels can contribute to weight 
gain and obesity (Su et al. 2012). In fact, metabolic abnormalities have been 
associated with alterations in REE (Merritt et al. 2010), which constitutes the largest 
component of energy expenditure (Guinan et al. 2013). Unfortunately, the research 
investigating the metabolic effects of BC treatments is very limited. Makari-Judson 
and her team (2009) investigated the relationship between markers of IR, BC 
treatments, and weight change in a prospective study of 95 women receiving 
adjuvant systemic treatment for BC. Mean weight change at six and at 12 months 
were + 0.4 kg (95% CI: 0.3 to 1.0, p=0.23) and + 0.9 kg (95% CI: 0.4 to 1.8, p=0.04) 
respectively. Six-months HOMA IR tended to increase by mean + 0.34 (p=0.34). 
Chemotherapy-treated patients exhibited adverse changes in HOMA-IR compared 
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with non-treated patients (mean change + 0.53 vs. -0.64, p=0.005). Conversely, 
hormone therapy, age or BMI were not associated with significant changes in 
HOMA IR (Makary-Judson et al. 2009).  
Further evidence exists showing that taxane-based chemotherapy to treat BC can 
raise insulin (Alacacioglu et al. 2016) and glucose levels (Hickish et al. 2009) and a 
population based study showed that BC survivors had an increased risk of diabetes 
(HR for chemotherapy users: 1.24, 95% CI: 1.12 to 1.38, and HR for non-
chemotherapy users: 1.11, 95% CI: 1.05 to 1.16) (Lipscombe et al. 2013). These 
findings support the hypothesis that chemotherapy drugs could affect the liver and 
the muscle, leading to disruptions of glucose metabolism and to IR (Makari-Judson 
et al. 2014), which potentially could explain weight change post-diagnosis (Makari-
Judson et al. 2007).  
Despite the fact that Makari-Judson et al. (2009) failed to find a relationship between 
hormone therapy and IR, findings from a case-control study with old BC survivors 
revealed that tamoxifen use was associated with an increased incidence of diabetes 
(Lipscombe et al. 2012). Furthermore, results from a randomise control trial with 
women at risk of BC exposed to either low-dose tamoxifen or fenretinide (a drug 
investigated for its potential use to treat cancer) showed that in overweight women, 
tamoxifen was associated with a reduced insulin sensitivity (Johansson et al. 2008). 
Finally a case-study described a patient who developed tamoxifen-induced severe 
hypertriglyceridemia and steatohepatitis, both of which are features of IR and 
glucose intolerance (Elisaf et al. 2000).  
The previous lines indicate that the literature on the impact of BC treatment on 
metabolic parameters is emerging. Similarly, the role of insulin or IR on BC 
treatment-related weight gain is unclear (Makari-Judson et al. 2009), and further 
research is needed to explore whether BC treatments affect insulin and glucose 
levels, as these might potentially explain weight change observed.  
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2.2.1.3.3 Energy intake and energy expenditure 
BC treatment-related side effects, such as fatigue, nausea and vomiting, and the 
demands of multiple treatment days, as well as psychological distress can all affect 
eating and physical activity behaviours, leading to weight changes post diagnosis 
(Kayl and Meyers 2006; Vance et al. 2011). Consequently, the effect of lifestyle on 
weight change post-diagnosis is an area of active research (Vance et al. 2011). Most 
evidence suggests that there are little or insignificant changes in food intake 
following BC diagnosis and these could not explain the reported magnitude of 
weight change (Nissen et al. 2011; Vance et al. 2011) or increases in FM (Goodwin 
et al. 1999; Kutynec et al. 1999; Demark-Wahnefried et al. 2001; Del Rio et al. 
2002; Harvie et al. 2004; Kumar et al. 2004; Wayne et al. 2004; Irwin et al. 2005; 
Francini et al. 2006; Genton et al. 2006).   
Similarly, the cohort study conducted by Goodwin et al. (1999) also found that 
physical activity levels could not explain weight change observed during the first 
year post-diagnosis. In their sample, physical activity levels (assessed as the number 
of hours devoted to mild, moderate and strong physical activity at work, at home, or 
during leisure activities), increased during the first year of diagnosis, particularly 
among women who received chemotherapy. This increase did not correlate with the 
weight change observed. Physical activity was self-reported and measured at 
baseline and one year later, and the authors recognised that an association of physical 
activity over the course of that year with weight change might have been missed. 
Conversely, results from the HEAL study found a statistically significant trend of 
increasing weight gain with decreasing hours of sports/recreational (i.e. walking) and 
household activities (i.e. gardening) per week, from baseline to within three years 
after diagnosis (p for trend: 0.03) (Irwin et al. 2003, 2005).  This finding is consistent 
with a report from the WHEL study stating that physical activity predicted weight 
stability in 1,116 BC survivors (Rock et al. 1999). Further small studies have 
provided additional evidence on the association between physical activity with 
weight and body fat gains following BC diagnosis (Demark-Wahnefried et al. 1997a; 
Kutynec et al. 1999; Demark-Wahnefried et al. 2001; Harvie et al. 2004; Genton et 
al. 2006; Broderick et al. 2014).   
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Other components of energy expenditure might also contribute to weight changes. 
Oestrogen withdrawal can reduce energy expenditure (Boonyaratanakornkit and 
Pateetin 2015). However, most studies found no significant changes in REE after BC 
diagnosis that could account for the increase of mean weight reported (Demark-
Wahnefried et al. 1997a; Kutynec et al. 1999; Demark-Wahnefried et al. 2001; 
Harvie et al. 2004). Only in Del Rio‘s et al. (2002) study, REE increased 
significantly as body weight increased, but chemotherapy use was not associated to 
that increase in REE, rather, the raised levels of REE were thought to be the result of 
the concomitant increase in FFM also observed. Consequently, changes in FFM 
might obscure the association between REE and weight gain. Measuring components 
of energy balance is difficult, and it is possible that a number of methodological 
issues in the previous studies (i.e. small sample, or timing of data collection) might 
have prevented authors to finding changes in eating and physical behaviours, or an 
association between them and weight change. Subjective methods of data collection 
could also result in systematic errors. Social desirability bias might lead to over-
reporting physical activity (Adams et al. 2005) or underreporting food intake 
(McNeill 2000).   
These lines suggest that further research with a large sample of women diagnosed 
with BC, and using adequate validated and reliable data collection instruments, could 
help to clarify the impact of those behaviours and REE on weight change post-
diagnosis. This could provide a clearer picture on their effect on weight change 
observed in this population. 
 
2.2.2 Genes associated with common forms of obesity and their effect on 
weight change after breast cancer diagnosis 
FTO and Mc4R, two genes associated with common forms of obesity, can determine 
the predisposition of individuals to gain weight (Loos et al. 2008). Hence, it is 
possible that these genes could play a role in weight changes post BC diagnosis. 
Reddy and colleagues reported for the first time data on the impact of genetic 
variables on weight change after BC diagnosis. At 18 months post-diagnosis 36% of 
the 459 participants had a BMI increase of more than 5kg/m
2
 from baseline and an 
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average weight change of + 5.1 kg (SD: 3.76kg). Weight change was best predicted 
by a model that incorporated age and BMI and diagnosis, as well as data on all 14 
SNPs explored from FTO and adiponectin genes which gave area under the receiver 
operating characteristic curve (AUC) value of 0.85 for 18-month weight gain. The 
model, as the authors argued, had a high discriminatory power to identify those at 
risk of weight gain post-diagnosis (Reddy et al. 2013). 
On the other hand, to the research knowledge, no study has explored the effect of 
Mc4R on weight change post BC.  
 
2.3 Summary and aims of the study  
The previous lines draw attention to the fact that despite considerable research being 
conducted, the causes of changes in weight and in body adiposity parameters (i.e. 
FM, waist circumference) post-diagnosis are not understood. Weight change patterns 
seem to be heterogenic across the population of women diagnosed with BC, as both 
weight gains and weight losses have been reported, whereas some women manage to 
maintain their body post BC diagnosis. In addition, it is not clear from previous 
research whether weight change is permanent or temporary or whether weight 
change fluctuates during BC treatment. Finally, also of concern, is the little research 
dedicated to explore the metabolic disturbances (i.e. changes in glucose and insulin 
metabolism) that might occur post-diagnosis. 
Therefore, the main aim of this study is to explore weight change following BC 
diagnosis and to identify factors associated to the change. A secondary aim is to 
determine body adiposity parameters and the metabolic status of BC survivors at the 
end of the follow up. 
In order to meet the first aim, the objectives of this longitudinal retrospective study 
are: 
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 To review participants‘ medical notes to collect data on weight from the time 
of the BC diagnosis to the end of follow up (the time they accepted to take 
part in this study).  
 Quantify the magnitude of weight change from diagnosis to different 
evaluation points after BC diagnosis (i.e. 12, 24, 36 and 48 months post-
diagnosis).   
 Quantify the frequency of weight change from diagnosis to those evaluation 
points.  
 Explore the association between the magnitude of weight change post-
diagnosis with: 
o Clinical factors: BC treatment and tumour characteristics.  
o Biological and behavioural factors: menopausal status at diagnosis, 
transition to menopause, age, genetic profile, weight at diagnosis and 
smoking status at diagnosis. 
 Create a model to describe patterns of weight change from the time of BC 
diagnosis to end of follow up that will: 
o Summarise how each participant‘s weight changes over time. 
o Identify groups of participants that experience different patterns of 
change. 
o Identify which of the following factors are associated with which 
patterns:  
 Clinical factors: BC treatment and tumour characteristics. 
 Biological and behavioural factors: menopausal status at 
diagnosis, transition to menopause, age, genetic profile, 
weight at diagnosis and smoking status at diagnosis. 
The specific objectives to meet the second aim of the study are:  
 To measure participants‘ body adiposity parameters (FM percentage, 
FM/FFM ratio and waist circumference) at study entry (end of follow up). 
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 To measure participants‘ metabolic parameters (levels of fasting glucose and 
fasting insulin) at the time of study entry.  
 To test the association between those body adiposity and metabolic 
parameters with: 
o Clinical factors: BC treatment and tumour characteristics. 
o Biological and behavioural factors: menopausal status at diagnosis, 
transition to menopause, age, genetic profile, weight at diagnosis, post-
diagnosis weight change and smoking status at diagnosis. 
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CHAPTER 3: RESEARCH METHODS 
 
3 Introduction 
This chapter explains the design of the study and the methods used to meet the 
study‘s aims described in Chapter 2. 
It starts with a description of the study design, a retrospective cohort study, 
explaining the adequacy of this kind of design to meet the research questions and its 
limitations. The chapter then introduces the target population and provides a 
rationale for the expected sample size chosen. The next section explains the 
participants‘ recruitment procedures, data collected from them and the instruments 
used in data collection. It follows with a description of the peculiarities of the 
dataset, providing useful information to understand the steps of data analysis. The 
last section of the chapter is devoted to ethical aspects taken into account when 
conducting this research. 
 
3.1 Study design, its advantages and limitations  
The main aim of this study was to explore weight change post BC and factors 
associated with it. The best approach to find a cause-effect relationship between two 
factors would be an experimental design, where the randomisation of participants to 
an intervention or to a control group is likely to prevent the introduction of 
confounding variables. Consequently, this would allow researchers to conclude that 
any change in the outcome can be attributed to the intervention (Black 1999). An 
experimental design like that was not appropriate to meet the aims of this study, as it 
would not have been ethical or possible to manipulate the variables under 
observation (i.e. BC treatment, menopause status, genes) to observe changes in the 
outcome (participants‘ weight following BC diagnosis). Therefore, a non-
experimental, longitudinal design constituted the best alternative to explore potential 
cause-effect relationship (Black 1999) when looking at weight change post-
diagnosis. More importantly, it could be used to observe patterns of weight change in 
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the target population (Singer and Willett, 2003), which was one of the aims of this 
study. Among the different types of observational longitudinal studies, a 
retrospective cohort study was adopted to guide this research project.  
 
3.1.1 Retrospective cohort study  
Retrospective cohort studies, as opposed to prospective cohort studies, are relatively 
quick to conduct and less costly, as both independent and outcome variables are 
already recorded (De Vaus 2001). In this project, data on weight (at diagnosis and 
during follow up) and other variables (i.e. BC treatment received) were documented 
in participants‘ medical notes as part of the routine care, prior to this research being 
planned. The only exception were weight at study entry and the metabolic and 
adiposity parameters, which were all measured by the researcher at study entry. Due 
to the limited time to conduct this research project, the fact that most weight records 
were already recorded in the medical notes was a very attractive and useful 
advantage. Other appealing attributes of retrospective cohort studies that were taken 
into account were firstly, its temporal dimension. It allows the observation of 
changes in the outcome over the time by collecting data at different follow up points. 
This temporal quality enables researchers to explore also different aspects of the 
outcome, including frequency of the outcome, when it occurs, whether it has a short 
or long term effect, or to observe patterns of occurrence (De Vaus 2001). Secondly, 
retrospective cohort studies also allow researchers to compare participants exposed 
to a predictor (independent variable) with an internal comparison group (a group of 
non-exposed participants from the same cohort without the predictor), in relation to 
the outcome under exploration, so as to observe the impact of different predictors on 
the outcome (i.e. differences in weight change between chemotherapy users vs. non-
chemotherapy users) (Boston University. School of Public Health 2015). Thirdly, it 
is also possible to observe the temporal order of exposures preceding outcome (De 
Vaus 2001). Temporality is an important feature when looking at factors that are 
associated with and could predict the outcome in the model to be created and is one 
of the criteria of causality proposed by Hill (1965). Nonetheless, it is important to 
acknowledge that with a retrospective cohort study, the researcher would not able to 
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probe a causal relationship between a factor and weight change, but only to get an 
idea of the association between the variables explored (De Vaus 2001). Nonetheless, 
with this design, it could be possible to observe the presence of other criteria 
suggested by Hill (1965) that would add support for a causal relationship, including 
the assessment of factors that could plausibly cause weight change, the strength or 
effect size of the association between those factors and weight change, or the 
consistency of findings with results from previous studies (Hill 1965). Finally, 
another advantage that was taken into account in the planning stages of this study 
was that retrospective cohort studies allow researchers to examine multiple outcomes 
(i.e. weight change, FM, insulin levels) potentially associated with an independent 
variable under examination (i.e. chemotherapy use) (Boston University. School of 
Public Health 2015). 
On the other hand, the fact that participants‘ weight (except the weight at study 
entry) and independent variables were already recorded in the medical notes as part 
of the routine care prior this study was conducted could pose some challenges: it 
may be detrimental to the internal validity of the study if the quality of data collected 
is poor (i.e. it might be inaccurate or collected with different degrees of precision). 
Moreover, different instruments might have been used to collect the same type of 
data, which might introduce measurement errors (De Vaus 2001). Nonetheless, the 
magnitude of these variations was assessed calculating the measurement error and 
the intra-class correlation (Peat et al. 2002). A further issue common in retrospective 
studies is missing data, as often data were collected in the past, outside the research 
context (Boston University. School of Public Health 2015). This study faced this 
problem as weight values were not always recorded, or were not always recorded at 
the same points following BC diagnosis (as explained later). Furthermore, in 
retrospective cohort studies it is important to account for the effect of other variables 
that could have an impact on the outcome (confounding variables). Once again, there 
is a chance that there was not accurate recorded information on confounding 
variables that could have been used in the research context (Boston University. 
School of Public Health 2015). These two issues were partly addressed with the data 
analysis approach proposed (see next section). 
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Finally, the validity of the results can be affected if the sample is not representative 
of the target population (De Vaus 2001). Due to the lack of randomised selection of 
the sample in this particular retrospective study, there was a risk of different types of 
bias, for example survival bias, as women who had died could not have been 
recruited into the study. Self-selection bias might be also present in this retrospective 
study if some subgroups of BC survivors were not interested in taking part in the 
study, for instance, women who gained weight could have been reluctant to agree 
take part in the study, or women who did not experienced weight change might have 
thought that their participation in a study looking at weight change was not relevant. 
These biases can lead to false conclusions because people with the outcome are 
overlooked and that can threaten the validity of the study (Lane et al. 2008). The way 
these biases were tackled in this study was by using different recruitment procedures: 
Firstly, trying to make target participants not feel ashamed by the weight gained. 
Secondly, by highlighting that it is a common event and that both weight changes 
and no weight changes are informative, and finally, by including women diagnosed 
as early as one year after BC diagnosis, so their chances of surviving that period 
were higher. In addition, the limitation imposed by lack of randomisation in relation 
to the effect of an independent variable on the outcome was overcome by collecting 
more independent variables and using multivariable analysis that accounted for the 
impact of these variables on the outcome. All these could help to improve the 
strength of evidence (De Vaus 2001).  
 
3.1.2 Cross-sectional data nested within the study 
Another aim of the study was to quantify body adiposity parameters (FM percentage, 
FFM/FM ratio and waist circumference) and metabolic parameters (insulin and 
glucose levels) at the time of study entry. These parameters are not measured 
routinely as part of the BC care, so they were measured only for the purpose of this 
research project, on one occasion only, at the time of study entry. Therefore, it was 
considered cross-sectional data (De Vaus 2001). As a consequence, it was not 
possible to analyse changes in these parameters following BC diagnosis. 
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Cross-sectional studies are also quick and cheap and allow researchers to describe 
the prevalence (not the incidence) of an outcome and explore associations with other 
variables that could be used to generate hypothesis about a causal relationship, rather 
than to test it (Centre for Evidence-Based Medicine 2014). 
 
3.2 Target population  
Weight change post-diagnosis has been particularly reported in women diagnosed 
with early stages of BC. As mentioned in Chapters 1 and 2, this group of patients 
have a good prognosis (Cancer Research UK 2014f), but unfortunately, it might be 
threatened by post-diagnosis weight changes (Caan et al. 2012b; Jackson et al. 
2017). Therefore, this study targeted women diagnosed with BC (stages I-III) 
(Cancer Research UK 2015), regardless of body weight at diagnosis or weight 
changes post-diagnosis. Participants were recruited from two main hospitals: Royal 
Bournemouth Hospital and Poole Hospital. They were diagnosed with BC from 2003 
up to a year before study entry. Women were not approached to enter the study if at 
the time of diagnosis: 
 Were under 18 years old, as the incidence of BC in that group of women is 
very low (Cancer Research UK 2014b) and all published research on this area 
included only women over 18 years old. 
 Had a history of BC recurrence, as their treatment for this recurrent BC could 
be different from that received by women diagnosed for the first time.  
Excluded were also women who at the time of diagnosis had health conditions that 
could have influenced body weight, such as: 
 Endocrine problems associated with the development of obesity. 
 Inflammatory bowel disease or malabsorption syndrome. 
 A history of invasive cancer other than completely resected non-melanoma 
skin cancer or successfully treated in situ carcinoma of the cervix. 
 Mental disorders directly related to food intake (i.e. anorexia and bulimia 
nervosa) (World Health Organization 2007). 
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Finally, following the Mental Capacity Act 2005 Code of Practice, (Department for 
Constitutional Affairs 2007), women who lacked the capacity to make informed 
decision, or were unable to take part in the study as a result of an impairment or a 
disturbance (i.e. dementia) defined according to the International Classification of 
Diseases (World Health Organization 2007) were also excluded. 
 
3.3 Sample size 
The sample size issue was considered from a variety of different angles, both 
practical (within the context of a PhD) and scientific. From a practical point of view, 
recruitment of women over a one-year period was achievable. Every year, a 
minimum of 500 women are followed up for early BC in Royal Bournemouth 
Hospital and in Poole Hospital. Assuming a recruitment rate of 50%, this meant it 
was likely that around 250 participants could be recruited into the study. 
To ascertain the magnitude of effect size that could be detected with this sample, a 
number of sample size/ power calculations were performed using nQuery Advisor 
(Statistical Solutions 2014), whilst looking at a variety of scenarios that are pertinent 
to the stated aims of the project.  
All the calculations conducted in this study and described in the following 
paragraphs assumed a two-tailed significance level of 0.05 (equivalent to 5%). Two-
tailed significance level is used in most research studies (Suresh and Chandrashekara 
2012). Under the null hypothesis that the mean is equal to x (i.e. no weight change), 
a two-tailed test will test both if the mean is significantly greater than x (i.e. weight 
gain) and if the mean significantly less than x (i.e. weight loss). Since there is 
evidence that weight post-diagnosis can either increase or decrease, or even no 
change, a two-tailed significance test was preferred over a one-tailed significance 
test, which only accounts for one scenario (i.e. weight gain).  
The statistical power was set up at 80%, which is appropriate for research studies 
(Martinez-Gonzalez 1998). The power represents the probability that the test 
performed will find a statistically significant difference between the two groups 
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compared, when there is a genuine difference in the population from where the 
samples were drawn. Increasing the power from 80% to 90% would reduce the 
probability of making a type-two error, but it will require increasing also the sample 
size by about 30%, something that could not be feasible due to time restrictions to 
conduct this research (Martinez-Gonzalez 1998). This could be a limitation for this 
study, as it is known that the bigger the sample size, the greater the power of the 
study to find smaller statistical differences. Nonetheless, attention should be given to 
the fact that despite smaller differences in weight change being statistically 
significant, they may not be clinically meaningful (Suresh and Chandrashekara 
2012). Therefore, the magnitude of the effect of interest, in this case weight change, 
will be reported.   
Standardised effect size is a scale-free measure that quantifies the magnitude of a 
difference in outcome between groups in relation to its SD. It emphasises the size of 
the effect of an independent variable, rather than the statistical significance of the 
effect (Coe 2002). Table 2 (Appendix I) summarises standardised effect sizes 
calculated from previous published research in the field, using the provided group‘s 
means, SD, or SE converted to SD and other relevant data. The calculations were 
assisted with nQuery Advisor (Statistical Solutions 2014).  Cohen‘s d, an effect size 
measurement used to indicate the standardised difference between two means, was 
calculated after applying this formula (Thalheimer and Cook 2002): 
d =
mean group 1 − mean group 2
pooled SD
 
 
Pooled SD was calculated as follow:  
     Pooled SD = √ [(nt – 1)SDt
2  
+ (nc – 1)SDc
2
]÷ (nt+ nc) 
 
Where n denotes the number of participants, or sample size, and the subscripts refer 
to each of the comparison groups.   
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If SD was not listed, SD was calculated from SE using this formula: 
                                   SD = SE √ n 
 
Using the calculations and the assumptions stated above, it was thought that with a 
sample of 250, this study would be powered to detect a minimum standardised effect 
size of 0.35 when using an independent sample t-test to compare mean weight 
change between two groups according to an independent variable (i.e. chemotherapy 
use). This assumed an equal sample size in each group compared. In this 
hypothetical scenario, the 0.35 standardised size effect would indicate that weight 
change (either weight gain or weight loss) of the average participant in the 
chemotherapy group would be higher than 64% of the participants in the non-
chemotherapy group (Coe 2002). 
A sample size of 250 could be adequate to find effect sizes of that magnitude when 
comparing mean weight change between two groups, which due to the aims of this 
study, was the most likely scenario to be faced when conducting data analysis (Table 
2, Appendix I). A high standardised effect size of 0.969 for the impact of 
chemotherapy was elicited from Makari-Judson‘s et al. (2007) modest study and a 
study with a much larger sample size (n=4561) found a standardised effect size of 
0.395 (Chen et al. 2011). Standardised effect sizes for tamoxifen on weight change 
were higher than 0.35 in Nissen‘s et al. (2011) study, however, in the rest of the 
studies looking at tamoxifen, the size of the effect ranged from -0.021 to 0.246. 
Finally, regarding menopausal status, several studies (Chen et al. 2011; Heideman et 
al. 2009; Makari-Judson et al. 2007) have provided evidence of standardised effect 
sizes higher than 0.35 (Table 2, Appendix I). 
In a second scenario, a sample size of 250 would allow researcher to detect a 
standardised effect size of that magnitude (0.35) when comparing the mean of an 
interval scaled independent variable (i.e. age or weight at diagnosis) between those 
whose weight changed (i.e. more than 5% of their weight at diagnosis) and those 
whose weight did not change. This would assume that 50% of women‘s weight 
would change and that the comparison would be made using the independent sample 
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t-test. In addition, it was expected that the study would be powered to detect a RR of 
weight change of 1.5 when comparing the proportion of participants that experience 
excessive weight change (i.e. changing more than 5% of their weight at diagnosis), 
between two groups (i.e. those who received chemotherapy and those who did not). 
This 1.5 RR would assume that the proportion of participants with the explored 
predictor would range between 0.3 to 0.6, and that between 58% to 64% of them 
experienced excessive weight change compared to 38% to 44% of participants 
without the predictor that also had their weight changed. Unfortunately, previous 
studies did not report effect sizes or enough data to calculate it, when weight change 
in their studies was treated as a dichotomous dependent variable. 
Finally, when looking at correlations between an interval scaled independent 
variable (i.e. age at diagnosis) and weight change measured in interval scale, it was 
expected that the study would have 80% power to detect correlation coefficient of 
0.16 and over. Table 2 (Appendix I) shows correlations of bigger magnitude (in 
absolute terms) for the effect of BMI on weight change (Makari-Judson et al. 2007). 
Nonetheless, correlations between age and weight change tended to be of a smaller 
magnitude (Goodwin et al. 1999; Makari-Judson et al. 2007). 
 
3.4 Research procedures 
3.4.1 Protocol amendments 
Recruitment and data collection started in August 2008 following the original 
protocol (approved in May 2008) and the successive first, second and third protocol 
amendments granted in October 2008, October 2009 and March 2011. The first 
protocol amendment sought to collect more outcome data (metabolic parameters and 
waist circumference) and to add new recruitment procedures. The second protocol 
amendment requested an extension of the recruitment period and due to that 
extension, a third protocol amendment was required to modify the definition of 
inclusion criteria to allow the recruitment of women diagnosed with breast cancer up 
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to one year before study entry (±2 months), rather than to December 2007, as 
previously specified. 
 
3.4.2 Participants’ recruitment  
Participants‘ recruitment was initially planned to commence in August 2008 and last 
twelve months. Recruitment of patients from Royal Bournemouth Hospital started as 
planned, however, recruitment in Poole Hospital started 10 months later. Due to this 
delay and the slow recruitment rate, the initial twelve months recruitment period was 
extended until June 2011.  
Initially, participants were given oral and written information about the study 
(Appendix VI) in the follow up clinics. Women treated for BC with chemotherapy 
are followed up yearly by the Oncology and Surgery team, whereas those who did 
not received chemotherapy are seen yearly by the Surgery team only. All women that 
potentially met the inclusion criteria and were seen in the BC follow up clinics in 
both hospitals were supposed to be invited to participate in the study by the clinician 
(oncologist, surgeon or nurse specialist). These women were previously identified by 
the researcher, so as to keep a record of the number of women seen and to facilitate 
the role of the clinicians in identifying candidates. The targeted women received oral 
information regarding the study and were handed an invitation envelope to take 
home which contained an information letter with further details about the study, the 
research procedures, relevant contact numbers, a consent form, a decline form and a 
return pre-paid envelope. Those who were interested in taking part in the study 
signed the consent form enclosed in the information letter and posted it to the 
researcher in the prepaid envelope. The researcher then contacted them to answer 
any possible questions, to verify that they were happy to take part in the study and to 
arrange a convenient date for data collection other than that collected from the 
medical notes. At arrival to the clinic for data collection, participants confirmed that 
they had signed the consent form and that they were happy to take part in the study.  
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In order to reach the target sample size quicker these new recruitment procedures 
were put in place: 
 By post: an invitation envelope was posted to women who met inclusion 
criteria but were not approached in the follow up clinics due to the fact they 
were already discharged from the BC follow ups clinics before starting the 
recruitment (August 2008), or because they attended the BC follow up clinics 
in Poole Hospital, from August 2008 to June 2009 (during the 10 months 
when women seen in the other hospital were recruited). 
 By hand: key cancer groups (i.e. Poole and Bournemouth Breast Cancer 
Support Group, or the Patient Partnership Panel), were contacted and were 
happy to give an invitation envelope to women who met the inclusion 
criteria.  
Finally, a reminder letter was sent to those women who had been invited to take part 
in the study and had not sent the consent or the deny form indicating whether they 
want to take part in the study. 
 
3.4.3 Data collection: variables, procedures and instruments 
Data collection took place in an office space that was located in the diabetes centre at 
Royal Bournemouth Hospital and in Poole Hospital. 
 
3.4.3.1 Outcome variables 
The main outcome was weight change. Therefore, any body weight recorded in the 
hospital medical notes at the time of BC diagnosis up to the study entry was 
collected. If weight at diagnosis was not available, weights available in the medical 
notes taken within two months prior BC diagnosis were included in the dataset. 
These weights taken from the medical notes could have been recorded during the BC 
follow up clinics, or by any staff in other departments or clinics at the hospital, that 
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the participant could have visited after being diagnosed with BC or near the time of 
diagnosis [i.e. cardiology reports, chemotherapy reports, et cetera (etc.)]. 
Three months after initial data collection, the first protocol amendment was approved 
and the following data were collected from the participants recruited from that date:  
 Metabolic parameters (fasting insulin and glucose) at study entry only.  
 Body adiposity parameters (FM, FM/FFM ratio and waist circumference), at 
study entry only. 
 
3.4.3.2 Independent variables 
Independent variables were retrieved from the hospital medical notes and also were 
self-reported in a brief interview conducted at the time of study entry which 
included:  
 Biographic and behavioural data: date of birth, nationality, education level, 
ethnic origin, number of biological children, smoking status and number of 
cigarettes per day at diagnosis. 
 Clinical data: height (at diagnosis and study entry), past and current medical 
history, menopausal status at diagnosis and at each year following diagnosis.  
 FTO and M4CR genetic profile at study entry only. 
 BC related data: diagnosis date, tumour characteristics, treatments received 
and dates of treatment‘s commencement and conclusion.  
Data collected from fasting participants were taken in the morning and participants 
were offered some breakfast after taking blood samples and measuring body 
adiposity parameters.  
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3.4.3.3 Procedures and instruments of data collection 
The instruments used for data collection for this study were blood samples, Tanita 
machine and a metric tape.  
Blood samples were collected to measure genetic profile and metabolic parameters.  
One sample was collected to measure genetic profile. A second sample was used to 
determine fasting insulin, and a third sample was taken to read fasting glucose levels. 
The samples were collected early morning, from fasting participants (nothing to eat 
or drink for at least eight hours before the test), from a vein in the arm. Samples were 
taken by qualified and experienced nurses working in the diabetes department and 
were taken to the hospital laboratory. In there, they were handed to the laboratory 
team for the immediate analysis of fasting glucose. 
Blood samples for genetic profile (FTO/Mc4R) were stored at -20 degrees Celsius 
(C), prior to deoxyribonucleic acid (DNA) extraction.  DNA was extracted using 
QIAamp DNA Blood Mini Kit and was stored at -70C until further analysis. The two 
SNPs genotyped (FTO associated SNP rs9939609 and Mc4R associated SNP 
rs17782313) were selected based on their significant associations with obesity 
(Frayling et al. 2007; Freathy et al. 2008; Loos and Bouchard 2008; Loos et al. 
2008). The genotyping of the two SNPs was performed using pyrosequencing with 
the QiagenPyroMark Q24 pyrosequencer using pyromark gold reagents. Results 
were automatically called using the proprietary software supplied with the analyser. 
All assays were performed in duplicate in a single run and where results were 
discordant/ambiguous the analysis was repeated in a separate run. 
Fasting insulin were spun in the centrifuges at the hospital laboratories, at 4000 
revolutions per minute for 10 minutes to obtain the serum, which was then stored at  
-40C until analysis. The samples were measured by automated chemiluminescence 
immunoassay. For insulin, the Siemens Immulite assay (Siemens Immulite assay kit, 
on a Siemens Immulite immunoassay analyser) was used. All analysis and 
calculation of results were automated. The lowest level that could be detected for 
insulin levels was 13.89 picomole per litre (pmol/l). The HOMA insulin sensitivity 
(HOMA IS) and HOMA IR were calculated using the HOMA Calculator developed 
by the Diabetes Trials Unit at the University of Oxford (Diabetes Trials Unit 2013). 
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On the other hand, glucose levels were determined using the standard protocol used 
in the hospital where the sample was drawn. 
Body weight at study entry and FM and FFM levels were measured using an eight 
polar Electrodes Tanita BC-418MA Segmental Body Composition Analyser. The 
Tanita is a machine that measures body fat percentage, FM, FFM, total body water 
and predicted muscle mass on the basis of data obtained by Dual Energy X-ray 
Absorptiometry (DXA) using Bioelectrical Impedance Analysis (BIA) and 
information on current weight, height, age and impedance. The Tanita was graduated 
to 0.1 kg (Tanita Corportation 2014). The performance of the Tanita has been 
compared to other impedance systems (i.e. Bodystat) and it has been demonstrated to 
be an accurate (Jebb et al. 2000) and reliable method to measure body fat (Tanita 
Corportation 2014). Participants were asked to stand in the machine with bare feet 
onto two contact electrodes and to hold a pair of handgrips. Participants were asked 
to remove heavy clothes and to empty their urinary bladder before the measurement. 
The measurements were taken in less than 30 seconds. 
Finally, a metric tape was used to record height and waist circumference. Height was 
measured by participants standing with bare feet against a wall. The measure 
contained one decimal. A waist circumference record had two decimals and was 
measured in centimetres (cm). Its value was obtained from the measure at the 
approximate midpoint between the lower margin of the last palpable rib and the top 
of the iliac crest, as recommended by the World Health Organization (World Health 
Organization 2008b), which also advised on other aspects when taking the 
measurement (i.e. participants‘ posture, respiration phase, or fasting state). There are 
difference protocols regarding the place of the tape when measuring waist 
circumference, i.e. using umbilical level or the minimal waist level. At the time of 
setting up this research protocol, the effects of the different methods of measurement 
used on measurement error or the prediction of abdominal fat had not been explored 
(World Health Organization 2008a), however, a systematic review concluded that 
the method of measuring waist circumference does not affect substantially the 
association between waist circumference values and health outcomes (i.e. mortality, 
risk of diabetes) (Ross et al. 2008). 
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With the emphasis lying on reducing the chances of measurement error, initially data 
collection was exclusively performed by the researcher. Nonetheless, as the study 
went on, a nurse researcher joined data collection and in order to reduce the 
likelihood of errors occurring and to preserve the integrity of the research, she 
received training and instructions on the correct use of instruments used.  
The researcher entered all data collected onto a spread sheet in the same program 
used to analyse data: the International Business Machines (IBM) Statistical Package 
for the Social Sciences (SPSS) Statistics 20 computer software. Researcher also 
performed a data cleaning process: data entries were reviewed twice to verify that 
there were not entry errors (i.e. unusually large or small body weight value, unusual 
menopausal status for a giving age, etc.) or missing data (i.e. missing weight, or 
missing information about treatment received, or treatment dates, tumour 
characteristics, etc.). In the event of suspicious or missing data, the researcher 
reviewed the medical notes for an answer, and if the issue was unresolved, she 
contacted the participant (Web Center for Social Research Methods 2006).  
 
3.5 Definition of the variables 
Diagnosis date was defined as the date of the first histopathology or cytology report. 
For 236 participants (99.15%) of the sample, this report was available one month 
before BC surgery or the start of other BC treatments (mean 1.51 months, SD: 2.12).  
If date of the first histopathology or cytology report was not available (n=24), the 
date used as diagnosis date was the date of the first surgery. If both dates were not 
available (n=1), diagnosis date was reported as missing in the dataset.  
The closest weight recorded around the BC diagnosis date was defined as weight at 
diagnosis. If there was no weight recorded within two months prior diagnosis and 
four months post-diagnosis date, weight value at diagnosis was considered missing. 
The definition of weight at diagnosis emerged after exploring the dataset and missing 
data (Appendix II), which showed that the window of margin chosen (± four months 
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post-diagnosis) decreased the number of participants with missing data for this 
variable. 
Menopausal status at diagnosis was retrieved from the medical notes and was 
corroborated by the participant. Menopausal status in the years following diagnosis 
was self-reported and when possible, contrasted with the information on the BC 
treatment received, as some treatments are not relevant for premenopausal women 
(i.e. AINs) or postmenopausal women (i.e. gonadorelin analogues).  
The guidance from the Faculty of Family Planning and Reproductive HealthCare 
(Faculty of Sexual & Reproductive Healthcare. Clinical Effectiveness Unit 2007) 
was used to assist classification of menopausal status when unsure, using age and 
menstrual cycle information, as these are the most useful factors to determine 
menopausal status (Faculty of Sexual & Reproductive Healthcare. Clinical 
Effectiveness Unit 2005). Accordingly, participants who fall into one of these 
conditions were considered postmenopausal:  
 Women 50 years old or older with no menstrual periods in the last 12 
months.  
 Women younger than 50 years with no menstrual period in the last 24 
months.  
 Women with bilateral oophorectomy. 
Furthermore, due to the fact that most women (95%) in the general population are 
menopausal by age 55 years and the perimenopausal period last for an average of 
five years (Faculty of Sexual & Reproductive Healthcare. Clinical Effectiveness Unit 
2005), participants with hysterectomy were also classified as postmenopausal if they 
were either: 
 Fifty-five years of age or older. 
 Less than 55 years old and were using HRT for more than five years. 
 Less than 55 years old and had symptoms of menopause for more than five 
years. 
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Participants were classified as premenopausal if:  
 They had a uterus and no changes in the menstrual cycles from previous 
years.  
 Women with hysterectomy, less than 55 years old, without HRT and without 
symptoms of menopause.  
Finally, participants were considered to be perimenopausal if they fell under one of 
these situations: 
 Younger than 55 years of age, who had a uterus and had experienced 
menstrual changes from previous years (i.e. period become irregular) and had 
at least one period in the past 12 months.  
 Women with hysterectomy who are either:  
o Less than 55 years old with less than five years use of HRT 
o Less than 55 years old, who have symptoms of menopause for less 
than five years.  
Participants who became either perimenopausal or postmenopausal in the interval 
between diagnosis to the evaluation point under examination were categorised as 
experiencing a change in menopausal status. Conversely, postmenopausal women at 
diagnosis and those pre or perimenopausal participants that did not experience any 
change in menopausal status were categorised as having no change in menopausal 
status. 
 
3.6 Features of the dataset 
The information described in this sub-section is useful to understand the terminology 
and the steps conducted for weight change modelling.  
Variables collected were organised in two formats. The first one, a ―person-level 
dataset‖ arrangement, was suitable to explore the magnitude and prevalence of 
weight change as well as to explore the body adiposity parameters and the metabolic 
status of BC participants. In this format, each participant had one record and multiple 
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variables: one for every weight record hold. This person-level dataset arrangement 
was then converted into a ―person-period dataset‖, a format in which each participant 
had multiple records, one for each time her weight was recorded. This person-period 
arrangement was most suitable for the modelling of weight change post-diagnosis. 
 
3.6.1 Outcome, metric of time and predictors 
The main outcome of the study was weight change, measured in kg. In order to 
quantify the frequency and magnitude of weight change post-diagnosis, weight was 
classified as weight at the time of BC diagnosis and weight post-diagnosis. Only the 
weights records at the desired evaluation points were used. On the other hand, all the 
weights available for each participant since the date of BC diagnosis to the study 
entry were used to model weight change. The metric of time used in the weight 
change modelling was months passed since BC diagnosis.  
The dataset contained time-varying and time-invariant predictors. Time-invariant 
predictors‘ value could not be changed during the follow up. Conversely, time-
varying predictors could take different values during the follow up.  
  
3.6.2 Follow up  
Follow up starting point was set up as the time of BC diagnosis and ended at the time 
of study entry. The length of follow up differed from one participant to another 
ranging from 10.25 months to a maximum of 91.17 months post-diagnosis. 
 
3.6.3 Waves of data collection and timing of weight measurement 
Another peculiarity of data was the total number of waves of data collection (the 
number of observations or weights records available for each participant). This 
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number varied across participants. Eight participants (3.3% of the sample) had only 
one wave of data collection and that was their weight measured by the researcher at 
the time of study entry. One participant had 43 weight records. Thirty nine 
participants (16.3%) had a second weight available and 27 participants (11.3%) had 
three weights recorded from diagnosis to the end of the follow up. The remaining 
165 participants (69.0%) have more weight records available since they were 
diagnosed with BC (Table 3, Appendix I). This number of weights recorded included 
those weights retrieved from the medical notes as well as the one weight taken as 
part of this research project at the time of study entry. 
The timing at which participants‘ weights were recorded varied within each 
participant and between participants. The total number of weights recorded across all 
participants was 2,172 (Table 3, Appendix I). Half of these weights were recorded 
during the first 12.5 months of diagnosis, there were 266 weights recorded during the 
second year, 219 weights recorded during the third year and so on. This indicated 
that the timing of the weights records was erratic. The different and decreasing 
number of weights records held by participants seemed to be related to the use of 
chemotherapy, as it is explained in Appendix II. 
 
3.6.4 Missing data 
The variation in the number of weight records across participants raised questions 
about the completeness of the dataset and the presence of missing weight values.  
Fourteen participants (5.9% of the available 239 participants) did not have weights 
recorded in the first 12 months post-diagnosis. In the second and third year post-
diagnosis, the proportion of participants with missing weights jumped to 44.5% and 
to 44.1% respectively. These figures highlighted the need to explore the reasons for 
the variations in the number of weight records across participants to assist decision 
making for data analysis. Could that variation represent missing records that were 
intended to be taken but were not? The following paragraphs answer that question 
and explain the potential mechanisms that led to the missing data, its impact and how 
missing data were dealt with during data analysis. 
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3.6.4.1 Are there missing data? Reasons for missing data 
Yes, there are missing data in this dataset. All participants should have had a weight 
record in their medical notes around the time of diagnosis, as following the clinical 
protocol, they should have been weighed before surgery. However, some participants 
had missing weight values at BC diagnosis. Conversely, there were no missing 
values at study entry, as this was the only planned measurement occasion in this 
study. 
A closer look at the dataset suggested that weight values might have been missing at 
any other point from the time of BC diagnosis to the end of the follow up. There 
were situations when it was obvious that a participant‘s weight was missing, for 
instance, if when reviewing the medical notes  the place allocated to write down 
patient‘s weight was empty (i.e. in the chemotherapy drug record or anaesthesiology 
record). This was easily observed among participants treated with chemotherapy 
(more details in Appendix II). Unfortunately, the researcher did not record 
information on whether the weight was missing or not. Conversely, among non-
chemotherapy-treated participants, the reduced number of weight records held was 
not considered missing data, as to the researcher‘s knowledge, this group of non-
treated participants were not meant to be weighed up routinely as per clinical 
protocol, hence, it was difficult to ascertain when a participant‘s weight failed to be 
recorded (Appendix II). 
 
3.6.4.2 Missingness mechanisms  
There were two possible reasons that could have led to missing weight values.  
Firstly, a weight value was actually recorded in the medical notes, but the researcher 
failed to retrieve it from there. Nonetheless, this was unlikely as the researcher 
reviewed the medical notes twice. Secondly, the weight value was not recorded in 
the medical notes, due to at least one or more of the following reasons: 1) the 
hospital staff forgot to weigh the patient attending the BC clinic or any other 
department, 2) the staff did weigh the patient, but forgot to record her weight in the 
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medical notes, and 3) a patient might have refused to be weighed. Nonetheless, this 
was highly unlikely as usually weight is a parameter used for clinical decisions (i.e. 
to adjust the doses of chemotherapy treatment or anaesthesia). Consequently, 
although missing values in this dataset appeared to be linked to chemotherapy use, 
which was one of the predictors under exploration, it was concluded that the 
missingness records was at random (MAR), which implied that the probability of a 
missing value did not depend on the unobserved weight value (Singer and Willett 
2003). 
Similarly, any missing secondary outcomes (body adiposity and metabolic 
parameters) were regarded as MAR. The measurements were taken at study entry. 
None of the participants refused to be weighed and have their body adiposity 
parameters measured, however, the metric tape was not available to measure four 
participants‘ waist circumference, and the Tanita machine did not provide all the 
requested readings in 24 participants, leading to missing data.  One participant did 
not want to have a blood test. The remaining 238 participants gave consent to have a 
blood test, although a number of different issues led to missing data: 1) the 
researcher failed to obtain a blood sample from four willing participants, 2) insulin 
levels could not be measured in seven haemolysed samples, 3) six blood samples 
were lost in the laboratory before any analysis was conducted on them, 4) fourteen 
samples were not stored properly and were lost, hence, some but not all the blood 
tests were conducted on them, and 5) there was insufficient funding to run the 
FTO/Mc4R tests on 96 samples. 
Worth noting, 55 participants were recruited before the first protocol amendment, 
therefore, data on metabolic parameters and waist circumference were not available 
for them.  
 
3.6.4.3 Dealing with missing data 
Exploring the presence of missing weight values was important as they could affect 
the parameter estimators (Graham 2009). A complete case analysis, a procedure that 
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excludes participants with missing data, was the approach used to explore weight 
change at particular evaluation points, as it could be a useful way to deal with 
missing data (Graham 2009). Sensitivity analysis conducted (Appendix III) showed 
the validity of using complete-case analysis for the results presented in Chapter 4. 
 
3.7 Data analysis 
Data analysis was conducted in two main parts, defined by the two aims of the study. 
The first part of the analysis explored weight change. The second part of data 
analysis focused on the analysis of the body adiposity and metabolic parameters 
collected at the time of study entry. Before these two parts, data were initially 
analysed descriptively to get familiar with the features of data, to present the 
biological, behavioural, clinical and other relevant characteristics of the participants 
and to determine whether or not any unusual or missing values existed. 
Weight change was explored from different angles and using different techniques 
that were considered more advantageous after taking into account the features of the 
dataset. The analysis started by looking at the magnitude of weight change between 
two evaluation points (i.e. from diagnosis to 12 months post-diagnosis, from 
diagnosis to 24 months post diagnosis, etc.). Most literature in the field explored 
weight change between two points. Therefore, this approach enhanced comparability 
with other studies, for instance with that of Makari-Judson and colleagues  (2007) 
who also used paired t-tests to explore weight changes at 12, 24 and 36 months post-
diagnosis.  
The analysis then examined the frequency of weight change. Body weight change 
was defined as using different categories according to the direction of the change 
(i.e. weight gain, weight loss, no change). The analysis looked at the frequency of 
participants within each category of weight change from diagnosis to a particular 
evaluation point (i.e. diagnosis to 12 months). That would inform the reader of the 
heterogeneity in the phenomena of weight change across the sample.  
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Finally, the last section of this analysis examined the trajectory of weight change 
using multilevel modelling. This is a very advantageous approach because as 
opposed to other repeated measures techniques such as repeated measurement 
ANOVA, it is a very flexible technique that could deal with the unplanned 
unbalanced design of this study, and is not affected by missing data to the same 
extent, which allowed the researcher to maximise all (or most of) the 2,172 weight 
records collected across participants (Singer and Willet 2003).  
All data analyses, including the multilevel modelling, were conducted with IBM 
SPSS Statistics 20 computer software.  
 
3.7.1 Exploring the magnitude and frequency of weight change after breast 
cancer diagnosis 
Weight change was analysed as difference in weight from diagnosis to each of the 
four evaluation points chosen: 12, 24, 36 and 48 months. Weight changes at 60, 72 
and 84 months were not analysed as the number of participants with weight measure 
available at those periods was small (n=39, 27 and 16 respectively). Magnitude of 
weight change and the frequency of weight change from diagnosis to the chosen 
evaluation points were both explored as absolute weight change (kg) as a continuous 
variable and also as relative to the diagnosis weight (%). This increased 
comparability with other studies in the field. 
The characteristics of the sample were summarised with means and SD for 
continuous variables and frequencies for categorical variables. Ninety-five percent 
CI were provided when exploring differences in the variable analysed. 
The magnitude of weight change was explored using the weight record closest to 
each specific evaluation point, within a window period of +/- four months. If there 
was no weight recorded at those desired points (+/- four months), weight at that 
particular point was considered missing. When there were two weights recorded on 
the same date, or equidistant from the desired month, the mean weight of those dates 
was used. The ± 4 months range was arbitrarily chosen and thought to be appropriate 
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as this period window raised the percentage of participants with weight available at 
diagnosis and at 12 months, 24 months, 36 and 48 months post-diagnosis (Appendix 
II).The magnitude of weight change at those evaluation points was calculated as the 
difference between weight at each evaluation-point and the weight at BC diagnosis.  
 
3.7.1.1 Analysis on the magnitude of weight change at 12, 24, 36 and 48 months 
post breast cancer diagnosis and factors related to it 
Paired t-tests were used to assess whether weight change from diagnosis to each of 
the defined evaluation points (12, 24, 36 and 48 months post-diagnosis) was 
statistically significantly different from zero. Paired t-tests offered researcher a good 
initial look at the data before taking a more sophisticated approach to exploring 
weight change (i.e. using multilevel modelling analysis). Due to the presence of 
missing data, paired t-tests were preferred over other techniques that used list wise 
deletion (i.e. repeated measured ANOVA), as it allowed researcher to maximise the 
amount of participants included in the analysis. Furthermore, the use of paired t-tests 
was considered a reasonable choice as the sample sizes in each of the periods 
explored were larger than 50 and because this robust test could handle moderate 
departures from normality, such as the small one observed in weight change 
distribution (Appendix III) (Lund and Lund 2013). This small departure of normality 
suggested that the analysis of weight change should be conducted using distribution-
free non-parametric tests. Unfortunately, non-parametric tests are less powerful 
compared to parametric tests, and therefore, they require a larger sample size to 
detect statistically significant differences. They also require that data from all groups 
to be compared in the analysis have the same dispersion. Conversely, parametric 
tests can deal with groups that have non-equal variances (Frost 2015). Most studies 
in the field have commonly used a parametric approach to explore weight change 
post-diagnosis. Parametric tests can work well with continuous variables that are 
non-normally distributed if the sample sizes are larger than 15 (Frost 2015), as it is 
the case of most of the analysis conducted in this study. Therefore, a parametric 
approach was used to analyse participants‘ weight change. Nonetheless, in order to 
verify the soundness of this decision, a sensitivity analysis was conducted and 
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weight change analysis was repeated using non-parametric tests (Appendix III). 
Furthermore, a sensitivity analysis was also conducted to explore the presence of 
outliers. Outliers were identified visually with boxplots (or scatter/dots for numerical 
variables). As routinely performed by the SPSS software used to analyse data, any 
value departing 1.5 or 3 box-lengths from the edge of the box was classified as 
outliers and was illustrated as a circular dot and as an asterisk respectively (Lund and 
Lund 2013). The outliers were dealt with according to the nature of the error: Data 
entry errors were corrected and the genuinely unusual values were not considered 
invalid and therefore, were initially included in the analysis (Lund and Lund 2013). 
In order to assess the impact of the outliers, the weight change analysis was 
conducted with and without outliers, as they can affect significantly the results of the 
parametric tests (Frost 2015). The results of the parametric tests were similar to the 
results of the non-parametric analyses, and the results of the tests conducted with 
outliers were comparable to the results conducted without outliers (Appendix III). 
Therefore, it was considered that both the use of parametric test and the inclusion of 
the outliers within the main analysis of weight change were decisions 
methodologically valid (Lund and Lund 2013a; Frost 2015). Weight change will be 
summarised with means and SD, as the visual inspection of the histograms of weight 
change suggested that the departure from normality was small (Figure 4, Appendix 
III).  
Parametric independent sample t-tests were used to test the association of weight 
change with biological (i.e. menopausal status, genes) and clinical factors (i.e. BC 
treatment). As many studies in the field, and according to the aims of the study, 
weight change was analysed as a continuous variable and was measured in absolute 
terms (kg).  
When exploring weight change in relation to BC treatment, participants were 
classified into one of the comparison groups (received treatment vs. not-received 
treatment) if they had been treated with the inspected treatment at any time from BC 
diagnosis to the evaluation point explored. As an example, if a participant started the 
treatment at 30 months post-diagnosis, she was included in the non-treatment group 
for the analysis of weight change at 12 and 24 months post-diagnosis and shifted to 
the treatment group for the analysis of weight change beyond 30 months (i.e. at 36 
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and 48 months post-diagnosis), as at those point, she had been or was being treated 
with that particular treatment.  
When looking at the association between weight change post BC diagnosis and 
menopausal status at diagnosis, premenopausal and perimenopausal participants 
were grouped together because the sample size of the premenopausal and 
perimenopausal groups in each of the period explored was small (Table  4, Appendix 
I). Change in menopausal status was updated for the analysis of weight change at 
each of the evaluation point explored and participants were grouped accordingly, as 
occurred in the analysis of weight change in relation to treatment. 
Due to small sample sizes in one of the three categories of the FTO and Mc4R genes 
(Table 5, Appendix I), the genetic variables were transformed into dichotonomous.  
The new categories were based on the presence vs. not presence of the risk allele A 
for the FTO gene and C for the Mc4R gene.  
The Pearson‘s product moment correlation test was used to assess the association 
between weight change at 12, 24, 36 and 48 months post-diagnosis with the 
following covariates: weight at diagnosis, age at diagnosis and invasive tumour size.  
One-way analysis of the variance (ANOVA) was used to explore stage of disease 
and weight change. Finally, smoking status at diagnosis and its impact of weight 
change post-diagnosis was analysed using independent sample t-tests.  
Standard multiple linear regressions were conducted to look at the combined effect 
of two or more predictors of weight change at each particular evaluation point (12, 
24, 36 and 48 months post-diagnosis). The variables of interest tested in the model 
were those mentioned in the aims of the study (Chapter 2): Clinical factors (BC 
treatments and tumour characteristics), biological and behavioural factors 
(menopausal status at diagnosis, transition to menopause, genetic profile, age, 
smoking status at diagnosis). All the variables were included into the models fitted. 
New models were created removing and adding new variables. Variables whose 
estimated coefficients were not statistically significant were removed from the 
analysis. The assumptions of homoscedasticity, linearity, independence of residuals, 
multicollinearity, normality of the residuals and the presence of unusual values of the 
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final model were assessed (data not shown) (Lund and Lund 2016). A scatter/dot plot 
of the studentized residuals and the unstandardised predicted values was used to 
check the assumption of linearity between the outcome and independent variables 
collectively, as well as the assumption of homoscedasticity. The linear relationship 
between the outcome and each independent variable was also analysed visual using 
partial regression plots. Independence of residuals was assessed using the Durbin-
Watson statistic. A value close to 2 indicated that residuals were not correlated 
(Lund and Lund 2016). The presence of outliers was examined looking at the 
studentized deleted residuals (greater than ± 3 SD). The leverage score for each case 
was also inspected and those cases with high leverage value (more than 0.5) were 
considered unusual values. Finally, cases were considered influential points, and 
therefore unusual values, if the Cook's Distance values were above 1.0. A repeated 
analysis was conducted without the unusual values identified and it is detailed in 
Chapter 4, and in Appendix III (Lund and Lund 2016). The assumption of normality 
of the residuals was checked with a Normal Q-Q Plot of the studentized residuals 
(Lund and Lund 2016). Finally, multicollinearity between the variables included in 
each model fitted was assessed with an inspection of correlation coefficients and 
tolerance values provided by the software (Lund and Lund 2016).  
Menopausal status at diagnosis and change in menopausal status post-diagnosis were 
correlated. Therefore, a new variable combining these two variables was created, 
with three categories: 1) pre and perimenopausal at diagnosis and change post-
diagnosis, 2) remained pre or perimenopausal and 3) remained postmenopausal. The 
variable was updated at each evaluation point explored (12, 24, 36 and 48). This new 
variable created representing menopausal status was also correlated with age at 
diagnosis. The researcher decided to include age at diagnosis in the multiple 
regression analysis, and to excluded menopausal status. The rationale behind that 
decision was that menopausal status is a criterion to determine the use of AINs and 
gonadorelin analogues to treat BC, therefore, menopausal status could be predicted 
from these two treatments. Hence, age, as well as AINs and gonadorelin analogues 
use were included in the analysis, as the correlation between these two BC 
treatments and other variables in the models were below 0.7, and their tolerance 
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values were greater than 0.1, confirming that there were no collinearity issues with 
those variables.  
Adjusted coefficient of determination (R
2
) was used to evaluate the proportion of the 
variance in weight change explained by the models fitted. The adjusted R
2 
and the p-
value of the model were also used as criterion to evaluate the goodness of fit of the 
model and to choose the final model.  
The final model will be presented with the unstandardised coefficients, 95% CI and 
their associated p-values. Included also will be the multiple Pearson‘s correlation 
coefficient (R), the ANOVA coefficients [regression‘ degrees of freedom (d.f.), the 
residuals‘ d.f. and the value of the F-statistics]. The statistical significance of the 
model will be also provided.  
In the event that multiple linear regression showed that only one predictor was 
significant for a particular outcome, a simple linear regression was conducted 
provided that the outcome and the independent variable were linearly related. The 
assumptions of independence of observations, no outliers, homoscedasticity and 
normality of residuals were also assessed (Lund and Lund 2016). 
A repeated analysis of the multiple regression was also conducted if the assumptions 
of the multiple regression analysis were not met (Appendix III). The repeated 
analysis indicated that the use of the multiple regression tests for the analysis 
presented in Chapter 4 was methodologically sound, except where stated.  
 
3.7.1.2 Analysis of the frequency of weight change at 12, 24, 36 and 48 months 
post breast cancer diagnosis 
The frequency of weight change was presented in absolute terms. Weight change 
was defined in three different ways, using different cut-offs. Firstly, weight change 
was defined as changes larger than 0.0 kg. Secondly, weight change was defined, as 
changes larger than 2.0 kg. Within this later classification, weight change was further 
sub-categorised as weight gain and as weight loss, and each sub-categories had 
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different groups (i.e. change of 2.1 to 5.0 kg, change of 5.1 to 10.0 kg and change 
larger than 10.1 kg).  Finally, weight change was also explored using a relative cut-
off: 0% of the weight at diagnosis. This was calculated as the percentage of weight 
change relative to weight at diagnosis:   
(Weight at a particular evaluation point – weight at diagnosis) x100 / weight  
at diagnosis 
 
The relative weight change category was divided in three sub-categories: lost weight 
(more than 0.0% of their weight at diagnosis), gained weight (more than 0.0%) and 
maintained weight. Again, sub-groups were defined within the lost and gain weight 
sub-categories: weight change of from 0.1 to 5.0%, from 5.1 to 10.0%, from 10.1 to 
15.0%, from 15.1 to 20.0% and more than 20.0%.  
The decision of defining weight change in absolute and relative terms, as well as the 
use of those sub-categories (i.e. + 2 kg, or 5% weight change) were inspired by 
previous literature on weight change after BC (Rock et al. 1999; Lankester et al. 
2002; Caan et al. 2006; Saquib et al. 2007; Caan et al. 2006, 2008; Han et al. 2009; 
Heideman et al. 2009; Caan et al. 2012b; Gu et al. 2010; Tredan et al. 2010; Chen et 
al. 2011; Nissen et al. 2011; Bradshaw et al. 2012; Sestak et al. 2012). The use of 
similar categories would facilitate the comparison of the results found in this study 
with previous literature. Furthermore, evidence showed that those figures could be 
clinically relevant (more details in Chapter 2). 
 
3.7.2 Multilevel modelling for weight change after breast cancer diagnosis 
The repeated weight measurements collected in this study were analysed using 
multilevel modelling. This is an advantageous technique to study weight change as it 
could answer two main types of questions: 1) how did each participant‘s weight 
change over time? And 2) is it possible to predict differences in weight change 
among participants with the variables collected in this study (i.e. BC treatment)?  
95 
 
Weight change multilevel modelling was conducted following the steps suggested by 
Singer and Willet (2003). It started with a descriptive exploratory analysis to get 
familiar with data, followed by the model fitting.  
 
3.7.2.1 Multilevel model for change: descriptive analysis 
Empirical weight growth plots were created to identify important data features, such 
as general patterns of weight change and functional forms, or to identify outlying 
participants whose weight values differ considerably from others (Singer and Willet 
2003). Initially, the plots were summarised with a smooth trajectory, applying a non-
parametric approach, and then using a parametric approach (ordinary least squares) 
regression (Singer and Willet 2003). The common functional form adopted for the 
exploratory analysis was a straight line, as this was the simplest functional form that 
could fit all data points. Nonetheless, because Heideman et al. (2009) modelled 
weight change after BC as a quadratic function, a set of polynomial shapes was also 
explored in this study to assess the quadratic effect of time (months from diagnosis) 
on weight change among participants. The visual inspection of the plots created 
suggested that weight change could be quadratic over time. Therefore, in order to 
simplify the analysis, the metric of the outcome (weight) and of time (months) were 
transformed aiming for linearity in the trajectory of weight change, but 
unfortunately, these techniques failed to achieve that goal. Consequently, data were 
initially modelled using a quadratic and a linear approach, as explained below. 
 
3.7.2.2 Multilevel model for change: model fitting 
The initial models fitted, explored weight change as a quadratic function. 
Participants with less than four recorded weights were excluded from the model in 
order to compare linear vs. quadratic weight change. Nonetheless, due to the 
complexity of the quadratic models fitted, a linear function was finally adopted to 
model weight change. This seemed adequate as previous research in the area also 
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analysed weight change post BC diagnosis as a linear trajectory (Camoriano et al. 
1990; Rock et al. 1999; Demark-Wahnefried et al. 2001; Kroenke et al. 2005; 
Makari-Judson et al. 2007; Heideman et al. 2009; Gu et al. 2010; Vagenas et al. 
2015). 
The models fitted were divided into a level-1 sub-model, which described how each 
participant‘s weight changed after diagnosis, and a level-2 sub-model that described 
differences in weight change patterns across participants, as well as the association 
between predictors and the patterns of each person‘s weight change (Singer and 
Willet 2003). Each sub-model contained two parts: the structural part (fixed effects), 
which represented true scores and the stochastic part, which representes the 
measurement error (the residuals). The introduction of predictors (i.e. BC treatments) 
in the models aimed to reduce the magnitude of the residual variability left in the 
models fitted (Singer and Willet 2003).  
Body weight was the outcome of level-1 sub-model, whereas the individual growth 
parameters (intercept and slopes) estimated in the level-1 sub-model were the 
outcomes of the level-2 sub-model. Consequently, the level-2 sub-model had two 
structural parts and two stochastic parts (one for each of its two outcomes). This 
feature allowed the level-1 parameters of one person to differ stochastically from 
those of others (Singer and Willet 2003). 
The variables of interest or predictors were the 1) clinical factors (BC treatments and 
tumour characteristics); 2) biological and behavioural factors (menopausal status at 
diagnosis, transition to menopause, genetic profile, age, smoking status at diagnosis). 
The parameters of the models were estimated using full maximum likelihood (ML) 
estimation. This is a popular approach for studies with large sample sizes because its 
estimates converge on the true values of the parameters of the population 
(asymptotically unbiased) and their sample distribution are approximately 
(asymptotically) normal with known variance. Furthermore, its SEs are smaller than 
those computed by other estimation methods (Singer and Willet 2003). The 
assumptions invoked for the ML estimation were: 1) the level-1 and level-2 residuals 
were normally distributed with mean zero, 2) the level-1 residuals were independent 
from level-2 residuals, and 3) all the residuals were independent of the predictors 
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included in the models (Singer and Willet 2003). An unstructured covariance matrix 
was specified for the model fitted. 
The first two models created were the unconditional means model and the 
unconditional growth model. The unconditional growth model added the predictor 
‗months‘ into the level-1 sub-model, to account for the effect of time elapsed since 
diagnosis on body weight. These models were needed to investigate whether there 
was variation in weight that was worth exploring and to find out where the variation 
existed. Subsequent models adding and removing predictors were fitted to generate 
the potential final model that best fitted data. A predictor was removed from a model 
if the associated p-value provided by the software used to fit the models was 
consistent with a null hypothesis (i.e. the outcome for the average participant with 
the predictor tested was similar to the outcome for the average participant without 
the predictor) (p>0.05). An interpretation of the estimated fixed effects was carried 
in order to determine if the model predictors were conceptually sound.  
In addition, pseudo-R
2 
statistics were used to compare the proportion of variation in 
the level-1 or level-2 variances left unexplained between two models. Ideally, a 
reduction in the unexplained residual variation would be observed in the nested 
model compared to the full model it was nested from, which would indicate an 
improvement in the fit.  
The Pseudo-R
2 
statistics were computed as: 
Pseudo-R
2 
statistics = (variance of model full model – variance of 
model nested model)/ variance of model full model 
 
Deviance statistics were used as a criterion for hypothesis testing of the models. 
Deviance was preferred to single parameter tests of the fixed effects and variance 
components because (Singer and Willett 2003, pp.116):  
 Had superior statistical properties.  
 Permitted composite tests on several parameters simultaneously. 
 Conserved the reservoir of type-one error.  
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Deviance statistics between two models were compared after ensuring that three 
conditions were met. First, the models were fitted using full ML. Second, the models 
were estimated using the same data. Third, one model (reduced model) was nested 
within the other (full model), in other words, every parameter of a nested (reduced) 
model appeared in the full model. The assumption hold by the difference in deviance 
statistics between the full and the nested model was that it is distributed 
asymptotically as a χ2 distribution with d.f. equal to the number of contrains imposed 
(the difference in the number of parameters between the models compared). 
Therefore, the criteria followed to choose the final model were: 1) the value of its 
deviance statistics (these were similar or smaller than those in other models), and 2) 
because it was the simplest and conceptually sounded model that included significant 
predictors that seemed relevant to characterise individual weight post BC diagnosis 
based on data and the predictors collected in this study. 
A correlation coefficient was used to explore the relationship between true initial 
status and true change, and was calculated using the following formula: 
  Correlation = σ01/√( σ0
2
 σ1
2
) 
 
BC treatments were explored as time-invariant and as time-varying predictors. The 
main focus of the time-invariant models was the interaction between the BC 
treatment and time elapsed since diagnosis. Time-varying models assumed that any 
effect of the treatment started after the commencement date of the treatment and had 
a persistent effect. Therefore time-varying models provided additional information 
on whether the effects of the BC treatment on weight vary over time (i.e. the rate of 
weight change might speed up after the start of a treatment) and were useful to 
predict average differences in weight according to the predictors, at particular times.  
In both cases, the models fitted explored the main effects of the predictors, as well as 
the interaction between the BC treatments and months elapsed since diagnosis.  
In the models with BC treatment used as time-varying predictors, the models looked 
at the main effects of the predictors as well as the interaction between the time-
varying predictors and time passed since diagnosis (months), to allow the 
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trajectories‘ slopes to vary by the predictor values. The models only included the 
fixed effects of the treatments, as the random effects could not be fitted (as explained 
in the results Chapter). Therefore, the main effects of the time-varying predictors and 
their interaction with time elapsed since diagnosis was assumed to be constant across 
the population.  
The first set of models fitted treated BC as time-invariant predictor. Therefore, each 
BC treatment had two mutually exclusive values: 1) users and 2) not-users. The 
models were split into sub-model 1 and sub-model 2. BC treatments were added as 
predictors in the between-person, level-2 sub-model. Hence, it was assumed that they 
were not going to be able to explain much of the within-person, level-1 sub-model‘s 
variance. The level-1 sub-model looked at individual weight change (within-person 
change) using months after BC diagnosis as a temporal predictor of the outcome 
(body weight) (Singer and Willet 2003): 
Yij =  0i + 1i Monthsij+ εij 
Where:  
 Yij is woman i‘s weight value on occasion j. 
 0i represents woman i‘s true initial status, the value of the outcome when 
Monthsij is zero. 
 1i represents woman i‘s true rate of weight change during the period under 
study. 
 εij represents the portion of woman i‘s outcome that is not predicted by the 
model on occasion j. 
The level-2 sub-model defined between-person differences in weight change. In this 
sub-model, the coefficients of the level-1 sub-model (true weight initial status 0i, and 
true rate of weight change 1ij) became the sub-model outcomes, as follows (Singer 
and Willet 2003): 
  0i = ϒ00 + ϒ01 PREDICTOR + ζ0i 
1i =  ϒ10  + ϒ11 PREDICTOR + ζ1i 
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Where: 
 ϒ00 and ϒ10 are the level-2 intercepts, and represent the population average 
initial weight (initial status, 0i) and the rate of weight change (1i) respectively, 
when the predictors have a value of zero.   
 ϒ01and ϒ11 are the level-2 slopes, and represent the effect of the predictor on 
the weight change trajectories, providing increments or decrements to initial 
weight (0i) and rate of weight change (1i ) for the average woman with the 
predictor.  If both parameters are zero, the average woman with the predictor 
weighs the same as the average women without the predictor, and their rate 
of weight change is also the same. 
 ζ0i and ζ1i are the level-2 residuals, and indicate the portion of initial weight 
and of rate of weight change that are not explained at level-2.  
The level-1 and level-2 sub-models could be condensed yielding a composite 
multilevel model for change (Singer and Willet 2003):  
Yij =  [ϒ00+ ϒ10Monthsij + ϒ01 PREDICTORi+ ϒ11PREDICTOR x (Monthsij)] 
+ [ζ0i + ζ1iMonthsij+ εij] 
Where: 
 ϒ00 + ϒ10 describe the population average of true initial status and true rate of 
change.  
 ϒ01+ ϒ11 describe between-person differences in initial status and rate of 
weight change, according to predictors. 
 [ζ0i + ζ1iMonthsij+ εij] describes the difference between the observed and the 
expected body weight for individual i on occasion j. 
In this composite specification, body weight depended simultaneously on the number 
of months (a level-1 predictor), the predictor(s) at level-2 and the cross-level 
interaction between months and predictor(s) (Singer and Willet, 2003). 
The next groups of models analysed BC treatments as time-varying predictors. The 
BC treatment values were: 1) using/had used (the treatment) and 2) have not used. 
Accordingly, any weight record measured before the commencement of the 
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treatment had a corresponding value of ―have not used‖, whereas any weight record 
collected at or after the first day of the treatment was given a ―using/had used‖ value. 
Therefore, these models assumed that any effect of the treatment would start after the 
commencement date of the treatment and have long lasting effects. As time-varying 
predictors, BC treatments were included as predictors in the level-1 sub-model, as 
follow:  
Yij =  0i + 1i Monthsij+ 2iPREDICTOR +εij 
On the other hand, the level-2 sub-model was defined as:    
  0i = ϒ00 + ϒ01 + ζ0i 
1i =  ϒ10  + ϒ11 + ζ1i 
2i  = ϒ20 
Where: 
 0i, the intercept, is the value of the outcome when months equals zero and no 
BC treatment (predictor) is used.  
 1i ,the slope, is the rate of weight change, controlled for the effect of the 
predictor.  
 2i  = ϒ20 
The composite multilevel model for change was represented as: 
Yij = [ϒ00+ ϒ10Monthsij + ϒ20PREDICTORij+  ϒ30PREDICTORijx Monthsij + 
[ζ0i + ζ1iMonthsij+ εij] 
Where: 
 ϒ00, the intercept, represents the weight when months equals zero and 
predictor(s) have a value of zero (i.e. no BC treatment is used).  
 ϒ10 is the population average rate of weight change per month, controlling for 
the effects of the predictor(s). 
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 ϒ20, ϒ30 and so on, represent the population average difference, over time, in 
weight values according to the predictor(s)‘ values (i.e. using/have used a BC 
treatment vs. non-users).   
The properties of the residuals of the final models fitted were explored to assess 
whether the assumptions invoked in the models were met (Appendix IV). The 
following assumptions were made when fitting these models (Singer and Willet 
2003).  
 The shape of the individual weight change trajectory was linear. Similarly, 
the relationship of each individual growth parameters (intercept and slope) 
with the predictors included in the models was linear. 
 The residuals were independently drawn from a univariate normal 
distribution at level-1 and a bivariate normal distribution at level-2.   
 The residuals were not correlated with the predictors and were homoscedastic 
over all values of the predictors. 
 The residuals could be autocorrelated and were heteroscedastic within-
person. 
Because information about the population from which the sample was drawn was 
lacking, it was not possible to ascertain completely the tenability of these 
assumptions (Singer and Willet 2003). Nonetheless, the observed properties of the 
residuals suggested that the models‘ assumptions were met (Appendix IV). 
Results of the multilevel modelling are presented with the parameter value and its 
corresponding SE. For the final model fitted, 95% CI will be also included. 
 
3.7.3 Adipose and metabolic parameters at the end of the follow up  
The analysis of body adiposity parameters the metabolic status of participants and 
the factors associated with them followed the same data procedures as the analysis of 
weight change at the four evaluation points. 
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Nine participants known to have diabetes at the time of study entry were not 
included in the analysis of metabolic parameters. Laboratory data revealed that 32 of 
the included participants had an insulin level lower than 13.89 pmol/l, the lowest 
level the assay could detect. Creating insulin categories to analyse insulin levels as 
an ordinal variable would lose information. Therefore, it was decided that the 
variable would be analysed as numerical variable. Hence, three analyses were 
conducted. In the first one, all of these 32 participants were given an insulin level of 
13.89 pmol/l, in the second one, a value of 7 pmol/l, and in the third one, a value of 1 
pmol/l. Due to the fact the results were similar (Appendix V), it was decided that the 
main analysis would be conducted providing participants with an insulin value of 7 
pmol/l.  
Waist circumference and the metabolic parameters at the time of collection were not 
normally distributed (Appendix V). The value of their mean was comparable to their 
median (Appendix V). Therefore, for consistency with other outcomes presented in 
the study, the mean and SD will be used to summarise metabolic and adiposity 
parameters in Chapter 4. The sample sizes were larger than 15 (Frost 2015), and a 
sensitivity analysis conducted showed similar results when using parametric and 
non-parametric tests. Similarly, the presence of outliers did not modify the results of 
the parametric test (Appendix V). Therefore, parametric test were used to explore 
those outcomes, and outliers were included in the analyses presented in Chapter 4 
(unless specified). Independent sample t-tests, correlation analysis and one-way 
ANOVA were used to explore factors associated to each body adiposity and 
metabolic parameters. Multiple linear regression analysis was performed to look at 
the combined effect of two or more variables that could predict those parameters, 
following the same steps conducted when exploring the magnitude of weight change 
at different evaluation points. As before, age at diagnosis was included in the 
analysis whereas the new variable created on menopausal status was excluded for the 
reasons explainer earlier on.   
A repeated analysis of the multiple regressions was conducted if the assumptions of 
the multiple regression analysis were not met. This repeated analysis provided 
rationale for the use of this test, unless otherwise explained (Appendix V). 
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3.8 Ethical considerations 
This study operates in accordance with Bournemouth University‘s ethic policies and 
procedures. The Royal Bournemouth and Christchurch Hospitals NHS Foundation 
Trust sponsored the study and since the target population involved NHS patients, the 
original study and the protocol ammendments obtained a favourable ethical opinioin 
and a site-specific assessment approval by the Dorset NHS Research Ethics 
Committee (REC reference 08/h0201/35). The study was also granted with the 
approval of the research governance from the NHS Research and development 
(R&D) department for the two NHS hospitals where participants were recruited and 
by the Research Governance Review Group at BU. The study was assessed as a 
basic science study type, as it involved procedures with human participants without 
affecting their clinical care that the participant would receive.As requested, the study 
commenced within 12 months of the date of the favourable ethical opinion and 
research governance approval. Annual progress reports were submitted to the Dorset 
NHS Research Ethics Committee, which also received the nofitication of the end of 
the study (June 2011), when data collection finished. A final report with a summary 
of the findings and arrangements for publication or dissemination will be submitted 
to the Dorset NHS Research Ethics Committee. All participants voluntarily gave 
written consent prior to taking part in the study and after they received accurate 
information about the study and its rights following local REC advice (Appendix 
VI).   
A main ethical issue was that health professionals dealing directly with BC women 
were personally inviting them to take part in the study. That may have put some 
pressure on them to participate in the study, so in order to avoid that, women were 
reassured that the decision was voluntary and would not affect in any way the quality 
of treatment that they were receiving or about to receive. Due to the delicate 
condition of the target population, confidentiality was ensured. Participants knew 
what information was going to be collected from them. Data were collected and 
stored following Bournemouth University‘s Data Protection Policy and Guidelines 
and principles of The Data Protection Act of 1998. 
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Foreseen potential negative effects were both uncomfortable and distressing feelings 
when obtaining a blood sample and the minimal but potential risk of developing 
lymphoedema resulting from an infection in the venepuncture place (Clark et al. 
2005). Therefore, in order to minimise the risks, qualified and experienced nurses 
took the blood samples. On the other hand, it is possible that participants felt comfort 
knowing that they were contributing to the improvement of future BC treatment. 
They knew they had access to the results of the test and study if they wished and that 
any adverse result identified during the study (i.e. unidentified diabetes) was going to 
be reported to the clinitians taking part in the study and the participant herself and 
that it was going to be effectively dealt with.  
Accurate reports from this research project‘s findings will be shared with the 
scientific community, and a  report with the main findings of this study will be 
available to the clinitians in the two hospitals where the study took place. They will 
be then able to share this findings with their patients and with the participants in this 
study, as they were told that they could have access to the findings of this study by 
contact their clinitians.  
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CHAPTER 4: RESULTS 
 
4 Introduction 
This chapter summarises data from the participants who were included in the 
database. The length of time that participants have been followed for varies across 
the cohort. Similarly, the numbers of participants with available outcome measures 
vary across the dataset, so sample sizes are provided for the analyses conducted. 
The results presented here will follow the aims of the study as detailed in Chapter 2. 
It begins with a description of the participants included in the dataset. It continues by 
presenting the results related to the primary aim of the study (to explore the 
magnitude and frequency of weight change at 12, 24, 36 and 48 months post-
diagnosis and the factors associated with the weight change), and then it shows the 
results of modelling weight change. The last section deals with the secondary aim of 
the study: exploring body adiposity and metabolic parameters at the end of the 
follow up, and the factors associated with them. A summary of the main findings is 
presented at the end of the chapter. Chapter 4 includes four appendixes. Appendix I 
collates the tables and figures of the main results described in this chapter, and 
appendixes III, IV and V present sensitivity analyses of the results presented here to 
validate the use of a parametric approach and to address the impact of outliers on the 
main findings.  
 
4.1 Baseline characteristics of participants  
4.1.1 General biological characteristics 
This retrospective cohort consisted of a total of 239 participants newly diagnosed 
with BC between January 2003 and December 2009. Follow up began at the time of 
BC diagnosis and ended at the date of study entry, when the participants‘ final 
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weight record, metabolic and body adiposity parameters were collected by the 
researcher. Mean follow up time was 47.46 months (SD: 20.45), ranging from a 
minimum of 10.25 months to a maximum of 91.17 months post-diagnosis. This 
variability in the length of follow up is reflected in the decreasing number of 
participants followed as time post-diagnosis increases (Figure 1, Appendix I). For 
instance, 237 participants were followed at least 12 months post-diagnosis, whereas 
only 14 had 84 months of follow up.  
Most participants (81.9%) were treated and recruited from Royal Bournemouth 
Hospital. On average, participants were diagnosed with BC when they were 57.5 
years old (SD: 10.41). At that time, most of them were postmenopausal (72.8%), and 
reported to be non-smokers (89.2%) (Table 6, Appendix I).  
Mean weight chosen as weight at diagnosis was 72.2 kg (SD: 13.6). This weight was 
recorded in the medical notes around 0.92 months (SD: 0.71) post-diagnosis. This 
was thought to represent a true baseline weight, despite the fact that 16 participants 
had just started their adjuvant treatment at the time of the record (four were receiving 
chemotherapy, three tamoxifen, eight were taking AINs and one was receiving 
gonadorelin analogues).  
To determine the magnitude of the weight change effect size (small, medium, or 
large effect size in the popular Cohen‘s terminology), the SD of the weight at 
diagnosis (13.6) was multiplied by Cohen‘s standard d values that represent small, 
medium or large effect (d=0.2, 0.5 and 0.8 respectively) (Table 7, Appendix I) 
(Cohen 1992). The resulting values can be used as a guide to interpret the results of 
the statistical tests of weight change.  
 
4.1.2 Breast cancer treatment received 
Nearly all participants (96.2%) received adjuvant treatment (Table 8, Appendix I). 
Most participants received or were being treated with hormone therapy (86.1%) 
during or at the end of the follow up. Nearly 45% of them were treated with 
combined therapy, predominantly tamoxifen plus AINs (Table 9, Appendix I). 
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Tamoxifen treatment started a mean of 4.84 (SD: 5.31) months post-diagnosis. In 
total, 131 participants took tamoxifen for a mean of 23.65 (SD: 15.61) months. 
Eleven participants resumed tamoxifen treatment after initially having discontinued 
it. Anastrozole was the most common AIN used (n=106), and was used for the 
longest duration (mean 30.73, SD: 18.34 months). Anastrozole therapy started a 
mean of 9.94 (SD: 10.76) months post-diagnosis. Three participants resumed therapy 
for a further 22.78 (SD: 10.18) months. Letrozole treatment (n=18) started 20.29 
(SD: 20.34) months post-diagnosis, and was used for a mean of 15.78 (SD: 11.89) 
months. Exemestane (n=48) commenced a mean of 27.49 (SD: 13.70) months after 
being diagnosed with BC, and was taken for a mean of 18.05 (SD: 13.25) months. 
Finally, gonadorelin use (n=21) started closer to diagnosis (4.98 months post-
diagnosis, SD: 8.99), and was continued for a mean of 24.81 (SD: 14.67) months. 
Chemotherapy was administered to over half of the sample (56.1%), whereas 
biological therapy with trastuzumab was rarely prescribed (5.5%) (Table 10, 
Appendix I). Chemotherapy was administered from a mean of 2.16 (SD: 1.31) 
months post-diagnosis to 6.47 (SD: 1.65) months post-diagnosis. Most participants 
treated with chemotherapy had anthracycline-containing regimens (95.5%) and 
52.3% of them also received taxanes.  
 
4.2 Number of participants with available weight data 
This section details the number of participants included in the analyses of the weight 
change at 12 (± 4), 24 (± 4), 36 (± 4) and 48 (± 4) months post-diagnosis. A ± 4 
months window period was chosen for those particular evaluation points because it 
produced larger sample size than smaller window periods (Appendix II).   
The numbers of participants that were expected to be followed at 12, 24, 36 and 48 
months differ from those represented in Figure 1 (Appendix I) (n=237, 207, 161 and 
112, respectively) (Appendix I). The reasons for this discrepancy is that the window 
period for each evaluation point was widened from ± 0.5 to ± 4 months so that more 
participants could be included (Figure 1, Appendix I). Consequently, the total 
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number of participants with a minimum follow up of 12 (± 4) months was 239 
(Table 11, Appendix I). A minimum follow up of 24 (± 4) months was achieved for 
224 participants and 178 and 128 participants were followed for at least 36 (± 4) 
months or 48 (± 4) months respectively.  
Participants were expected to have weight records available at diagnosis as well as at 
12, 24, 36 and 48 months post-diagnosis. However, at the time of diagnosis weight 
records were only available for 92.5% of the sample population. The percentage of 
participants with recorded weight measurements at 12 months post-diagnosis 
dropped to 42.3% and continued at a similar level at 24 and 36 months post-
diagnosis (46.4% and 43.8%, respectively). Weight at 48 months post-diagnosis was 
available for 68 out of the 128 (53%) participants who were expected to have a 
weight recorded at that evaluation point.  
Participants with missing weight records either at diagnosis or at the month under 
exploration were excluded from the relevant analyses. Accordingly, only 41.4% 
(n=99) of the eligible participants were included in the analysis of weight change at 
12 months post-diagnosis, 44.6% (n=100) at 24 months, 41.6% (n=74) at 36 months, 
and finally, 48% (n=62) were analysed for weight change at 48 months post-
diagnosis. 
There were no statistical differences in weight at diagnosis between participants 
included in the analyses presented in this chapter and those excluded due to missing 
values (details in Appendix II). Consequently, a complete-case analysis approach 
was taken for data analysis of weight change at 12, 24, 36 and 48 months post-
diagnosis. 
 
4.3 Magnitude and frequency of weight change after breast cancer diagnosis 
One participant had two weights recorded on the same date. Because the weight 
values were different (77 and 76 kg respectively), the mean weight for that 
participant on that date was calculated. There were no weights measured at 
equidistant time from the desired evaluation point. 
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During the first 12 months post-diagnosis, mean weight change across all 
participants was + 1.30 kg (95% CI: 0.33 to 2.32, p=0.01), the equivalent of a mean 
of + 2.2% (95% CI: 0.91 to 3.41, p=0.01) over their baseline weight (Table 12 and 
Figure 2, Appendix I). The largest magnitude of mean weight change across the 
sample was observed at 36 months post-diagnosis: + 1.59 kg (95% CI: 0.39 to 2.79, 
p=0.01), the equivalent of a 2.67% increase relative to weight at diagnosis (95% CI: 
1.05 to 4.29, p<0.01). The smallest magnitude of mean weight change occurred a 
year later (mean change + 0.42 kg, 95% CI: -0.99 to 1.84), which represented a non-
statistically significant increase of 0.88% over the diagnosis weight (95% CI: -0.97 
to 2.73, p=0.34). 
The frequency of weight change varied according to the cut-off used. When looking 
at changes larger than 0.0 kg, results showed that most women experienced weight 
changes in the first two years of diagnosis (92.0% and 98% respectively). In the last 
two evaluation points explored, the totality of the sample100% had weight changes 
(Table 13, Appendix I). When weight change was defined as changes larger than 2 
kg, data revealed that between 32.3 and 38% of the sample maintained their weight. 
Among those who experience weight changes larger than 2.0 kg, the percentage of 
women who gained weight at the four evaluation points ranged from 38.7% to 
48.6%, and was larger than the percentage of women who lost weight at those points 
(ranging from 17.6% to 29.0%) (Table 14, Appendix I). 
Seven participants had no weight change (more than 0.0 kg) at 12 months (Table 13, 
Appendix I). Nonetheless, records showed that five of them had lost weight by the 
next evaluation points, and one gained weight. The last one had missing data on 
weight beyond 12 months period.  
Available data from 35 of the 60 participants who gained weight (at least + 0.1kg) 
during the first 12 months post-diagnosis revealed that eight of them had a net 
weight loss by the end of the follow up period: four of them lost between 0-5% of 
their baseline weight at diagnosis, three lost up to 10% of their baseline weight and 
one participant lost more than 10% of her weight at diagnosis. The remaining 27 
participants gained weight at the end of the follow up in relation to their baseline 
weight.   
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On the other hand, data from 27 of the 32 participants who lost weight by the end of 
the first year post-diagnosis showed that 67% of them continued to lose weight by 
the end of the follow up period, whereas 33% had a net weight gain despite their 
initial weight loss.  
In relative terms, weight changes larger than 0.0% of the weight at diagnosis were 
seen in nearly all participants. Half of the sample experienced weight changes larger 
than 5% of their baseline weight in the first year of diagnosis, and weight change 
over 10% relative to baseline weight were seen in around 12% (Table 15, Appendix 
I). In the following years, the frequency of weight change larger than 10% increased 
to 14% at 24 months post-diagnosis, to 16.2% at 36 months post-diagnosis and to 
12.8% at 48 months post-diagnosis (Table 15, Appendix I). At all periods explored, 
the frequency of weight gain was superior to the frequency of weight loss. For 
instance, in the first year of diagnosis, 35.4% of participants gained more than 5% of 
their baseline weight and 8.1% have more than 10% weight increases. Conversely, 
15.1% of the sample experienced weight loses of 5% of baseline weight, and 4% of 
participants had a weight loss of more than 10% of their weight at diagnosis (Table 
15, Appendix I).    
The effect size of the weight changes at 12, 24, 36 and 48 months-post-diagnosis was 
small according to Cohen‘s convention (Table 7, Appendix I). 
 
4.4 Factors associated with weight change post-diagnosis 
4.4.1 Univariable analysis of weight change 
4.4.1.1 Breast cancer treatment 
Tamoxifen and anastrozole were the only two treatments statistically associated with 
weight change (Table 16, Appendix I).  
In all four evaluation points explored, the magnitude of the mean weight change was 
always larger and positive, among participants who had taken or were taking 
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tamoxifen (mean weight change ranting from +1.52 kg to +2.87 kg) compared to 
those who had never used it, who experienced an average negative weight change at 
24 and 48 months post-diagnosis (mean weight change -0.81 kg and -1.01 kg 
respectively), and an average positive weight change in the remaining periods (mean 
weight change +0.67 and + 0.23 kg). Nonetheless, the differences in mean weight 
change between tamoxifen users and non-users reached statistical significance only 
at 24 and 36 months post-diagnosis (mean difference 3.68 kg, 95% CI: 1.62 to 5.75, 
p<0.01, and 2.38 kg, 95% CI: 0.01 to 4.75, p=0.05, respectively). Conversely, the 
magnitude of mean weight change was inferior among the group of participants that 
used anastrozole compared to non-users. The differences between the groups reached 
statistically significance at 48 months post-diagnosis, when anastrozole users‘ body 
weight decreased by an average of -0.97 kg, whereas non-users had a mean weight 
change of + 2.16 kg (mean difference between the groups: -3.13 kg, 95% CI: -5.92 to 
-0.34, p=0.03).  
No other treatment was statistically associated with weight change post-diagnosis 
(Table 16, Appendix I). The magnitude of all the differences in mean weight change 
found was small considering Cohen‘s criteria (Table 7, Appendix I).  
 
4.4.1.2 Menopausal status 
On average, participants diagnosed before the menopause had a positive weight 
change in all of the four evaluation points explored, which ranged from + 1.90 kg to 
+ 3.90 kg. The magnitude of their average weight change was larger than the mean 
weight change observed among postmenopausal participants, whose weight change 
was more erratic: It was positive in the first three years post-diagnosis (ranging from 
+ 0.37 kg to + 1.23 kg), and negative at 48 months post-diagnosis (-0.69 kg). 
Differences in mean weight change between the groups were statistically significant 
at 48 months post-diagnosis only (mean difference 4.59 kg, 95% CI: 1.47 to 7.70, 
p<0.01) (Table 17, Appendix I). 
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After diagnosis, fewer than 30% of the pre and perimenopausal participants become 
peri or postmenopausal (Table 18, Appendix I), and on average, there was a larger 
weight change in this group of participants (mean weight change ranging from +2.01 
kg to 3.91 kg) compared to participants who did not experience a change in 
menopausal status (mean weight change ranging from -0.35 kg to +1.33 kg). The 
magnitude of the differences in weight change between the two groups was small 
and only statistically significant at 12 and 48 months post-diagnosis when the mean 
differences were 2.29 kg (95% CI: 0.20 to 4.37, p=0.03) and 4.27 kg (95% CI: 1.08 
to 7.45, p=0.01), respectively (Table 17, Appendix I). 
 
4.4.1.3 Genetic profile 
Participants carrying the A-allele of the FTO gene that has been associated with 
increased body weight had similar body weight at the time of BC diagnosis to non-
carriers (mean difference -1.31 kg, 95% CI: -6.88 to 4.25, p=0.64). Both groups 
experienced an average positive weight change at the four evaluation points explored 
ranging from + 0.97 kg to + 1.30 kg in the A-allele carriers group, and from + 0.32 
kg to 3.30 kg in the non-carriers group. Findings on the association of weight change 
post-diagnosis with FTO profile are inconsistent. Larger average weight changes 
were seen in the carriers group at 24 and 48 months post-diagnosis, whereas the 
opposite was seen at 12 and 36 months post-diagnosis. Nonetheless, the differences 
in mean weight change between the groups were not statistically significant (Table 
19, Appendix I). 
Similarly, there was no statistically significant differences in weight at diagnosis 
between carriers of the allele of the Mc4R gene associated with higher body weight 
(C allele) and non-carriers (mean difference 0.12 kg, 95% CI: -5.11 to 5.35, p=0.96). 
Unexpectedly, on average, carriers of the risk allele C experienced negative weight 
change at 24 and 48 months post-diagnosis (mean weight change -0.16 kg and -1.61 
kg respectively). Conversely the non-carriers group had an average positive mean 
weight change at all the four evaluation points explored, and the magnitude of 
overall weight change was always larger compared to the non-carriers group (mean 
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weight differences between the groups ranged from -0.86 kg to -3.19 kg) (Table 19, 
Appendix I). Nonetheless, the magnitude of the differences was small and not 
statistically significant.  
 
4.4.1.4 Other covariates of interest 
Mean weight change was negatively correlated with lower body weight at diagnosis 
(at 36 months post-diagnosis: r=-0.32, p<0.01), and with age at the time of diagnosis 
(at 48 months post-diagnosis: r=-0.29, p=0.03 (Table 20, Appendix I). 
Participants who smoke at the time of BC diagnosis experienced an average positive 
weight change post-diagnosis at the four evaluation points (ranging from + 0.66 kg 
to + 4.55 kg). The magnitude of their mean weight change was larger compared to 
the one observed among non-smokers, who experienced mean weight changes 
ranging from - 0.16 kg to + 1.38 kg. The differences between the groups were 
statistically significant at 12 and at 48 months post-diagnosis (mean difference + 
3.49 kg, 95% CI: -0.18 to 6.80, p=0.04, and + 4.00 kg, 95% CI: 0.08 to 7.91, p=0.04 
respectively) (Table 20, Appendix I). 
 
4.4.2 Multivariable analysis of weight change 
4.4.2.1 Weight change at 12 months after breast cancer diagnosis 
Multiple regression analysis confirmed that weight at diagnosis and smoking status 
at diagnosis were statistically significantly associated with weight change in the first 
year of diagnosis (Table 21, Appendix I). The model that included these two 
variables was able to predict 19.5% of the variability in weight change observed at 
12 months post-diagnosis (as determined by adjusted R
2, 
p<0.01).   
When all the other predictors were constant, the model predicted that at 12 months 
post-diagnosis: 
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 Each kg increase in body weight at diagnosis reduced body weight by 0.12 
kg.  
 Additionally, smokers had a weight change value that was + 5.44 kg (on 
average) higher than non-smokers. 
 
4.4.2.2 Weight change at 24 months after breast cancer diagnosis 
The model that explained the largest amount of the variance (18.9%) of weight 
change at 24 months included two variables: tamoxifen use and weight at diagnosis 
(both p<0.01) (Table 22, Appendix I). 
In this model, when weight at diagnosis was similar, the model predicted that: 
 Tamoxifen users had a weight change value that was + 4.05 kg (on average) 
higher than that of non-users. 
 Each kg of body weight at diagnosis was associated with a reduction of 0.08 
kg in the weight at 24 months post-diagnosis.  
The analysis was repeated excluding an outlying participant who gained 15.92 kg 
and had a large studentized deleted residual (3.33). Both analyses showed similar 
results (Table 53, Appendix III). 
 
4.4.2.3 Weight change at 36 months after breast cancer diagnosis 
Weight at diagnosis and tamoxifen use were able to predict 12.5% of the variability 
in weight change at 36 months post-diagnosis (p<0.01, Table 23, Appendix I).  
The model indicated that each kg at BC diagnosis was associated with a - 0.12 kg 
weight change at 36 months post-diagnosis (p<0.01), suggesting that heavier women 
experienced less weight change. Tamoxifen users had a weight change value that 
was 2.23 kg (on average) higher than that of non-users (p=0.05). 
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Data from one outlying participant with large weight change (+ 20.1 kg) and 
studentized deleted residual value (4.33) were included, as her inclusion in the 
analysis did not alter the results (Table 54, Appendix III). 
 
4.4.2.4 Weight change at 48 months after breast cancer diagnosis 
The model exploring weight change at 48 months excluded one outlier participant 
whose weight change was -18.5 kg, as sensitivity analysis showed that the exclusion 
of this participant from the analysis reduced R
2
 (from 0.15 to 0.09) and changed the 
statistical significance of the predictors included in the model (Tables 55 and 56 in 
Appendix III).   
Sensitivity analysis showed that after excluding this outlier participant, the only 
variable that remained associated with weight change at 48 months post-diagnosis 
was age at diagnosis. 
A visual inspection of a scatter/dot plot of weight change at 48 months post-
diagnosis against age at diagnosis (figure not shown) indicated a linear relationship 
between these two variables. All the assumptions were met to conduct a linear 
regression analysis: independence of observations, no outliers, homoscedasticity and 
normality of residuals. 
Average age at diagnosis statistically significantly predicted weight change at 48 
months post-diagnosis [F (1, 54) =5.31, p=0.02] and accounted for 7.3% of the 
variation in weight change at that point, a small size effect. In this linear model, each 
year of age at diagnosis reduced weight change at 48 months post-diagnosis by 0.12 
kg (p=0.02, 95% CI: 1.41 to 13.86).  
Overall, although the difference in weight change related to the predictors in these 
models was statistically significant, its magnitude was small. Nonetheless, the 
estimates of models fitted had medium to large effect sizes (R value) (Cohen 1992).  
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4.5 Multilevel model for weight change after breast cancer diagnosis 
The multilevel models fitted describe individual‘s weight change after BC diagnosis 
and explore whether the individual trajectories of body weight differ according to the 
clinical (i.e. BC treatments), behavioural (i.e. smoking) and biological (i.e. genetic 
profile) variables analysed earlier. The outcomes shown in Tables 24-27 (Appendix 
I) represent part of the journey to find the best model to fit data.  
 
4.5.1 Trajectory of weight change after breast cancer diagnosis 
An exploratory assessment of data using empirical weight growth plots suggested 
some degree of heterogeneity in the pattern of weight change post-diagnosis. Some 
participants seemed to have a linear trend in weight change, whereas others‘ weight 
trajectories seemed to be quadratic (data not shown). Consequently, the first models 
were fitted to evaluate whether a higher order trajectory would fit data better than a 
linear one. The final number of participants included was 165. The first quadratic 
model seemed to provide a better fit than the linear change model, as evidenced by 
its smaller deviance statistic value compared to the linear model (difference 386), a 
value that exceeded the 0.05 probability threshold of a χ2 distribution with four d.f. 
(value of 9.49). Unfortunately, the next quadratic models fitted to explore the effect 
of the variables (predictors) of interest became very complex, i.e. the coefficient for 
the quadratic term was statistically significant in the models with five or more 
predictors (data not shown), and there were convergence problems when exploring 
the random effects.  Therefore, considering this and the fact that the dataset was 
severely unbalanced, it was deemed inappropriate to continue using quadratic 
models to explore weight change post BC-diagnosis. A cubic model was also fitted 
(data not shown) with those participants that had five or more weights recorded 
(n=138), however, there were convergence problems. Consequently, weight change 
was explored as a linear function.  
In the first linear models created, BC treatments were included as time-invariant 
predictors (i.e. their values did not change over time). In the next section, BC 
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treatments were treated as time-varying predictors. Their values for any participant 
changed during the follow up. 
 
4.5.2 Linear models with breast cancer treatment as time-invariant predictors 
The models in Table 24 (Appendix I) explored the fixed effects of the BC treatments 
analysed as time-invariant predictors.   
Model A, the unconditional means model (Table 24, Appendix I), was the first 
model fitted. The estimated within-person variance (8.95, SE: 0.03) and the 
estimated between-person variance (173.48, SE: 16.10) in this model were both 
statistically significant, suggesting that the average woman‘s body weight varies 
over time and that women‘s weight differ from each other. Because these variance 
components were statistically significant, their values could be reduced with the 
addition of predictors. 
The intra-class correlation coefficient of 0.95 indicated that most of the variance was 
attributable to differences between participants. It also showed that for each person, 
the average correlation between any pair of residuals (i.e. between occasions 1 and 2, 
or 2 and 3) was 0.95. Hence, the composite residuals were auto-correlated. 
Model B, the unconditional growth model (presented in Tables 24 and 26), 
accounted for the effect of time elapsed since diagnosis on body weight. The fixed 
effects showed that weight of the average woman diagnosed with BC increases 
steadily at a rate of 0.03 kg per month. The sub-level-1 within-person variance of 
Model B (σε
2
: 5.79, SE: 0.20) was smaller than the within-person variance in Model 
A (σε
2
: 8.95, SE: 0.29), which indicated that some of the within-person variation in 
weight could be attributable to months passed since diagnosis. The pseudo-R2 
statistic computed from the differences in within-person variances in models A and 
B confirmed that finding: 35% of the within-person variation in weight could be 
explained by time elapsed since diagnosis in a linear trajectory. Therefore, Model B 
was better at predicting weight than Model A. Nonetheless, the within-person 
variance was still statistically significant, hence, there was room for other level-1 
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time-varying predictors that could further explain within-person variation in body 
weight. The variance components at level-2 showed that there was statistically 
significant variation in true individual initial status (σ0
2
: 171.61, SE:16.05) and, 
more importantly, in true rate of weight change (σ1
2
: 0.01, SE: 0.0014), which 
implied that there are differences among women in rate of weight change post-
diagnosis that could be explained by predictors at level-2.  
The population covariance of the level-2 residuals σ01 transformed into a correlation 
coefficient (value 0.10) showed that the relationship between the residual body 
weight at diagnosis and the residual true rate of weight change was negative and 
weak. Moreover, it was not statistically significant suggesting that weight at 
diagnosis was not statistically associated with rate of weight change. 
The models C, D, E and F included BC treatments explored as time-invariant 
predictors (Table 24, Appendix I). Models C and D (and others not shown) guided 
decision-making leading to the final model (F). Model E included months, tamoxifen 
use and exemestane use as predictors of weight post-BC diagnosis. These two BC 
treatments were the only two that made a statistically significant contribution to the 
outcomes in previous models. The difference in deviance statistics between Model E 
and Model B was 13.47, a value that exceeded the 0.05 probability threshold of a χ2 
distribution with four d.f. (value of 9.49). Therefore, Model E with time-invariant 
predictors (tamoxifen and exemestane use) provided a better fit than Model B, which 
only accounted for the effects of months passed since diagnosis. The fixed effects 
shown in Table 24 (Appendix I) revealed that in Model E the interaction between 
exemestane use and months elapsed was not statistically significant. Hence, 
exemestane was not included in the next model fitted (F). Deviance statistics in 
Model F were statistically similar to the previous model E (Table 24, Appendix I), as 
the value of the difference (4.36) was inferior to the 0.05 probability threshold of a χ2 
distribution with two d.f. (value of 5.99). Because of the similarity of the deviance 
statistics and because Model F was more parsimonious than Model E, the former 
was considered the final model and is described as follows:  
Model F included tamoxifen use as a predictor of initial status and of rate of weight 
change. The fixed effects in the final model F suggested that: 
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 The estimated initial weight for a women diagnosed with BC who received 
no treatment was 72.9 kg (SE: 2.64, p<0.01). 
 The estimated rate of weight change for an average woman diagnosed with 
BC who was not taking tamoxifen was 0.0 kg per month (SE: 0.02, p<0.01). 
 The estimated differential in the rate of weight change between tamoxifen 
users and non-users was 0.05 kg per month (SE: 0.01, p<0.01). 
The level-1 residual (σε
2 
within-person) variance in model F was nearly similar to 
that in the unconditional growth model B (5.7900 vs. 5.7915). This was expected 
because time-invariant predictors cannot explain much of the within-person variance.  
Nonetheless, this variance was still statistically significant, therefore it could be 
possible to reduce it by introducing more time-varying predictors. The only time-
varying predictor in this study was menopausal status. However, because change in 
menopausal status correlated with age at diagnosis (r=0.74), age at diagnosis was 
chosen to be tested in multilevel modelling, as it is a more reliable measure than 
menopausal status. Age at diagnosis was also correlated with gonadorelin analogues 
use (r=0.61), a value that allowed both variables to be tested in the analysis. 
Nonetheless, neither age at diagnosis nor gonadorelin analogues use contributed 
significantly to the final model. The pseudo-R
2  
statistic computed from the 
differences in between-person variances in rate of change in models B and models F 
showed that just 4.62% of the between-person variation in true rate of change was 
explained by tamoxifen use. As both level-2 variances were significant (individual 
initial status σ0
2
: 171.75, SE: 16.07, rate of weight change σ1
2
: 0.01, SE: 0.0014) 
additional predictors at level-2 could further reduce them. However, no other 
variable explored in this study (i.e. genes, smoking status at diagnosis, invasive 
tumour size or cancer stage) contributed statistically to Model F. Therefore, using the 
composite multilevel model for change, Model F was described as: 
Weightij = [72.9 + 0.10Monthsij - 0.46tamoxifeni - 0.05(tamoxifeni x 
Monthsij)] + [ζ0i + ζ1iMonthsij+ εij] 
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4.5.3 Linear models with breast cancer treatments treated as time-varying 
predictors  
The first two models fitted were the unconditional means model A and the 
unconditional growth model B (Table 24, Appendix I). Their features and 
characteristics were described earlier and will not be repeated in here. Nonetheless, 
the parameters estimated in unconditional growth model B were presented again in 
Table 26 (Appendix I) as they were used for comparison with later models to assess 
whether they fit data better.  
Models in Table 26 (Appendix I) (and others not included in that table) present part 
of the journey of model fitting leading to the final model (4). Model 1 included all 
the BC treatments and models 2 and 3 were fitted after removing BC treatments that 
did not contribute statistically to the previous model fitted (Table 26, Appendix I). 
The final model 4 included tamoxifen, anastrozole and letrozole. The value of the 
differences in deviance statistics between Model 4 and the unconditional growth 
model B was 118.84, a value that exceeded the 0.05 probability threshold of a χ2 
distribution with four d.f. (value of 9.49). Therefore, in accounting for the effects of 
these three BC treatments, Model 4 provided a better fit than the unconditional 
growth model B which only accounted for the effects of months passed since 
diagnosis.   
The fixed effects in the final model 4 indicated that: 
 The estimated weight for a women diagnosed with BC, at the time of 
diagnosis and who was not receiving tamoxifen, anastrozole or letrozole was 
70.7 kg (SE: 1.59, p<0.01). 
 The estimated population average rate of weight change was -0.06 kg/month 
(SE: 0.02, p<0.01), after controlling for the effects of these three treatments. 
 The estimated population average difference, in weight values between those 
who used (or were using) tamoxifen and non-users was 1.09 kg (SE: 0.27, 
p<0.01). 
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 The estimated population average difference, in weight values between those 
who used (or were using) anastrozole and non-users was 0.85 kg (SE: 0.32, 
p<0.01). 
 The estimated population average difference, in weight values between those 
who used (or were using) letrozole and non-users was 2.60 kg (SE: 0.54, 
p<0.01). 
 The coefficient for interaction of anastrozole with months was statistically 
significant (0.05, p<0.01), indicating that the effect of anastrozole on weight 
varies over time.  
The level-1 residual (σε
2 
within-person) variance in Model 4 was lower than the 
variance component in the unconditional growth model B (5.64 vs. 5.79). The 
variance was statistically significant; therefore the addition of other time-varying 
predictors might have reduced its value. However, no other predictor in this study 
improved the variance components of Model 4. Level-2 variance was also lower in 
Model 4 compared to Model B, nonetheless, changes in level-2 variances might not 
be meaningful (Singer and Willet, 2003) and therefore will not be mentioned. 
Using the composite multilevel model for change, Model 4 was described as: 
Weightij = [70.7 + 0.06Monthsij - 1.09tamoxifenij - 0.85anastrozoleij + 
2.60letrozoleij + 0.05anastrozoleijx Monthsij + [ζ0i + ζ1iMonthsij+ εij] 
The parameters for the main effects of tamoxifen and anastrozole were negative, 
implying that treatment users had higher weight compared to non-users. Conversely, 
the parameters for the main effect of letrozole were positive, therefore, the estimated 
weight of letrozole users was lower than that of non-users.  The estimated weights 
for each year of diagnosis as predicted by Model 4 are presented in Table 28 
(Appendix I). 
A final question that was explored was whether the main effects of tamoxifen, 
anastrozole, or letrozole could vary across the population. Unfortunately, due to 
convergence problems it was not possible to fit a model exploring the random effects 
of the main effects of these three BC treatments to data. Nonetheless, a new model 
looking at the random effects of the interaction of anastrozole with months passed 
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since diagnosis was fitted (Model 5 in Table 27, Appendix I). However, allowing the 
interaction of anastrozole with months passed since diagnosis to vary across the 
participants, and not allowing the main effect of the treatment to vary would not be 
wise. For that reason, Model 4 was chosen as the final model.  
 
4.6  Adiposity parameters at the end of the follow up 
On average, participants had a mean of 37.8% (SD: 6.24) body fat, a mean of 28.48 
kg (SD: 9.43) of FM, a mean of 45.05 kg (SD: 5.65) of FFM and a mean FM/FFM 
ratio of 0.62 (SD: 0.16). The mean waist circumference was 92.3 cm (SD: 11.82). 
 
4.6.1 Univariable analysis of body adiposity parameters at the end of the 
follow up 
4.6.1.1 Breast cancer treatment  
Chemotherapy users had healthier body adiposity parameters than non-users, with 
lower fat levels and lower waist circumference values, although the differences 
between users and non-users were not statistically significant (Table 29, Appendix 
I). Taxane-containing regimens were not statistically associated with the body 
adiposity parameters measured (data not shown). Anastrozole was the only hormonal 
treatment associated with body adiposity outcomes. Participants who had taken or 
were taking anastrozole had significantly higher body fat % (mean difference 2.04%, 
95% CI: 0.39 to 3.69, p=0.02) and higher FM/FFM ratio (mean difference 0.05, 95% 
CI: 0.00 to 0.09, p=0.03) compared to non-users. Waist circumference was also 
higher among anastrozole users, but the differences were not statistically significant 
(Table 29, Appendix I). 
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4.6.1.2 Menopausal status 
Participants diagnosed with BC after the menopause had significantly higher levels 
of body fat percentage (mean difference 2.42%, 95% CI: -4.25 to -0.58, p=0.01), 
FM/FFM ratio (mean difference 0.05, 95% CI: -0.10 to -0.00, p=0.03) and waist 
circumference (mean difference 4.45 cm, 95% CI: -8.52 to -0.38, p=0.03) than 
participants who were pre or perimenopausal at the time of BC diagnosis (Table 30, 
Appendix I).  
Change in menopausal status post-diagnosis was also statistically related to body 
adiposity parameters. Fewer than 30% of participants experienced a change in 
menopausal status during the follow up period. Those who did had less body fat and 
a lower waist circumference than those whose menopausal status did not change 
after BC diagnosis (mean difference of body fat percentage: 2.42%, 95% CI: -4.31 to 
-0.53, p=0.02, difference of FM/FFM ratio: 0.05, 95% CI: -0.10 to -0.00, p=0.04, 
and difference of waist circumference: 3.65cm, 95% CI: -7.85 to -0.55, p=0.05) 
(Table 30, Appendix I).  
 
4.6.1.3 Genetic profile 
Participants with the risk A and C alleles of the FTO and Mc4R genes had a non-
significantly lower body fat percentage and smaller waist circumferences than non-
carriers (Table 31, Appendix I).   
 
4.6.1.4 Other covariates of interest  
Older age was associated with larger body adiposity parameters (Pearson‘s r 
coefficient ranged from 0.15 to 0.21, p-values from <0.01 to 0.03) (Table 32, 
Appendix I). 
 
 125 
 
4.6.2 Multivariable analysis of body adiposity parameters at the end of the 
follow up   
4.6.2.1 Percentage of body fat  
Percentage of body fat were predicted by a model that included weight and age at 
diagnosis (adjusted R
2 
=0.53, p<0.01) (Table 33, Appendix I). When these variables 
were accounted for, anastrozole was no longer associated with fat %. 
The model indicated that when all the other predictors were similar: 
 Body fat percentage increased by 0.35 per one kg of body weight at 
diagnosis. 
 Each one year of age increased body fat by 0.11%.  
The results of the model did not vary after excluding one outlier participant with a 
studentized deleted residual value of - 3.70, and 27.7% of body fat (Table 69, 
Appendix V). 
 
4.6.2.2 Fat mass/fat free mass ratio 
The combination of weight at diagnosis and age at diagnosis was able to explain 
54.4% of the variance of FM/FFM ratio (p<0.01) (Table 34, Appendix I).  
According to the model: 
 Each kg of weight at diagnosis increased the FM/FFM ratio by 0.01.  
 Each year of age added 0.002 to the FM/FFM ratio value. 
The magnitudes of the coefficients and of the p-values were very similar to those 
conducted excluding two participants with studentized deleted residual values of -
3.60, and 3.28 respectively, and with FM/FFM ratio values of 0.38 and 1.04, 
respectively (Table 70, Appendix V). 
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4.6.2.3 Waist circumference 
After considering all the variables explored, waist circumference was best predicted 
by the combination of weight at diagnosis and age at diagnosis (all p<0.01, adjusted 
R
2
: 0.56) (Table 35, Appendix I).  
According to the model: 
 Each one year of age predicted an increase of 0.17 cm to the waist 
circumference, when weight at diagnosis was kept constant.  
 Each kg of body weight at BC diagnosis increased waist circumference by 
0.66 cm. 
A repeated analysis excluding one participant with a large studentized deleted 
residual value (-3.71) and a waist circumference of 86 cm produced similar 
coefficients and p-values (Table 71, Appendix V). Hence, her data were included in 
the analysis presented in Table 35 (Appendix I). 
 
4.7 Metabolic parameters at the end of the follow up 
Nine participants known to have diabetes at the time of study entry were excluded 
from the analysis of metabolic parameters. Data from the remaining participants with 
available records showed that average fasting glucose was 5.14 milimol per litre 
(mmol/l) (SD: 0.77), ranging from 3.10 to 10.80 mmol/l (n=167), and their average 
fasting insulin level was 39.31 pmol/l (SD: 2.63), ranging from 7.00 to 184.74 
pmol/l (n=147). HOMA IS and HOMA IR values were 128.92 (SD: 59.19) and 0.99 
(SD: 0.56) respectively. 
Eight participants (4.8%) had fasting glucose levels above the normal level (more 
than 6.0 mmol/l). Three of them had values corresponding to pre-diabetes (6.1 to 6.9 
mmol/l) and five participants had glucose levels that fall within the diabetic range 
(more than 6.9 mmol/l) (Diabetes.co.uk 2016).   
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4.7.1 Univariable analysis of metabolic parameters at the end of the follow up 
Chemotherapy and exemestane use were statistically significantly associated with 
insulin levels. The mean difference between chemotherapy users and non-users was -
10.43 pmol/l (95% CI: -20.74 to -12, p=0.04), and mean difference between 
exemestane users and non-users was - 6.00 pmol/l (95% CI: -24.82 to -1.10, p=0.03). 
Conversely, letrozole users had higher insulin levels compared to non-users (mean 
difference 24.03 pmol/l, 95% CI: 4.56 to 43.49, p=0.02) (Table 36, Appendix I).  
Menopausal status was not associated with metabolic parameters (Table 37, 
Appendix I). 
Carriers of the risk alleles for higher body weight of both FTO and Mc4R genes had 
statistically non-significantly lower glucose levels and higher insulin levels than 
non-carriers (Table 38, Appendix I).  
Insulin levels were negatively related to time elapsed between BC diagnosis and 
measurement of metabolic parameters (r=-0.21, p=0.01), but not with weight change 
post-diagnosis (r=-0.07, p=0.44) (Table 39, Appendix I).  
 
4.7.2 Multivariable analysis of metabolic parameters at the end of the follow 
up 
Initially, the model predicting glucose levels that best fitted data included weight at 
diagnosis and letrozole use. However, sensitivity analysis showed that after 
excluding two outlier participants with the highest glucose levels (10.8 and 8.80 
mmol/l, studentized deleted residual values: -7.90 and 4.43, and Cook‘s distance: 
1.80), letrozole use no longer added any statistical value to the model‘s prediction of 
glucose levels (Tables 72 and 73, Appendix V), and R
2 
decreased from 0.13 to 0.09. 
Therefore, Multiple linear regression analysis was repeated without those 
participants and the final model included weight at diagnosis and FTO genetic 
profile (adjusted R
2
: 0.10, p=0.02) (Table 40, Appendix I). The model predicted that 
when the other predictors were held constant:  
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 Each kg of body weight at the time of diagnosis was associated with an 
increase in glucose levels by 0.01 pmol/l (p<0.01).  
 Carriers of the risk FTO A-allele had 0.28 pmol/l higher glucose levels 
compared to non-carriers. 
The resulting model met all the assumptions of a multiple regression analysis.  
Similarly, fasting insulin level was best predicted by a model that included weight at 
diagnosis and FTO genetic profile (R
2
:
 
0.37%, p<0.01) (Table 41, Appendix I). 
When the other predictors were held constant, the model predicted that: 
 Each kg of body weight at the time of diagnosis was associated with an 
increase of insulin levels by 1.17 pmol/l (p<0.01). 
 Carriers of the risk FTO A-allele had 15.20 pmol/l higher insulin levels than 
those of non-carriers.  
This model included a participant with an outlying large studentized deleted residual 
value (3.5) and fasting insulin level of 142.48 pmol/l as inclusion of her data did not 
alter the findings (Table 74, Appendix V).  
The addition of other predictors to the model did not add any significant predictive 
value to the models fitted. 
 
4.8 Summary of the findings 
A mean positive weight change was found from diagnosis to the four evaluation 
points explored. Weight change across the sample was statistically significant, 
although it magnitude was small. Most participants experienced weight change 
(defined as changes larger than 0.0kg or 0.0% of baseline weight). At each of the 
four evaluation points explored, the number of participants that experienced weight 
gain was larger than the number of participants that experience weight loss. For 
instance, among those whose weight changed, relative weight gains over 5% were 
seen in 24.1% to 35.5% of participants, whereas a 5% or more decrease of weight 
was seen in 13.5% to 17.7% of participants. 
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 Multilevel modelling of weight change also indicated that weight varied over time 
and that most of the variance in body weight was found between-person rather than 
within-person. It also suggested that weight change was heterogenic across the 
sample, and for most participants, it followed a quadratic trajectory rather than a 
linear trajectory. In line with that, weight change was observed in both directions, 
and a small number of participants who gained weight in the first 12 months post-
diagnosis lost it later on, and some of those who lost weight in the first year gained 
weight by the time of study entry. 
The factors associated with weight changes from diagnosis to 12, 24, 36 and 48 
months post-diagnosis were body weight, smoking status and age at diagnosis, as 
well as tamoxifen use post-diagnosis. Multilevel modelling predicted that the rate of 
weight change varied according to tamoxifen use and that body weight at any time 
post-diagnosis could be predicted by tamoxifen, anastrozole and letrozole use.  
Multiple regression analysis showed that body adiposity parameters at study entry 
were associated with weight and age at the time of diagnosis. Together with FTO 
genetic profile, weight at diagnosis was also a predictor of insulin and glucose levels 
at study entry. No other factor explored in this study was associated with 
participants‘ adiposity and metabolic parameters.  
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CHAPTER 5: DISCUSSION AND CONCLUSSIONS 
 
5 Introduction 
This retrospective cohort study of 239 participants diagnosed with early BC aimed to 
explore weight changes from diagnosis to the end of the follow up period, on 
average, 48 months post-diagnosis, and to look at the association of BC treatments, 
menopausal status and genes with weight change post-diagnosis. A further aim was 
to test the association of those parameters with body adiposity and metabolic 
parameters collected at the end of the follow up period.  
This chapter discusses the results presented in the previous chapter, demonstrating 
how they coincide with other studies, and how they add new evidence which might 
open lines of investigation for a better understanding of changes in weight, metabolic 
and adiposity parameters after BC diagnosis. The implications for practice will be 
detailed just before the conclusions of the discussion. 
 
5.1 The sample  
It was expected that at least 500 women treated with early BC would be seen in the 
Oncology and Surgical follow up clinics. Nonetheless, it was not possible to know 
whether they all would meet the inclusion criteria of this study, and therefore, the 
rate of participation in the study is unknown. Moreover, since the researcher was not 
the person directly inviting BC patients to take part in this study, it is not possible to 
know the exact number of BC patients approached. However, it is known that non-
participation existed, as some BC patients filled out the optional decline slip to 
inform the research team that she did not want to take part in the study and the 
reasons why. It is also unknown whether those who declined to take part in this 
study were different to those who participated.  
It is possible that self-selection bias are present if those who gained a lot of weight 
and felt embarrassed by and did not take part in the study. Similarly, it is possible 
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that those who lost weight or those who felt their weight was not altered after 
diagnosis thought that this study was not applicable to them.  This risk of selection 
bias was addressed by explaining to the potential participants the importance of 
taking part in the study, regardless of whether they experienced weight changes or 
either direction of weight change.   
Arguably, the participants in this study are fairly representative of the UK population 
of BC patients. The participants‘ characteristics presented in Chapter 4 seem to 
reflect UK national figures. Nearly 50% of study participants were 60 years of age or 
older, a proportion that is representative of BC women over 60 years diagnosed in 
the UK each year (46%) (Cancer Research UK 2014a). In addition, the prevalence of 
ER and HER-2 tumours in the sample is comparable to cases in the UK (Cancer 
Research UK 2014b). Furthermore, the percentages of different non-white ethnic 
groups mirror the English national figures: 1.5% Asian cases, 1% black cases, or 
0.2% Chinese cases (National Cancer Intelligence Network 2010). 
Interestingly, findings showed that in this study, 117 participants (around 60% of the 
sample) were overweight or obese at the time of diagnosis. Eighty nine of them were 
postmenopausal and 28 were pre or peri menopausal (data not shown). These figures 
are consistent with the fact that obesity is a risk factor for post-menopausal BC 
(Neuhouser et al. 2015). Nonetheless, the prevalence of overweight or obesity in this 
study is slightly higher than the figures reported in other cohort studies like the 
WHEL (57%) (Saquib et al. 2007), or the LACE and WHEL combined (50.85%) 
(Caan et al. 2006). The higher prevalence of overweight/obese participants in this 
study might have led to an underestimation of the true association between predictors 
and weight change, as findings showed that weight at the time of diagnosis was 
negatively correlated with weight change in the first three years post-diagnosis, 
which suggests that heavier participants tend to experience less weight change than 
leaner participants. Arguably, this finding could be the result of the regression to the 
mean, a common statistical artefact in repeated datasets with non-systematic 
(random) errors and random fluctuation, where initial extreme values far from the 
true mean (i.e. low or large body weight) would be likely to be followed by less 
extreme values nearer the subject's true mean (Barnett et al. 2005). Nonetheless, it is 
a finding that has been reported by large cohort studies (i.e. Kroenke et al. 2005; 
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Caan et al. 2006; Saquib et al. 2007; Chen et al. 2011), Consequently, it is possible 
that weight changes of higher magnitude could have been observed if the percentage 
of overweight or obese participants would have been lower.   
Most participants were recruited from Royal Bournemouth Hospital because 
recruitment in Poole Hospital started ten months later. It is possible that patients 
attending Royal Bournemouth Hospital might be different from those attending 
Poole Hospital. Nonetheless, no statistically significant differences were found 
between the two groups in the frequency of baseline characteristics or outcomes 
values (i.e. age, education level, percentage of smokers at diagnosis, rate of 
pre/perimenopausal women/postmenopausal status at diagnosis, treatment and 
tumour characteristics, weight at diagnosis, months from diagnosis to the end of the 
follow up, weight at study entry, adiposity parameters, insulin and glucose levels) 
(data not shown). Therefore, the fact that most participants were recruited from 
Royal Bournemouth Hospital might not have implications affecting the findings in 
this study, and hence, both groups of participants might benefit equally from the 
recommendations derived from the results of this study detailed in the next 
paragraphs.  
 
5.2 Weight change after breast cancer diagnosis 
5.2.1 Magnitude and frequency of weight change after breast cancer diagnosis 
The analysis of the magnitude and the frequency of weight change revealed that 
weight changed at 12, 24, 36 and 48 months post-diagnosis. On average, the largest 
magnitude of weight change was observed 36 months post-diagnosis (mean change 
of + 2.67% of diagnosis weight, representing a weight change of + 1.59 kg). The 
smallest change in weight was found a year later (mean + 0.88%, a + 0.42 kg weight 
change). This finding is consistent with previous studies in the field which indicated 
that for 10% of BC survivors, the weight gained post-diagnosis reverses during 
follow up (Saquib et al. 2007). In this study nearly 23% of participants who gained 
weight 12 months post-diagnosis lost all the weight gained by the end of follow up. 
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Interestingly, more than 33% of the participants who initially lost weight gained 
weight later on.  
The true weight at diagnosis in the population from which this sample was drawn is 
unknown. Therefore, it is difficult to ascertain whether the weight change found is a 
real weight change, or an expected finding resulting from the regression to the mean. 
Nonetheless, the regression to the mean effect was addressed in the multivariable 
analysis, which controls for the effect of weight at diagnosis. 
The percentage of participants that experienced weight change larger than 0.0 kg was 
over 92% in the first year and nearly 100% in the years after that. Weight changes 
over 5% and 10% were seen in both directions. At each of the four period explored, 
around 8% of the sample gained more than 10% of their diagnosis weight and around 
5% of the sample lost that amount. And the percentage of participants that 
experienced 5% weight gain, or 5% weight loss, ranged from 24.1 to 35.4% and 
from 13.5 to 17.7% respectively. These findings are comparable to previous small 
and large cohort studies, including the ABCPP, that reported that 10% to 60% of BC 
survivors gained more than 5.0% of initial body weight, and 15% to 27% lost 
weight, over an average of two to seven years post-diagnosis (Rock et al. 1999; Caan 
et al. 2006, 2008; Han et al. 2009; Tredan et al. 2010; Nissen et al. 2011; Bradshaw 
et al. 2012; Caan et al. 2012b; Sedjo et al. 2014).  
In this study, weight from diagnosis to 12 months remained unchanged in seven 
participants (0.0% weight change), although available data indicated that their 
weight changed after that. Several studies reported that some women diagnosed with 
BC maintained their weight post-diagnosis (Lankester et al. 2002; Han et al. 2009; 
Gu et al. 2010; Chen et al. 2011; Bradshaw et al. 2012). Nonetheless, it is worth 
mentioning that the definition of weight maintenance, in other words, no weight 
change, varies across the studies, and in most cases, it involved some degree of 
weight change. Therefore, findings in this study did not contradict previous 
literature. Most commonly used definition of weight maintenance in the field of 
weight change post BC included within 2 kg of baseline (Lankester et al. 2002; Gu et 
al. 2010; Chen et al. 2011), or within 5% of body weight (Rock et al. 1999; Han et 
al. 2009; Nissen et al. 2011; Bradshaw et al. 2012; Caan et al. 2012b).  
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Exploring the magnitude as well as the frequency of weight change allowed 
researcher to indentify different groups of participants: those who experienced small 
magnitude of weight change, those whose weight suffered large variations, as well as 
those whose weight did not change (at least in the first year of diagnosis). The 
clinical implications for these subgroups of participants seem to be different in the 
light of knowledge derived from survival studies, as it is explained below.    
 
5.2.1.1 Is the magnitude of weight change different from the healthy 
population? 
In the general population, weight change is common among women as they age. The 
National Health and Nutrition Examination Survey found that in a 10-year period, 
women aged 25 to 34 gained 3.45 kg (0.35 kg/year), and those 45 to 55 years gained 
0.79 kg (0.08 kg/yr), whereas women 55 and older lost weight (Williamson et al. 
1990). Results from the IBSI-1 of postmenopausal women with a high risk of BC 
found weight gains of 1.0 kg (SD: 1.5) after 12 months follow up, and a gain of 1.3 
kg (SD: 5.7) at 60 months (Sestak et al. 2012). Although the findings from those 
studies cannot be compared directly with the results in the present investigation, their 
findings and this study‘s findings suggest that on average, women diagnosed with 
BC experienced larger weight changes (which on average were positive) than 
women not diagnosed with BC. Supporting that, at least three studies have provided 
evidence that BC patients gain more weight than age-matched controls (Sestak et al. 
2012; Gross et al. 2015; Vagenas et al. 2015). BC survivors gained significantly 
more weight [β = + 3.06 pounds (lb), 95% CI: 0.94 to 5.17] than cancer-free women 
in Gross‘et al. (2015) study. Vagenas and colleagues (2015) found that 56% of BC 
patients gained weight (mean + 5.3 kg) between six and 72 months post- BC surgery, 
and nearly 80% of them experienced greater gains than the average weight gain seen 
in sex- and age-matched controls. 
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5.2.1.2 Potential clinical implications of the weight change found 
There is evidence that large weight changes (in both directions) post-diagnosis could 
have and undesirable effect on BC prognosis and on women‘s health.   
Nichols et al. (2009) found that each 5 kg gained during the first six years post-
diagnosis was associated with a 12% increase in all-cause mortality, a 13% increase 
in BC specific mortality, and a 19% increase in mortality from cardiovascular 
disease. Nonetheless, in the ABCPP, the risk of death was only associated with 
substantial weight gain (more than 10% of diagnosis weight, mean + 10.5 kg) during 
the first two years of diagnosis (Caan et al. 2012b). The Nurses Health Study also 
showed an adverse prognosis among non-smoking women who gained a mean of 6.6 
lb (around 3 kg) within the first three years post-diagnosis (RR all cause mortality: 
1.59, 95% CI: 1.07 to 2.51 and RR of BC recurrence: 1.53, 95% CI: 1.04 to 2.24) 
(Kroenke et al. 2005). Weight gains of 5% after BC diagnosis have also been 
associated with worse physical functioning (Imayama et al. 2013). Furthermore, BC 
survivors who gained more than 10% of their baseline weight by two years post-
diagnosis had an increased risk of developing type-two diabetes (OR: 1.38, 95% CI: 
1.06 to 4.76, p=0.04) (Erickson et al. 2012), and were more likely to report hot-
flushes (Caan et al. 2012a). 
On the other hand, evidence has shown that weight loses of more than 10% of the 
baseline weight in the first two years of diagnosis increased the risk of all cause 
mortality in subgroups of populations: for instance, in women who smoked (HR: 
1.58, 95% CI: 1.20 to 2.09), in underweight women with no comorbidities (HR: 
2.16, 95% CI: 1.25 to 3.75), and in overweight/obese women with comorbidities 
(HR: 1.89, 95% CI: 1.25 to 3.75) (Caan et al. 2012b). Nevertheless, normo-weight 
women might also have an increased risk of mortality following BC if they 
experience moderate weight losses of 5% to 10% (mean: - 4.9 kg) (Caan et al. 
2012b). Similarly, in a previous study, BC survivors who lost more than 1 kg by 18 
months post-diagnosis had higher risk of all cause mortality (HR: 2.41, 95% CI: 1.62 
to 3.58) and BC recurrence (HR: 1.60, 95% CI: 1.03 to 2.48) (Chen et al. 2010).  
Nonetheless, the current evidence on the association between weight loss and BC 
prognosis should be taken with cautious as it might be the result of unintentional 
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weight loss that might hide other issues (i.e. more advanced stages of BC, or 
comorbidities) (Jackson et al. 2017). 
In the present study, although the mean weight change post-diagnosis was 
statistically significant, its magnitude was small according to Cohen‘s criteria 
(Cohen 1992) ranging from + 1.44% to + 2.67% of diagnosis weight (a mean of + 
0.85 kg to + 1.59 kg). In the light of those survival studies, the magnitude of weight 
change experienced by most participants in this study is unlikely to be clinically 
relevant. Nonetheless, the study uncovered that at least 20% of participants gained 5 
kg or more in the first year of diagnosis, and when exploring weight change in 
relative terms, between 8 and 10% of participants gained more than 10% of their 
diagnosis weight. Furthermore, findings revealed that 4% to 6% of the sample lost 
large amount of weight (more than 10% of their diagnosis weight) in the first four 
years post-diagnosis. Based on the results of the survival studies above cited, 
attention should be given to these subgroups of participants whose magnitude of 
weight change (either weight gain or weight lost) poses a threat to their health and 
BC prognosis.  
Attention should be also paid to the 60% of participants who were already 
overweight/obese at the time of diagnosis. Obesity at diagnosis is a negative 
prognostic factor (Protani et al. 2010; Druesne-Pecollo et al. 2012; Niraula et al. 
2012; Jain et al. 2013; Azrad and Demark-Wahnefried 2014; Chan et al. 2014). In a 
study conducted by Nichols et al. (2009), women categorized as obese (BMI more 
than 30 kg/m
2
) before a BC diagnosis had a 52% increase in all-cause mortality risk 
(95% CI: 1.17 to 1.98), a risk of death from BC 2.28 times higher (95% CI: 1.43 to 
3.64) and a cardiovascular disease mortality rate 1.65 times higher (95% CI: 0.97 to 
2.83) than that of women with a normo-weight (BMI of 18.5 to 24.9 kg/m
2
). Azra 
and Demark-Wahnefried (2014) conducted a review of the literature and concluded 
that obesity contributed to negative clinical outcomes in BC patients. The association 
appeared to be strongest in women with ER positive tumours regardless of 
menopausal status, whereas there was no evidence to suggest that obesity was 
associated with outcomes in women with triple negative disease.   
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To date, the association between obesity and BC outcomes is poorly understood and 
many hypotheses have been suggested, including that BC occurs at more advanced 
stages in obese women, or less aggressive treatment might be given to those patients 
(Goodwin 2015a). It is also possible that BC treatments are less effective in obese 
women. Results from two clinical trials, the ATAC trial (Howell et al. 2005) and the 
Australian Breast and Colorectal Cancer Study Group trial 6 (ABCSG-6) (Schmid et 
al. 2003) suggest that obesity at the time of BC diagnosis might alter the efficacy of 
AINs. Furthermore, the physiological changes arising from a metabolically active 
adipose tissue (i.e. changes in insulin, oestrogens and other inflammatory 
substances) could also explain the association between adiposity and BC (Goodwin 
2015b), as detailed later on in this chapter.  
The findings reported in this study confirm that weight changes occur post-diagnosis 
and that the magnitude of weight change varies across the sample. This highlights 
the need to investigate the causes leading to weight changes post BC diagnosis. In 
order to contribute to that knowledge, the second objective of this study was to 
explore whether weight change was associated with BC treatment, biological and 
behavioural factors. Because of the retrospective nature of the study, the findings 
reported here only indicate
 
a relationship and not a causal association (Hill 1965). 
 
5.2.2 Factors associated with weight change post-diagnosis 
5.2.2.1 Chemotherapy 
In this study, a non-statistically significant mean weight increase post-diagnosis was 
seen among participants treated with chemotherapy and among participants who did 
not receive chemotherapy. The differences in the magnitude of weight change 
between the two groups were erratic and both multiple linear regression analysis and 
multilevel weight change modelling confirmed that chemotherapy was not associated 
with weight change. This finding correlates with several studies that did not find a 
relationship between chemotherapy and weight gain post-diagnosis (Kutynec et al. 
1999; Freedman et al. 2004; Gu et al. 2010; Sestak et al. 2012; Reddy et al. 2013; 
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Arpino et al. 2015), but contradicts many others showing a statistically significant 
association between the two (Goodwin et al. 1999; Rock et al. 1999; Demark-
Wahnefried et al. 2001; Caan et al. 2006, 2008; Chen et al. 2011). One possible 
explanation for the inconsistent association between chemotherapy and positive 
weight change post BC diagnosis is the difference in chemotherapy agents used. 
Although at least two studies found that all chemotherapy regimens resulted in some 
weight gain (Goodwin et al. 1999; Irwin et al. 2005), emerging literature suggests 
that anthracycline-containing regimens are associated with less weight gain than 
other regimens (Rock et al. 1999; Saquib et al. 2007; Reddy et al. 2013; Makari-
Judson et al. 2014). For example, one study found that the highest weight gain (+ 2.9 
kg) was recorded in a group of women receiving non-anthracycline agents (i.e. 
cyclophosphamide, methotrexate and fluorouracil), compared to + 0.9 kg weight 
change observed in the anthracycline-based group (Liu et al. 2014). In the current 
study, most chemotherapy users (95.5%) were treated with anthracycline-containing 
regimens either alone or in combination with taxanes. Hence, this could explain the 
lack of association with weight change. Due to the small number of chemotherapy 
users who did not receive anthracyclines in this study, it was not possible to compare 
weight changes based on anthracycline use. However, comparing taxane-based 
chemotherapy with other chemotherapy regimens found similar weight changes. 
Because of the evolving nature of BC treatment, it is important to continue 
investigating the role that different chemotherapy regimens play in body weight 
changes, as the variations in pharmacokinetics that could provide a plausible 
explanation for the differences in weight change, if they exist. 
 
5.2.2.2 Hormone therapy  
Univariable analysis showed that weight change was larger (and overall positive), 
among tamoxifen and gonadorelin analogue users at all four evaluation points 
explored, compared to the average weight change seen among non-users, who on 
average, had a negative weight change.   
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On the other hand, both letrozole users and non-users, and exemestane users and 
non-users have a mean positive weight change post-diagnosis. Interestingly, the 
magnitude of weight change was larger among letrozole and exemestane non-users 
at 12 and 24 months post-diagnosis, whereas in the next two periods explored, users 
had larger weight changes than non-users. Like chemotherapy, anastrozole use was 
associated with erratic patterns of weight change, with positive and negative mean 
weight change post-diagnosis. 
Multilevel weight change modelling support the role of these hormone therapy 
agents in weight change post-diagnosis, an association that is biologically plausible. 
Hormone therapy aims to reduce the availability of endogenous oestrogen to tumour 
cells (Goel et al. 2009), and it is known that oestrogens can reduce food intake and 
affect body weight (Roesch 2006). Studies conducted in animals have provided 
evidence that AINs can produce weight gain (Kubatka et al. 2008a; Kubatka et al. 
2008b; Sadlonova et al. 2009). In multiple linear regression analysis, tamoxifen use 
was associated with positive weight change at 24 months post-diagnosis, with a quite 
low significance level (p-value <0.01). Moreover, weight change modelling showed 
that the rate of weight change was higher among tamoxifen users and the estimated 
body weight at any time post-BC diagnosis was higher among tamoxifen and as well 
as among anastrozole users compared to non-users. Conversely, the estimated body 
weight was lower among letrozole users. Nonetheless, findings about the apparently 
contradictory effect of anastrozole and letrozole on weight use should be taken with 
caution as they might the result of the reduced sample size of letrozole users. 
In the BC research field, the association of tamoxifen use with weight gain is not 
new. Some studies have shown higher weight gain in BC survivors using tamoxifen 
compared with a control group of women not receiving hormone therapy (Hoskin et 
al. 1992). In the Nurses Health Study, women treated with chemotherapy or 
tamoxifen tended to experience the largest weight gains (Kroenke et al. 2005). Sedjo 
et al. (2014) reported for the first time lower weight gain among AINs users as 
compared with tamoxifen users. However, the literature reporting the role of 
hormone therapy in weight gain is controversial, as there is also evidence of greater 
increases among non-users. Data from the WHEL study revealed that tamoxifen use 
was not associated with significant weight gain and did not modify the effect of 
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chemotherapy use on weight gain (Saquib et al. 2007). WHEL‘s findings are in line 
with other studies (Camoriano et al. 1990; Kumar et al. 1997; Lankester et al. 2002; 
Freedman et al. 2004; Irwin et al. 2005; Genton et al. 2006; Makari-Judson et al. 
2007; Gu et al. 2010; Chen et al. 2011; Sestak et al. 2012). However, a light into the 
controversy comes from Nissen et al. (2011), who found that although tamoxifen use 
did not affect weight change, it increased body fat. These findings are compatible 
with those reported by Nguyen et al. (2001), although they contradict many others 
(Freedman et al. 2004; Irwin et al. 2005; Francini et al. 2006).  
 
5.2.2.3 Menopausal status and change in menopausal status 
In this, and in several studies (Camoriano et al. 1990; McInnes and Knobf 2001; 
Freedman et al. 2004; Caan et al. 2006, 2008; Heideman et al. 2009; Basaran et al. 
2011; Chen et al. 2011; Caan et al. 2012b) the magnitude of mean weight change 
following BC diagnosis was positive in the premenopausal/perimenopausal group 
and was larger than the magnitude of weight change found among postmenopausal 
women.  
Average weight changes were also positive among those who became peri or 
postmenopausal post-diagnosis. The magnitude of the weight change observed in 
this group was larger compared to that seen among those whose menopausal status 
did not change (postmenopausal women and a few premenopausal women) and was 
statistically significant at 12 (p=0.03) and 48 months (p=0.01) post-diagnosis. 
Although it is possible that the significant associations found are a type-one error 
inflation, the associations are not surprising. In the general population, the transition 
to menopause is commonly associated with weight gain and with a redistribution of 
body fat (Toth et al. 2000; Boonyaratanakornkit and Pateetin 2015). A limited 
number of studies have also reported an association between transition to menopause 
and weight gain in BC survivors. In one of them the effect vanished after other 
variables were taken into account (Reddy et al. 2013), whereas in another it 
remained a significant predictor together with chemotherapy use (Goodwin et al. 
1999). On the other hand, Irwin et al. (2005) found that in both adjusted and non-
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adjusted analysis, postmenopausal women gained more weight compared to 
premenopausal women and women who became postmenopausal after diagnosis. 
In the current study, the association between menopausal status change and weight 
change mirrored the association seen between chemotherapy and weight change. 
Weight change was positive among chemotherapy users and non-users. Nonetheless, 
the magnitude of the change was larger among chemotherapy users at 12 and 48 
months post-diagnosis, whereas at 24 and 36 months post-diagnosis, the magnitude 
of weight change was inferior among chemotherapy users compared to non-users. 
Age and menopausal status at diagnosis were highly correlated, and like others 
(Sedjo et al. 2014), this study used the variable age in the multiple linear regression 
analysis and in the multilevel weight change modelling. Both showed that neither 
age nor chemotherapy use were predictors of weight change after accounting for 
other variables. Hence, it is likely that other factors (i.e. tamoxifen use) might be 
more relevant to explain weight change post-diagnosis. However, it is possible that 
smaller sample size of this study compared with others studies and the difficulties in 
defining menopausal status after one year post-diagnosis (as discussed by Reddy and 
colleagues, 2013) could explain the opposite results found by other researchers 
(Goodwin et al. 1999; Irwin et al. 2005; Reddy et al. 2013). In addition, it is possible 
that the timing of recording baseline weight could have masked the impact of 
treatment-related amenorrhoea on body weight change (i.e. if adjuvant treatment had 
already commenced). Therefore, the question of whether the observed weight 
changes can be attributed to menopausal status change, ageing, or BC treatment 
remains to be answered. 
 
5.2.2.4 Genes 
Growing research is pointing to the importance of FTO and Mc4R in determining 
body weight.  
The prevalence of the homozygous risk allele A at the rs9939609 FTO variant in this 
study was 8.3%, a bit lower than the prevalence reported in the general population 
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(Frayling et al. 2007; Lourenço et al. 2014). This finding is not consistent with 
results from one study showing that the presence of risk allele A at the rs9939609 
SNP increases the risk of BC (additive effect OR: 3.719, 95% CI: 1.43 to 9.68) 
(Kaklamani et al. 2011). Nonetheless, evidence on the relationship between FTO 
genotype and BC risk is not firm and another study found no differences in the 
frequencies of the FTO gene A allele and the Mc4R gene C allele between BC 
patients and controls (Kusinska et al. 2012). Consistent with this, the prevalence of 
homozygosity (also 8.3%) for the C-allele of the Mc4R gene rs17782313 
polymorphism among participants in this study is comparable with that found by Liu 
et al. (2011) among the general population, although other studies have found lower 
prevalence of the risky alleles (Arrizabalaga et al. 2014). Therefore, the reason for 
the prevalence of the risky alleles among participants is not understood.   
To the researcher knowledge, this is the second study looking at the effect of FTO on 
weight changes post BC diagnosis and the first one exploring the role of Mc4R. 
Findings revealed that all categories of FTO and Mc4R genotypes experienced a 
positive weight change. The pattern of weight change associated with FTO SNP 
rs9939609 was not consistent, a finding not supported by those reported by Reddy 
and colleagues (2013), who conducted the first study published looking at FTO in 
the field. In their study, weight change post-diagnosis was best predicted by a model 
that incorporated age and BMI and diagnosis, as well as data on all 14 SNPs 
explored from FTO and adiponectin genes. The model had a high discriminatory 
power to identify those at risk of weight gain post-diagnosis (Reddy et al. 2013). 
On the other hand, findings from this study showed a non-significantly lower weight 
change at all 4 evaluation points explored among those with the obesity-increasing C 
allele (high-risk allele) of the Mc4R gene compared to those without the high-risk 
allele. This finding contradicts the literature showing that the high-risk allele 
predisposes people to obesity (OR=1.18, 95% CI: 1.15 to 1.21, p<0.001) (Xi et al. 
2012a).  
This study‘s findings should be taken with caution. Genetic studies usually require 
larger sample sizes, hence, the small sample size of this study might only detect 
larger effects (Reinhart 2015). Additionally, in this study insufficient funding left 96 
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samples un-analysed. In addition, the large SD found in this study suggests that the 
mean weight change would be likely to vary should other samples of participants be 
analysed (Reinhart 2015). 
Although FTO and Mc4R have been linked to common forms of obesity, the 
molecular bases of the relationship is not clear (Olszewski et al. 2009, Xi et al. 
2012a; Arrizabalaga et al. 2014). These two genes seem to be highly expressed in the 
central nervous system which regulates the energy metabolism (Xi et al. 2012a). It is 
possible that the effect of the environment or other changes associated with the 
diagnosis of BC could interact with the genes, leading to weight changes post-
diagnosis. Therefore, further studies with bigger sample sizes are warranted, as they 
could provide evidence on whether these two genes could be used to understand 
weight change post-diagnosis and to identify women at risk of gaining weight post-
diagnosis.  
 
5.2.2.5 Other variables of interest 
Multiple linear regression analysis showed that weight at diagnosis was significantly 
and negatively correlated with weight change. Arguably, this could be a type-one 
error due to the use of un-adjusted significance testing. Nonetheless, it is worth 
mentioning that that association found could have met more strict significance levels, 
as the p-value found for the association was lower than 0.01. Furthermore, the 
finding agrees with most of the literature in the field showing larger weight gain 
among leaner women (Rock et al. 1999; Saquib et al. 2007; Gu et al. 2010; Nissen et 
al. 2011; Caan et al. 2012b; Reddy et al. 2013; Sedjo et al. 2014). However, the 
multilevel modelling conducted with all weight records collected from participants 
showed that weight at the time of diagnosis was not a predictor of rate of weight 
change. Therefore, it is possible that the statistical artefact of regression to the mean 
could be behind the association between weight at diagnosis and subsequent weight 
change. 
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Multiple linear regression analysis revealed that smoking status at diagnosis was also 
a significant predictor of the mean positive weight change found at 12 months post-
diagnosis. The nine participants who were smokers at the time of BC diagnosis 
tended to have a higher magnitude of weight change, which was positive, compared 
to non-smokers, which is consistent with other studies (Chen et al. 2011; Sedjo et al. 
2014), although Sestak et al. (2012) did not find significant differences in the risk of 
gaining weight post-diagnosis between smokers and non-smokers at the time of BC 
diagnosis. The reason for the association found in this study between being smoker 
at the time of BC diagnosis and an average positive weight change post-diagnosis is 
unclear. Findings could be the result of a small sample size, as in this study, like in 
that of Chen‘s et al. (2011) the number of smokers was small compared to the 
number of non-smokers. However, the most parsimonious explanation for the 
association found might be related to changes in smoking status post-diagnosis. 
Numerous studies have shown that smokers have typically lower body weight than 
non-smokers (Albanes et al.  1987; Himokata et al. 1998; Molarius et al. 1997). 
There is also abundant evidence that quitting smoking is associated with weight gain 
(Travier et al. 2012). For instance, results from a meta-analysis of 62 studies showed 
that smoking cessation is associated with a mean weight gain of 4.5 kg during the 
first 12 months of abstinence (Aubin et al. 2012). Although the mechanisms leading 
to post-cessation weight gain remain unclear, it is possible that the metabolic effects 
of the nicotine (i.e. increases in metabolic rate and decreases in appetite) play a role 
(Chiolero et al. 2008).  In this study, five out of the nine participants that were 
smokers at BC diagnosis and were included in the analysis of weight change at 12 
months post-diagnosis quitted smoking after diagnosis. In addition, another 
participant reduced the number of cigarettes per day and the remaining three 
participants said they did not change their smoking habits. These changes in smoking 
habits post-BC diagnosis among participants in this study could explain the larger 
weight change found among smokers. In fact, Sedjo et al. (2014) claimed that was 
the reasons for the positive association found in their study between smoking and 
weight gain post BC diagnosis. Unfortunately, participants were not able to specify 
the exact time at which they quit smoking. Therefore this study did not assess the 
impact of smoking cessation on weight gain post BC diagnosis. This is something 
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that might be worth taking into account in other studies looking at weight changes 
among BC patients. 
 
5.3 Multilevel models for weight change 
In addition to the findings from the multilevel weight change modelling already 
discussed in the previous paragraphs, the weight change models fitted also showed 
that the pattern of weight change post BC diagnosis seemed to follow a quadratic 
trajectory. However, due to the peculiarities of data, weight change could only be 
modelled using a linear function, an approach that added to previous research in the 
field using linear regression analysis (Camoriano et al. 1990; Rock et al. 1999; 
Demark-Wahnefried et al. 2001; Kroenke et al. 2005; Makari-Judson et al. 2007; 
Heideman et al. 2009; Gu et al. 2010; Vagenas et al. 2015). 
The magnitude of the rate of weight change estimated in the models was small but 
statistically significant. Findings indicate that women differ in their rate of change, 
and that the only predictor explaining those differences was tamoxifen use. 
Furthermore, the time-varying models fitted allowed the effects of BC treatment to 
vary over time, adding further support for the role of hormone therapy in weight 
change post-diagnosis as mentioned earlier. The models showed that estimated 
weight following BC diagnosis depends on tamoxifen, anastrozole and letrozole use. 
 
5.4 Body adiposity parameters 
Participants had a mean of 28.5 kg (SD: 9.43) of body fat, a fat percent of 37.8% 
(SD: 6.24) of body weight and an FM/FFM ratio of 0.62 (SD: 0.16). On average, 
their waist circumference measured a mean of 92.3 cm (SD: 11.82). These body 
adiposity parameters are comparable to those reported in the literature of BC 
(Kutynec et al. 1999; Demark-Wahnefried et al. 2001; McTiernan et al. 2003; 
Freedman et al. 2004; Harvie et al. 2004; Guinan et al. 2014; Alacacioglu et al. 
2016). 
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5.4.1 Are these adiposity parameters different from the healthy population? 
Although findings cannot be directly compared, the body fat and waist 
circumference values found in this study, as well as those reported in other samples 
with BC women seem to be higher than in the average population of women in the 
UK (Kutynec et al. 1999; Demark-Wahnefried et al. 2001; McTiernan et al. 2003; 
Freedman et al. 2004; Genton et al. 2006; Harvie et al. 2004; Guinan et al. 2014; 
Alacacioglu et al. 2016). Premenopausal women in the UK were found to have an 
average body FM of 24.4 kg (SD: 9.6), body fat percentage of 33.8% (SD: 7.0) and a 
waist circumference of 80.6 cm (SD: 11.3), whereas postmenopausal women had 
higher levels of body fat mass (25.8 kg, SD: 8.8), body fat percentage (36.2%, SD: 
6.4) and waist circumference (83.2 cm, SD: 11.2) (Guo et al. 2015). 
Typical weight gain is often associated with an increase in FM and FFM (Forbes et 
al. 1986). In this study, FM, FFM and waist circumference were only measured once 
at the end of the follow up (mean 48 months post-diagnosis), therefore, changes in 
those parameters following BC diagnosis were not assessed. Nonetheless, previous 
studies in the field have shown deteriorations in adiposity parameters at different 
points after BC diagnosis (Arpino et al. 2015 and Sheean et al. 2012 for a review of 
previous studies). The magnitude of the increment in fat percentage levels reported 
by some studies varied from 0.72% to 2.5% during chemotherapy (Aslani et al. 
1999, Freedman et al. 2004), and from 1.37% to 6.2% one year after diagnosis and 
the final fat percent reported reached values ranging from 35.2% to 46.9% (Kutynec 
et al. 1999; Demark-Wahnefried et al. 2001; McTiernan et al. 2003; Freedman et al. 
2004; Harvie et al. 2004; Thomson et al. 2009; Guinan et al. 2014; Alacacioglu et al. 
2016). Similarly, increases in waist circumference from 0.9 cm to 5.1cm have been 
observed around one or two years after diagnosis, which resulted in final levels of 
82.4 to 89.9 cm (Goodwin et al. 1999; Freedman et al. 2004; Harvie et al. 2004; 
Arpino et al. 2015). Differences in the magnitude of change found in previous 
studies could be attributed to the different instruments used to measure body fat (i.e. 
BIA analysis, skinfold thickness, dual energy x-ray absorptiometry, or CT scan) as 
discussed by Freedman and colleagues (2004).  
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5.4.2 Potential clinical implications of the excess body fat and waist 
circumference observed 
The adipose tissue is an important endocrine organ (Kershaw and Flier 2004) that 
participates dynamically in regulation of energy (Ruan and Lodish 2003) and body 
weight (Su et al. 2012) through different ways: 1) its effects on other hormones also 
implicated in the regulation of energy, like insulin, 2) through active interaction with 
other organs (Morton and Schwartz 2011), and 3) the substances that it secretes, 
including oestrogen and leptin (Galic et al. 2010).  
In this study, the participants‘ mean body fat percentage was above the healthy range 
(36% for women 60 years and older, 34% for 40- to 59-year-old women) (Tanita 
Corporation 2014), a worrying finding since it has been suggested that excessive 
adipose tissue might change the cellular composition of the adipose tissue, leading to 
alterations in the number, phenotype and  location of cells, affecting the secretory 
activity of the adipose tissue (Ouchi et al. 2011), and ultimately contributing to 
cellular transformation and carcinogenesis (Ozbay and Nahta 2008). Adipose tissue 
is found in the mammary gland, around breast tumours and in the tumours 
themselves (Dirat et al. 2010). Consequently, it could potentially exert its effects on 
BC through endocrine, paracrine and autocrine mechanisms (Vona-Davis and Rose 
2007). In fact, Wang et al. (2012) suggests that the effects of the adipose tissue 
located in the breast might be increased in obese women, which could explain in part 
the adverse BC prognosis associated with obesity found in many investigations 
(Kumar et al. 2000; Rose et al. 2002; de Azambuja et al. 2010; Azra and Demark-
Wahnefried 2014; Sun et al. 2015). Also worrying is the fact that a study conducted 
with Asian women indicated that high levels of abdominal fat were correlated with 
greater chemotherapy toxicity, a finding that, as the author concluded, adds to the 
emerging evidence suggesting that body composition has a role in chemotherapy 
dose determination (Wong et al. 2014). And as mentioned earlier on, it is believed 
that obesity influences the response and resistance of BC tumours to AINs (Schmid 
et al. 2003; Howell et al. 2005; Pfeiler et al. 2012; Schech et al. 2015). 
Waist circumference (a marker of abdominal adiposity) and general obesity are also 
associated with cardiovascular disease risk, type-two diabetes, overall mortality, as 
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well as colorectal cancer and postmenopausal BC (World Health Organization 
2008). According to the International Diabetes Federation, a waist circumference 
more than 80 cm increases the risk of metabolic complications in women from 
different ethnic groups (Alberti et al. 2009). In the current study, participants‘ mean 
waist circumference of 92.3 cm exceeded that cut-off point, which highlights the 
potential risk that this group of women are exposed to.  
Finally, the greater content of body fat among BC patients, if accompanied by lower 
FFM, could lead to sarcopenic obesity, and can have several adverse effects. 
Sarcopenia has been associated with higher risk of developing dose-limiting toxicity 
in BC treatment (Prado et al. 2009), and with poorer prognosis, independently of 
body adiposity (Villasenor et al. 2012). It also leads to reduced physical performance 
in the general population (Lang et al. 2010). 
 
5.4.3  Factors associated with body adiposity parameters at the end of the 
follow up 
5.4.3.1 Chemotherapy 
In this study, chemotherapy users had non-significantly lower body fat and waist 
circumference levels at the end of the follow up. The lack of association between 
body adiposity parameters and chemotherapy is consistent with some studies that 
report no changes in body fat associated with BC treatment at two years post-
diagnosis (Irwin et al. 2005), or three years post-diagnosis (Guinan et al. 2014). In 
contrast, numerous studies have reported increased levels of fat content during 
chemotherapy or during the first year of diagnosis (Cheney et al. 1997; Aslani et al. 
1999; Kutynec et al. 1999; Demark-Wahnefried et al. 2001; Del Rio et al. 2002; 
Harvie et al. 2004; Campbell et al. 2007a; Gordon et al. 2011; Porciúncula Frenzel et 
al. 2013). Altogether, these findings suggest that the effect, if any, of chemotherapy 
on body fat might not be sustained over time, which is a hypothesis that deserves 
further exploration. 
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5.4.3.2 Hormone therapy  
Anastrozole was statistically significantly associated with higher waist 
circumference levels, and with fat percentage in univariable analysis, but not in the 
multiple linear regressions conducted. Results also showed a non-significant trend 
for higher body fat and waist circumference levels among letrozole users. Tamoxifen 
users had non-significant larger weight circumference levels, which could explain 
their common verbalised complaint that the drug is causing them to put on weight. 
On the other hand, exemestane users tended to have lower body fat and waist 
circumference levels than non-users, a finding in line with that reported by Francini 
and colleagues (2006), who found that switching obese patients from tamoxifen to 
exemestane reduced FM. 
In general, these findings add to the increasing literature in the field that insinuates a 
role for hormone therapy, or tamoxifen in particular, in body adiposity levels 
(Nguyen et al. 2001; Knobf et al. 2008; Nissen et al. 2011). However, the fact that 
not all the literature shows an association between adiposity and BC treatment or 
tamoxifen use (McTiernan et al. 2003; Irwin et al. 2005) indicates that it is 
worthwhile to continue exploring the role of hormone therapy on post-diagnosis 
changes in adiposity, using studies that have long follow up and adequate control 
groups. This is important since the association is biologically plausible. It is known 
that a reduction of oestrogens, which is one of the effects of AINs (Burstein 2011), is 
associated with changes in body fat (Davis et al. 2012). Letrozole is a potent AIN 
(Jain et al. 2013). Suppression of oestrogens is greater with letrozole compared with 
anastrozole across the full range of BMIs (Folkerd et al. 2012). The small number of 
participants who took letrozole in this study (less than 44) might not have provided 
enough power to find a statistical association between letrozole and body adiposity 
parameters when other variables were accounted for. 
5.4.3.3 Menopausal status and change in menopausal status 
Worth noting is the fact that an increasing number of studies in the field are 
reporting a distinctive pattern of weight change consistent with sarcopenia (Cheney 
et al. 1997; Kutynec et al. 1999; Demark-Wahnefried et al. 2001; Freedman et al. 
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2004; Gordon et al. 2011; Nissen et al. 2011; Hojan et al. 2013). Interestingly, 
Nissen and colleagues (2011) found that this peculiar pattern of weight gain was 
only seen in normo-weight women, rather than in overweight or obese women. 
Currently it is unclear whether sarcopenia is caused by BC treatment, or is the 
consequence of ageing and entry into the menopause (Sheean et al. 2012). A 
preliminary study by Gordon and colleagues (2011) showed that women who 
suffered chemotherapy-induced ovarian failure tended to gain FM (+ 1.8 kg) and 
lose FFM (- 0.6 kg), whereas those who retained their ovarian function during 
chemotherapy treatment also gained FM (+ 0.9 kg) but did not have significant 
changes in FFM. In the present study, the opposite was found: those pre and 
perimenopausal participants who changed their menopausal status post-diagnosis 
(nearly 92%) had lower body adiposity parameters than those who did not. Arguably, 
the finding could be the consequence of the analytical approach. The number of 
participants who remained pre or perimenopausal was small (n=5), therefore, their 
data were combined with data from postmenopausal women (73% of the sample), 
whose body adiposity parameters were significantly higher than those of pre and 
perimenopausal women. The higher adiposity parameters seen among 
postmenopausal participants might have masked the effect of the transition to the 
menopause on body fat in pre and perimenopausal participants. In fact, fat 
percentage and FM/FFM showed an upward trend associated with gonadorelin 
analogue use, a finding consistent with Gordon‘s study. This was not a surprise as 
goserelin, the type of gonadorelin analogue used in this study to produce chemical 
ovarian ablation, can suppress circulating oestrogens to postmenopausal levels 
(Cancer Research UK 2014). And, as stated previously, it is known that the change 
in the hormonal milieu during the transition into the menopause is associated with an 
increase in abdominal and total body fat (Davis et al. 2012).  
Nonetheless, in this study, multiple linear regression analysis indicated that 
menopausal status was not a statistically significant predictor of body adiposity 
parameters. Hence, other factors might be more relevant to explain body adiposity 
parameters after BC.  
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5.4.3.4 Genes 
The FTO and the Mc4R have been associated with common forms of obesity. In this 
study, the presence of the FTO SNP rs9939609 risk A-allele and the risk C-allele at 
SNP rs17782313 of the Mc4R gene were both non-significantly associated with 
healthier adiposity parameters, a finding which is in line with their association with 
weight change, but that contradicts findings from previous studies with small 
(Arrizabalaga et al. 2014) and large samples (Frayling et al. 2007; Liu et al. 2010; 
Hertel et al. 2011; Xi et al. 2012a and 2012b; Kvaløy et al. 2013) that supported the 
effects of those risk alleles on increased adiposity. In view of the results of these 
investigations, this study might have not had enough power to identify an association 
between genotype and adiposity levels post-diagnosis. Nonetheless, it is important to 
uncover the factors that could explain changes in adiposity, since higher levels of 
body fat have been linked with poorer prognosis (Sun et al. 2015), with greater 
chemotherapy toxicity (Wong et al. 2014) and with the response and resistance of 
BC tumours to AINs (Schech et al. 2015).  
 
5.4.3.5 Other variables of interest 
Participants‘ age at the time of BC diagnosis was positively correlated with 
menopausal status. Accordingly, postmenopausal participants had statistically 
significant higher body adiposity parameters than premenopausal women. This is an 
expected finding as substantial evidence has demonstrated that the transition to the 
menopause favours increases in FM, particularly abdominal fat (Davis et al. 2012), 
and waist circumference is known to increase with age (World Health Organization 
2008). Multiple linear regression analysis showed that when other factors were 
accounted for, the only predictors of body adiposity parameters in this study were 
age at diagnosis and weight at diagnosis (both p<0.01). Arguably, these associations 
could be the result of lack of p-level adjustment. Nonetheless, the associations could 
have meet more strict significance levels than the used (p<0.05), and they are present 
in the general population (World Health Organization 2008). 
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In this study, adiposity parameters were cross-sectional only and therefore, a cause-
effect relationship cannot be concluded (Hill 1965). Nonetheless, a temporal feature 
exists as age and weight were recorded at diagnosis, the starting point of the follow 
up period, whereas body fat and waist circumference were measured at the end of 
follow up. It is also worth mentioning that although multiple linear regression 
analysis was conducted, there could be other factors contributing to the magnitude of 
the adiposity parameters found among participants that were not explored (i.e. diet or 
physical activity). In line with this, it is acknowledged that this study might not have 
enough power to detect statistically significant effects of other variables (i.e. genes). 
 
5.5 Metabolic parameters at the end of the follow up  
The literature on metabolic status after BC diagnosis is limited. In this study, the 
average fasting glucose level was 5.14 mmol/l (SD: 0.77), ranging from 3.10 to 
10.80 mmol/l. Average fasting insulin level was 39.31 pmol/l (SD: 2.63) ranging 
from 7.00 to 184.74 pmol/l. HOMA IS and HOMA IR values were 128.92 (SD: 
59.19) and 0.99 (SD: 0.56) respectively. Glucose levels measured at the end of 
follow up are similar in magnitude to figures reported in another BC population 
(Goodwin et al. 2012). And Thompson et al. (2009) found glucose levels of 98.7 
mg/dl (SD: 12.9) (equivalent to 5.48 mmol/l) when exploring metabolic syndrome in 
a sample of BC patients who were 6 to 72 months from surgery or completion of 
radiation or chemotherapy. Conversely, in this study, participants‘ insulin mean and 
range values were higher than those reported by Alacacioglu and colleages (2016) 
six months post-chemotherapy (30 pmol/l, SD: 77.9), but lower than those reported 
by other authors who found insulin levels ranging from 44.6 pmol/l (SD: 31.1) to 
92.9 pmol/l (SD: 77.9) pre-adjuvant therapy (Goodwin et al. 2002; Borugian et al. 
2004), or a mean fasting insulin value of 66.9 pmol/ml, measured two-and-a-half 
years post-diagnosis (Duggan et al. 2011).  
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After excluding nine participants with known diabetes at study entry, blood samples 
taken a mean of 48 months post-diagnosis revealed that 1.8% of the participants with 
available fasting glucose levels had values corresponding to pre-diabetes (6.1 to 6.9 
mmol/l) and nearly 3% had glucose levels that fell within the diabetic range (more 
than 6.9 mmol/l) (Diabetes.co.uk 2016). This finding, together with the high 
prevalence of overweight/obesity found among participants at the time of their BC 
diagnosis is consistent with those from the WHEL study which showed that higher 
BMI was statistically significantly associated with incidence of diabetes post-
diagnosis (Erickson et al.2012). Therefore, findings in this study highlight the need 
of exploring metabolic parameters among BC survivors. Furthermore,  
 
5.5.1 Potential clinical implications of the high glucose and insulin levels 
observed 
Elevated fasting glucose has been associated with chemo-resistance in multiple 
tumour types (Song et al. 2016) and with poor prognosis after BC diagnosis 
(Monzavi-Karbassi et al. 2016). Similarly, high insulin levels have been associated 
with several diseases, including heart disease and type-two diabetes (Reaven 1988). 
Insulin‘s role in cancer is well documented, and currently, insulin offers a potential 
mechanism to explain the postulated causal relationship between obesity and BC 
(Vona-Davis and Rose 2009). Insulin can activate insulin, IGF and oestrogen 
signalling pathways related to carcinogenesis, tumour progression, invasion and 
metastasis (Goodwin 2015b). In line with that, insulin has been implicated in 
tumour-related angiogenesis (Vona-Davis and Rose 2009). Studies have also 
demonstrated that higher levels of insulin and IR both are associated with adverse 
BC prognosis, even after adjusting for BMI and other prognosis factors (Goodwin et 
al. 2002; Borugian et al. 2004; Duggan et al. 2011), particularly during the first five 
years of diagnosis (Goodwin et al. 2012). Hence, IR has been described as one of the 
most significant metabolic disturbances in cancer (Hursting et al. 2007). In the 
context of this study examining insulin and glucose levels acquires additional 
relevance as Chapter 2 detailed, they can also take part in the regulation of body 
weight, body fat , appetite and leptin levels (Trayhurn and Beattie 2001; Dulloo 
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2005; Pliquett et al. 2006; Su et al. 2012). It has been suggested that a reduction in 
the response to the effects of insulin in areas in the brain relevant to eating 
behaviours could lead to the association between IR and weight gain (Anthony et al. 
2006), an hypothesis that may be worth exploring further to understand reasons for 
weight gain post BC diagnosis.   
 
5.5.2 Factors associated with metabolic parameters at the end of the follow up 
5.5.2.1 Chemotherapy 
In this study, insulin levels were statistically significantly lower among participants 
who received chemotherapy (p<0.04). This finding adds to the limited and 
inconsistent literature on the effect of chemotherapy on insulin levels. Two studies 
found an increase of insulin levels during chemotherapy treatment (Makari-Judson et 
al. 2009; Alacacioglu et al. 2016), whereas another found a decrease (Chala et al. 
2006). Furthermore, a local study found a statistically significant increase in blood 
glucose levels in the last cycles of chemotherapy prescribed with dexamethasone, 
and 14 out of the 39 participants in that study developed degrees of glucose 
intolerance (Hickish et al. 2009). Finally, a population-based study showed that BC 
survivors had an increased risk of diabetes (HR for chemotherapy users: 1.24, 95% 
CI 1.12 to 1.38 and HR for non-chemotherapy users: 1.11, 95% CI 1.05 to 1.16) 
(Lipscombe et al. 2013). Differences between insulin levels observed in the current 
and published studies may be attributed to the longer follow up of this study, 
although effects of the characteristics of participants in the study, or a type-I error 
due to the use of multiple hypothesis testing (the level of significance was 4%) 
cannot be ruled out. In fact, chemotherapy was not a statistically significant predictor 
of metabolic parameters in multiple regression analysis. 
It has been suggested that chemotherapy drugs affect the liver and the muscle, 
leading to disruptions of glucose metabolism and IR (Makari-Judson et al. 2014). In 
addition, the elevated insulin levels post-chemotherapy in BC patients might result 
from the chemotherapy regimen used (Alacacioglu et al. 2016), as it is known that 
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the chemotherapy agent docetaxel can activate the extracellular signal‑regulated 
kinases (ERK1/2) pathway in ovarian carcinomas (Seidman et al. 2001), a pathway 
that has been shown to play a part in glucose-stimulated insulin secretion in a 
subgroup of pancreatic mouse cells (Niu et al. 2016). More research is needed to 
firstly, explore a possible association between chemotherapy and insulin and glucose 
levels, secondly, to understand the mechanisms underlying that possible association, 
and thirdly, to identify the prognostic consequences of altered metabolic parameters.  
The negative correlation between time elapsed from BC diagnosis to the end of 
follow up (the time when insulin levels were taken) suggests that insulin levels 
decrease during follow up. Unfortunately, this investigation did not explore changes 
in insulin levels post BC-diagnosis. Nonetheless, a study which explored glucose 
metabolism in the long term (before adjuvant BC therapy, during treatment and two 
years after BC diagnosis) found no statistically significant changes in glucose and 
insulin levels over time (Arpino et al. 2015). Given this evidence, more research is 
needed to understand whether insulin and glucose levels fluctuate or their trajectory 
is linear after BC diagnosis. 
 
5.5.2.2 Hormone therapy     
In this study, exemestane and tamoxifen users had higher glucose levels and lower 
insulin levels than non-users. Conversely, anastrozole and letrozole treatments were 
associated with higher levels of serum insulin. It should be noted that only the 
associations with letrozole and exemestane reached statistical significance (p=0.02 
and p=0.03). Similarly to the association found between chemotherapy and insulin, 
these significant findings should be taken with caution as they could also be type-one 
errors due to the use of multiple hypothesis testing, as they were not significant 
predictors of insulin in multiple regression analysis. Nevertheless, findings are in 
line with evidence from animal models, which suggests that tamoxifen use could 
interfere with overall hepatic function (Marek et al. 2011). A previous study, 
tamoxifen-treated rats had statistically higher insulin levels after tamoxifen treatment 
than control rats (Hozumi et al. 2005). Nonetheless, two recent studies showed 
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mixed results. In one of them tamoxifen administration induced mitogen-activated 
protein kinase kinase kinase kinase four (MAP4K4) deletion in mice, causing a 
decrease of fasting glucose levels and improvements in insulin signalling in the 
adipose tissue and liver (Danai et al. 2015). In the second study tamoxifen 
significantly increased glycated haemoglobin (HbA1c), a measure that reflects 
previous glucose levels (Hesselbarth et al. 2015).  
Interestingly, the findings related to insulin, chemotherapy and hormone therapy are 
in line with those found when exploring the association between waist circumference 
and BC treatments. Therefore, in view of the suggestive findings in this study, and 
considering evidence from investigations conducted on animals, it is concluded that 
the effects of hormone therapy (of tamoxifen in particular) deserve further 
exploration. 
 
5.5.2.3 Other variables of interest 
Multiple linear regression analysis showed that only weight at diagnosis and FTO 
genotype remained significant predictors of glucose and insulin levels measured at 
the end of the follow up, after accounting for the effect of BC treatment. These 
findings are the result of unadjusted p-value analysis, nonetheless, the significance 
level was quite small (p<0.01 and p=0.01), which suggest that the association might 
be true. The positive correlation found between body weight at the time of diagnosis 
with insulin levels at the end of the follow up is consistent with the knowledge that 
obese individuals have higher basal insulin levels than lean individuals (Frank et al. 
2014). Unfortunately, the findings in relation to FTO genotype cannot be supported 
with previous literature as at the point of writing this discussion, no published study 
has reported the effect of weight at diagnosis and FTO genotype on insulin levels in 
the BC population. Nonetheless, among the general population, the association 
between FTO and insulin and glucose metabolism is not new: non-significantly 
higher levels of insulin and IR have been found in carriers of the high-risk A-allele 
of the FTO gene SNP rs9939609 in obese and overweight participants taking part in 
a weight loss intervention (Zheng et al. 2015). A study with an Indian population 
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found a significant positive association between the FTO gene SNP rs9939609 and 
fasting insulin, insulin resistant traits and HOMA-index (Prakash et al. 2016). In 
addition, the AA genotype has been related to higher glucose levels in 
postmenopausal Brazilian (Ramos et al. 2011), Pakistani (Shahid et al. 2016) and 
Tunisian women (Elouej et al. 2016). These findings, in combination with those 
reporting that specific FTO genotypes are associated with increased risk of diabetes 
in different populations (Frayling et al. 2007; Ortega-Azorín et al. 2012; Xi et al. 
2012a; Vasan et al. 2014) suggest that the A-allele of the SNP rs9939609 might alter 
glucose metabolism (Prakash et al. 2016). However, other studies have found no 
association between the A-allele and measures of glucose homeostasis in African-
Americans, Hispanic-Americans or non-Hispanics white Americans (Wing et al. 
2011).  
As Chapter 2 explains, insulin is involved in body weight regulation (Dullo 2005; 
Szablewsksi 2011). Unfortunately, insulin levels in this study were cross-sectional 
data collected at the end of the follow up, and therefore, it was not possible to 
explore the role of changes of insulin levels on body weight post BC diagnosis. On 
the other hand, an increase of body weight could affect metabolic parameters 
(Vagenas et al. 2015). The correlation test conducted in this study indicated that 
weight change post-diagnosis was not associated with insulin levels at the end of the 
follow up. Arguably, the fact that in this study weight change was bidirectional 
(weight gain and weight loss were observed) could have masked a plausible 
association between those variables.   
 
5.6 Contribution to the knowledge. Implications for clinical practice and 
research 
Findings in this study showed that participants‘ adiposity levels were high and that 
weight changed following BC diagnosis. Although on average the magnitude of 
weight change across the sample was small and probably not clinically relevant, 
there were a few women for whom larger weight changes (either gains or losses) 
could pose a health risk, as suggested by survival studies that have shown the 
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negative effects body change and adiposity on BC prognosis and other aspects of 
health. Therefore, this study joins many others in the conclusion that there is a need 
for professionals to understand which factors are associated with the weight changes 
observed after BC diagnosis.  
Although BC usually has a good prognosis, there is a growing interest in 
understanding the changes in body adiposity and metabolic parameters that this 
clinical population may experience, as they might have a negative impact in 
women‘s health. Acknowledging the factors that contribute to those adverse changes, 
either clinical (i.e. BC treatment), biological (i.e. ageing, genes), behavioural (diet or 
physical activity), or a combination of all, and putting in place best available care 
based on current knowledge may result in a prevention of unhealthy body weight and 
unhealthy metabolic changes, and possibly could improve BC outcomes and overall 
health. This study has addressed that need. Its findings expand on the current and 
controversial knowledge of the effects of chemotherapy and hormone therapy, and 
present novel evidence on the possible association of factors such as obesity-related 
genes with the weight changes observed.  
The information derived from the use of multilevel modelling to characterise weight 
change following BC diagnosis contributes significantly to the knowledge of the 
topic. Multilevel modelling is a very appealing approach, but it has been relatively 
under-utilised in this field, perhaps because it requires several waves of data, 
something that this study‘s dataset has. Findings from the weight change modelling 
expand the knowledge of weight change as it not only looked at differences between 
participants, but also described how weight varied within each individual, suggesting 
that the weight change trajectory might be quadratic rather than linear, and that the 
association of the BC treatments with body weight might vary over time.  
This study reports on the metabolic status of women diagnosed with BC in the long 
term (average 48 months post-diagnosis), which expands on findings from previous 
literature that have focused on insulin and/or glucose levels at periods closer to 
diagnosis. This information contributes to the knowledge of the phenomenon of 
changes in body weight, adiposity post BC diagnosis and, as emerging literature is 
starting to show, alterations in metabolic parameters. The repercussions of these 
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changes on BC outcomes and other aspects of women‘s health have been highlighted 
earlier in the discussion. 
There are different ways in which knowledge gained from this study might be 
applied to improve care of BC patients: 1) it advocates the need for implementing a 
protocol to assess not just weight, but also body adiposity parameters and metabolic 
status post-diagnosis; and 2) it provides evidence suggesting that newly diagnosed 
BC patients might benefit from tailored care plans to manage those outcomes. 
 
5.6.1 Assessment of body weight, body adiposity and metabolic parameters  
Some participants in this study gained a significant amount of weight post-diagnosis, 
had elevated levels of body fat, and some also presented with high insulin and 
glucose levels.   
Considering the above-mentioned potential adverse consequences that both obesity 
at the time of BC diagnosis and subsequent weight changes post-diagnosis seem to 
pose for women diagnosed with BC, findings in this study imply that is imperative to 
integrate the regular assessment of body weight in the BC care plan. This 
recommendation could be particularly useful for the Surgery team in the follow up 
clinics at the hospitals where participants were recruited, as at the time of data 
collection, the measurement of patient‘s body weight was not part of the routine 
care. Moreover, the presence of missing body weight data in the medical notes 
highlight 1) the need to inform clinicians the impact that changes in body weight can 
have on patient‘s health, and 2) the need to ensure that the body weight measures are 
registered in the medical notes.  
Findings from this study also suggest that it is necessary to measure not just body 
weight, but also adiposity parameters because firstly, changes in FM or FFM cannot 
be captured by measuring changes in weight or BMI alone, and secondly, because 
imaging studies in cancer populations have shown that body adiposity varies across 
the BMI spectrum (Sheean et al. 2012). Excessive adipose tissue could have 
metabolic effects including IR, elevated glucose levels, or dyslipidemia (Kershaw 
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and Flier 2004). Nonetheless, the risk of IR is likely to be higher in individuals with 
increased visceral adipose tissue as compared with increased subcutaneous fat 
(Laharrague and Castiella 2010).  In addition, visceral adiposity has been associated 
with higher levels of glucose (Kershaw and Flier 2004), which is one of the 
components of the metabolic syndrome (Alberti et al. 2009).  
This study has identified a small percentage of participants whose glucose levels 
corresponded to pre-diabetes or fall within the diabetic range. This finding and those 
related to high body fat levels provide an opportunity to advocate the assessment and 
management of metabolic status during BC treatment. This also invites further 
research into metabolic changes post-diagnosis and BC-related factors associated 
with unhealthy glucose and insulin changes. This would add to the emerging 
literature revealing that BC chemotherapy could affect insulin levels (Makari-Judson 
et al. 2009; Alacacioglu et al. 2016), and that higher levels of glucose might produce 
chemo-resistance (Song et al. 2016).  
Highlighting the clinical implications of the assessment of body weight, body 
adiposity and metabolic parameters, to both patients and clinical staff, might 
promote the implementation of these recommendations in the clinical setting. 
Benefits from an accurate assessment would also extend to researchers, who will be 
able to continue investigating the effects of body weight, adiposity and insulin on 
BC prognosis, as well as other aspects such as psychological and functional well-
being post BC diagnosis.  
Weight and FM and FFM can be easily and quickly measured through BIA using a 
Tanita machine. However, the measurement of waist circumference might be subject 
to error as there are different places to locate the tape when measuring it. The World 
Health Organization (2008) recommends measuring at the midpoint between the 
lower margin of the last palpable rib and the top of the iliac crest, although the 
method of measuring waist circumference does not substantially affect the 
association between its value and health outcomes (i.e. risk of diabetes) (Ross et al. 
2008). 
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5.6.2 Care plan to improve control of weight, adiposity and metabolic 
parameters 
The findings from this study have identified some factors which are statistically 
significantly associated with weight change and larger body fat and insulin levels 
(i.e. smoking status, body weight at diagnosis, hormone therapy). These are valuable 
findings which suggest that some subgroups of patients might be at higher risk of 
experiencing potentially harmful changes in body weight and body fat post-
diagnosis. In addition, the study identified a large number of participants that were 
overweight or obese at the time of BC diagnosis.  
Considering the apparently negative impact of both obesity and  post-diagnosis 
weight changes on BC prognosis (Nichols et al. 2009; Protani et al. 2010; Druesne-
Pecollo et al. 2012; Niraula et al. 2012; Jain et al. 2013; Azrad and Demark-
Wahnefried 2014; Chan et al. 2014), findings from this study propose that newly 
diagnosed overweight/obese women, as well as those with an increased risk of 
weight change (i.e. to those who smoke, those who are leaner or younger and those 
who will be treated with hormone therapy) might benefit from weight 
control/management interventions as compared with other subgroups of patients. 
This recommendation is supported by the American Cancer Society, which advises 
patients to maintain a healthy body weight during and after cancer treatment (Rock 
et al. 2012).  
Additionally, in view of the emerging literature on the impact of chemotherapy on 
glucose levels, metabolic monitoring might be beneficial for women receiving 
chemotherapy. Luckily, numerous observational and interventional studies have 
demonstrated that body weight and the body adiposity and metabolic outcomes 
explored in this study can be modified to reach optimal levels. Vanegas et al. (2015) 
found that those BC patients meeting national physical activity guidelines had lower 
body weights than those who were insufficiently active or sedentary. In addition, 
behavioural interventions and counselling on exercise and diet have been shown to 
contribute to prevention of body fat gains (for a review Sheean et al. 2012), to 
favourable changes in body weight and body adiposity levels (Campbell et al. 2007b; 
Irwin et al. 2009; Friedenreich et al. 2011; Playdon et al. 2013), to improvements in 
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insulin levels and other biomarkers (Campbell et al. 2007b; Ligibel et al. 2008; 
Harrigan et al. 2016) and to better psychological and functional well-being among 
BC survivors (Knobf et al. 2014).  
Weight loss interventions published have taken different approaches (in-person, 
telephone, individual or group counselling). In general, these interventions seem to 
be feasible for BC survivors, although there is a need to promote activities to 
increase compliance with the interventions (Paydon et al. 2013). As explained in 
Chapter 1, weight loss have been associated with poorer BC prognosis, nonetheless, 
it is likely that that weight loss was unintentional rather than intentional (Jackson et 
al. 2017). Among the general population, intentional weight loss leads to changes in 
biomarkers that are plausibly linked with cancer-related outcomes (Jackson et al. 
2017). Therefore, it is likely that weight loss interventions in BC patients could be 
beneficial. In fact, several (intentional) weight loss interventions among BC 
survivors have improved symptoms and side effects of BC treatments, showing the 
potential benefits of weight loss interventions among BC survivors (Jackson et al. 
2017). Moreover, the fact that obesity is associated with poorer prognosis clearly 
underline the importance of interventions aiming to reduce overweight and obesity 
prevalence among BC survivors (Druesne-Pecollo et al. 2012). Hence, an emphasis 
should be put in integrating behavioural interventions into a BC care plan to promote 
better health outcomes (Knobf and Coviello 2011).  
Research has shown that weight-loss multi-component interventions (i.e. diet and 
exercise) are more successful than single-component interventions (Playdon et al. 
2013), nonetheless, more research is needed to ascertain details of these 
interventions, such as the most effective intervention for each specific outcome or 
the optimal timing of the intervention (Vagenas et al. 2015). Also further research is 
needed on the prevention of potentially harmful unintentional weight changes 
following BC diagnosis, and on the repercussions that intentional weight loss and 
improvements in metabolic and adiposity parameters might have on BC outcomes 
(Playdon et al. 2013; Goodwin 2015a). This would enable professionals to provide 
timely interventions to prevent increases in body fat and body weight, or to achieve 
an optimal body weight for those participants with initial weight concerns. 
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5.7 Limitations of the study 
Several limitations of this study warrant discussion. 
 
5.7.1 Representativeness of the sample 
Because of the lack of random sampling, it is difficult to ensure that the sample is 
truly representative of the BC population in the UK. This might limit the 
generalisability of the findings. Nonetheless, as discussed earlier, the characteristics 
of the participants seem equivalent to those of the BC population in the UK. 
Moreover, many findings are comparable to other studies with BC patients, 
suggesting that the study has good external validity.    
 
5.7.2 Validity of data collected 
Most data were retrospective. The validity of the weights collected from the medical 
notes from the time of diagnosis to the end of the follow up was dependent on the 
reliability and validity of the scales measuring it and on the precision and accuracy 
of the clinical staff recording it. This might have lead to measurement errors, data 
entry errors, or missing data, which can affect the internal validity of the findings 
(De Vaus 2001). Multilevel modelling showed that the intra-class correlation, a test 
which can be used to assess the magnitude of measurement error (Peat et al. 2002), 
was 0.95, which indicates that the repeated weight measures were highly correlated. 
Waist circumference measurements can be expected to have an intra-measurement 
error of 1.31 cm and inter-measurer error of 1.56 cm (World Health Organization 
2008).   
In order to reduce errors when measuring weight and body adiposity parameters, 
measurements were taken by trained nurses following the same data collection 
protocol. Furthermore, an attempt was made to ensure uniform measurement 
conditions across participants. For instance, measurements were taken early in the 
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morning and participants were asked to fast, avoid physical activity as much as 
possible, and to empty their bladder before the measurement, as it is known that BIA 
is susceptible to changes in the quantity and distribution of body water (Tanita 
Corportation 2014). Finally, data entry was double-checked in order to minimise 
errors (Web Center for Social Research Methods 2006). Measurement error may 
have made the results less precise. Hence, when possible, it was reported whether the 
magnitude found falls within the range of results from previous studies. 
The issue of missing data is a common problem in retrospective studies and was 
explored in depth in Chapter 3 and in Appendix II, with the aim of identifying 
sources of missing data and the mechanisms leading to missing data. This exhaustive 
analysis led to the conclusion that a complete case analysis was the best approach to 
deal with missing data. In addition, the multilevel modelling conducted in this study 
was able to handle missing data (Singer and Willet 2003). 
A final potential source of error in this study is that participants reported the values 
of some of the variables collected (i.e. change in menopausal status, smoking status 
at diagnosis). Recall and/or social desirability bias might have affected the validity 
of those variables. When possible, their answers were validated with data from their 
medical notes to demonstrate veracity.  
 
5.7.3 Lack of control group 
The lack of a healthy control group makes it difficult to ascertain whether the weight 
changes found in women with BC differ from the usual weight change of healthy 
women of a comparable age. Unfortunately, the number of participants receiving 
local therapy alone (surgery and radiotherapy) was small so they could not serve as a 
control arm. However, this reflects current clinical practice in the UK (most women 
with BC receive adjuvant therapy) and this study was designed to overcome these 
limitations by comparing weight change in participants with and without the factor 
explored. 
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5.7.4 Lack of statistical power 
The total number of participants is slightly lower than the target sample size planned 
from power calculations conducted prior to enrolling the study. This might have 
resulted in a lack of statistical power to detect statistically significant results when 
exploring the associations tested. With a target sample size of 250 participants, the 
study was expected to be able to detect minimum effect sizes of 0.35 when looking 
at differences in weight change between groups of treatment use. Fortunately, the 
effect sizes for the difference in weight change between treatment groups are 
reassuring (data not shown). The magnitudes of the effect sizes found when looking 
at the effect of tamoxifen use ranged from 0.31 to 0.72, figures that were mainly 
larger than 0.35. Furthermore, the effect size of the difference in weight change at 36 
months post-diagnosis depending on chemotherapy use was 0.36, which is also 
larger than 0.35. These figures are reassuring and indicate that despite the smaller 
sample size, the study was powered to detect differences when looking at weight 
changes associated with some independent variables.  
Missing data and the characteristics of the sample itself (i.e. small number of 
participants with or without a factor) might also have reduced statistical power when 
conducting some analyses. Nonetheless, many of the findings agreed with previous 
studies. When discrepancies were found, an attempt was made to find a plausible 
explanation for the results, or alternatively, the findings were taken as preliminary, 
and for hypothesis generation. 
 
5.7.5 Unbalanced data 
Weight values were collected retrospectively from the medical notes. Therefore it 
was not possible to control the number of observations recorded nor the timing of the 
measures, which led to a severely unbalanced dataset. This reduced the sample size 
of the analyses conducted and complicated the planned multilevel analysis, as some 
models (i.e. quadratic models) could not be fitted due to convergence problems 
which did not allow the estimation of one or more variance components. 
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Furthermore, the large range of months of follow up (from 10.25 to 91.17 months), 
and the fact that body adiposity and metabolic assessments were not completed at a 
standardised time post-diagnosis led to considerable sample heterogeneity. 
 
5.7.6 Causality 
Because of the study‘s retrospective nature, it was not possible to prove a causal 
relationship between factors that were statistically significantly associated with 
weight change and the weight change itself, a limitation that extends to the cross-
sectional data collected on adiposity and metabolic parameters. Nonetheless, other 
features of the research add support for a causal relationship for the associations 
found in this study, including the magnitudes of the effect sizes of the associations 
found between independent variables and the outcomes, the agreement with results 
from other studies, and the fact that current knowledge and findings from 
experimental studies provide evidence of the biological plausibility of the 
associations found (Hill 1965). 
It is worth acknowledging that the weight change observed as well as the levels of 
adiposity and metabolic status might be influenced by other factors that due to the 
retrospective nature of the study were not able to be explored (i.e. energy intake and 
expenditure, psychological status, sleeping patterns).  
 
5.7.7 Data analysis 
Weight change has been analysed looking at mean changes from diagnosis to several 
evaluation points (i.e. 12, 24, 36 and 48 months post-diagnosis) and, as in the 
analysis of the adiposity and metabolic parameters, using a large number of single 
inference parametric and non-parametric significance tests to check their association 
with the independent variables explored (i.e. BC treatment, genes, menopausal 
status, etc.). As stated earlier, the use of multiple hypotheses tests in the same group 
of participants could have increased the probability of finding a false statistically 
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significant association between weight change and some of the factors, when there is 
not a true association ( phenomena known as type-one error) (Bland and altman 
1995). This limitation could have been overcome using one of the several methods to 
control for the probability of making a type-one error when performing multiple 
hypotheses tests (i.e. the Bonferroni correction, the Holm–Bonferroni method and 
the Šidák correction) (Miller 1966; Frane 2015). Nonetheless, although these results 
should be taken with caution as the multiplicity was not adjusted for, it is worth 
mentioning several points. First, the independent variables analysed in this study 
were chosen based on previous studies in the field of this research, after considering 
the fact those variables could provide a plausible biological justification for the 
association tested. Secondly, the findings in this study have been discussed in 
relation to existing literature in the field, offering explanation for the associations 
found. Thirdly, a number of significant associations found in the study would have 
met stricter significance levels (e.g. 1% or 0.1%), as discussed earlier on. Finally, the 
use of multilevel modelling, an analytical approach that address the problem of 
multiple hypothesis testing (Gelman et al. 2012), have confirmed some of the 
statistical significant associations found in univariable and multiple regression 
analysis (i.e. the effect of tamoxifen).  
The study analysed weight change and factors associated with weight change 
measured as a continuous variable. Consistent with most literature in the field, 
findings revealed that on average, weight tended to increase post-diagnosis. 
Nonetheless, it should be noted that at an individual level, some participants gained 
weight, some participants lost weight and others remained the same. This is relevant 
as both large weight gain and weight loss post-diagnosis could have clinical 
implications. By looking at the frequency of weight change, the study have identified 
a small group of participants with large weight changes (i.e. more than 10% of their 
weight at diagnosis), which according to results from survival studies among BC 
cancer survivors, might put them at risk of poorer BC outcomes and other health 
issue. Investigating the characteristics of these subgroups of participants with large 
weight gains or large weight loses on a larger sample size would be an area of further 
research, but was out of the scope of this study. Furthermore, the number of 
participants who experienced large weight changes at those time points was small 
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(five to eight participants gained more than 10% and three to six participants lost 
more than 10%). Therefore, the study might not have been powered to explore the 
clinical and biological characteristics associated with different categories of weight 
change, nor to observe differences between them. Aige et al. (2014) observed that 
findings comparing factors associated with weight change can vary depending on 
how weight change is modelled and defined. For instance, the found that education 
level was not associated with mean weight change (continuous variable). However, 
when weight change was modelled as a categorical variable, they found a 
statistically significant association between the two variables. Consequently, further 
research could look at weight change and factors related to it, using both continuous 
and categorical weight change. This will avoid losing directional information on 
weight change and would increase comparability with other studies in the field, 
which as Table 1 (Appendix I) showed, was explored in different ways. 
A final limitation comes from the fact that the number of weight records held by 
participants decreased considerably after the first year of diagnosis, which may have 
influenced the estimation of the weight change function (Singer & Willett 2003).  
 
5.8 Strengths of the study 
Some of the strengths of this study come from the methods of conducting the study. 
 
5.8.1 Data collection 
Body fat and FFM levels as well as metabolic data were collected with validated 
measurement tools (i.e. Tanita machine) following recommended protocols as stated 
by the manufacturer or the recognised authorities (i.e. the World Health 
Organization).  
Weight change was measured from diagnosis, an advantage over other studies that 
explored weight change from later points, as it is possible that some women might 
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have already experienced changes in body weight after diagnosis but before 
enrolment into those studies.  
 
5.8.2 Repeated measures and long follow up 
This study is one of the few that has examined weight changes post-BC diagnosis 
beyond three years, which allowed the researcher to explore the effects of 
chemotherapy in the long term and allowed the effects of hormone therapy (if any) 
on weight change to emerge. 
Longitudinal data such as the one found in this study are required for exploring 
change (Singer and Willet 2003). The repeated weight measures from diagnosis to 
end of follow up offered the potential to explore different aspects of the outcome, 
such as number of participants that experienced weight change, weight changes at 
key evaluation points from diagnosis and patterns of occurrence. This is an 
improvement compared with many studies in the field that were restricted to weights 
measures at two time points. 
 
5.8.3 Data analysis 
The meticulous data analysis also should be noted. An intense assessment of the data 
collected was conducted with the aim of assessing the validity of the results, 
determining the adequacy of using a parametric approach for data analysis, 
identifying the source and impact of missing data, and the presence and effects of 
outliers.  
This study explores an array of factors potentially responsible for the weight changes 
and the values of adiposity and insulin levels observed among participants. These 
factors were chosen based on literature review and were explored in detail, looking 
at subcategories of hormone therapy (tamoxifen, anastrozole, letrozole, etc.). In 
addition, the study was designed to look at the impact of FTO and Mc4R genotypes 
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on the outcomes, as there was no published evidence looking at those genes in the 
context of this study. 
Multiple linear regression analysis was used to improve the validity of the study by 
taking into account the combined effect of these known and novel factors which 
might be related to weight gain post-diagnosis.  
Final strengths of this study are two important elements exploring weight change: 1) 
many participants had more than three weight records and 2) a sensible metric for 
clocking time. These allowed the researcher to conduct a multilevel analysis to 
characterise each person‘s pattern of weight change over time and also to identify 
differences in weight and rate of weight change among women, as well as factors 
which could predict those differences (Singer and Willet 2003). 
 
5.9 Conclusions 
This study showed changes in weight post BC diagnosis. The magnitude of body 
weight, fat and waist circumference seemed to be higher than those found in the 
general population, which could negatively affect the quality of life of BC survivors, 
and may put them at risk of metabolic disorders. Worryingly, a small percentage of 
the sample lost large amounts of weight and one quarter of participants gained more 
than 5% of their body weight at diagnosis, magnitudes that have been associated 
with worse BC prognosis and increase risk of obesity-related diseases such as 
diabetes. In fact, this study identified a small percentage of participants whose 
glucose levels corresponded to pre-diabetes or fell within the diabetic range.  
Understanding the characteristics associated with changes or levels of those 
outcomes can help health professionals identify patients at risk. Findings in this 
study suggests that hormone therapy might contribute to differences in weight and 
rate of weight change post-diagnosis, and that weight at the time of BC diagnosis 
could predict body adiposity parameters and metabolic status post-diagnosis. 
Nonetheless, the effects of other variables (i.e. smoking status, genetic profile and 
other variables not included in this study) cannot be ruled out. 
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Since higher levels of body weight, fat and insulin are associated with poorer 
prognosis and other health risks, it is imperative to assess those parameters following 
BC diagnosis and to implement care plans to control them. This may help newly 
diagnosed BC patients to achieve optimal weight, body adiposity parameters, and a 
healthy metabolic profile. Given that the tendency to change weight seems to 
continue in the long term, these strategies should continue during the adjuvant 
chemotherapy and hormone therapy. 
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APPENDIX I: TABLES AND FIGURES  
 
Appendix I Introduction 
This appendix contains all the tables mentioned in the Chapters 1 to 5. 
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Table 1 Appendix I - Summary of results from previous studies on weight change after breast cancer diagnosis and factors associated with weight 
change  
 
Authors 
 
Follow up for 
weight recordings 
 
Sample 
Size 
 
Frequency of  weight gain and 
weight lost 
 
Magnitude of changes in weight and body 
adiposity parameters
a
  
 
 
 
Factors associated with weight change and 
body adiposity
a
 changes 
 
Aslani et al. 
1999 
 
 
Prospective. 
  
During 
chemotherapy. 
 
 
 
25 
 
Not given. 
 
Weight: + 2.35 kg
b 
FM: + 1.49 kg 
 
 
 
Weight gain not associated with menopausal 
status or age within each menopausal status. 
 
Basaran et 
al. 2011 
 
 
 
Retrospective. 
 
From 
chemotherapy, to 
one year later. 
 
176 
 
 
 
At completion of  
chemotherapy: 
67% gained weight. 
22% lost weight. 
 
One year follow up:  
72% gained weight.  
18% lost weight. 
 
 
At completion:  
Weight: + 1.7 kg (2.4% of baseline weight).  
 
One year follow up:  
Weight: + 3 kg (4.2% of baseline weight).  
 
 
Weight gain associated with younger age, 
premenopausal status, multiparity and 
comorbidity. 
 
Bradshaw 
et al. 2012 
 
Prospective. 
 
One year prior 
diagnosis to five 
years post-
diagnosis. 
 
 
1,436 
 
 
One year post-diagnosis:  
22% gained (>5% of initial 
weight). 
23% lost >5% 
 
At five years follow up:  
35% gained weight.  
21% lost weight.  
 
 
Overall mean weight change not reported. 
 
Not measured. 
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Caan et al. 
2006 
 
 
 
Prospective. 
 
From one year prior 
diagnosis to mean 
of 22.9 months 
post-diagnosis. 
 
3,215 
 
39.59% gained weight (>5% of 
initial body weight). 
 
14.96% lost weight (>5%). 
 
 
 
Mean weight gain:  
Chemotherapy:  
    Yes: + 4.6%   
    No: + 2.5%   
Tamoxifen: 
    Never: + 4.3%  
    Past: + 5.5%  
   Current: + 3.4%  
Premenopausal: + 5.6%  
Postmenopausal: + 3.0%  
 
Weight gain associated with chemotherapy, 
height, and inversely associated with pre-
diagnosis BMI. 
 
Younger and premenopausal women were more 
likely to have greater weight gain than older or 
postmenopausal women. 
 
Caan et al. 
2008 
 
Prospective. 
 
From one year prior 
diagnosis to mean 
of 22.7 months 
post-diagnosis. 
 
1,692 
 
25.9% gained (within5% of 
initial weight). 
 
27.1% lost weight. 
 
 
 
Weight: + 1.7 kg 
 
Weight gain associated to chemotherapy and 
cancer stage. 
 
Younger and premenopausal women were more 
likely to gain more weight than older or 
postmenopausal women. 
 
 
Caan et al. 
2012b 
 
Prospective. 
 
From one year prior 
diagnosis to mean 
of 2.1 years post-
diagnosis. 
 
12,915 
 
United States site:  
33.7% gained >5% of initial 
weight.   
15.0% loss weight. 
 
Shanghai site:  
36.6% gained weight. 
13.9% loss weight. 
 
Weight: + 1.6 kg  
 
 
Weight gain was more common in normo- 
weight women and in premenopausal women. 
 
 
Camoriano 
et al. 1990   
 
 
 
Retrospective. 
 
During 
chemotherapy.  
 
545 
 
 
88.95% gained weight. 
 
Median weight change: 
 
Treated premenopausal: + 5.9 kg 
Treated postmenopausal: + 3.6 kg 
Non-treated postmenopausal: + 1.8 kg 
 
Weight gain associated with premenopausal 
status and lower baseline weight (in 
premenopausal women).  
Weight gain was not associated with: age, 
developing amenhorrea, or tamoxifen. 
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Campbell et 
al. 2007 
 
 
Prospective. 
 
During 
chemotherapy. 
 
10 
 
 
 
7 gained weight.  
3 lost weight. 
 
No significant weight change.   
 
FM: + 2.3 kg 
 
No changes in muscle mass or resting energy 
expenditure (REE)
c
 
 
 
Body weight, REE
c
 and body composition were 
not associated with treatment. Premenopausal 
women tended to gain more weight compared 
with postmenopausal women.  
 
 
Chen et al. 
2011 
 
 
 
Retrospective. 
 
One year pre-
diagnosis to 18 
months post-
diagnosis.  
 
4,561 
 
51% gained >2 kg  
27% lost >2 kg 
14% maintained their weight (± 
2 kg). 
 
Weight: + 1.73 kg  
 
 
 
Weight gain associated with chemotherapy and 
radiotherapy use, younger age, premenopausal 
status, high caloric intake, advanced disease 
stage and smoking. Weight gain not associated 
to treatment, exercise, menopausal symptoms. 
 
 
Costa et al. 
2002 
 
Retrospective. 
 
During 
chemotherapy.  
 
74 
 
81.1% gained weight. 
 
Weight: + 0.91% per month.  
 
 
Weight gain was not associated with age, 
menopausal status or BMI at diagnosis. 
 
Del Rio et 
al. 2002 
 
Prospective. 
 
During 
chemotherapy and 
six months later. 
 
 
30 
 
 
 
100% gained weight. 
 
Weight: + 2.8 kg   
FFM: + 1.6 kg  
FM: + 1.2 kg 
 
 
Weight gain not associated to changes in REE
c 
. 
Chemotherapy was not associated with changes 
in REE
c
. Increased REE
c
 likely due to the 
increase in FFM. 
 
Demark-
Wahnefried 
et al. 1997 
 
 
 
Prospective. 
 
From chemotherapy 
to one year later. 
 
20 
 
 
 
Not reported. 
 
At the end of chemotherapy:  
No changes in weight or FM during 
chemotherapy. 
Trend towards losing FFM (- 0.4 kg). 
 
At one year follow up 
Weight: + 3.8 kg  
 
Lack of weight change not associated with 
changes in caloric intake, physical activity or 
resting metabolic rate. 
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Demark-
Wahnefried 
et al. 2001 
 
 
 
Prospective. 
 
12 months from 
starting treatment.  
 
53 
 
 
 
Not reported. 
 
Chemotherapy user: 
Weight: + 2.1 kg 
 FM: + 2.3 kg 
 FFM: - 0.4 kg 
 
Surgery ± radiotherapy group: 
Weight: + 1 kg 
FM: + 0.1 kg 
FFM: + 0.8 kg 
 
 
Weight gain not associated with caloric intake, 
or REE
c
, but might be associated to a decrease 
of physical activity. 
 
Francini et 
al. 2006 
 
 
 
Prospective. 
 
12 months post 
randomisation. 
 
 
 
60 
 
 
Not provided. 
 
Exemestane group: weight - 1.99 kg, FM and 
FFM/FM ratio: decreased.  
 
Tamoxifen group: weight: - 0.58 kg.  There 
was no change in FM and FFM/FM ratio. 
 
 
Significant differences in FM and FFM/FM 
ratio between the groups. 
 
Freedman 
et al. 2004 
 
 
 
Prospective. 
 
During and six 
months after 
chemotherapy. 
 
20 
 
 
 
During Chemotherapy: Treated 
group: 12 gained, and 8 lost 
weight.  
 
After Chemotherapy:  12 gained 
and 7 lost weight. 
 
Chemotherapy users: % FM, minimal waist 
and hip circumference increased and FFM 
decreased. 
 
At the end of follow up: 
Chemotherapy group: weight + 0.1 g/day.  
Control group: weight + 2.1 g/day.   
 
 
Weight gain associated to premenopausal status.  
 
Weight change was not associated with  
chemotherapy,  physical activity, or appetite.  
 
No differences in weight change between the 
groups.        
 
 
Genton et 
al. 2006 
 
Prospective. 
 
During and six 
weeks post 
radiotherapy. 
 
37 
 
 
81.08% gained.  
6 weeks post radiotherapy. 
 
From diagnosis to radiotherapy: 
  Weight: + 2.2 kg   
 
Six weeks post-radiotherapy: 
  Weight: + 3.3 kg  
   FFM: + 0.8 kg 
 
 
Weight gain not associated with treatment, 
physical activity or appetite. 
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Goodwin et 
al. 1999 
 
 
 
Prospective. 
 
12 months post-
diagnosis. 
 
445 
 
 
84%  gained weight. 
 
 
Mean weight gain: 
Chemotherapy group: + 2.50 kg 
Tamoxifen group: weight + 1.26 kg  
No treatment group: weight +  0.63 kg  
 
Waist: + 1cm  
Hip: + 1.4 cm   
 
Weight gain associated with chemotherapy and 
change of menopause status. 
 
Weight gain not associated with energy intake 
or physical activity. 
 
Gu et al. 
2010 
 
 
 
Prospective. 
 
Diagnosis to 36 
months post-
diagnosis. 
 
5,014 
 
 
At 36 months: 
46% gained > 2 kg 
 
And 17% lost > 2 kg  
 
Median weight change from diagnosis to: 
 6 months: + 1.0 kg 
18 months: + 2.0 kg   
36 months:  + 1.0 kg 
 
 
Weight gain associated with younger age, lower 
BMI
 
at diagnosis, less comorbidty and lower 
disease stage.  
 
Weight gain not associated with treatment 36 
months post-diagnosis. 
 
Guinan et 
al. 2014 
 
 
 
Retrospective. 
 
From surgery to 
mean 3.28 years 
post surgery. 
 
61 
 
 
No significant weight gain. 
 
Weight: + 0.91 kg  
% FM: + 1.37%  
FFM: - 0.09 kg   
 
 
Adjuvant treatment was not associated with 
weight or body adiposity levels changes. 
 
Han et al. 
2009 
 
Prospective.  
 
Baseline to 24 
months of adjuvant 
treatment. 
 
260 
 
10.4% gained > 5% of baseline 
body weight at 1 year. 
 
Weight:  
At 3 months: + 0.30 kg  
At 6 months: + 0.16 kg  
At 12 months: - 0.34 kg  
At 24 months:  - 0.40 kg   
 
 
Weight gain not associated with any clinical 
variable explored. 
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Harvie et al.  
2004 
 
 
 
Prospective. 
 
During and six 
months post 
chemotherapy.   
 
17 
 
 
Not reported. 
 
Weight: + 5.0 kg  
FM:  + 7.15 kg  
%FM: + 6.2%  
FFM: - 1.7 kg  
Waist circumference: +5.1cm   
 
 
Not reported. 
 
Heideman 
et al. 2009 
 
 
 
Retrospective. 
 
Diagnosis to five 
years post-
diagnosis.  
 
271 
 
At 1 year: 26% gained >5 kg 
 
 
 
 
 
Weight change at one year: 
Radiotherapy only: + 1.5 kg  
Chemotherapy only: + 2.2 kg  
Hormone therapy only: + 1.4 kg  
Chemo + Hormone therapy: + 2.6 kg  
 
At end of follow up: + 2.4 kg  
 
 
Greatest weight gain at end of follow up 
associated with combination of chemotherapy 
and hormone therapy. Radiotherapy or hormone 
therapy alone not associated with weight gain. 
 
Irwin et al. 
2005 
 
 
 
 
Prospective.  
 
From within the 
first year of 
diagnosis to two 
years later. 
 
514 
 
 
68% gained weight. 
32% lost weight. 
 
 
 
 
Weight: + 1.7 kg  
FM: +  2.1%  
 
Chemotherapy ± tamoxifen: +  3.0 kg 
Tamoxifen ± chemotherapy + 1.7 kg   
Surgery only: + 1.5 kg 
 
Premenopausal: + 0.3 kg  
Pre to post: + 2.0 kg  
Postmenopausal: +  3.3 kg  
 
 
Weight gain associated with greater disease 
stage, younger age, postmenopausal status and 
reduced physical activity, and with 
chemotherapy in a subgroup of patients. It was 
not associated with tamoxifen. 
 
Change in body fat was associated with 
decrease of physical activity, but not with 
chemotherapy, tamoxifen or menopausal status. 
 
 
Kroenke et 
al. 2005 
 
 
Prospective. 
 
From two years 
before to three 
years post-
diagnosis. 
 
 
5,204 
 
 
46.3% gained (>0.5 kg/m
2
 of 
their baseline BMI). 
 
22.69% lost BMI 
 
Weight: + 3.8 lb 
 
Women with the largest gains in weight tended 
to be more likely to have received 
chemotherapy or tamoxifen, and to have later 
stage tumours. 
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Kumar et 
al. 2004  
 
 
 
Prospective. 
 
During and six 
months post 
chemotherapy. 
 
198 
 
 
22% gained > 5 lb 
 
Weight: + 3.1 kg  
 
 
 
Weight gain associated to fatigue and sex 
hormone serum globulin levels.  
 
Weight gain not associated to physical activity, 
or caloric intake. 
 
 
Kutynec et 
al. 1999 
 
 
 
Prospective. 
 
During 12 weeks of 
treatment.  
 
18 
 
 
After 66 weeks: 
Chemotherapy group: 4 of 7 
participants gained > 1 kg  
 
After 103 weeks: Radiotherapy 
group: 4 of 6 participants gained 
> 1 kg  
 
Chemotherapy group: 
% FM:  + 1.4% 
FFM:  - 1.0 kg 
 
Radiotherapy group: 
% FM: + 1.0% 
FFM: - 0.6 kg 
 
 
No differences in weight, FM, FFM changes 
between the two treatment groups.  
 
 
Lankester 
et al. 2002 
 
 
 
Prospective. 
 
During 
chemotherapy. 
 
100 
 
64% gained > 2 kg  
31% maintained weight. 
5% lost > 2 kg 
 
Weight: + 3.68 kg  
 
 
Weight gain was not associated with disease 
stage, different chemotherapy regimens, 
tamoxifen, or menopausal status. 
 
 
Makari-
Judson et 
al. 2007 
 
 
 
Retrospective. 
 
Diagnosis to three 
years post-
diagnosis. 
 
185 
 
71% gained weight at year 1. 
29% lost weight at year 1. 
 
 
 
From diagnosis to: 
Year 1: + 1.5 kg  
Year 2: + 2.7 kg  
Year 3: + 2.8 kg   
 
 
Weight gain at year 1 and 2 was associated with 
chemotherapy, younger age and BMI. No factor 
associated to weight gain from year 2 to year 3. 
 
Hormone therapy, chemotherapy regimens, 
duration of chemotherapy, or dexamethasone 
not associated with weight gain. 
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Makari-
Judson et 
al. 2009 
 
Prospective.  
 
Before adjuvant 
therapy to 12 
months later. 
 
95 
 
Not available. 
 
Not changes in waist or waist to hip ratio. 
 
 At 6 months: weight : + 0.4 kg  
At 12 months: weight: + 0.9 kg  
 
 
 
Chemotherapy associated with significant 
changes in homeostasis model assessment of 
insulin resistance (HOMA-IR), glucose/insulin 
and waist to hip ratio at 12 months. 
 
Hormone therapy or exercise not associated 
with significant changes in outcomes.  
 
 
McInnes 
and Knobf 
2001  
 
 
 
Retrospective.  
 
Three years from 
diagnosis.  
 
44 
 
 
> 65% gained >5 lb at years 
one, two and three.  
 
Weight gain from diagnosis to: 
1 year: + 9.0 lb  
2 years: + 8.93 lb  
3 years: + 10.85 lb 
 
Weight gain was associated with premenopausal 
status. It was not associated with tamoxifen. 
 
Nissen et al. 
2011 
 
 
 
Prospective.  
 
Start of 
chemotherapy to 12 
months later. 
 
49 
 
13 out of 49 gained <5% of 
initial body weight.  
 
Weight change:  
   Normo-weight women: + 4.3 lb 
   Overweight women: - 3.0 lb 
   Obese women: - 4.1 lb 
 
Normo-weight women gained FM and FFM. 
Neither obese or overweight women gained 
FM, but they lost FFM. 
 
 
Weight gain was associated with decreased 
physical activity and BMI at diagnosis. It was 
not associated with chemotherapy regimens, 
tamoxifen, AINs, or with caloric intake. 
 
 
 
Reddy et al. 
2013 
 
Retrospective. 
 
Diagnosis, to 18 
months post-
diagnosis. 
 
 
459 
 
At six months:  
13% gained >5 kg/m
2
. 
 
At 18 months: 
36% gained >5 kg/m
2
. 
 
Weight change: 
At 6 months: + 0.3 kg 
At 12 months:  + 1.0.kg  
At 18 months: + 1.9.kg 
 
 
 
Weight gain was inversely associated with age 
and BMI at diagnosis, and positively with 
absence of chemotherapy. 
There was support for weight gain with 
tamoxifen, although results were not significant 
across all points.  
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Rock et al. 
1999 
 
 
 
 
Retrospective. 
 
From one year 
before diagnosis to 
the end of the 
follow up (mean 
23.7 months).  
 
1,116 
 
60% gained >5% of initial body 
weight. 
 
26% lost weight. 
 
 
 
 
Weight change:  
No chemotherapy group: + 1.5 kg                                                                                         
Chemotherapy groups
b
:  
    AC: +1.8 kg  
    CFA: + 3.3 kg  
    CMF: + 4.4 kg   
    Other regimen: + 3.4 kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 
Weight gain positively associated with 
chemotherapy, time since diagnosis and caloric 
intake, and negatively associated with BMI at 
diagnosis and physical activity. Hormone 
therapy or radiotherapy not associated with 
weight gain. 
 
Saquib et 
al. 2007 
 
 
 
Retrospective. 
 
 
From one year 
before diagnosis to 
a mean 23.7 
months. 
 
 
3,045 
 
Not reported. 
 
 
 
 
OR for weight gain (>5% or more ) in women 
receiving: 
 
 Chemotherapy only:  1.65  
 Tamoxifen only:  1.03    
 Both treatments:  1.69  
 
Weight gain associated with chemotherapy, but 
not with tamoxifen or with chemotherapy 
regimens. Younger age and women with lower 
pre-cancer BMI tend to gain more weight. 
 
Sestak et al. 
2012 
 
 
 
Retrospective. 
 
Zero to 60 months 
post-randomisation. 
 
6,186 
 
At 12 months: 
39.7% gained > 2 kg 
14.8% lost weight. 
 
At 60 months: 
40% gained weight.  
29% lost weight. 
 
Weight change: 
12 months: + 1.4 kg 
60 months: - 0.35 kg 
 
 
 
 
Weight gain at 12 months associated with being 
younger than 60 years old, smoking at entry and 
having had a mastectomy, and not associated 
with treatment. Radiotherapy was associated 
with less weight gain. 
 
Tredan et 
al. 2010 
 
 
 
 
 
Prospective.  
 
During to 15 
months later. 
 
272 
 
At nine months:  
52.1%gained weight. 
29.8% lost weight.  
 
At 15 months: 
59.7% gained weight.  
29.2% lost weight. 
 
Weight gain: 
 At 9 months: + 0.6 kg (1%of baseline weight)  
At 15 months: + 1.5kg (+2.3%).   
 
 
Weight gain not associated with age, baseline 
BMI, chemotherapy, or menopausal status. 
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Vagenas et 
al. 2015 
 
Prospective. 
 
From sx to 72 
months post-
surgery. 
 
287 
 
 
 
From 6-18 months: 
24% gained >1 unit BMI. 15% 
lost >1 unit BMI. 
 
From 6-72 months: 
39% gained >1 unit BMI. 24% 
lost >1 unit BMI. 
 
Weight change 6-18 months: 
Chemotherapy group: + 0.2 kg 
No chemotherapy: + 0.1 kg 
 
Hormone therapy: - 0.2 kg 
No hormone therapy: + 0.5 kg 
 
Weight gain associated with radiotherapy. 
 
Wayne et 
al. 2004 
 
Prospective. 
 
Diagnosis to two 
years post-
diagnosis. 
 
260 
 
 
23% gained >3kg. 
 
7.69% lost weight. 
 
 
Weight: + 1.5 kg 
 
 
 
Weight gain not associated with caloric intake. 
 
        a 
Body adiposity parameters: FM: fat mass,  FFM: fat free mass, WHR: waist to hip ratio. 
        b 
Abbreviations used: kg: kilograms, REE: resting energy expenditure.BMI: body mass index, HOMA-IR: homeostasis model assessment of insulin resistance, AINs: aromatase  
        inhibitors and chemotherapy regimens: AC = doxorubicin + cyclophosphamide, CFA: cyclophosphamide + 5-fluorouacil + doxorubicin, CMF = cyclophosphamide + methotrexate +  
        5-fluorouacil.  
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Table 2 Appendix I - Standardised effect sizes of weight change after breast cancer diagnosis found in previous studies in the field 
 
Authors 
 
Sample size  
and  follow up 
 
Standardised effect size   
(Cohen’s d) for weight change according to treatment 
 
 
Standardised effect size for weight change according to 
menopausal staus, body mas index, weight at diagnosis and 
age  
 
Caan et al. 
2006 
 
 
3,215 
From one year pre diagnosis to  
almost two years post-diagnosis. 
 
Chemotherapy vs. no chemotherapy: 0.214 
Past users of tamoxifen vs. never users: 0.118 
Current tamoxifen users and never users: -0.091 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.271 
 
 
Chen et al. 
2011 
 
 
4,561 
18 months post-diagnosis. 
 
 
Chemotherapy vs. no chemotherapy: 0.395 
Tamoxifen vs. no tamoxifen: 0.246 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.465 
 
Comparing younger age (40-49 years) vs. older age (50-59 
years) (Cohen‘s d): 0.291 
 
Goodwin 
et al. 1999 
 
445 
12 months post-diagnosis. 
 
Not enough information to calculate it.  
 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.219 
 
Pearson‘s r values for weight gain and: 
   Age: -0.09 (p=0.05) 
   Baseline weight: 0.08 (p=0.11) 
 
Heideman 
et al. 2009 
 
 
 
271 
12 months post-diagnosis. 
 
At year one: 
Chemotherapy vs. radiotherapy: 0.174 
Chemotherapy vs. hormone therapy:   0.191 
Chemotherapy + hormone therapy vs. radiotherapy:  0.212 
At year five: 
Chemotherapy vs. radiotherapy:    0.183 
Chemotherapy vs. hormone therapy:    0.161 
Chemo + hormone therapy vs. radiotherapy: 0.700 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 
     at year one: 0.123 
     at year five: 0.522 
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Irwin et 
al. 2005 
 
 
 
 
514 
From a mean of six months from 
diagnosis to two years later.  
 
Chemotherapy vs. surgery only:    0.308 
Tamoxifen vs. no tamoxifen:  -0.021 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.025 
Comparing change of menopausal status vs. remaining 
premenopausal (Cohen‘s d): 0.313 
 
Makari-
Judson et 
al. 2007 
 
 
185 
From diagnosis to year one, two 
and three. 
 
 
Chemotherapy vs. no chemotherapy:    0.969    
Hormone therapy vs. no hormone therapy: -0.259  
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.417  
 
Pearson‘s r values for weight gain and:  
     Age: -0.030 (p=0.0001) 
     Body mass index diagnosis: -0.2 (p=0.026) 
 
Nissen et 
al. 2011 
 
 
49  
From start of chemotherapy and 
12 months later. 
 
Tamoxifen users vs. never users:  0.5336  
 
Not enough information to calculate it. 
 
Rock et al. 
1999 
 
 
 
 
1,116  
From one year before diagnosis to 
maximum four years post-
diagnosis. 
 
Chemotherapy vs. no chemotherapy:  0.040      
Hormone therapy past used vs. never used:  0.128 
 
 
Cohen‘s d when comparing: : 
Young post vs. premenopausal:  0.27 
 
Old post vs. premenopausal:  0.06 
 
Linear regression for weight gain R
2  
value =0.13 
 
Saquib et 
al. 2007 
 
 
3,045  
From one year before diagnosis to 
a mean of two years. 
 
OR (gain >5% or more of baseline weight)  
 
Chemotherapy only : 1.65    
Tamoxifen only : 1.03    
Tamoxifen + chemotherapy: 1.69 
 
 
Not enough information to calculate it. 
 
Tredan et 
al. 2010 
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During to 15 months later. 
 
n/a 
 
Comparing premenopausal vs. postmenopausal women 
(Cohen‘s d): 0.177 
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Table 3 Appendix I - Number of weight records hold by participants from breast cancer diagnosis to the end of the follow up 
 
All follow up 
(from diagnosis to the end 
of the follow up) 
During the 1
st
 
year 
(from diagnosis to 
12.50 months ) 
During the 2nd 
year 
(from 12.51 to 
24.50 months) 
During the 3rd 
year 
(from 24.51 to 
36.50 months) 
During the 4th 
year 
(from 36.51 to 
48.50 months) 
During the 5th 
year 
(from 48.51 to 
60.50 months) 
During the 6th 
year 
(from 60.51 to 
72.50 months) 
During the 7th 
year 
(from 72.51 to 
84.50 months) 
Number of 
weight records  
 
2,172
a
 
 
1,290 
 
266 
 
219 
 
173 
 
111 
 
63 
 
38 
Mean number 
of weight 
records 
(Standard 
deviation) 
 
 
9.09 (7.34) 
 
 
5.42 (4.91) 
 
 
1.13 (1.51) 
 
 
1.09 (1.32) 
 
 
1.08 (1.33) 
 
 
1.02 (1.35) 
 
 
0.98 (0.92) 
 
 
1.05 (0.94) 
Number of 
weight records 
 
Number of participants 
None  0 14 105 89 56 37 23 9 
1  8 62 56 52 63 54 26 23 
2  39 36 45 35 30 11 11 2 
3  27 17 14 15 8 2 5 1 
4 27 8 11 7 2 2 0 2 
5 15 4 4 2 0 1 0 0 
6 9 6 0 1 1 1 0 0 
7 9 6 0 0 0 0 0 0 
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8 1 6 0 1 0 0 0 0 
9 3 17 0 0 0 0 0 0 
10 7 11 0 0 0 1 0 0 
11 4 20 0 0 0 0 0 0 
12 9 12 0 0 1 0 0 0 
13 9 6 0 0 0 0 0 0 
14 15 5 1 0 0 0 0 0 
15 7 2 0 0 0 0 0 0 
16 11 2 0 0 0 0 0 0 
17 7 2 0 0 0 0 0 0 
18 4 1 0 0 0 0 0 0 
19 5 2  0 0 0 0 0 0 
20 2 0 0 0 0 0 0 0 
21 3 0 0 0 0 0 0 0 
22 5 0 0 0 0 0 0 0 
23 5 0 0 0 0 0 0 0 
25 2 0 0 0 0 0 0 0 
26 3 0 0 0 0 0 0 0 
27 1 0 0 0 0 0 0 0 
28 1 0 0 0 0 0 0 0 
43 1 0 0 0 0 0 0 0 
Number of 
participants  
 
239 
 
239 
 
236 
 
202 
 
161   
 
109 
 
65 
 
37  
        a 
This number includes one woman with missing information on how many months her only weight recorded was taken after diagnosis. This number also includes eleven women, each  
      one having 1 weight recorded more than 88 months post-diagnosis.  
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Table 4 Appendix I - Number of pre, peri and postmenopausal participants at breast cancer diagnosis and at 12, 24, 36 and 48 months post-diagnosis  
  
At diagnosis 
n=239 
 
At 12 months post-
diagnosis
a
 
 
 
At 24 months post-
diagnosis
a
 
 
 
At 36 months post-
diagnosis
a
 
 
 
At 48 months post-
diagnosis
a
 
 
 
Premenopausal n (%) 
 
52 (21.8%) 
 
4 (4.0%) 
 
 
4 (4.5%) 
 
2 (3.0%) 
 
1 (1.9%) 
 
Perimenopausal n (%) 
 
 
13 (5.4%) 
 
15 (15.2%) 
 
5 (5.7%) 
 
4 (6.1%) 
 
2 (3.7%) 
 
Postmenopausal n (%) 
 
 
174 (72.8%) 
 
80 (80.8%) 
 
79 (89.8%) 
 
60 (90.9%) 
 
51 (94.4%) 
       a 
Participants included in each period explored were those that were included in the analysis of weight change at 12, 24, 36  and 48 months post-diagnosis, and whose  
      menopausal status was available (n=99, n=88, n=66 and n=54, respectively). 
 
Table 5 Appendix I - Number of participants grouped according to genetic profile included in the analysis of weight change from breast cancer 
diagnosis to 12, 24, 36 and 48 months post-diagnosis  
  
Weight change from diagnosis to: 
 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
FTO (n):  
AA 
AT 
TT 
 
 
8 
37 
24 
 
 
7 
38 
21 
 
 
4 
23 
13 
 
 
4 
22 
7 
 
McR4 (n): 
CC 
TC 
TT 
 
 
5 
22 
42 
 
 
6 
19 
41 
 
 
2 
14 
24 
 
 
2 
9 
22 
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Table 6 Appendix I - Participants' 
biological characteristics at breast 
cancer diagnosis 
Participants’ biological 
characteristics 
Mean (SD)
a
 
Weight (kg
b
) 
Missing, n  
 
72.2 (13.6) 
18 
 
Height (m
c
) 
Missing, n 
 
1.6 (0.1) 
39 
 
BMI
d
 range (kg/m
2
 ): 
  
    <18.5 n(%) 
    18.5-24.9 
     25-30  
    >30, obesity 
  
Missing 
 
 
26.9 ± 5.0 
 
1 (0.5%) 
68 (36.6%) 
77 (41.4%) 
40 (21.5%) 
 
53 
 
 
Age (years): 
 
     <40, n (%) 
      40-49 
      50-59 
      60-69 
      ≥ 70 
 
Missing 
 
57.5 ±10.4 
 
14 (6.2%) 
34 (15.1%) 
67 (29.8%) 
86 (38.2%) 
24 (10.7%) 
 
14 
 
 
Genetic profile, (n%): 
  
FTO:   
       AA 
       AT 
       TT 
 
Missing  
 
Mc4R: 
      TT 
      TC 
      CC 
 
Missing 
 
 
 
 
 
10 (8.3%) 
72 (60.0%) 
38 (31.7%) 
 
119 
 
69 (57.4%) 
41 (34.7%) 
10 (8.3%) 
 
 
119 
 
Menopausal status,      
n (%): 
 
Premenopausal 
Perimenopausal 
Postmenopausal 
 
 
 
 
 
52 (21.8%) 
13 (5.4%) 
174 (72.8%) 
 
Education level,  
n (%): 
 
    No qualification 
    Other qualification  
    GCSE grades 
    Higher education  
 
Missing 
 
 
 
 
41 (17.2%) 
58 (24.4%) 
70 (29.4%) 
69 (28.9%) 
 
1 
 
Number of cigarettes,  
n (%):  
 
      None 
      1-5 
      6-10 
     11-15 
     16-20 
     >21 
 
Missing 
 
 
 
 
 
214 (89.9%) 
3 (1.3%) 
9 (3.8%) 
7(2.9%) 
3(1.3%) 
2(0.8%) 
 
1 
 
Ethnic background,  
n (%): 
 
       White British  
       White Irish 
        Indian 
        Chinese  
        Black Caribbean  
        Black African 
 
 
 
 
231 (96.6%) 
2 (0.8%) 
2 (0.8%) 
1 (0.4%) 
1 (0.4%) 
1 (0.4%) 
 
      a
 Unless otherwise indicated.
 
        b 
Kg stands for kilograms. First weight available from  
      two months prior diagnosis to up to 4 months post- 
      diagnosis recorded a mean of 0.92 (SD: 0.71)  
      months post-diagnosis.   
        c
 M stands for metres. 
      
d 
BMI: body mass index using participants‘ height  
      (in meters, m) and weight (in kilograms, kg) at  
      diagnosis. 
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Table 7 Appendix I - Magnitude of the weight change post-diagnosis calculated in this study, corresponding to the conventional small, medium and 
large Cohen‘s conventional criteria  
 
Cohen’s d 
 
Weight change (kilograms)
a
 
 
Cohen's conventional criteria 
 
 
0.2 small 
 
 
2.72 
 
Small effect size 
 
0.5 medium 
 
 
6.79 
 
Medium effect size 
 
0.8 large 
 
 
10.86 
 
Large effect  size 
        a 
Calculated as Cohen‘s d value multiplied by the sample‘s standard deviation of weight at diagnosis. 
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Table 8 Appendix I - Participants' clinical characteristics 
 
Participants’ clinical 
characteristics 
 
 
n (%) 
 
Tumour stage 
a
: 
I 
II 
III 
Missing 
 
 
 
105 (45.1%) 
88 (37.7%) 
40 (17.2%) 
6 
 
Nodal status: 
Positive 
Negative 
Missing  
 
 
 
85 (36.0%) 
151 (64.0%) 
3 
 
ER status: 
Positive 
Negative 
Missing  
 
 
 
206 (86.6%) 
32 (13.4%) 
1 
 
Her-2 R status: 
Positive 
Negative 
Missing 
 
 
 
23 (15.9%) 
121 (83.1%) 
94 
 
Treatment type: 
Surgery ± radiotherapy only    
Adjuvant  
Neo-adjuvant  
Missing
 
 
 
9 (3.8%) 
197 (82.8%) 
32 (13.4%) 
1 
 
Surgery: 
Mastectomy 
Conservation 
Missing  
 
 
79 (33.2%) 
159 (66.8%) 
1 
 
Chemotherapy: 
Yes  
No
 
 
 
134 (56.1%) 
105 (43.9%) 
 
Hormone therapy: 
No 
Yes 
Missing 
 
 
 
33 (13.8%) 
205 (86.1%) 
1 
 
Radiotherapy: 
Yes 
No 
Missing
 
 
 
180 (75.6%) 
58 (24.4%) 
1 
Biological therapy: 
Yes 
No  
Missing 
 
13 (5.5%) 
225 (94.5%) 
1 
        a 
Cancer stage: including participants treated with neo-adjuvant treatment.
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Table 9 Appendix I - Details of the hormone therapy used by the 205 participants treated with hormone therapy after breast cancer diagnosis  
 
Hormone therapy characteristics 
 
n (%) 
 
Hormone therapy, n (%)
a
: 
     No 
     Yes 
 
Tamoxifen
a
 
Aromatase inhibitors (AINs)
a
 
Gonadorelin analogues
 a
 
 
Missing 
 
 
 
33 (13.8%) 
205 (86. 1%) 
 
131 (55.0%) 
152 (63.9%) 
21 (8.82%) 
 
1 
 
Hormone therapy modality n (%)
b
: 
 
 Single therapy
b
: 
         Tamoxifen only
c 
         AINs only
c 
         Gonadorelin analogues only
c 
 
Combined therapy
b
: 
         Tamoxifen + AINs
d 
         Tamoxifen + Gonadorelin analogues
d 
         AINs +Gonadorelin analogues
d 
         Tamoxifen + AINs + Gonadorelin analogues
d 
 
 
 
 
113 (55.1%) 
43 (38. 1%)
 
69 (61%)
 
1(0.9%)
 
 
92 (44.8%)
 
72 (78.3%)
 
9 (9.8%)
 
4 (4.3%)
 
7 (7.6%) 
       a 
Percentage calculated over the total number of participants in this cohort (excluding 1 with missing information on treatment received) (n=238). 
       b 
Percentage calculated over the total number of participants who received hormone therapy (n=205). 
       c 
Percentage calculated over the total number of participants who received single hormone therapy (n=113).  
       d 
Percentage calculated over the total number of participants who received combined hormone therapy (n=92). 
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Table 10 Appendix I - Details of chemotherapy regimens used by the 134 participants treated with chemotherapy after breast cancer diagnosis  
 
Chemotherapy regimens 
 
n (%) 
Anthracycline containing regimens:  
   Yes
a
: 
             Epirubicin
b 
             Doxorubicin
b 
  No
a 
 Missing  
 
126 (95.5%) 
126 (100.0%) 
2 (1.6%) 
6 (4.5%) 
2 
Taxane containing regimens: 
    Yes
a
: 
            Paclitaxel
c 
            Docetaxel
c 
     No
a 
Missing 
 
69 (52.3%) 
44 (63.8%) 
26(37.7%) 
63 (47.7%) 
2 
Regimens
a&d 
: 
CMF  
FEC 
FEC + docetaxel 
FEC + paclitaxel 
FEC +docetaxel + paclitaxel 
FEC +docetaxel + gemitabine + cisplatin 
EC + paclitaxel 
EC + paclitaxel + gemitabine 
EC + docetaxel 
paclitaxel + gemitabine  
paclitaxel + gemitabine + cyclophosphamide  
Methotrexate + mitozantrone 
Missing 
 
2  (1.5%) 
59 (44.7%) 
19(14.3%) 
1 (0.8%) 
1 (0.8%) 
1 (0.8%) 
19 (14.3%) 
21 (15.9%) 
5 (3.8%) 
1 (0.8%) 
1 (0.8%) 
2  (1.5%) 
2 
        a 
Percentage calculated over the total number of participants treated with chemotherapy, excluding 2 participants with missing information (n=132). 
        b 
Percentage calculated over the total number of participants treated with anthracycline agent (n=126). 
        c
 Percentage calculated over the total number of participants treated with taxanes (n=69). 
        d 
CMF (cyclophosphamide, methotrexate and fluorouracil), FEC (fluorouracil, cyclophosphamide and epirubicin), EC  (cyclophosphamide and epirubicin). 
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Figure 1 Appendix I - Number of participants followed at 12, 24, 36, 48, 60, 72 and 84 months post-diagnosis 
 
  a 
A ± 0.5 months window period was chosen for consistency with data provided in Chapter 3.  
 
237 
participants at 
12 months 
(±0.5 monthsa )
207 
participants at 
24 months 
(±0.5 monthsa )
161 participants 
at 36 months 
(±0.5 monthsa )
112
participants at 
48  months 
(±0.5 monthsa )
71 participants 
at 60 months 
(±0.5 monthsa )
38
participants at 
72  months 
(±0.5 monthsa )
14 participants 
at 84 months 
(±0.5 monthsa )
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Table 11 Appendix I - Number of participants with available and missing weight records at diagnosis and at 12, 24, 36 and 48 months after breast 
cancer diagnosis 
  
 
At diagnosis
a 
 
 
At 
12 months
b 
 
 
At 
24 months
b 
 
At 
36 months
b 
 
At 
48 months
b 
 
 
Total number of participants 
 
239 
 
239 
 
224 
 
178 
 
128 
 
Participants with available  
weight records (%)
c 
 
 
 
221 
(92.5%) 
 
 
101 
(42.3%) 
 
 
104 
(46.4%) 
 
 
 
78 
(43.8%) 
 
 
68 
(53.1%) 
 
Participants with missing weight 
records (%)
c 
 
 
 
18 
(7.5%) 
 
 
138 
(57.7%) 
 
 
120 
(53.6%) 
 
 
 
100 
(56.2%) 
 
 
60 
(46.9%) 
 
Participants with weight 
available at both diagnosis and 
each month explored (%)
c 
 
 
 
n/a 
 
 
99 
(41.4%) 
 
 
100 
(44.6%) 
 
 
74 
(41.6%) 
 
 
62 
(48.4%) 
        a 
From minus 2 months to up to four months of diagnosis. 
        b 
± 4 months.
 
        c 
Percentage based on total number of participants within each evaluation point (at 12 months: 239; at 24 months: 224; at 36 months: 178 and at 48 months: 128). 
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Table 12 Appendix I - Participants‘ body weight at, and body weight change from, breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis 
  
Diagnosis
d 
 
 
12 months
 
 
 
Diagnosis
d 
 
 
24 months
 
 
  
Diagnosis
d 
 
36 months
 
 
 
Diagnosis
d 
 
48 months
 
 
 
Number of 
participants
a
 (%)
b
 
 
99 (41.4%) 
 
 
100 (44.6%) 
 
 
74 (41.6%) 
 
 
62 (48.4%) 
 
 
Mean weight( kg
c
) (SD
c
) 
 
 
70.8 
(12.9) 
 
72.1 
(12.5) 
 
72.6 
(14.2) 
 
73.5 
(14.2) 
 
70.3 
(12.9) 
 
71.9 
(12.3) 
 
73.4 
(15.7) 
 
73.8 
(15.7) 
 
Mean weight change: 
Kg,  (95% CI
c
),  
p-value 
 
 
% change
d  
p-value 
 
 
1.30   
(0.33 to 2.27) 
p=0.01
e 
 
 
2.20  
(0.91 to 3.49) 
p=0.01
 
 
 
0.85 
(-2.24 to 1.93) 
p=0.12
e 
 
 
1.44  
(0.05 to 2.84) 
p=0.04 
 
1.59  
(0.39 to 2.79) 
p=0.01
e 
 
 
2.67  
(1.05 to 4.29) 
p<0.01
 
 
 
0.42  
(-0.99 to 1.84) 
p=0.55
e 
 
 
0.88  
(-0.97 to 2.73) 
p=0.34
 
 
        a 
Number of participants with available weight records for both at diagnosis and the explored evaluation point. 
        b
 Percentage based on the total number of participants available within each follow up period (at 12 months: 239, at 24 months: 224, at 36 months: 178 and at 48 months:128 ).    
        c 
Kg stands for kilograms, SD stands for standard deviation, CI stands for confidence interval.
       
        d 
Diagnosis date from minus 2 months prior diagnosis to 4 months post-diagnosis. 
        d 
Paired t-test p-value. Percentage of weight change relative to weight at diagnosis.  
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Figure 2 Appendix I - Weight change from diagnosis to 12, 24, 36 and 48 months post BC diagnosis 
0
0.5
1
1.5
2
diagnosis
12 months
24 months
36 months
48 months
Weichg change from diagnosis (kilograms)
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Table 13 Appendix I - Frequency of weight change (larger than 0.0 kg) from breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis 
  
From diagnosis to: 
12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 
Number of participants included 
 
99 
 
100 
 
74 
 
62 
 
Number of participants who had no weight 
change (0.0 kg
a
), n (%)
b
 
 
 
7 (7.1%) 
 
 
2 (2.0%) 
 
 
0 
 
 
0 
 
Number of participants who had weight 
change (more than 0.0 kg
a
), n (%)
b
: 
 
 
92 (92.9%) 
 
 
98 (98%) 
 
 
74 (100%) 
 
 
62 (100%) 
 
    Lost weight (more than 0.0  kg
a
), n (%)
b 
 
   
    Mean weight lost (kg
a
) (95% CI
a
) 
 
 
32 (32.3%) 
 
-4.08 (-5.47 to -2.70) 
 
37 (37.0%) 
 
-4.62 (-5.78 to 3.13) 
 
21 (28.4%) 
 
-4.26 (-5.93 to -2.59) 
 
27 (43.5%) 
 
-4.20 (-5.79 to -2.60) 
 
    Gained weight (more than 0.0 kg
a
), n(%)
b
 
   
    Mean weight gained (kg
a
) (95% CI
a
) 
60 (60.6%) 
 
4.33 (3.68 to 4.97) 
61 (61.0%) 
 
4.10 (3.21 to 4.98) 
53 (71.6%) 
 
3.91 (2.91 to 4.91) 
35 (56.5%) 
 
3.98 (2.74 to 5.23) 
         a 
Kg stands for kilograms, CI stands for confidence interval. 
   
    b 
Percentage based on total number of participants included in each period. 
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Table 14 Appendix I - Frequency of weight change (larger than 2.0 kg) from breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            a 
Kg stands for kilograms. 
   
       b 
Percentage based on total number of participants included in each period. 
  
From diagnosis to:  
 
12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 
Number of participants included 
 
99 
 
100 
 
74 
 
62 
 
Number of participants who had no 
weight change (within 2.0 kg
a
),  n (%)
b
 
 
 
34 (34.3%) 
 
 
 
38 (38.0%) 
 
 
 
25 (33.8%) 
 
 
 
20 (32.3%) 
 
Number of participants who had weight 
change (more than 2.0 kg
a
), n (%) 
 
 
65 (65.7%) 
 
 
62 (62%) 
 
 
49 (66.2%) 
 
 
42 (67.7%) 
 
  Lost weight (more than 2.0 kg
a
), n 
(%)
b
: 
 
        From 2.1 to 5.0 kg
a
 
        From 5.1 to 10.0 kg
a
 
        10.1 kg
a
 and more 
 
 
18 (18.2%) 
 
8(8.1%) 
9(9. 1%) 
1(1.0%) 
 
 
22 (22.0%) 
 
8 (8.0%) 
10 (10.0%) 
4 (4.0%) 
 
 
13 (17.6%) 
 
7 (9.5%) 
5 (6.8%) 
1 (1.4%) 
 
 
18 (29.0%) 
 
11 (17.7%) 
5 (8.1%) 
2 (3.2%) 
 
   Gained weight (more than 2.0 kg
a
),  
   n(%)
b 
: 
 
        From 2.1 to 5.0 kg
a
 
        From 5.1 to 10.0 kg
a
 
        10.1 kg
a
 and more 
 
 
47 (47.5%) 
 
26 (26.3%) 
20 (20.2%) 
1 (1.0%) 
 
 
40 (40.0%) 
 
23 (23.0%) 
13 (13.0%) 
4 (4.0%) 
 
 
36 (48.6%) 
 
26 (35.1%) 
7 (9.5%5%) 
3 (4.1%) 
 
 
24 (38.7%) 
 
14 (22.6%) 
9 (14.5%5%) 
1 (1.6%) 
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Table 15 Appendix I - Frequency of weight change (larger to 0.0% relative to weight at diagnosis), from breast cancer diagnosis to 12, 24, 36 and 48 
months post-diagnosis 
 From diagnosis to: 
 
12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 
Number of participants included 
 
99 
 
100 
 
74 
 
62 
 
Number of participants who had no 
weight change (0.0%), n (%)
a 
  
  
7 (7.1%) 
 
 
2 (2.0%) 
 
 
0 
 
 
0 
 
Number of participants who had weight 
change (more than 0.0%), n (%): 
 
 
92 (92.9%) 
 
 
98 (98%) 
 
 
74 (100%) 
 
 
62 (100%) 
 
Lost weight (more than 0.0%), n (%)
a
: 
 
      From 0.1 to 5.0% 
      From 5.1 to 10.0% 
      From 10.1 to15.0% 
      From 15.1to 20.0% 
      20.1 % and more 
 
32 (32.3%) 
 
17 (17.2%) 
11 (11.1%) 
3 (3.0%) 
1 (1.0%) 
0 
 
37 (37.0%) 
 
21 (21.0%) 
10 (10.0%) 
5 (5.0%) 
1 (1.0%) 
0 
 
21 (21.6%) 
 
11 (14.9%) 
6 (8.1%) 
4 (5.4%) 
0 
0 
 
27 (43.5%) 
 
16 (25.8%) 
8 (12.9%) 
1 (1.6%) 
2 (3.2%) 
0 
 
Gained weight (more than 0.0%), n (%)
a
: 
 
     From 0.1 to 5.0% 
     From 5.1 to 10.0% 
     From 10.1to 15.0% 
     From 15.1 to 20.0% 
     20.1 % and more 
 
60 (60.6%) 
 
25 (25.3%) 
27 (27.3%) 
6 (6.1%) 
2 (2.0%) 
0 
 
61 (61.0%) 
 
32 (32.0%) 
21 (21.0%) 
5 (5.0%) 
3 (3.0%) 
0 
 
53(59.5%) 
 
33 (44.6%) 
12 (16.2%) 
5 (6.8%) 
0 
3 (4.0%) 
 
35 (56.5%) 
 
20 (32.3%) 
10 (16.1%) 
2 (3.2%) 
2 (3.2%) 
1 (1.6%) 
      
a 
Percentage based on total number of participants included in each period.
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Table 16 Appendix I - Parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 12, 24, 
36 and 48 months post-diagnosis and breast cancer treatment 
  
Weight Change from diagnosis to: 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
 n Mean 
Weight 
change 
(kg
b
) 
(SD
b
) 
Mean 
difference, 
(95% CI
b
),      
p-value 
n Mean 
Weight 
change 
(kg
b
) 
(SD
b
) 
Mean 
difference, 
(95% CI
b
),       
p-value 
n Mean 
Weight 
change 
(kg
b
) 
(SD
b
) 
Mean 
difference, (95% 
CI
b
),    
     p-value 
n Mean 
Weight 
change 
(kg
b
) 
(SD) 
Mean 
difference, 
(95% CI
b
),   
    p-value 
Chemotherapy
a
: 
Yes 
 
 
No  
 
 
84 
 
 
15 
 
 
1.34  
(5.03) 
 
1.09  
(3.82) 
 
 
 
0.25 
(-2.46 to 2.96) 
p=0.86
c 
 
 
 
75 
 
 
25 
 
 
0.65  
(5.14) 
 
1.44  
(6.45) 
 
 
 
-0.79 
(-3.31 to 1.73) 
p=0.53
c 
 
 
 
53 
 
 
21 
 
 
1.07  
(4.68) 
 
2.90  
(6.19) 
 
 
 
-1.84 
(-4.48 to 0.81) 
p=0.17
c
 
 
 
 
36 
 
 
26 
 
 
 
0.61 
(6.22) 
 
0.17 
(4.61) 
 
 
 
0.44 
(-2.45 to 3.32) 
p=0.76 
Hormone 
therapy
a
: 
Yes 
 
 
No  
 
 
 
 
86 
 
 
13 
 
 
 
1.24 
(4.93) 
 
1.73 
(4.5) 
 
 
 
-0.49 
 (-3.37to 0.39) 
p=0.73
c
 
 
 
 
90 
 
 
9 
 
 
 
0.98  
(5.39) 
 
-0.26  
(6.81) 
 
 
 
1.23  
(-2.60 to 5.06) 
p=0.52
c
 
 
 
 
 
66 
 
 
7 
 
 
 
1.79  
(5.35) 
 
-0.06 
(3.42) 
 
 
 
1.85  
(-2.28 to 5.98) 
p=0.38
c
 
 
 
 
 
55 
 
 
6 
 
 
 
0.28  
(5.24) 
 
2.17  
(8.72) 
 
 
 
-1.88  
(-6.71 to 2.95) 
p=0.44
c
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Tamoxifen
a
: 
Yes 
 
 
No  
 
 
41 
 
 
58 
 
 
2.19 
(4.22) 
 
0.67  
(5.21) 
 
 
 
1.51 
 (-0.44 to3.47) 
p=0.13
c
 
 
 
 
45 
 
 
55 
 
 
2.87  
(4.65) 
 
-0.81 
(5.58) 
 
 
 
3.68  
(1.62 to 5.75) 
p<0.01
c
 
 
 
 
42 
 
 
32 
 
 
2.62  
(4.79) 
 
0.23  
(5.42) 
 
 
 
2.38 
(0.01 to 4.75) 
p=0.05
c
 
 
 
 
35 
 
 
27 
 
 
1.52  
(3.59) 
 
-1.01 
(7.22) 
 
 
 
2.53  
(-0.70 to 5.33) 
p=0.08
d
 
 
Aromatase inh.
a
: 
Yes 
 
 
No  
 
 
47 
 
 
52 
 
 
0.82 
(5.33) 
 
1.73  
(4.38) 
 
 
-0.90  
(-2.84 to 1.03) 
p=0.39
 c
 
 
 
59 
 
 
39 
 
 
-0.02 
(5.36) 
 
2.43  
(5.34) 
 
 
-2.45  
(-4.64 to-0.26) 
p=0.03
c
 
 
 
 
 
45 
 
 
27 
 
 
 
1.86  
(6.06) 
 
1.36  
(3.49) 
 
 
0.50  
(- 2.05 to 3.05) 
p=0.70
 c
 
 
 
 
48 
 
 
12 
 
 
-0.01 
(5.41) 
 
2.24  
(6.45) 
 
 
-2.23  
(- 5.86 to1.40) 
p=0.22
c
 
 
 
Anastrozole
a
: 
Yes 
 
 
No  
 
 
40 
 
 
59 
 
 
0.88  
(5.42) 
 
1.59  
(4.45) 
 
 
-0.71  
(-2.69 to 1.27) 
p=0.47
c
 
 
 
45 
 
 
54 
 
 
-0.27 
(5.74) 
 
1.81  
(5.15) 
 
 
-2.09 
(-4.27 to 0.09) 
p=0.06
c
 
 
 
33 
 
 
40 
 
 
 
1.38  
(6.76) 
 
1.80  
(3.53) 
 
 
-0.42  
 (-2.88 to 2.04) 
p=0.75
c
 
 
 
33 
 
 
28 
 
 
-0.97  
(5.97) 
 
2.16  
(4.69) 
 
 
-3.13  
(-5.92 to-0.34) 
p=0.03
c
 
 
 
Letrozole
a
: 
Yes 
 
 
No  
 
 
 
7 
 
 
92 
 
 
0.54 
(5.19) 
 
1.36 
(4.85) 
 
 
-0.09  
(-4.61 to 2.97) 
p=0.67
c 
 
 
9 
 
 
91 
 
 
-0.06 
(4.12) 
 
0.94  
(5.60) 
 
 
-0.10  
(-4.81 to 2.81) 
p=0.60
c 
 
 
3 
 
 
71 
 
 
2.48  
(1.44) 
 
1.55  
(5.28) 
 
 
0.93  
(-5.19 to 7.05) 
p=0.76
c 
 
 
2 
 
 
60 
 
 
4.20 
(1.69) 
 
0.29  
(5.61) 
 
 
3.90  
(-4.11to11.91) 
p=0.33
c 
Exemestane
a
: 
Yes 
 
 
No  
 
 
 
4 
 
 
95 
 
 
1.12  
(2.59) 
 
1.31  
(4.93) 
 
 
-0.19  
(-5.13 to 4.75) 
p=0.94
c 
 
 
10 
 
 
89 
 
 
0.73 (5.65) 
 
 
0.96 (5.44) 
 
 
-0.23  
(-3.85 to 3.38) 
p=0.90
c 
 
 
15 
 
 
58 
 
 
3.45 
(3.15) 
 
 
1.18 
(5.53) 
 
 
2.26  
(-0.70 to 5.24) 
p=0.13
c 
 
 
15 
 
 
46 
 
 
0.53  
(5.11) 
 
0.37  
(5.82) 
 
 
0.16  
(-3.21 to 3.53) 
p=0.92
c 
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Gonadorelin 
analogues
a
: 
Yes 
 
 
No 
 
 
 
 
13 
 
 
86 
 
 
 
2.48 
(4.06) 
 
1.12 
(4.96) 
 
 
 
1.35  
(-1.51 to 4.22) 
p=0.35
c 
 
 
 
15 
 
 
85 
 
 
 
2.74 
(5.30) 
 
0.51  
(5.47) 
 
 
 
2.23 
(-0.80 to 5.25) 
p=0.15
c 
 
 
 
11 
 
 
63 
 
 
 
3.04 
(4.82) 
 
1.33 
(5.23) 
 
 
 
1.71 
(-1.66 to 5.07) 
p=0.32
c 
 
 
 
9 
 
 
53 
 
 
 
2.88  
(4.88) 
 
0.00  
(5.61) 
 
 
 
2.88 
(-1.09 to 6.86) 
p=0.16
c 
        a
 All participants had surgery and they might have also received other treatments (I.e. radiotherapy, biological therapy).  
        b 
Kg stands for kilograms, SD stands for standard deviation, CI stands for confidence interval. 
        c 
Independent sample t-test. Equal variances assumed.  
        d 
Independent sample t-test. Equal variances not assumed.
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Table 17 Appendix I - Parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 12, 24, 
36 and 48 months post-diagnosis and 1) menopausal status at diagnosis and 2) change in menopausal status from  diagnosis to 12, 24, 36 and 48 
months post-diagnosis  
  
Weight Change from diagnosis to: 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
 n Mean 
Weight 
change 
(kg
a
)(SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),        
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
At diagnosis:  
Pre &peri 
menopausal 
 
 
Postmenopausal 
 
 
 
36 
 
 
63 
 
 
 
1.90 
(5.08) 
 
0.96  
(4.73) 
 
 
 
0.93 
(-1.08 to 
2.94) 
p=0.36
 
 
 
 
31 
 
 
69 
 
 
 
1.92 
(5.50) 
 
0.37  
(5.44) 
 
 
 
1.55 
(-0.79 to 3.89) 
p=0.19
 
 
 
 
20 
 
 
54 
 
 
 
2.58  
(5.52) 
 
1.23 
(5.04) 
 
 
 
1.35  
(-1.34 to 4.05) 
p=0.32
 
 
 
 
15 
 
 
47 
 
 
 
3.90 
(6.34) 
 
- 0.69 
(4.86) 
 
 
 
4.59 
(1.47 to 7.70) 
p<0.01
 
 
Change in 
menopause 
status: 
Yes 
 
 
No 
 
 
 
 
29 
 
 
70 
 
 
 
 
2.92 
(4.33) 
 
0.63 
(4.93) 
 
 
 
 
2.29 
(0.20 to 
4.37) 
p=0.03
 
 
 
 
 
23 
 
 
65 
 
 
 
 
2.01 
(4.95) 
 
0.35 
(5.67) 
 
 
 
 
1.65 
(-0.99 to 4.30) 
p=0.22
 
 
 
 
 
17 
 
 
49 
 
 
 
 
2.36 
(5.81) 
 
1.33 
(5.03) 
 
 
 
 
1.03 
(-1.91 to 3.97) 
p=0.49
 
 
 
 
 
 
13 
 
 
41 
 
 
 
  
 3.91 
(6.81) 
 
-0.35 
(4.30) 
 
 
 
 
4.27 
(1.08 to 7.45) 
p=0.01 
             a 
Kg stands for kilograms, SD stands for standard deviation, CI stands for confidence interval. 
             b 
Independent sample t-test. Equal variances assumed.  
 
  
 
231 
Table 18 Appendix I - Number of participants whose menopausal status changed from breast cancer diagnosis to 12, 24, 36 and 48 months post-
diagnosis 
  
Menopausal status change from diagnosis to
a
: 
 
12 months post-diagnosis 
 
24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 
 
Yes, n (%) 
 
 
29 (29.3%) 
 
23 (26.1%) 
 
17 (25.7%) 
 
 
13 (24.1%) 
 
No, n (%) 
 
 
70 (70.7%) 
 
65 (73.9%) 
 
49 (74.3%) 
 
41 (75.9%) 
     
a
 participants included in each period explored were those that are included in the analysis of weight change at 12, 24, 36 and 48 months post-diagnosis, and whose                       
       menopausal status was available at diagnosis and at each of the evaluation points explored (n=99, n=88, n=66 and n=54, respectively).  
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Table 19 Appendix I - Parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 12, 24, 
36 and 48 months post-diagnosis and genetic profile 
  
Weight Change from diagnosis to: 
 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
 n Mean 
Weight 
change 
(kg
a
)(SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),        
p-value
b 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b 
FTO: 
AA + AT 
 
 
TT 
 
 
45 
 
 
24 
 
 
0.97 (3.91) 
 
1.16 (6.32) 
 
 
-0.19 
(-2.65 to 2.27) 
p=0.88
 
 
 
 
45 
 
 
21 
 
 
1.27  
(5.05) 
 
0.32  
(6.02) 
 
 
0.95 
(-1.88 to 3.79) 
p=0.50
 
 
 
 
27 
 
 
13 
 
 
1.30  
(3.26) 
 
3.30  
(2.65) 
 
 
-2.00 
(-4.10 to 1.11) 
p=0.06
 
 
 
26 
 
 
7 
 
 
1.00 
(5.86) 
 
0.76  
(4.14) 
 
 
0.24 
(-4.59 to 5.07) 
p=0.92
 
 
Mc4R: 
CC +CT 
 
 
TT 
 
 
27 
 
 
42 
 
 
0.51  
(5.10) 
 
1.37  
(4.68) 
 
 
-0.86 
(-3.24 to 1.53) 
p=0.48
 
 
 
 
25 
 
 
41 
 
 
-0.16 
(6.11) 
 
1.66  
(5.78) 
 
 
-1.81 
(-4.50 to 0.88) 
p=0.18
 
 
 
 
16 
 
 
24 
 
 
0.99  
(2.80) 
 
2.60  
(3.32) 
 
 
-1.61 
(-3.65 to 0.43) 
p=0.12
 
 
 
 
11 
 
 
22 
 
 
-1.18  
(5.65) 
 
2.01  
(5.20) 
 
 
-3.19 
(-7.22 to 0.84) 
p=0.12
 
        a 
Kg stands for kilograms, SD stands for standard deviation, CI stands for confidence interval. 
     
b 
Independent sample t-test. Equal variances assumed.  
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Table 20 Appendix I - Parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 12, 24, 
36 and 48 months post-diagnosis and biological, behavioural and tumour-related variables 
 Weight Change from diagnosis to: 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
 n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),       
p-value 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),        
p-value 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value 
Smoking 
status at 
diagnosis: 
Smoker 
 
 
Non smoker 
 
 
 
 
9 
 
 
90 
 
 
 
 
4.48  
(5.90) 
 
0.99 
 (4.65) 
 
 
 
 
3.49 
(0.18 to 6.80) 
p=0.04
b
 
 
 
 
 
9 
 
 
91 
 
 
 
 
0.66  
(6.73) 
 
0.86  
(5.39) 
 
 
 
 
-0.21  
(-4.03 to 3.61) 
p=0.91
b
 
 
 
 
 
5 
 
 
69 
 
 
 
 
4.55 
(11.05) 
 
1.38  
(4.57) 
 
 
 
 
3.17  
(-1.58 to 7.93) 
p=0.58
c
 
 
 
 
 
9 
 
 
53 
 
 
 
 
3.84 
(7.48) 
 
-0.16 
(5.03) 
 
 
 
 
4.00 
 (0.08 to 7.91) 
p=0.04
b 
 n Correlation coefficient
d
   
  p-value 
n Correlation coefficient
d
  
p-value 
n Correlation coefficient
d
  
  p-value 
n Correlation coefficient
d
  
   p-value 
Weight at 
diagnosis  
 
 
99 
 
 
r=-0.27 
p<0.01 
 
 
100 
 
 
r=-0.19 
p=0.05 
 
 
74 
 
 
r=-0.32 
p<0.01 
 
 
62 
 
 
r=-0.18 
p=0.17 
Age at 
diagnosis  
(years) 
 
 
93 
 
 
r=-0.13  
p=0.21 
 
 
95 
 
 
r=-0.16 
p=0.13 
 
 
72 
 
 
r=-0.06  
p=0.63 
 
 
57 
 
 
r=-0.29 
p=0.03 
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Tumour 
Size (cm
a
) 
 
94 
 
r=-0.05 
p=0.61 
 
96 
 
r=0.10 
p=0.32 
 
72 
 
r=-0.14 
p=0.24 
 
60 
 
r=-0.01  
p=0.97 
 n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
 
One-way 
ANOVA
a 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
 
One-way 
ANOVA 
n Mean 
Weight 
change 
(kg
a
) (SD
a
) 
 
One-way 
ANOVA
a 
n Mean 
Weight 
change  
(kg
a
) (SD
a
) 
 
One-way 
ANOVA
a 
Stage of 
disease: 
 
Stage 1 
Stage 2 
Stage 3 
 
 
 
 
 
30 
39 
26 
 
 
 
 
1.15 (4.87) 
2.04 (5.03) 
0.34 (4.89) 
 
 
 
 
  F (2, 92) 
F=0.93 
p=0.40 
 
 
 
 
36 
37 
25 
 
 
 
 
0.31 (5.95) 
1.53 (5.55) 
0.51(4.88) 
 
 
 
 
  F (2, 95) 
F=0.50 
p=0.61 
 
 
 
 
24 
31 
16 
 
 
 
 
 
2.99 (5.50) 
1.45 (5.04) 
-0.20(5.59) 
 
 
 
 
  F (2, 68) 
F=1.90 
p=0.16 
 
 
 
 
26 
23 
10 
 
 
 
 
-0.10 (4.45) 
1.10(6.90) 
-0.31(4.93) 
 
 
 
 
  F (2, 56) 
F=0.36 
p=0.70 
        a 
Kg stands for kilograms, SD stands for standard deviation, CI stands for confidence interval, cm stands for centimetres, ANOVA stands for analysis of the variance. 
        b 
Independent sample t-test. Equal variances assumed.  
        c 
Independent sample t-test. Equal variances not assumed.  
        d Pearson‘s product moment correlation. 
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Table 21 Appendix I - Multiple linear regression analysis on factors associated with participants‘ weight change from breast cancer diagnosis to 12 
months post-diagnosis 
Variables included n Unstandardised coefficients (95% CI
a
) p-value Correlation coefficient  
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Smoking status at diagnosis
b 
 
 
99 
 
19.55 (10.46 to 28.63) 
 
-0.12 (-0.20 to -0.03) 
 
-5.44 (-9.45 to -1.43) 
 
p<0.01 
 
p<0.01 
 
p<0.01  
 
R=0.34 
F (2, 63) 
F=8.88 
p<0.01 
        a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
     
 b 
Categories: 0) smokers, 1) non-smokers. 
 
Table 22 Appendix I - Multiple linear regression analysis on factors associated with participants‘ weight change from breast cancer diagnosis to 24 
months post-diagnosis 
Variables included n Unstandardised coefficients (95% CI
a
) p-value Correlation coefficient  
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Tamoxifen
b 
 
 
95 
 
12.27 (6.60 to 17.54) 
 
-0.08 (-0.14 to -0.01) 
 
-4.05 (-5.99 to -2.11) 
 
 
p <0.01 
 
p=0.03 
 
p<0.01 
 
 
R=0.45 
F (2, 92) 
F=11.90 
p<0.01 
        a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
    
  b 
Categories: 0) smokers, 1) non-smokers.
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Table 23 Appendix I - Multiple linear regression analysis on factors associated with participants‘ weight change from breast cancer diagnosis to 36 
months post-diagnosis 
Variables included n Unstandardised coefficients (95% CI
a
) p-value Correlation coefficient 
 ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
)
 
 
Tamoxifen
b 
 
 
74 
 
13.52 (6.60 to 20.44) 
 
-0.12 (-0.21 to -0.04)  
 
-2.23 (-4.50 to 0.04) 
 
 
 p<0.012 
 
p<0.01 
 
p=0.05 
 
 
R=0.38 
F (2, 71) 
F=6.2 
p<0.01 
         a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
      
b 
Categories: 0) smokers, 1) non-smokers. 
  
 
237 
Table 24 Appendix I - Multilevel models for linear weight change after breast cancer diagnosis, using breast cancer treatments as time-invariant 
predictors 
 
Parameter Model A
a 
Model B
a 
Model C
a
 Model D
a
 Model E
a
 Model F
a
 
Number of participants 
  
238 
 
238 
 
238 
 
238 
 
238 
 
238 
Fixed effects  
       
Initial 
status  
π0i 
 
 
 
 
 
 
 
 
 
 
 
 
Rate of 
change 
π 1i  
 
 
 
Intercept (initial status) 
 
Chemotherapy 
 
Tamoxifen 
 
Anastrozole 
 
Letrozole 
 
Exemestane 
 
Gonadorelin analogues 
 
 
Months  
 
Chemotherapy by months 
 
Tamoxifen by months 
 
Anastrozole by months 
 
Letrozole by months 
 
ϒ00 
ϒ01 
ϒ02 
ϒ03 
ϒ04 
ϒ05 
ϒ06 
 
ϒ10 
 
ϒ11 
 
ϒ12 
 
ϒ13 
 
ϒ14 
 
72.8* (SE: 0.86) 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
 
n/a 
 
n/a  
 
n/a 
 
n/a 
 
n/a 
 
72.2* (SE: 0.858) 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
 
0.030* (SE:0.007) 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
79.4* (SE: 10.44) 
 
0.91 (SE: 1.79) 
 
-2.52 (SE: 1.92) 
 
-3.29 (SE: 1.77) 
 
-5.59 (SE: 3.25) 
 
4.52* (SE: 2.19) 
 
1.53 (SE: 3.09) 
 
 
0.05 (SE: 0.09) 
 
0.01 (SE: 0.02) 
 
-0.03* (SE: 0.02) 
 
0.03* (SE: 0.01) 
 
0.05 (SE: 0.03) 
 
69.3* (SE: 7.97) 
 
n/a 
 
-2.22 (SE: 1.83) 
 
-2.81 (SE: 1.76) 
 
n/a 
 
4.36* (SE: 2.20) 
 
1.40 (SE: 3.02) 
 
 
0.14* (SE: 0.07) 
 
n/a 
 
-0.04* (SE: 0.02) 
 
0.03 (SE: 0.01) 
 
n/a 
 
66.2* (SE: 4.16) 
 
n/a 
 
-1.51 (SE: 1.78) 
 
n/a 
 
n/a 
 
4.55* (SE: 2.21) 
 
n/a 
 
 
0.10* (SE: 0.04) 
 
n/a 
 
-0.04* (SE:0.02) 
 
n/a 
 
n/a 
 
72.9* (SE: 2.64) 
 
n/a 
 
-0.46 (SE: 1.72) 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
 
0.10* (SE: 0.02) 
 
n/a 
 
-0.05* (SE:0.01) 
 
n/a 
 
n/a 
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Exemestane by months 
 
Gonadorelin analogues by months  
ϒ15 
 
ϒ16 
n/a  
 
n/a 
n/a  
 
n/a 
0.004 (SE: 0.02) 
 
-0.06* (SE: 0.03) 
0.005 (SE: 0.02) 
 
-0.06* (SE: 0.03) 
0.001 (SE: 0.02) 
 
n/a 
n/a 
 
n/a 
Estimates of Variance components 
 
       
Level-1 
 
 
Level-2 
Within-person 
 
 
In intercept  
 
 
In rate of change 
 
 
Covariance 
σε
2
 
 
 
σ0
2
 
 
 
σ1
2
 
 
 
σ01 
8.9504*  
(SE: 0.2879) 
 
173.4851* 
(SE:16.0975) 
 
n/a 
 
 
n/a 
 
5.7915*  
(SE: 0.1994) 
 
171.6079* (SE: 
16.0528) 
 
0.01017*  
(SE: 0.0014) 
 
-0.1297  
(SE: 0.1067) 
5.7887* 
(SE:0.1989) 
 
164.7607* 
(SE: 15.4235) 
 
0.0089*  
(SE: 0.0012) 
 
-0.0953 
(SE: 0.1003) 
5.7919* 
(SE: 0.1992) 
 
166.90 38* 
(SE: 15.6222) 
 
0.0090*  
(SE: 0.0013) 
 
-0.1109 
(SE: 0.1013) 
5.7900*  
(SE: 0.1991) 
 
168.66 51* 
(SE: 15.7866) 
 
0.0097* 
(SE: 0.0014) 
 
-0.1456 
(SE: 0.1041) 
5.7900*  
(SE: 0.1991) 
 
171.7578*  
(SE: 16.0693) 
 
0.0097* 
(SE: 0.0014) 
 
-0.1447  
(SE: 0.1051) 
 
Goodness of fit of the total model 
       
  
Deviance 
 
AIC (Akaike‘s Information 
Criterion) 
 
BIC (Schwarz‘s Bayesian 
Criterion) 
  
12,067.30 
 
 
12,073.30 
 
 
12,090.35  
 
11,554.19 
 
 
11,566.19 
 
 
11,600.29 
 
11,525.04 
 
 
11,561.04 
 
 
11,663.33 
 
11,530.20 
 
 
11,558.20 
 
 
11,637.763 
 
11,540.72 
 
 
11,560.72 
 
 
11,617.55 
 
11,545.08 
 
 
11,561.08 
 
 
11,606.54 
       a 
These linear models predict weight in the months following BC diagnosis as a function of the BC treatments analysed as time-invariant predictors. Model A is the unconditional means   
     model. Model B is the unconditional growth model. Model C adds the main effects and the interaction between BC treatments and time passed since diagnosis (months) of all BC  
     treatments explored in this study. Model D excluded the main effects and the interaction effects of those BC treatments that were not statistically significant in the preceding model.  
     Model E includes the main effects and the interaction effects of the only two predictors that remained statistically significant: tamoxifen and exemestane. Model F excluded exemestane  
     as its interaction effects were not significant in model E. The main effects of the BC treatments in all these models are treated as fixed effects. The values for the BC treatments are: 1)  
     users; and 2) non-users. 
    * p-value <0.05. 
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Table 25 Appendix I - Final multilevel models for linear weight change after breast cancer diagnosis among participants, using breast cancer 
treatments as time-invariant predictors 
  
Parameter 
 
Model E
a 
 
 
Model F
a
 
Number of participants 
 
  
238 
 
238 
Fixed effects  
   
Initial status  
π0i 
 
 
 
 
 
 
 
 
Rate of change 
π 1i  
 
 
 
Intercept  
(initial status) 
 
Tamoxifen 
 
 
Exemestane 
 
 
 
Months  
 
 
Tamoxifen by months 
 
 
Exemestane by months 
 
ϒ00 
 
 
ϒ01 
 
 
ϒ02 
 
 
 
ϒ10 
 
 
ϒ11 
 
 
ϒ12 
 
66.2 (SE
b
: 4.16) 
(95% CI
b
: 58.05 to 74.42), p<0.01 
 
-1.51 (SE
b
: 1.78) 
(95% CI
b
: -5.03 to 2.00), p=0.40 
 
4.55 (SE
b
: 2.21) 
(95% CI
b
: 0.19 to 8.91), p=0.04 
 
 
0.10 (SE
b
: 0.04) 
(95% CI
b
: 0.02 to 0.17), p<0.01 
 
-0.04 (SE
b
: 0.02) 
(95% CI
b
: -0.08 to -0.01), p<0.01 
 
0.001 (SE
b
: 0.02) 
(95% CI
b
: -0.04 to 0.04),  p=0.09 
72.9 (SE
b
: 2.64) 
(95% CI
b
: 67.67 to 78.10), p<0.01 
 
-0.46 (SE
b
: 1.72) 
(95% CI
b
: -3.86 to 2.94), p=0.79 
 
n/a 
 
 
 
0.10 (SE
b
: 0.02) 
(95% CI
b
: 0.05 to 0.14), p<0.01 
 
-0.05 (SE
b
: 0.01) 
(95% CI
b
: -0.08 to -0.06), p<0.01 
 
n/a 
Estimates of Variance components 
 
   
Level-1 
 
Within-person 
 
σε
2
 
 
5.7900 (SE
b
: 0.1991) 
(95% CI
b
: 5.41 to 6.19), p<0.01 
5.7900 (SE
a
: 0.1991) 
(95% CI
a
: 67.67 to 78.11), p<0.01 
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        a 
These two linear models predict weight in the months following BC diagnosis as a function of the BC treatments analysed as time-invariant predictors. They are the same as                                       
 
      in the previous table but additional information (95% CI and p-values have been added). Model E includes the main effects and the interaction effects of tamoxifen and           
      exemestane. Model F included the main effects and the interaction effects of tamoxifen only. The main effects of the treatments in all these models are treated as fixed effects. The   
      values for the BC treatments are: 1) users; and  2) non-users. 
        b 
SE stands for standard error, CI stands for confidence interval.  
 
 
 
Level-2 
 
In intercept  
 
 
In rate of change 
 
 
Covariance 
 
σ0
2
 
 
 
σ1
2
 
 
 
σ01 
 
168.66 51 (SE
b
: 15.7866) 
(95% CI
b
: 140.39 to 202.62), p<0.01 
 
0.0097  (SE
b
: 0.0014) 
(95% CI
b
: 0.007 to 0.012), p<0.01 
 
-0.1456  (SE
b
: 0.1041) 
(95% CI
b
: -0.34 to 0.58), p=0.16 
 
 
171.7578 (SE
b
: 16.0693) 
(95% CI
b
: 0.05 to 0.14), p<0.01 
 
0.0097 (SE
b
: 0.0014) 
(95% CI
b
: -0.08 to -0.02), p<0.01 
 
-0.1447  (SE
b
: 0.1051) 
(95% CI
b
: -3.86 to 2.94), p=0.79 
 
 
Goodness of fit of the total model 
   
 
 
 
 
 
 
 
 
 
 
 
Deviance 
 
AIC (Akaike‘s 
Information Criterion) 
 
BIC (Schwarz‘s 
Bayesian Criterion) 
 
 
 
 
 
 
 
 
11,540.72 
 
 
11,560.72 
 
 
11,617.55 
 
 
11,545.08 
 
 
11,561.08 
 
 
11,606.54 
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Table 26 Appendix I - Multilevel models for linear weight change after breast cancer diagnosis among participants, using breast cancer treatments as 
time-varying predictors 
 
Parameter Model B
a
 Model 1
a
 Model 2
a
 Model 3
a
 Model 4
a
 
Number of participants 
 
 
238 238 238 238 238 
 
Fixed effects  
      
 
Initial 
status  
π0i 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rate of 
change 
π 1i  
 
 
 
Intercept  
(initial status) 
 
Chemotherapy 
 
Tamoxifen 
 
Anastrozole 
 
Letrozole 
 
Exemestane 
 
Gonadorelin analogues 
 
 
Months  
 
Chemotherapy by 
months 
 
Tamoxifen by months 
 
 
 
ϒ00 
 
ϒ10 
 
ϒ20 
 
ϒ30 
 
ϒ40 
 
ϒ50 
 
ϒ60 
 
 
ϒ70 
 
ϒ80 
 
 
ϒ90 
 
 
 
72.2* (SE
b
: 0.86) 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
 
0.030* (SE: 0.01) 
 
n/a 
 
 
n/a 
 
 
 
73.1* (SE
b
: 2.49) 
 
-0.01 (SE
b
: 0.02) 
 
-1.42* (SE
b
: 0.34) 
 
-0.73* (SE
b
: 0.32) 
 
3.01* (SE
b
: 0.85) 
 
-1.30 (SE
b
: 0.75) 
 
-0.21 (SE
b
: 0.57) 
 
 
-0.01 (SE
b
: 0.08) 
 
0.00 (SE
b
: 0.02) 
 
 
-0.02 (SE
b
: 0.02) 
 
 
 
80.0* (SE
b
: 2.37) 
 
n/a 
 
-1.44* (SE
b
: 0.33) 
 
0.74* (SE
b
: 0.32) 
 
2.97* (SE
b
: 0.84) 
 
-1.28 (SE
b
: 0.74) 
 
n/a 
 
 
-0.06 (SE
b
: 0.07) 
 
n/a 
 
 
0.02* (SE
b
: 0.02) 
 
 
 
70.3* (SE
b
: 2.02) 
 
n/a 
 
-1.18* (SE
b
: 0.32) 
 
-0.83* (SE
b
: 0.32) 
 
2.85* (SE
b
: 0.85) 
 
n/a 
 
n/a 
 
 
-0.05 (SE
b
: 0.06) 
 
n/a 
 
 
0.01 (SE
b
: 0.02) 
 
 
 
70.7* (SE
b
: 1.59) 
 
n/a 
 
-1.09* (SE
b
: 0.27) 
 
-0.85* (SE
b
: 0.32) 
 
2.60* (SE
b
: 0.54) 
 
n/a 
 
n/a 
 
 
-0.06* (SE
b
: 0.02) 
 
n/a 
 
 
n/a 
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Anastrozole by months 
 
Letrozole by months 
 
Exemestane by months 
 
Gonadorelin analogues 
by months 
ϒ100 
 
ϒ110 
 
ϒ120 
 
ϒ130 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
0.05* (SE
b
: 0.01) 
 
-0.01 (SE
b
: 0.03) 
 
0.000 (SE
b
:0.02) 
 
-0.03 (SE
b
:0.03) 
 
0.05* (SE
b
: 0.01) 
 
-0.01 (SE
b
: 0.03) 
 
-0.00 (SE
b
: 0.02) 
 
n/a 
 
0.05* (SE
b
: 0.01) 
 
-0.01 (SE
b
: 0.03) 
 
n/a 
 
n/a 
 
0.05* (SE
b
: 0.01) 
 
n/a 
 
n/a 
 
n/a 
 
Estimates of Variance 
components  
      
Level-1 
 
 
Level-2 
Within-person 
 
 
In intercept  
 
 
In rate of change 
 
 
Covariance 
σε
2
 
 
 
σ0
2
 
 
 
σ1
2
 
 
 
σ01 
5.7915*  
(SE
b
: 0.1994) 
 
171.6079*  
(SE
b
:16.0528) 
 
0.01017*   
(SE
b
: 0.0014) 
 
-0.129799 
 (SE
b
: 0.1067) 
5.5011* 
(SE
b
: 0.1905) 
 
170.2522*  
(SE
b
: 16.0738) 
 
0.0095*  
(SE
b
: 0.0014) 
 
-0.0339  
(SE
b
: 0.1061) 
5.4957* 
(SE
b
: 0.1904) 
 
169.7898* 
(SE
b
: 16.0076) 
 
0.0099* 
(SE
b
: 0.0014) 
 
-0.0340 
(SE
b
: 0.1063) 
5.63989* 
(SE
b
: 0.1947) 
 
170.5178* 
(SE
b
: 15.9594) 
 
0.009429*  
(SE
b
: 0.0013) 
 
-0.0715  
(SE
b
: 0.1036) 
5.6427* 
(SE
b
: 0.1945) 
 
170.56 28*  
(SE
b
: 15.9537) 
 
0.0094*  
(SE
b
: 00013) 
 
-0.072954  
(SE
b
: 0.1034) 
Goodness of fit of the total model 
 
      
 Deviance 
AIC (Akaike‘s Information 
Criterion) 
BIC (Schwarz‘s Bayesian 
Criterion)  
 
 
 
 
 
11,554.19 
 
11,566.19 
 
11,600.29 
11,349.40 
 
11,385.40 
 
11,487.52 
11,532.18 
 
11,380.18 
 
11,459.60 
11,435.04 
 
11,459.04 
 
11,527.17 
11,435.35 
 
11,455.35 
 
11,512.12 
     
a 
These linear models predict weight post-diagnosis as a function of the BC treatments analysed as time-varying predictors. Model 1: the unconditional growth model. Model 2 adds the    
     main effects and the interaction between BC treatments and time since diagnosis of BC all treatments in this study. Model 3 and 4 excluded the main effects and the interaction effects of  
     those treatments that were not statistically significant in the preceding model. Model 5 excluded the interaction effects of tamoxifen and letrozole, as these were not significant in model  
     4. The main effects of the BC treatments in models 2, 3, 4 and 5 are treated as fixed effects. The values for the BC  treatments are: 1) using/had used; and 2) non-users.      
     
b 
SE stands for standard error. 
     * p-value <0.05.
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Table 27 Appendix I - Final multilevel models for linear weight change after breast cancer diagnosis among participants, using breast cancer 
treatments as time-varying predictors 
  
Parameter 
 
 
Model 4
a 
 
 
Model 5
a 
 
Number of participants 
 
 
238 238 
Fixed effects  
   
 
Initial status  
π0i 
 
 
 
 
 
 
 
 
 
 
 
Rate of change 
π 1i  
 
 
 
Intercept  
(initial status) 
 
 
Tamoxifen 
 
 
Anastrozole 
 
 
Letrozole 
 
 
Months  
 
 
Anastrozole by 
months 
 
 
ϒ00 
 
 
ϒ10 
 
 
ϒ20 
 
 
ϒ30 
 
 
ϒ40 
 
 
ϒ50 
 
 
 
70.7 (SE
b
: 1.59) 
(95% CI
b
: 67.56 to 73.81), p<0.01 
 
-1.09 (SE
b
: 0.27) 
(95% CI
b
: -1.63 to -0.56), p<0.01 
 
-0.85 (SE
b
: 0.32) 
(95% CI
b
: -1.48 to -0.21), p<0.01 
 
2.60 (SE
b
: 0.54) 
(95% CI
b
: 1.53 to 3.67), p<0.01 
 
-0.06 (SE
b
: 0.02) 
(95% CI
b
: -0.11 to -0.02), p<0.01 
 
0.05 (SE
b
: 0.01) 
(95% CI
b
: 0.2 to 0.08), p<0.01  
 
 
70.6 (SE
b
: 1.57) 
(95% CI
b
: 67.47 to 73.64), p<0.01 
 
-1.02 (SE
b
: 0.27) 
(95% CI
b
: -1.54 to -0.49), p<0.01 
 
-1.01 (SE
b
: 033) 
(95% CI
b
: -1.65 to -0.35), p<0.01 
 
2.72 (SE
b
: 0.53) 
(95% CI
b
: 1.67 to 3.76), p<0.01 
 
-0.07 (SE
b
: 0.03) 
(95% CI
b
: -0.12 to -0.02), p=0.01 
 
0.06 (SE
b
: 0.02) 
(95% CI
b
: 0.03 to 0.09), p<0.01 
Estimates of Variance components 
 
   
Level-1 
 
Within-person 
 
σε
2
 
 
5.6427  (SE
b
: 0.1945) 
(95% CI
b
: 5.27 to 6.04), p<0.01 
5.5829 (SE
b
: 0.1963) 
(95% CI
b
: 5.21 to 5.98), p<0.01 
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Level-2 
 
In intercept  
 
 
In rate of change 
 
 
Covariance 
 
 
In anastrozole 
 
 
In anastrozole by 
months 
 
Covariance 
 
σ0
2
 
 
 
σ1
2
 
 
 
σ01 
 
 
σ2
2 
 
 
σ3
2
 
 
 
σ02 
 
170.56 28 (SE
b
: 15.9537) 
(95% CI
b
: 141.99 to 204.88), p<0.01 
 
0.0094 (SE
b
: 00013) 
(95% CI
b
: 0.007 to 0.012), p<0.01 
 
-0.072954 (SE
b
: 0.1034) 
(95% CI
b
: -0.28 to 0.13), p=0.48 
 
n/a 
 
 
n/a 
 
 
n/a 
 
168.4360 (SE
b
: 15.7521) 
(95% CI
b
: 140 to 202.32), p<0.01 
 
0.03708 (SE
b
: 0.0109) 
(95% CI
b
: 0.02 to 0.06), p<0.01 
 
-0.8030 (SE
b
: 0.3183) 
(95% CI
b
: -1.42 to -0.18), p=0.01 
 
0.5052 (SE
b
: 0.1897) 
(95% CI
b
: 0.13 to 0.88), p<0.01 
 
0.0122 (SE
b
: 0.0052) 
(95% CI
b
: 0.00 to 0.03), p=0.02 
 
-0.0196 (SE
b
: 0.0077) 
(95% CI
b
: -0.03 to-0.00), p=0.01 
 
Goodness of fit of the total model 
   
 
 
 
 
 
 
 
 
Deviance 
 
AIC (Akaike‘s 
Information Criterion) 
 
BIC (Schwarz‘s 
Bayesian Criterion) 
 
 
 
 
 
 
 
11,435.35 
 
11,455.35 
 
 
11,512.12 
 
 
11,414.88 
 
11,440.88 
 
 
11,514.69 
              a 
These linear models predict weight in the months following BC diagnosis as a function of the BC treatments analysed as time-varying predictors. Model 5 includes the main effects  
          of tamoxifen, anastrozole and  letrozole, and the interaction between anastrozole and time elapsed since diagnosis.  The effects of the treatments are treated as fixed effects. Model 6   
          allows the interaction between anastrozole and time since diagnosis to have both fixed and random effects. The values of the BC treatments are: 1) using/had used; and 2) non-users. 
              b 
CI stands for confidence intervals, SE stands for standard error.
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Table 28 Appendix I - Estimated body weight after breast cancer diagnosis of a woman diagnosed with breast cancer predicted by model 4 
 Estimated weight (kg
a
) at: 
 
 12 months post-
diagnosis 
24 
months 
post-
diagnosis 
36 months 
post-diagnosis 
48 months 
post-diagnosis 
60 months 
post-diagnosis 
72 months 
post-diagnosis 
84 months 
post-diagnosis 
 
Tamoxifen 
Yes  
No 
 
 
 
71.4 
70.3 
 
 
 
72.1 
71.0 
 
 
 
72.9 
71.8 
 
 
 
73.6 
72.5 
 
 
 
74.3 
73.2 
 
 
 
75.0 
73.9 
 
 
 
75.7 
74.6 
 
 
Anastrozole 
Yes  
No 
 
 
 
71.4 
71.1 
 
 
 
72.1 
72.4 
 
 
 
72.9 
73.8 
 
 
 
73.6 
75.1 
 
 
 
74.3 
76.4 
 
 
75.0 
77.7 
 
 
 
75.7 
79.0 
 
 
Letrozole
 
Yes  
No 
 
 
 
71.4 
74.0 
 
 
 
72.1 
74.7 
 
 
 
72.9 
75.5 
 
 
 
73.6 
76.2 
 
 
 
74.3 
76.9 
 
 
 
75.0 
77.6 
 
 
 
75.7 
78.3 
       a 
Kg stands for kilograms. Estimated weight when the rest of the BC treatments are hold constant. 
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Table 29 Appendix I - Parametric univariable analysis on the association between participants‘ body adiposity parameters at the end of the follow up 
and breast cancer treatment 
  
Fat % 
 
 
FM/FFM 
 
Waist circumference   
 n Mean  
(SD
a
) 
Mean difference, 
(95% CI
a
),            
p-value
b
 
n Mean 
(SD
a
) 
Mean difference, 
(95% CI
a
),             
p-value
b
 
n Mean (cm
a
) 
(SD
s
) 
Mean difference, 
(95% CI
a
),             
p-value
b
 
Chemotherapy: 
Yes 
 
No 
 
 
123 
 
99 
 
 
37.33 (6.50) 
 
38.31 (5.89) 
 
 
-0.98 
(-2.64 to 0.67) 
p=0.24 
 
 
118 
 
97 
 
 
0.62 (0.17) 
 
0.64 (0.15) 
 
 
-0.02 
(-0.06 to 0.02) 
p=0.33 
 
 
89 
 
91 
 
 
90.62 (11.40) 
 
93.92 (12.05) 
 
 
-3.30 
(-6.75 to 0.16) 
p=0.06 
Hormone therapy: 
Yes 
 
No 
 
 
189 
 
32 
 
 
37.99 (6.27) 
 
36.21(5.87) 
 
 
 
1.78 
(-0.56 to 4.12) 
p=0.14 
 
 
183 
 
31 
 
 
0.63 (0.16) 
 
0.59 (0.15) 
 
 
 
0.04 
(-0.02 to 0.10) 
p=0.17 
 
 
157 
 
22 
 
 
92.96 (11.84) 
 
86.54 (9.38) 
 
 
 
6.42 
(1.22 to11.62) 
p=0.02 
Tamoxifen: 
Yes 
 
No  
 
 
126 
 
95 
 
 
37.52 (6.66) 
 
38.02 (5.64) 
 
 
 
-0.50 
(-2.17 to 1.17) 
p=0.56 
 
 
122 
 
92 
 
 
0.62 (0.17) 
 
0.63 (0.15) 
 
 
 
-0.00 
(-0.04 to 0.04) 
p=0.81 
 
 
101 
 
78 
 
 
 
92.77 (12.52) 
 
91.40 (10.67) 
 
 
 
1.37 
(-2.13 to4.86) 
p=0.44 
Aromatase inhibitors: 
Yes 
 
No 
 
 
138 
 
83 
 
 
38.46 (6.16) 
 
36.53 (6.22) 
 
 
1.92 
(0.23  to 3.62) 
p=0.03 
 
 
135 
 
79 
 
 
0.64 (0.17) 
 
0.60 (0.15) 
 
 
 
0.04 
(-0.01 to 0.08) 
p=0.14 
 
 
123 
 
56 
 
 
 
93.32 (11.46) 
 
89.66 (12.04) 
 
 
 
3.65 
(-0.05 to 7.36) 
p=0.05 
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Anastrozole: 
Yes 
 
No 
 
 
 
95 
 
126 
 
 
38.90 (5.99) 
 
36.86 (6.30) 
 
 
 
2.04 
(0.39  to 3.69) 
p=0.02 
 
 
92 
 
122 
 
 
0.65 (0.16) 
 
0.60 (0.16) 
 
 
 
0.05 
(0.00 to 0.09) 
p=0.03 
 
 
82 
 
97 
 
 
 
93.86 (10.82) 
 
90.74 (12.33) 
 
 
 
3.11 
(-0.34 to 6.56) 
p=0.08 
Letrozole: 
Yes 
 
No 
 
 
 
17 
 
204 
 
 
39.38 (5.15) 
 
37.60 (6.31) 
 
 
 
1.78  
(-1.32 to 4.88) 
p=0.26 
 
 
17 
 
197 
 
 
0.66 (0.15) 
 
0.62 (0.16) 
 
 
 
0.04 
(-0.04 to 0.12) 
p=0.33 
 
 
14 
 
165 
 
 
 
95.11 (11.18) 
 
91.92 (11.78) 
 
 
 
3.19  
(-3.25 to 9.64) 
p=0.33 
Exemestane: 
Yes 
 
No 
 
 
 
43 
 
178 
 
 
37.11 (6.21) 
 
37.88 (6.25) 
 
 
 
-0.77 
(-2.86 to 1.32) 
p=0.47 
 
 
42 
 
172 
 
 
0.59 (0.67) 
 
0.63 (0.16) 
 
 
 
-0.04 
(-0.09 to 0.02) 
p=0.19 
 
 
40 
 
139 
 
 
 
91.73 (11.58) 
 
92.30 (11.82) 
 
 
 
-0.57 
(-4.73 to 3.60) 
p=0.79 
Gonadorelin 
analogues: 
Yes 
 
No 
 
 
 
 
19 
 
202 
 
 
 
38.58 (5.56) 
 
37.65 (6.30) 
 
 
 
 
0.93 
(-2.03 to 3.88) 
p=0.93 
 
 
 
19 
 
195 
 
 
 
0.64 (0.15) 
 
0.62 (0.16) 
 
 
 
 
0.018 
(-0.06 to 0.09) 
p=0.65 
 
 
 
12 
 
167 
 
 
 
 
91.58 (11.57) 
 
92.21 (11.78) 
 
 
 
 
-0.63 
(-7.57 to 6.30) 
p=0.86 
 
       a 
SD stands for standard deviation, CI stands for confidence interval, cm stands for centimetres. 
        b 
Independent sample t-test. Equal variances assumed. 
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Table 30 Appendix I - Parametric univariable analysis on the association between participants‘ body adiposity parameters at the end of the follow up 
and 1) menopausal status at diagnosis and 2) change in menopausal status after breast cancer diagnosis 
  
Fat % 
 
 
FM/FFM 
 
Waist circumference  
 n Mean (SD
a
) Mean difference, 
(95% CI
a
),          
p-value
b
 
n Mean (SD
a
) Mean difference, 
(95% CI
a
),  
p-value
b
 
n Mean 
(cm
a
)(SD
a
) 
Mean difference, 
(95% CI
a
),  
p-value
b 
 
 
Menopausal status 
at diagnosis: 
Pre + peri 
menopausal 
 
Postmenopausal 
 
 
 
 
 
60 
 
162 
 
 
 
 
36.00 (6.20) 
 
38.42 (6.14) 
 
 
 
 
 
-2.42  
(-4.25 to -0.58) 
p=0.01 
 
 
 
 
58 
 
157 
 
 
 
 
0.59 (0.14) 
 
0.64 (0.16) 
 
 
 
 
 
-0.05  
(-0.10 to -0.00) 
p=0.03 
 
 
 
 
42 
 
138 
 
 
 
 
 
88.88 (10.58) 
 
93.33 (12.01) 
 
 
 
 
 
-4.45  
(-8.52 to -0.38) 
p=0.03 
 
 
Menopausal status 
change: 
Yes 
 
No 
 
 
 
55 
 
167 
 
 
 
 
35.95 (6.25) 
 
38.36 (6.14) 
 
 
 
 
-2.42 
(-4.31 to -0.53) 
p=0.02 
 
 
 
53 
 
162 
 
 
 
0.59 (0.14) 
 
0.64 (0.16) 
 
 
 
 
-0.05 
(-0.10 to -0.00) 
p=0.04 
 
 
 
39 
 
141 
 
 
 
 
89.44 (10.35) 
 
93.09 (12.11) 
 
 
 
 
-3.65 
(-7.85 to -0.55) 
p=0.05 
 
       a 
SD stands for standard deviation, CI stands for confidence interval, cm stands for centimetres. 
        b 
Independent sample t-test. Equal variances assumed. 
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Table 31 Appendix I - Parametric univariable analysis on the association between participants‘ body adiposity parameters at the end of the follow up 
and genetic profile 
  
Fat % 
 
 
FM/FFM 
 
Waist circumference  
 n Mean (SD
a
) Mean difference, 
(95% CI
a
),            
p-value
a
 
n Mean (SD
a
) Mean difference, 
(95% CI
a
),            
p-value
a
 
n Mean 
(cm
a
)(SD
a
) 
Mean difference, 
(95% CI
a
),            
p-value
 
 
FTO: 
AA + AT 
 
TT 
 
 
 
75 
 
31 
 
 
36.86 (6.31) 
 
37.15 (6.68) 
 
 
 
-0.29 
(-3.01 to 2.42) 
p=0.83
b 
 
 
71 
 
30 
 
 
0.60 (0.16) 
 
0.62 (0.16) 
 
 
 
-0.02 
(-0.89 to 0.05) 
p=0.60
b 
 
 
45 
 
21 
 
 
 
91.10 (11.01) 
 
94.82 (13.30) 
 
 
 
-3.71 
(-9.93 to 2.49) 
p=0.24
b 
 
 
Mc4R: 
CC +CT 
 
TT 
 
 
 
41 
 
65 
 
 
36.27 (6.32) 
 
37.37 (6.45) 
 
 
 
-1.10 
(-3.63 to 1.43) 
p=0.39
b 
 
 
40 
 
61 
 
 
0.59 (0.15) 
 
0.62 (0.17) 
 
 
 
-0.02 
(-0.09 to 0.04) 
p=0.44
b 
 
 
30 
 
36 
 
 
 
91.90 (13.69) 
 
92.60 (10.17) 
 
 
 
-0.70 
(-6.58 to 5.12) 
p=0.82
c 
 
        a 
SD stands for standard deviation, CI stands for confidence interval, cm stands for centimetres. 
        b 
Independent sample t-test. Equal variances assumed. 
        c 
Independent sample t-test. Equal variances not assumed 
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Table 32 Appendix I - Parametric univariable analysis on the association between participants‘ body adiposity parameters at the end of the follow up 
and biological, behavioural and tumour-related variables 
  
Fat % 
 
 
FM/FFM 
 
Waist circumference  
 n Mean (SD
a
) Mean 
difference, 
(95% CI),        
p-value
b
 
n Mean (SD
a
) Mean 
difference, 
(95% CI
a
),       
p-value
b
 
n Mean 
(cm
a
)(SD
a
) 
Mean 
difference, 
(95% CI
a
),      
p-value
b
 
Smoking status at 
diagnosis: 
Smoker 
 
Non-smoker 
 
 
 
 
24 
 
197 
 
 
 
36.96 (7.62) 
 
37.83 (6.07) 
 
 
 
-0.87 
(-3.53 to 1.79) 
p=0.52 
 
 
 
22 
 
192 
 
 
 
0.64 (0.17) 
 
0.62 (1.16) 
 
 
 
0.02 
(-0.06 to 0.09) 
p=0.69 
 
 
 
16 
 
163 
 
 
 
93.96 (11.65) 
 
92.10 (11.88) 
 
 
 
1.87 
(-4.27 to 8.00) 
p=0.55 
 n 
 
Correlation coefficient
c 
p-value 
n 
 
Correlation coefficient
c 
p-value 
n 
 
Correlation coefficient
c 
 p-value 
Time since diagnosis to 
the end of the follow up 
 
 
222 
 
 
r=0.09  
p=0.20 
 
 
215 
 
 
r=0.06 
p=0.42 
 
 
180 
 
 
r=-0.02 
p=0.80 
 
Weight at diagnosis  
 
221 
 
r=0.70 
p<0.01 
 
215 
 
r=0.72 
p<0.01 
 
180 
 
r=0.75 
p<0.01 
Weight at the end of the 
follow up) 
 
 
222 
 
 
r=0.75 
p<0.01 
 
 
215 
 
 
r=0.77 
p<0.01 
 
 
180 
 
 
r=0.81 
p<0.01 
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Weight change from 
diagnosis to the end of the 
follow up 
 
 
221 
 
 
r=0.16 
p=0.02 
 
 
215 
 
 
r=0.17 
p=0.02 
 
 
180 
 
 
r=0.21 
p=0.01 
Age at diagnosis (years) 
 
 
222 
 
r=0.21 
p<0.01 
 
215 
 
r=0.16 
p=0.02 
 
180 
 
r=0.20 
p=0.01 
Age at the end of the 
follow up (years) 
 
 
222 
 
 
r=0.21 
p<0.01 
 
 
215 
 
 
r=0.15 
p=0.03 
 
 
180 
 
 
r=0.17 
p=0.02 
Tumour size (cm) 
 
222 
 
r=-0.04 
p=0.57 
 
215 
 
r=-0.06 
p=0.39 
 
180 
 
r=-0.06 
p=0.44 
 n Mean (SD
a
) 
 
One-way 
ANOVA
a 
n Mean (SD
a
) 
 
One-way 
ANOVA
a 
n Mean (cm
a
)(SD
a
) 
 
One-way  
ANOVA
a 
Stage of disease: 
Stage 1 
Stage 2 
Stage 3
 
 
 
98 
81 
37 
 
 
37.91 (6.01) 
37.94 (6.14) 
37.03 (7.12) 
 
 
   F (2, 206) 
F=0.68 
p=0.94 
 
 
95 
80 
34 
 
 
0.62 (0.16) 
0.63 (0.16) 
0.61 (0.17) 
 
 
 F (2, 206) 
F=0.68 
p=0.94 
 
 
81 
69 
25 
 
 
93.67 (11.92) 
91.12 (11.33) 
90.80 (11.02) 
 
 
 F (2, 172) 
F (1.13) 
   p=0.32 
       a 
SD stands for standard deviation, CI stands for confidence interval, cm stands for centimetres, ANOVA stands for analysis of the variance. 
        b 
Independent sample t-test. Equal variances assumed. 
        c Pearson‘s product moment correlation test. 
        d 
Independent sample t-test. Equal variances not assumed. 
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Table 33 Appendix I - Multiple linear regression analysis on factors associated with participants‘ fat mass percentage at the end of the follow up 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
 
193 
 
7.46 (2.76 to 12.67) 
 
0.34 (0.29 to 0.38) 
 
0.11 (0.05 to 0.16) 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.73 
F (2, 190) 
F=108.57 
p<0.01 
        a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
 
Table 34 Appendix I - Multiple linear regression analysis on factors associated with participants‘ fat mass/fat free mass ratio at the end of the follow   
up 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years)
 
 
186 
 
-0.14 (-0.271 to -0.024) 
 
0.01 (0.008 to 0.010) 
 
0.002 (0.001 to 0.004) 
 
p=0.02 
 
p<0.01 
 
p<0.01 
 
R=0.74 
F (2, 183) 
F=111.97 
p<0.01 
        a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
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Table 35 Appendix I - Multiple linear regression analysis on factors associated with participants‘ waist circumference at the end of the follow up 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
 (95% CI
a
)  
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficient 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
 
158 
 
29.17 (20.90 to 37.44) 
 
0.70 (0.56 to 0.96) 
 
0.19 (0.95 to 29.4) 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.83 
F (3, 154) 
F=111.16 
p<0.01 
         a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
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Table 36 Appendix I - Parametric univariable analysis on the association between participants‘ glucose and insulin levels at the end of the follow up 
and breast cancer treatment  
  
Glucose  
 
 
Insulin  
 n Mean (mmol/l
a
) (SD
a
) Mean difference, (95% CI
a
),    
p-value
b
 
n Mean (pmol/l
a
) (SD
a
) Mean difference, (95% 
CI
a
),    p-value
b
 
 
Chemotherapy: 
Yes 
 
No 
 
 
82 
 
85 
 
 
5.07 (0.91) 
 
5.20 (0.60) 
 
 
-0.14 
(-0.37 to .10) 
p=0.25 
 
 
71 
 
76 
 
 
33.92 (30.23) 
 
44.35 (32.83) 
 
 
-10.43 
(-20.74 to -1.20) 
p=0.04 
 
Hormone therapy:  
Yes 
 
No 
 
 
144 
 
22 
 
 
5.17 (0.80) 
 
4.94 (0.54) 
 
 
0.23 
(-0.11 to 0.58) 
p=0.18 
 
 
130 
 
16 
 
 
39.35 (32.04) 
 
37.07 (32.00) 
 
 
2.28 
(-14.49 to 19.06) 
p=0.79 
 
Tamoxifen: 
Yes 
 
No  
 
 
93 
 
73 
 
 
5.16 (0.68) 
 
5.11 (0.88)  
 
 
0.04 
(-0.19 to 0.28) 
p=0.71 
 
 
83 
 
63 
 
 
37.13 (30.54) 
 
41.69 (33.75) 
 
 
-4.56 
(-15.11 to 5.99) 
p=0.39 
 
Aromatase inhibitors:  
Yes 
 
No 
 
 
112 
 
54 
 
 
5.20 (0.85) 
 
5.01 (0.55) 
 
 
0.19 
(-0.06 to 0.44) 
p=0.15 
 
 
103 
 
43 
 
 
39.41 (30.80) 
 
38.35 (34.77) 
 
 
1.06 
(-10.43 to 12.56) 
p=0.85 
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      a Mmol/l stands for milimol per litre, pmol/l stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
       b 
Independent sample t-test. Equal variances assumed. 
 
 
Anastrozole: 
Yes 
 
No 
 
 
73 
 
93 
 
 
5.10 (0.60) 
 
5.17 (0.09) 
 
 
-0.07 
(-0.30 to 0.17) 
p=0.57 
 
 
66 
 
80 
 
 
40.97 (27.56) 
 
37.56 (35.23) 
 
 
3.40 
(-7.11 to 13.92) 
p=0.53 
 
Letrozole: 
Yes 
 
No 
 
 
12 
 
154 
 
 
5.67 (1.68) 
 
5.09 (0.65) 
 
 
0.57 
(-0.12 to 1.02) 
p=0.26
c
 
 
 
11 
 
135 
 
 
61.31 (47.39) 
 
37.29 (29.87) 
 
 
24.03 
(4.56 to 43.49) 
p=0.02 
 
Exemestane: 
Yes 
 
No 
 
 
38 
 
128 
 
 
5.28 (0.76) 
 
5.10 (0.77) 
 
 
0.18 
(-0.10 to 0.46) 
p=0.12 
 
 
37 
 
109 
 
 
29.42 (24.98) 
 
42.39 (33.39) 
 
 
-6.00 
(-24.82 to -1.10) 
p=0.03 
 
Gonadorelin analogues: 
Yes 
 
No 
 
 
12 
 
154 
 
 
4.88 (0.37) 
 
5.16 (0.79) 
 
 
-0.28 
(-0.73 to 0.18) 
p=0.23 
 
 
12 
 
134 
 
 
36.17 (39.29) 
 
39.36 (31.36) 
 
 
-3.19 
(-22.27 to 15.88) 
p=0.74 
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Table 37 Appendix I - Parametric univariable analysis on the association between participants‘ glucose and insulin levels at the end of the follow up 
and 1) menopausal status at diagnosis and 2) change in menopausal status after breast cancer diagnosis  
  
Glucose  
 
 
Insulin  
 n Mean (mmol/l
a
) (SD
a
) Mean difference, (95% 
CI
a
), p-value
b
 
n Mean (pmol/l
a
) (SD
a
) Mean difference, (95% 
CI
a
), p-value
b 
 
Menopausal 
status at 
diagnosis: 
Pre + peri 
menopausal 
 
Post-menopausal 
 
 
 
 
 
 
41 
 
126 
 
 
 
 
 
4.92 (0.62) 
 
5.21 (0.80) 
 
 
 
 
 
-0.28 
(-0.56 to -0.01) 
p=0.04 
 
 
 
 
 
36 
 
111 
 
 
 
 
 
37.64 (32.33) 
 
40.47 (31.94) 
 
 
 
 
 
-4.72 
(-16.83 to 7.41) 
p=0.44 
Menopausal 
status change: 
Yes 
 
No 
 
 
 
38 
 
129 
 
 
 
4.99 (0.55) 
 
5.18 (0.82) 
 
 
 
 
-0.19 
(-0.41 to 0.09) 
p=0.18 
 
 
 
35 
 
112 
 
 
 
 
36.57 (32.33) 
 
40.16 (31.94) 
 
 
 
-3.59 
(-15.84 to 8.65) 
p=0.56 
        a Mmol/l stands for milimol per litre, pmol/l stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
         b 
Independent sample t-test. Equal variances assumed. 
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Table 38 Appendix I - Parametric univariable analysis on the association between participants‘ glucose and insulin levels at the end of the follow up 
and genetic profile  
  
Glucose  
 
 
Insulin  
 n Mean (mmol/l
a
) (SD
a
) Mean difference, (95% CI
a
),    
p-value
b
 
n Mean (pmol/l) (SD
a
) Mean difference, (95% CI
a
),    
p-value
b
 
 
FTO: 
AA + AT 
 
TT 
 
 
 
43 
 
19 
 
 
5.08 (0.40) 
 
5.19 (.1.44) 
 
 
 
-0.11 
(-0.58 to 0.36) 
p=0.65 
 
 
 
41 
 
19 
 
 
43.01 (27.84) 
 
33.07 (18.48) 
 
 
9.94 
(-4.12 to 24.00) 
p=0.17 
 
Mc4R: 
CC +CT 
 
TT 
 
 
 
29 
 
33 
 
 
5.05 (0.61) 
 
5.18 (1.12) 
 
 
 
-0.12 
(-0.56 to 0.31) 
p=0.57 
 
 
27 
 
33 
 
 
42.80 (27.85) 
 
37.46 (23.61) 
 
 
5.33 
(-7.97 to 18.63) 
p=0.43 
       a Mmol/l stands for milimol per litre, pmol/l stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
       b 
Independent sample t-test. Equal variances assumed. 
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Table 39 Appendix I - Parametric univariable analysis on the association between participants‘ glucose and insulin levels at the end of the follow up 
and biological, behavioural and tumour-related variables 
  
Glucose  
 
Insulin  
 
 n Mean (mmol/l
a
) (SD
a
) Mean difference, (95% CI
a
),   
p-value
b
 
n Mean (pmol/l
a
)(SD
a
) Mean difference, (95% CI
a
), 
p-value
b
 
Smoking status at 
diagnosis: 
Smoker 
 
Non-smoker 
 
 
 
16 
 
150 
 
 
 
5.13 (0.48) 
 
5.14 (0.98) 
 
 
 
-0.01 
(-0.41 to 0.39) 
p=0.98 
 
 
 
13 
 
133 
 
 
 
35.53 (32.79) 
 
39.48 (31.48) 
 
 
 
-3.95 
(-22.36 to 14.46) 
p=0.67 
 n 
 
Correlation coefficient
c
 
p-value 
n 
 
Correlation coefficient
c 
p-value 
Time since diagnosis to 
the end of the follow up 
 
 
166 
 
r=-0.01 
p=0.22 
 
146 
 
r=-0.21 
p=0.01 
 
Weight at diagnosis  
 
 
153 
 
r=0.34 
p<0.01 
 
133 
 
r=0.34 
p<0.01 
 
Weight at the end of the 
follow up  
 
 
167 
 
r=0.31 
p<0.01 
 
147 
 
r=0.33 
p<0.01 
 
Weight change from 
diagnosis to the end of 
the follow up 
 
 
153 
 
 
r=-0.09 
p=0.25 
 
 
133 
 
 
r=-0.07 
p=0.44 
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Age at diagnosis (years) 
 
 
160 
 
r=0.13 
p=0.09 
 
141 
 
r=0.10 
p=0.25 
 
 
Age at the end of the 
follow up (years) 
 
 
161 
 
r=0.15 
p=0.15 
 
142 
 
r=0.05 
p=0.54 
 
Tumour size (cm) 
 
 
163 
 
r=-0.08 
p=0.29 
 
143 
 
r=-0.04 
p=0.67 
 n Mean (mmol/l
a
) (SD
a
) One Way ANOVA
a 
n Mean (pmol/l
a
)(SD
a
) One Way ANOVA
a 
 
Stage of disease: 
Stage 1 
Stage 2 
Stage 3
 
 
 
74 
63 
23 
 
 
5.07 (0.63) 
5.17 (0.65) 
5.32 (1.32) 
 
 
 
 F(2, 158) 
F=0.58 
p=0.39 
 
 
66 
53 
22 
 
 
42.59 (33.05) 
36.35 (28.28) 
39.72 (37.98) 
 
 
  F (2, 138) 
F=0.55 
p=0.57 
 
        a Mmol/l stands for milimol per litre, pmol/l stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval, ANOVA stands for analysis of the     
      variance. 
        b 
Independent sample t-tests. Equal variances assumed. 
        c Pearson‘s product moment correlation test. 
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Table 40 Appendix I - Multiple linear regression analysis on factors associated with participants‘ glucose levels at the end of the follow up  
 
Variables included 
 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
FTO
b 
 
 
57 
 
4.74 (4.058 to 5.430) 
 
0.01 (0.000 to 0.018) 
 
-0.28 (-0.528 to -0.029) 
 
 
p<0.01 
 
p=0.05 
 
p=0.03 
 
 
R=0.37 
F (2, 54) 
F=4.24 
p=0.02 
             a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
             b 
Categories FTO: 0) AA + AT and 1) TT. 
 
Table 41 Appendix I - Multiple linear regression analysis on factors associated with participants‘ insulin levels at the end of the follow up 
 
Variables included 
 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
s
) 
 
FTO
a 
 
 
56 
 
-21.99 (-53.84 to 9.86) 
 
1.17 (0.75 to 1.59) 
 
-15.20 (-27.12 to -3.28) 
 
 
p=0.17 
 
p<0.01 
 
p=0.01 
 
 
R=0.63 
F (2, 53) 
F=17.26 
p<0.01 
             a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance.  
             b 
Categories FTO: 0) AA + AT and 1) TT. 
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APPENDIX II: EXPLORING MISSING DATA 
 
Appendix II. Introduction  
This appendix explores the number of weight records available for participants at 
different evaluation points. This information, as explained, was used to determine the 
appropriate window margins chosen for the investigated evaluation points post-
diagnosis and had repercussions on the sample sizes for each evaluation point. The 
appendix then investigates the presence of missing data on the outcome of interest: 
body weight post-BC diagnosis.   
 
Appendix II.A. Number of participants with available weight records  
Table 42 (Appendix II, all the tables are found at the end of this appendix) reports on 
a relevant feature that should guide data analysis: the number of participants with 
available weight records at different evaluation points. Table 42 (Appendix II) shows 
the numbers of participants with weight measured at specific evaluation points: at 
BC diagnosis and at 12, 24, 36, 48, 60 and 72 months post-diagnosis. Initially, the 
window margin was arbitrarily chosen to be ± 0.5 months. However, only 59 
participants (24.69%) had weight records within that window period at the time of 
diagnosis and less than 10% of the sample had weight records measured at any of the 
other exact evaluation points. In an attempt to explore whether participants had 
weights recorded near those points, the window margin was widened to ± 3 and ± 4 
months, respectively. As expected, the number of participants with available data 
increased when the window margins were expanded. 
The window margins were arbitrarily chosen as the literature in the area is not 
consistent. In some studies (i.e. Irwin et al. 2005; Kroenke et al. 2005) the window 
period for the review points was very large (i.e. weight taken from biannual surveys).  
Other researchers have reported using a smaller window-period for their follow up 
measurements, such as ± 1 month (Basaran et al. 2011) or ± 2 months (Makari-
Judson et al. 2007; Reddy et al. 2013). Some studies provided vague information in 
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this regard, reporting that weight values were taken ―approximately‖ at specific 
points (i.e. approximately at 18 months, 36 months after diagnosis) (Chen et al. 
2011; Gu et al. 2011), yet other authors opted for reporting the average months/years 
at which the follow up point occurred in relation to a baseline measure (i.e. mean of 
9.1 months from baseline), rather than providing the interval of time at which the 
weight measures were taken (Goodwin et al. 1999; Rock et al. 1999; Saquib et al. 
2007; Tredan et al. 2010; Guinan et al. 2014). In the current study, selecting a ± 2 
months period window would not raise the number of participants with available 
weight records to a much higher percentage than the original ± 0.5 month window 
(Table 42, Appendix II).  
 
Appendix II.B. Number of weights across participants according to main 
predictors 
The frequency of weight records available for each participant varied across BC 
treatment and menopause status (Figure 3, Appendix II). This variation could be 
attributed mainly to the use of chemotherapy. On average, during all follow up, 
participants who received chemotherapy were weighed more times than non-users 
(mean 13.57 times vs. 3.37 times, p <0.01). Similarly, within each year, participants 
who received chemotherapy had more weights recorded than their counterparts 
(Table 43, Appendix II). 
Participants who took AINs were also weighed more times than those that did not 
take AINs (10.14 vs. 7.33 times, p <0.01). Those treated with tamoxifen were 
weighed an average of eight times after diagnosis to the point of study entry, 
whereas those who did not take tamoxifen were weighed a mean of 10.58 times 
(p<0.01). When looking at each year of follow up, the differences reached statistical 
significance in the first two years post-diagnosis for tamoxifen use, and during the 
fourth, fifth and sixth years when looking at AINs use (Table 43, Appendix II).   
There were no statistically significant differences in the total number of weights 
available among the pre, peri and postmenopausal participant groups across the 
length of follow up. Nonetheless, during the first and fourth year post-diagnosis, 
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premenopausal women had a higher number of weight records compared with peri 
and postmenopausal women (Table 43, Appendix II). 
 
Appendix II.C. Reasons for differences in number of weight records between 
chemotherapy users and non-users. Is this missing data? 
The differences in number of weights recorded might lie in the clinical team looking 
after BC patients. All the patients were followed by the Surgery team, which, as part 
of routine care, does not assess patient‘s body weight. Conversely, the Oncology 
team only follows women who receive chemotherapy, and patients are weighed 
before each cycle of chemotherapy and yearly during their Oncology follow up. This 
suggests the presence of missing values among the chemotherapy group, but not 
among the non-treated group. Forty-five participants (34.6%) had the same number 
of weight records as cycles of chemotherapy, whereas 39 participants (30.1%) 
seemed to have missing weight records, as the number of cycles received was higher 
than the number of weights recorded in their medical reports during the length of the 
chemotherapy course. In addition, it was expected that chemotherapy-treated 
participants would have at least one weight record per year following BC diagnosis, 
however, at different evaluation points, between 25% to 35.1% of chemotherapy-
treated participants had missing weight records beyond 12 months post-diagnosis.  
On the other hand, because of the retrospective nature of the study and the unplanned 
measurement occasions from the time of BC diagnosis to the end of the follow up, it 
was difficult to ascertain when a weight had failed to be recorded in the group of 
women who did not receive chemotherapy. Therefore, it can be argued that the lower 
number of weights recorded in the chemotherapy non-treated group (Table 44, 
Appendix II) should not be considered missing data.  
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Appendix II.D. What are the reasons for differences in number of weight 
records between tamoxifen and/or aromatase inhibitors users and non-users? 
Are there missing data? 
A plausible reason for the higher number of weight records among tamoxifen non-
users compared with tamoxifen users and among AINs users vs. non-users could be 
related to chemotherapy use (Table 43, Appendix II). During the first and the second 
year post-diagnosis, the largest number of participants receiving chemotherapy 
(n=74) was found among participants who did not take tamoxifen. They hold the 
highest mean number of weights recorded (mean of 9.11 during first year and 1.82 
during the second year) (Table 45, Appendix II). Similarly, the percentage of 
participants who received chemotherapy compared with those who did not is always 
higher in the subgroup of participants that received AINs (Table 46 – App II). No 
other plausible reason seems to explain the differences in number of weight records 
between the compared groups. However, it is possible that random effects could 
offer an alternative or complementary explanation for the effect of tamoxifen and 
AINs use on number of weights recorded following BC diagnosis. 
To summarise, results presented here suggest the presence of missing weight data, 
particularly among participants who received chemotherapy. The differences found 
seem to be linked to chemotherapy use rather than to other potential factors (i.e. 
tamoxifen or AINs use). 
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Table 42 Appendix II - Number of participants with weight records available at breast cancer diagnosis and at 12, 24, 36 and 48 months post-
diagnosis, looking at different window periods (±0.5, ±3.0 and ±4.0 months) 
Window (±0.5 
months) 
At diagnosis 
(±0.5 months) 
At 12 months post-
diagnosis 
(±0.5 months) 
At 24 months 
(±0.5 months) 
At 36 months 
(±0.5 months) 
At 48 months 
(±0.5 months) 
At 60 months 
(±0.5 months) 
At 72 months 
(±0.5 months) 
At 84 months 
(±0.5 months) 
Total number 
of participants 
 
 
239 
 
 
237 
 
 
215 
 
 
172 
 
 
121 
 
 
78 
 
 
41 
 
 
16 
Number of 
participants 
with weight 
records (%) 
 
 
 
 
59 (24.69%) 
 
 
 
 
20 (8.44%) 
 
 
 
18 (8.37%) 
 
 
 
11 (6.39%) 
 
 
 
11 (9.1%) 
 
 
 
7 (8.97%) 
 
 
 
2 (4.88%) 
 
 
 
4 (25%) 
Number of 
participants 
without weight 
records (%) 
 
 
 
180 (75.31%) 
 
 
 
219 (91.56%) 
 
 
197 (91.63%) 
 
 
161 (93.61%) 
 
 
110 (90.9%) 
 
 
71 (91.03%) 
 
 
39 (95.12%) 
 
 
12 (75%) 
Window (± 3.0 
months) 
At diagnosis 
(From -2.0 to 
3.0 months of 
diagnosis date) 
At 12 months post-
diagnosis 
(±3.0 months) 
At 24 months 
(±3.0 months) 
 
At 36 months 
 (±3.0 months) 
 
At 48 months 
(±3.0 months) 
 
At 60 months 
(±3.0 months) 
 
At 72 months 
(±3.0 months) 
 
At 84 months 
(±3.0 months) 
 
Total number 
of participants  
 
 
239 
 
 
239 
 
 
215 
 
 
172 
 
 
122 
 
 
78 
 
 
41 
 
 
16 
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Number of 
participants 
with weight 
records (%)  
 
 
 
217 (90.8%) 
 
 
86 (36%) 
 
 
88 (40.93%) 
 
 
67 (38.95%) 
 
 
53 (43.44%) 
 
 
28 (35.9%) 
 
 
 
20 (48.78%) 
 
 
13 (81.25%) 
Number of 
participants 
without weight 
records (%) 
 
 
 
22 (9.2%) 
 
 
153 (64%) 
 
 
127 (59.07%) 
 
 
105 (61.05%) 
 
 
69 (56.56%) 
 
 
50 (64.1%) 
 
 
21 (51.22%) 
 
 
3 (18.75%) 
 
Window (± 4.0 
months) 
 
At diagnosis 
(From -2.0 to 
4.0 months of 
diagnosis date) 
At 12 months post-
diagnosis 
(±4.0 months) 
At 24 months 
(±4.0 months) 
 
At 36 months 
(±4.0 months) 
 
At 48 months 
(±4.0 months) 
 
At 60 months 
(±4.0 months) 
 
At 72 months 
(±4.0 months) 
 
At 84 months 
(±4.0 months) 
 
Total number 
of participants  
 
 
239 
 
 
239 
 
 
224 
 
 
178 
 
 
128 
 
 
82 
 
 
44 
 
 
16 
Number of 
participants 
with weight 
records (%)  
 
 
 
221 (92.5%) 
 
 
101 (42.3%) 
 
 
104 (46.4%) 
 
 
78 (32.6%) 
 
 
68 (53.1%) 
 
 
39 (47.6%) 
 
 
27 (61.4%) 
 
 
16 (84.2%) 
Number of 
participants 
without weight 
records (%) 
 
 
 
18 (7.5%) 
 
 
 
 
138 (57.7%) 
 
 
 
 
120 (53.6%) 
 
 
 
100 (56.2%) 
 
 
 
60 (46.9%) 
 
 
 
43 (52.4%) 
 
 
 
17 (38.6%) 
 
 
 
3 (15.8%) 
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Figure 3 Appendix II - Histogram representing the total number of weight records hold by participants from breast cancer diagnosis to the end of the 
follow up, according to breast cancer treatments and menopausal status 
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         Note: AINs stands for aromatase inhibitors
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Table 43 Appendix II - Number of weight records hold by participants from breast cancer diagnosis to the end of the follow up, according to breast 
cancer treatment and menopausal status at diagnosis  
 
 
From diagnosis to 
the end of the follow 
up
 
 
During the 1
st
  
year
a
 
 
During the 2
nd
   
year
a
 
 
During the 3
rd
   
year
a 
 
During the 4
th
   
year
a
 
 
During the 5
th
   
year
a
 
 
During  the 
6
th
  year
a 
 
During the 7
th
   
year
a
 
 
Number of 
participants 
followed 
 
 
 
239 
 
239 
 
 
236 
 
 
202 
 
 
161 
 
 
109 
 
 
64 
 
 
37 
 
Number of 
weight records 
 
 
n  Mean (SD
b
)        
p-value of the 
difference 
 
 
n       Mean (SD
b
)   
p-value of the difference      
 
 
Chemotherapy:  
 Yes 
       
No
 
 
 
134
     
1
 
3.57 (6.95)        
 
105    3.37 (1.65)  
       
p<0.01
c 
 
 
134     8.43 (4.6) 
 
105     1.52 (0.94) 
 
p<0.01
c 
 
 
132   1.67 (1.72) 
 
104   0.43 (0.73) 
 
p<0.01
c 
 
 
114  1.60 (1.46) 
 
88    0.42 (0.71) 
 
p<0.01
c
 
 
 
90   1.38 1.58) 
 
71   0.69 (0.77) 
 
p<0.01
c 
 
 
64   1.33 (1.62) 
 
45   0.58 (0.58) 
 
p<0.01
c 
 
 
37  1.14 (1.03) 
 
27  0.74 (0.71) 
 
p=0.07
 c 
 
 
 
23  1.0 (1.00) 
 
14  1.07 (0.92) 
 
p=0.82
d 
 
Tamoxifen: 
 Yes  
      
No
 
 
 
131    7.93 (7.35)         
 
107    10.58 (7.1)    
 
p=0.01
d
 
 
 
131   4.31 (4.49) 
 
107   6.78 (5.06) 
 
p<0.001
c 
 
 
 
128   0.85 (1.16) 
 
107   1.47 (1.78) 
 
p<0.01
c
 
 
 
114  1.01 (1.32) 
 
87    1.20 (1.33) 
 
p=0.32
 d
 
 
 
92   1.15 (1.57) 
 
68   0.97 (0.89) 
 
p=0.39
 d
 
 
 
64   1.13 (1.64) 
 
45   0.87 (0.76) 
 
p=0.33
d
 
 
 
39  1.00 (0.92) 
 
25  0.92 (0.95) 
 
p=0.74
d
 
 
 
23   0.96 (1.06) 
 
14    1.14 (0.77) 
 
p=0.57
d 
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Aromatase 
inhibitors:  
Yes 
 
 No
 
  
 
 
 
152  
 
10.14 (7.65)        
  
86       7.33 (6.4)          
 
p<0.01
c
 
 
 
 
152   5.78 (4.94) 
 
86     4.79 (4.78) 
 
p=0.13
d
 
 
 
 
152  1.25 (1.33) 
 
83     0.92 (1.78) 
 
p=0.11
d
 
 
 
 
134   1.15 (1.30) 
 
67     0.97 (1.37) 
 
p=0.37
d
 
 
 
 
111  1.23 (1.48)  
 
49    0.71 (0.79) 
 
p=0.05
d
 
 
 
 
79   1.24 (1.48) 
 
30   0.43 (0.62) 
 
p<0.01
d
 
 
 
 
41  1.15(0.99) 
 
23  0.65(0.71) 
 
p=0.02
d
 
 
 
 
25  1.26 ( (1.07) 
 
12   0.75 (0.62) 
 
p=0.15
d
 
 
Menopausal 
status at 
diagnosis: 
Premenopausal 
 
Perimenopausal  
 
Postmenopausal 
 
 
 
 
 
52   11.25 (7.23)     
 
13     8.38 (7.63)          
 
 174  8.49 (7.26)      
 
p=0.05
e 
 
 
 
 
52     7.23 (5.21) 
 
13      5.77 (6.22) 
 
174    4.82 (4.58) 
 
p<0.01
e 
 
 
 
 
50   1.24 (1.20) 
 
13   0.85 (1.14) 
 
173 1.12 (1.61) 
 
p=0.69
e
 
 
 
 
 
42     1.52 (1.61) 
 
11     0.64 (0.50) 
 
149   0.99 (1.25) 
 
p=0.04
e
 
 
 
 
 
32   1.19 (1.28) 
 
7     1.43 (1.13) 
 
122 1.02 (1.35) 
 
p=063
e
 
 
 
 
 
20    1.2 (1.61) 
 
4       0.5 (0.58) 
 
85     1.0 (1.31) 
 
p=0.61
e
 
 
 
 
 
12   1.0 (0.85) 
 
3     0.33(0.58) 
 
49   1.0 (0.96) 
 
p=0.48
e
 
 
 
 
 
7    0.57 (0.53) 
 
2     1.5 (0.71) 
 
28  1.11 (1.03) 
 
p=0.33
e 
 
        a 
1
st
 year (from diagnosis to 12.50 months post-diagnosis); 2
nd
 year (from 12.51 to 24.50 months post-diagnosis); 3
rd
 year (24.51 to 36.50 months post-diagnosis); 4
th
 year (36.51 to 48.50  
     months post-diagnosis); 5
th
 year (48.51 to 60.50 months post-diagnosis); 6
th
 year (60.51 to 72.50 months post-diagnosis); and 7
th
 year (72.51 to 84.50 months post-diagnosis).  
     
b 
SD stands for standard deviation.  
       c 
Independent sample t-test. Levene‘s Test for Equality of Variances significant. 
       d 
Independent sample t-test. Levene‘s Test for Equality of Variances no significant.  
       e
 One-Way analysis of the variance (ANOVA).  Levene‘s Test for Equality of Variances not significant. 
  
 
272 
Table 44 Appendix II - Number of participants with available weight records from breast cancer diagnosis to 1
st
, 2
nd
, 3
rd
, 4
th
, 5
th
, 6
th
and 7
th
 year post 
diagnosis and to the end of the follow up, stratified by chemotherapy use 
  
All follow up
 a
 
 
(from diagnosis 
to the end of the 
follow up) 
 
During the 1
st
 
year 
 
(from diagnosis 
to 12.50 
months post-
diagnosis) 
 
During the 2
nd
 
year 
 
(from 12.51 to 
24.50 months)
 
 
 
During the 3
rd
 
year 
 
(from 24.51 to 
36.50 months) 
 
 
During the 4
th
 
year 
 
(from 36.51 to 
48.50 months)
 
 
During the 5
th
 
year 
 
(from 48.51 to 
60.50 months)
 
 
During the 6
th
 
year 
 
(from 60.51 to 
72.50 months) 
 
During the 7
th
 
year 
 
(from 72.51 to 
84.50 months) 
 
Chemotherapy 
 
 
Yes No Yes No Yes No Yes No Yes No Yes No Yes No Yes No 
 
Number of 
participants 
 
 
 
134 
 
105 
 
134 
 
105 
 
132 
 
104 
 
114 
 
88 
 
90 
 
71 
 
64 
 
45 
 
37 
 
27 
 
23 
 
14 
 
Total 
number of 
weight 
records 
 
 
 
1,818 
 
354 
 
1,130 
 
160 
 
221 
 
45 
 
168 
 
37 
 
124 
 
49 
 
85 
 
26 
 
42 
 
20 
 
23 
 
15 
 
Mean 
number of 
weight 
records (SD
b
) 
 
 
 
13.7 
(6.5) 
 
3.37 
(1.65) 
 
8.43 
(4.6) 
 
1.52 
(0.94) 
 
1.67 
(1.72) 
 
0.43 
(0.73) 
 
1.59 
(1.47) 
 
0.42 
(0.71) 
 
1.38 
(1.58) 
 
0.69 
(0.77) 
 
1.33 
(1.62) 
 
0.58 
(0.59) 
 
1.14 
(1.03) 
 
0.74 
(0.71) 
 
1.0 
(1.0) 
 
1.07 
(0.92) 
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Number of Participants (%) 
Number of 
weight 
records
 
 
Yes  
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
 
Yes 
 
No 
0 0 0 4  
(3)
 
10 
(9.5)
 
34 
(25.8)
 
71 
(68.3)
 
29 
(25.4)
 
60 
(68.2)
 
23 
(25.6)
 
33 
(46.5)
 
16 
(25)
 
21 
(46.7)
 
13 
(35.1)
 
10 
(3.07)
 
7 
(30.4)
 
2 
 (14.3)
 
1-5 22 
 (16.4)
 
94 
(89.45)
 
32 
(23.9)
 
95 
(90.5)
 
97 
(73.5)
 
33 
(31.7)
 
83 
(72.8)
 
28 
(31.8)
 
65 
(72.2)
 
48  
(53.5)
 
46 
(71.8)
 
24 
(53.3)
 
24 
(64.8)
 
17 
(63.0)
 
17 
(69.6)
 
12 
(85.7)
 
6-10 18 
(13.4)
 
11 
(10.6)
 
46 
(34.33)
 
0 0 0 2 
(1.75)
 
0 1 
(1.1)
 
0 2 
(3.2)
 
0 0 0 0 0 
11-15 44  
(32.8)
 
0 45 
(36.58)
 
0 1  
(0.8)
 
0 0 0 1 
(1.1)
 
0 0 0 0 0 0 0 
16-20 29 
(21.6)
 
0 7 
(5.22) 
0 0 0 0 0 0 0 0 0 0 0 0 0 
21-25 15 
 (11.2)
 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
26-30 5 
 (3.7)          
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
43 1  
(0.7)          
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
             a 
Including eleven women with each one having 1 weight recorded more than 84.51 months post-diagnosis (nine received chemotherapy and two did not). 
             b 
SD stands for standard deviation.  
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Table 45 Appendix II - Number of weight records hold by participants during the 1
st
 and 2
nd
 year post breast cancer diagnosis stratified by tamoxifen 
and chemotherapy use 
 
During 1st year During 2nd Year  
 
Chemotherapy Chemotherapy 
Yes No Yes No 
 
 
 
 
Tamoxifen 
 
 
Yes 
Number of participants 59 72 57 71 
Mean number of weight 
records (SD
a
) 
 
 
7.73 (4.74) 
 
 
1.51 (0.99) 
 
 
1.51 (1.36) 
 
 
0.32 (0.58) 
 
No 
Number of participants 74 33 74 33 
Mean number of weight 
records (SD
a
) 
 
 
9.11 (4.35) 
 
 
1.55 (0.83) 
 
 
1.82 (1.95) 
 
 
0.67 (0.96) 
         a
 SD stands for standard deviation.
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Table 46 Appendix II - Number of weight records hold by participants during the 4th, 5th and 6th year post breast cancer diagnosis, stratified by 
aromatase inhibitors (AINs) and chemotherapy use 
 
During 4
th
 year During 5th year During 6th year  
 
Chemotherapy Chemotherapy Chemotherapy 
Yes No Yes No Yes No 
 
 
 
 
 
 
 
 
 
AINs 
 
 
 
Yes 
Number of participants 61 50 47 32 47 32 
Mean number of weight 
records (SD
a
) 
 
 
1.59 (1.78) 
 
 
0.8 (0.83) 
 
 
1.57 (1.73) 
 
 
0.72 (0.58) 
 
 
1.57 (1.73) 
 
 
0.72 (0.58) 
 
 
No 
Number of participants 28 21 17 13 17 13 
Mean number of weight 
records (SD
a
) 
 
 
0.93 (0.9) 
 
 
0.43 (0.51) 
 
 
0.59 (0.71) 
 
 
0.23 (0.44) 
 
 
0.59 (0.71) 
 
 
0.23 (0.44) 
          a
 SD stands for standard deviation. 
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APPENDIX III: SENSITIVITY ANALYSIS OF WEIGHT 
CHANGE AFTER BREAST CANCER DIAGNOSIS  
  
Appendix III. Introduction  
This appendix was designed as a complement to Chapter 4, with the aim of 
providing a rationale for the analytical approach used within the chapter. It evaluates 
the main results on weight change at 12, 24, 36 and 48 months post BC diagnosis. 
The appendix reviews the weight values of participants included in the main analysis 
presented in Chapter 4 and those participants who were excluded due to missing 
values. The appendix then provides details on the distribution of the main outcomes. 
The next two sections show the results of the analysis of weight change post-
diagnosis and factors associated with it using a non-parametric approach. The 
following three sections deal with the presence of outliers and their impact on the 
findings regarding weight change post BC diagnosis. The appendix finishes by 
showing the repeated multiple regression analysis of weight change. 
 
Appendix  III.A. Similarities between participants included in, and 
participants excluded from the analysis of weight change after breast cancer 
diagnosis: Comparison of their weights at breast cancer diagnosis 
Results from both parametric and non-parametric tests confirmed that there were no 
differences in weight at the time of BC diagnosis between those participants included 
in the analysis of weight change detailed in Chapter 4 and those excluded from the 
analysis due to missing weight records (Table 47, Appendix III). This provided a 
rationale for the complete-case data analysis approach used in the main analysis of 
Chapter 4. 
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Appendix III.B. Non-parametric approach for the analysis of weight change 
at 12, 24, 36 and 48 months post breast cancer diagnosis 
Participants' weight values were not normally distributed. At 12, 24, 36 and 48 
months post-diagnosis Shapiro-Wilk normality test‘s p-values were 0.025, 0.004, 
0.131 and 0.018 respectively.  
Similarly, weight change at 12, 24, 36 and 48 months post-diagnosis was also not 
normally distributed (Shapiro-Wilk normality test‘s p-values: 0.003, 0.018, 0.002 
and 0.012 respectively). Although the departures from normality seemed small 
(Figure 4, Appendix III), the weight change analysis was conducted using a non-
parametric approach (Wilcoxon signed-rank tests) (Table 47, Appendix III). Results 
were similar to those obtained from the parametric paired t-tests in Chapter 4 except 
at month 24 when, unlike the paired t-test‘s results, the Wilcoxon signed-rank test p-
value reached significance. Nonetheless, the magnitude of the difference in p-values 
was very small (0.008). Hence, after considering the comparable results using 
parametric and non-parametric tests, the small differences in p-values between the 
two approaches and the sample size (n=100), the use of the parametric paired t-tests 
for the analysis of weight change at 12, 24, 36 and 48 months post BC diagnosis as 
presented in Chapter 4 was considered valid (Lund and Lund 2013a).  
 
Appendix III.C. Factors associated with weight change at 12, 24, 36 and 48 
months after breast cancer diagnosis analysed using a non-parametric 
approach 
Results from the non-parametric tests conducted to analyse factors associated with 
weight change are presented in tables 48 to 51(Appendix III). Only the major 
differences between the results of the parametric and non-parametric tests will be 
detailed. Parametric and non-parametric analytical approaches showed that weight 
change post-diagnosis was not statistically associated with chemotherapy, the use of 
anastrozole, letrozole and exemestane, or with the use of gonadorelin analogues. 
Small differences were found between results of parametric and non-parametric tests 
in relation to tamoxifen use. The non-parametric test (table 48, Appendix III) showed 
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that tamoxifen use was significantly associated with weight change 24 months post-
diagnosis (p<0.01), whereas the parametric tests presented in Chapter 4 did not 
indicate a statistically significant association (p=0.08). However, although the 
significance level changed when the non-parametric tests were used, the p-values 
were of nearly similar magnitude. Therefore, the results of both parametric and non-
parametric test could be considered similar. Furthermore, the results of the 
parametric and non-parametric tests for the association of tamoxifen with weight 
change at other periods were similar. Hence the parametric results presented within 
the main results of Chapter 4 regarding weight change and its association with BC 
treatments were deemed valid.  
Parametric and non-parametric tests revealed comparable findings when evaluating 
the association between weight change and menopausal status, change in 
menopausal status post-diagnosis, FTO and Mc4R genetic profile and weight 
change, as well as other factors (i.e. tumour size, age at BC diagnosis) (tables 49 to 
51, Appendix III). Conversely, the statistically significant associations between 
weight at BC diagnosis and weight change at 12 and 36 months post-diagnosis in 
Chapter 4 were not supported under a non-parametric approach (Spearman‘s 
correlation p-values: 0.10 and 0.19 respectively). Arguably, the p-values were not 
very different and in both tests the correlation coefficients were of small magnitude 
(Pearson‘s product moment correlation r values: -0.27 and -0.32, vs. Spearman‘s 
correlation rho values: -0.16 and -0.15 respectively). 
Smoking status was no longer statistically significantly associated with weight 
change at 48 months post-diagnosis when data were analysed non-parametrically 
(Table 51, Appendix III), although the p-value was small (Mann-Whitney U test 
p=0.15), a result similar to that found when using the parametric approach 
(independent sample t-test p-value: 0.04). 
Overall, the results of the analysis of factors associated with weight change post-
diagnosis using a parametric approach were not very different to the results of the 
non-parametric approach.  
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Appendix III.D. Outlier values in the analysis of weight change at 12, 24, 36 
and 48 months post breast cancer diagnosis 
A sensitivity analysis was conducted to explore the presence of outliers, the nature of 
these outliers and its impact of their presence in the findings. There were 12 
participants whose weight change was more than 1.5 box-lengths from the edge of 
the box in a box-and-whisker plot, and one participant with an extreme weight gain 
at 36 months post-diagnosis (more than 3 box-lengths from the edge of the box). 
Seven of these participants had a large weight loss. Six participants had a large 
weight gain compared to other participants‘ weight change. 
There were 30 outliers noted (ranging from 7 to 16) when exploring the association 
between weight change and different variables (i.e. treatments, menopausal status, 
etc). Data inspection suggested that the weights of these outliers were genuinely 
unusual values and not the consequence of data entry or measurement error. 
Therefore, they were not treated as invalid. Nonetheless, in order to see the impact of 
these outliers on the main results, the analysis was repeated excluding them from the 
analysis. 
The magnitude of weight change was slightly greater at 12, 24, 36 and 48 months 
after removing the outliers from the analysis of weight change (Table 52, Appendix 
III). Statistically, the only difference was found at 24 months, when weight change 
became significant after removing outliers (p=0.04 vs. p=0.12). Nonetheless, the 
magnitude of the p-values was very close, and the magnitude of the difference in 
weight change in the two comparison groups was small before and after removing 
the outliers (0.85 kg vs. 0.90 kg). Moreover, it might not be clinically significant. 
Therefore, the main analysis on weight change post-diagnosis presented in Chapter 4 
included all participants. 
Similarly, the presence of outliers did not modify most of the results reported in 
Chapter 4 of factors associated with weight change (data not shown). The outliers 
did not create or remove any significant association of weight change with most 
variables (chemotherapy use, hormone therapy, letrozole, exemestane, FTO, tumour 
size, stage of disease, or weight and age at BC diagnosis). However, after removing 
the outliers, the statistically significant association between weight change and 
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tamoxifen, AINs, anastrozole, change in menopausal status and smoking status at 
diagnosis disappeared. Conversely, weight change became statistically significantly 
associated with use of gonadorelin analogues, menopause status at diagnosis and 
with Mc4R status.  
Nonetheless, despite these changes, the participants with outlying weight change 
values were kept in the main analysis for several reasons. Firstly, the large number of 
outliers found could indicate that these values were informative. Secondly, the 
number of the outlying participants with large weight gain values (n=14) was similar 
to the number of outliers with large weight loss values (n=16). Thirdly, although the 
presence of the outliers modified the statistical impact of some factors of weight 
change post-diagnosis, the direction of the findings and the magnitude of the weight 
change was not altered greatly. Fourthly, a repeat analysis excluding the outliers 
produced few changes in the significance level of the associations found between 
different factors and weight change post BC diagnosis. Finally, these changes only 
affected one or two out of the four evaluation points explored for each variable.  
 
Appendix III.E. Multivariable analysis of factors associated with weight 
change at 12, 24, 36 and 48 months post breast cancer diagnosis. Repeated 
analysis 
The multiple regression analysis presented in Chapter 4 met all the assumptions for 
the test, except for the presence of participants with unusually large studentized 
deleted residual values. Therefore, a repeat analysis of weight change was conducted 
after removing those participants (Tables 53 to 56, Appendix III). Most of the results 
showed coefficients of nearly similar magnitudes and comparable p-values to the 
ones in Chapter 4. This suggested that the use of multiple regression tests for the 
analysis presented in Chapter 4 was methodologically sound. The only exception 
was found in the analysis of weight change 48 months post-diagnosis (Tables 55 and 
56, Appendix III) and it is detailed in Chapter 4.
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Table 47 Appendix III - Differences in weight at diagnosis between participants included in, and those excluded from the analysis of weight change 
from breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis, using parametric and non-parametric tests  
  12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
  Included Excluded Included Excluded Included Excluded Included Excluded 
 
Number of 
participants 
With follow up 
at: 
 
99 
 
140 
 
100 
 
124 
 
74 
 
104 
 
62 
 
62 
With diagnosis  
weight at:  
 
99 
 
122
a
 
 
100 
 
106
b
 
 
74 
 
89
c
 
 
66 
 
54
d
 
Mean weight at diagnosis (kg
e
) 
(SD) 
70.8 
(12.9) 
73.3 
(14.0) 
72.6 
(14.2) 
71.3 
(12.5) 
70.3 
(12.9) 
72.1 
(13.6) 
73.4 
(15.7) 
69.5 
(14.1) 
Median weight at diagnosis (kg
e
) 
 
70.0 
 
70.6 
 
69.5 
 
70.0 
 
70.3 
 
69.0 
 
70.9 
 
69.5 
Mean difference, (95% CI
e
),          
p-values 
 
-2.51 (-6.12 to 1.10) 
p=0.17
f 
 
1.33 (-2.36 to 5.01) 
p=0.48
g
 
 
-1.74 (-5.87 to 2.39) 
p=0.41
e
 
 
2.52 (-2.68 to 7.73) 
p=0.33
g
 
 
Mann-Whitney U test 
U, Z and p-values 
 
U=5,540.50 
Z=-1.05 
p=0.29
h
 
 
U=5,144.50 
Z=-0.364 
p=0.72
h
 
 
U=3,126.50 
Z=-0.555 
p=0.58
h
 
 
U=1,569.00 
Z=-0.581 
p=0.56
h 
         a 
Of those 140 participants excluded, weight at diagnosis was calculated with data from 122 of them,  as weight records at the time of diagnosis were missing from  18 participants. 
         b 
From those 124 participants excluded from the analysis, weight records at the time of diagnosis were missing from 18 participants. 
 
         c 
From those 104 participants excluded from the analysis, weight records at the time of diagnosis were missing from 15 participants. 
         d 
From those 66 participants excluded from the analysis, weight records at the time of diagnosis were missing from 12 participants.
 
         e 
Kg stands for kilograms, CI stands for confidence interval. 
         f 
Independent samples t-test, equal variances assumed. 
         g 
Independent samples t-test, equal variances not assumed. 
         h 
Asymptotic statistical significance level (2-tailed). 
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Figure 4 Appendix III - Distribution of weight change from diagnosis to 12, 24, 36 and 48 months post-diagnosis 
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Table 48 Appendix III - Non-parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 
12, 24, 36 and 48 months post-diagnosis and breast cancer treatment 
  
Weight Change from diagnosis to: 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
  
N 
 
Median 
Weight 
change 
(kg
b
)  
 
Mann-
Whitney U 
test 
 
 
n 
 
Median 
Weight 
change 
(kg
b
)  
 
Mann-
Whitney U 
test 
 
 
n 
 
Median 
Weight 
change 
(kg
b
)  
 
Mann- 
Whitney U  
test 
 
 
n 
 
Median 
Weight 
change 
(kg
b
)  
 
Mann- 
Whitney U  
test 
 
Chemotherapy
a
: 
Yes 
 
No  
 
 
84 
 
15 
 
 
2.00 
 
0.60 
 
 
U=580.50 
Z=-0.48 
p=0.63 
 
 
75 
 
25 
 
 
1.40 
 
0.70 
 
 
U=898.00 
Z=-0.31 
p=0.75 
 
 
53 
 
21 
 
 
2.00 
 
2.40 
 
 
U=487.00 
Z=-0.83 
p=0.40 
 
 
36 
 
26 
 
 
0.95 
 
0.85 
 
 
U=458.00 
Z=-0.143 
p=0.89 
Hormone 
therapy
a
: 
Yes 
 
No  
 
 
 
86 
 
13 
 
 
 
2.00 
 
2.00 
 
 
 
U=535.00 
Z=-0.25 
p=0.80 
 
 
 
90 
 
9 
 
 
 
1.67 
 
-0.40 
 
 
 
U=299.00 
Z=-1.29 
p=0.20 
 
 
 
66 
 
7 
 
 
 
2.35 
 
1.30 
 
 
 
U=158.50 
Z=-1.36 
p=0.17 
 
 
 
55 
 
6 
 
 
 
1.0 
 
-1.60 
 
 
 
U=157.50 
Z=-0.18 
p=0.86 
Tamoxifen
a
: 
Yes 
 
No  
 
 
41 
 
58 
 
 
2.50 
 
1.00 
 
 
U=1,018.00 
Z=-1.21 
p=0.22 
 
  
45 
 
55 
 
 
3.00 
 
0.00 
 
 
U=749.00 
Z=-3.38 
p <0.01 
 
 
42 
 
32 
 
 
2.05 
 
1.65 
 
 
U=573.50 
Z=-1.07 
p=0.28 
 
 
35 
 
27 
 
 
2.00 
 
-1.70 
 
 
U=329.50 
Z=-2.03 
p=0.04 
Aromatase 
inhibitors
a
: 
Yes 
 
No  
 
 
 
47 
 
52 
 
 
 
1.30 
 
2.20 
 
 
 
U=1,139.00 
Z=-0.58 
p=0.56 
 
 
 
59 
 
39 
 
 
 
1.0  
 
2.00 
 
 
 
U=917.00 
Z=-1.69 
p=0.09 
 
 
 
45 
 
27 
 
 
 
2.40 
 
1.50 
 
 
 
U=540.00 
Z=-0.78 
p=0.43 
 
 
 
48 
 
12 
 
 
 
0.85 
 
1.25 
 
 
 
U=253.50 
Z=-0.64 
p=0.52 
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Anastrozole
a
: 
Yes 
 
No  
 
 
40 
 
59 
 
 
1.75 
 
2.00 
 
 
U=1,126.50 
Z=-0.38 
p=0.70 
 
 
45 
 
54 
 
 
1.00 
 
2.00 
 
 
U=1,019.50 
Z=-1.37 
p=0.17 
 
 
33 
 
40 
 
 
2.40 
 
1.95 
 
 
U=640.50 
Z=-0.22 
p=0.83 
 
 
33 
 
28 
 
 
-1.50 
 
2.00 
 
 
U=326.50 
Z=-1.96 
p=0.05 
Letrozole
a
: 
Yes 
 
No  
 
 
7 
 
92 
 
 
0.00 
 
2.00 
 
 
U=292.50 
Z=-0.40 
p=0.69 
 
 
9 
 
91 
 
 
-0.50 
 
1.45 
 
 
U=347.00 
Z=-0.75 
p=0.45 
 
 
3 
 
71 
 
 
2.40 
 
2.00 
 
 
U=90.00 
Z=-0.45 
p=0.68 
 
 
2 
 
60 
 
 
4.20 
 
0.65 
 
 
U=23.00 
Z=-1.47 
p=0.16 
Exemestane
a
: 
Yes 
 
No  
 
 
4 
 
95 
 
 
1.50 
 
2.00 
 
 
U=171.00 
Z=-0.34 
p=0.74 
 
 
10 
 
89 
 
 
3.20 
 
1.00 
 
 
U=402.00 
Z=-0.50 
p=0.62 
 
 
15 
 
58 
 
 
2.40 
 
1.65 
 
 
U=317.00 
Z=-1.61 
p=0.11 
 
 
15 
 
46 
 
 
2.00 
 
0.30 
 
 
U=318.00 
Z=-0.45 
p=0.65 
Gonadorelin 
analogues
a
: 
Yes 
 
No 
 
 
 
13 
 
86 
 
 
 
4.40 
 
1.75 
 
 
 
U=460.00 
Z=-1.03 
p=0.30 
 
 
 
15 
 
85 
 
 
 
3.00 
 
1.00 
 
 
 
U=480.00 
Z=-1.52 
p=0.13 
 
 
 
11 
 
63 
 
 
 
4.00 
 
1.90 
 
 
 
U=233.50 
Z=-1.71 
p=0.09 
 
 
 
9 
 
53 
 
 
 
2.80 
 
0.50 
 
 
 
U=166.50 
Z=-1.44 
p=0.15 
         a
 All participants had surgery and they might have also received other treatments (i.e. radiotherapy, biological therapy). 
       b
 Kg stands for kilograms.
 
 
 
 
  
 
286 
Table 49 Appendix III - Non-parametric univariable analysis on the association between weight change from breast cancer diagnosis to 12, 24, 36 
and 48 months post-diagnosis and 1) menopausal status at diagnosis and 2) change in menopausal status from diagnosis to 12, 24, 36 and 48 months 
post-diagnosis 
 Weight Change from Diagnosis to: 
12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 n Median 
Weight 
change 
(kg
a
)  
Mann-
Whitney U 
test 
 
n Median 
Weight 
change 
(kg
a
)  
Mann-
Whitney U 
test 
 
n Median 
Weight 
change 
(kg
a
)  
 
Mann- 
Whitney U 
 test 
 
n Median 
Weight 
change 
(kg
a
)  
 
Mann- 
Whitney U  
test 
 
Menopausal status 
at diagnosis:  
Pre &peri 
menopausal 
 
Postmenopausal 
 
 
 
 
36 
 
63 
 
 
 
 
3.25 
 
0.70 
 
 
 
 
U=958.50 
Z=-1.27 
p=0.20
 
 
 
 
 
31 
 
69 
 
 
 
 
2.00 
 
0.70 
 
 
 
 
U=904.50 
Z=-1.23 
p=0.22 
 
 
 
 
20 
 
54 
 
 
 
 
2.80 
 
2.95 
 
 
 
 
U=421.00 
Z=-1.45 
p=0.15 
 
 
 
 
15 
 
47 
 
 
 
 
3.00 
 
0.10 
 
 
 
 
U=195.50 
Z=-2.58 
p=0.01 
 
Change in 
menopause status: 
Yes 
 
No 
 
 
 
29 
 
70 
 
 
 
3.25 
 
0.70 
 
 
 
U=958.50 
Z=-1.27 
p=0.20
 
 
 
 
23 
 
65 
 
 
 
2.00 
 
0.70 
 
 
 
 
U=904.50 
Z=-1.23 
p=0.22 
 
 
 
17 
 
49 
 
 
 
2.80 
 
2.95 
 
 
 
U=421.00 
Z=-1.45 
p=0.15 
 
 
 
13 
 
41 
 
 
 
3.00 
 
0.10 
 
 
 
U=195.50 
Z=-2.58 
p=0.01 
      
a
 Kg stands for kilograms.
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Table 50 Appendix III - Non-parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 
12, 24, 36 and 48 months post-diagnosis and genetic profile 
 
Weight Change from diagnosis to: 
12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 n Median 
Weight 
change 
(kg
a
) 
Mann-
Whitney U 
test 
n Median 
Weight 
change 
(kg
a
) 
Mann-
Whitney U 
test 
n Median 
Weight 
change 
(kg
a
) 
 
Mann- 
Whitney U 
test 
n Median 
Weight 
change 
(kg
a
) 
 
Mann- 
Whitney U  
test 
 
FTO: 
AA + AT 
 
TT 
 
 
45 
 
24 
 
 
0.20 
 
2.50 
 
 
 
U=456.50 
Z=-1.05 
p=0.29 
 
 
45 
 
21 
 
 
1.65 
 
0.70 
 
 
U=438.00 
Z=-0.47 
p=0.63 
 
 
27 
 
13 
 
 
1.80 
 
2.90 
 
 
U=114.00 
Z=-1.78 
p=0.07 
 
 
26 
 
7 
 
 
0.70 
 
-1.50 
 
 
U=85.50 
Z=-2.42 
p=0.81 
 
Mc4R: 
CC +CT 
 
TT 
 
 
27 
 
42 
 
 
0.00 
 
2.00 
 
 
U=521.50 
Z=-0.56 
p=0.58 
 
 
 
25 
 
41 
 
 
1.20 
 
1.40 
 
 
 
U=428.50 
Z=-1.11 
p=0.28 
 
 
 
16 
 
24 
 
 
1.40 
 
2.85 
 
 
U=119.50 
Z=-2.03 
p=0.04 
 
 
 
11 
 
22 
 
 
-1.30 
 
0.70 
 
 
 
U=92.00 
Z=-1.11 
p=0.28 
 
      
a
 Kg stands for kilograms.
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Table 51 Appendix III - Non-parametric univariable analysis on the association between participants‘ weight change from breast cancer diagnosis to 
12, 24, 36 and 48 months post-diagnosis with biological, behavioural and tumour-related variables  
 
Weight Change from diagnosis to: 
12 months post-diagnosis 
 
24 months post-diagnosis 
 
36 months post-diagnosis 
 
48 months post-diagnosis 
 
 n 
 
Median 
weight 
change 
(kg
a
)   
 
Mann-
Whitney U 
test
 
 
n 
 
Median 
weight 
change (kg
a
)   
 
Mann-
Whitney U 
test
 
 
n 
 
Median 
weight 
change 
(kg
a
)   
 
Mann- 
Whitney U  
test
 
 
n 
 
Median 
weight 
change 
(kg
a
)   
 
Mann- 
Whitney U  
test
 
 
Smoking 
status at 
diagnosis: 
Smoker 
 
Non smoker 
 
 
 
 
9 
 
90 
 
 
 
 
6.00 
 
1.75 
 
 
 
 
U=185.50 
Z=-2.67 
p<0.01 
 
 
 
 
9 
 
91 
 
 
 
 
0.00 
 
1.65 
 
 
 
 
U=353.00 
Z=-0.68 
p=0.50 
 
 
 
 
5 
 
69 
 
 
 
 
6.45 
 
2.00 
 
 
 
 
U=121.50 
Z=-0.88 
p=0.38 
 
 
 
 
9 
 
53 
 
 
 
 
2.10 
 
0.50 
 
 
 
 
U=166.00 
Z=-1.44 
p=0.15 
 n Correlation coefficient
b  
p-value 
n Correlation coefficient
b
  
p-value 
n Correlation coefficient
b
  
p-value 
n Correlation coefficient
b
   
 p-value 
 
Weight at 
diagnosis 
(kg
a
) 
 
 
99 
 
 
r=-0.16 
p=0.10 
 
 
 
100 
 
 
r=-0.14 
p=0.18 
 
 
 
74 
 
 
r=-0.15 
p=0.19 
 
 
62 
 
 
r=-0.16 
p=0.22 
 
Age at 
diagnosis  
(years) 
 
 
93 
 
 
r=-0.12 
p=0.25 
 
 
 
95 
 
 
r=-0.12 
p=0.26 
 
 
 
72 
 
 
r=-0.05 
p=0.65 
 
 
 
57 
 
 
r=-0.24 
p=0.07 
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Tumour 
Size (cm
a
) 
 
 
94 
 
r=-0.14 
p=0.17 
 
 
 
96 
 
 
r=0.10 
p=0.31 
 
 
 
72 
 
 
r=-0.05 
p=0.68 
 
 
 
60 
 
 
r=-0.05 
p=0.71 
 
 n Kruskal Wallis Test n Kruskal Wallis Test n Kruskal Wallis Test n Kruskal Wallis Test 
Stage of 
disease: 
Stage 1 
Stage 2 
Stage 3 
 
 
 
30 
39 
26 
 
 
 
χ 2 =2.69 
d.f.
a
=2 
p=0.26 
 
 
 
 
36 
37 
25 
 
 
 
χ 2 =2.90 
d.f.
a
=2 
p=0.23 
 
 
 
24 
31 
16 
 
 
 
χ 2 =4.08 
d.f.
a
=2 
p=0.13 
 
 
 
26 
23 
10 
 
 
 
χ 2 =1.05 
d.f.
a
 =2 
p=0.59 
         a 
Kg stands for kilograms, cm stands for centimetres and d.f. stands for degrees of freedom. 
         b Spearman‘s correlation rho.
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Table 52 Appendix III - Repeated analysis of participants‘ weight change from breast cancer diagnosis to 12, 24, 36 and 48 months post-diagnosis, 
after excluding outliers  
 12 months post-diagnosis 24 months post-diagnosis 36 months post-diagnosis 48 months post-diagnosis 
 
 
Diagnosis
c
 
 
12 months
d
 
 
Diagnosis
c 
 
24 monthsd 
 
Diagnosis
c
 
 
36 months
d
 
 
Diagnosis
c
 
 
48 months
d
 
Number of 
participants
a
 
(%)
b
 
 
92 (40.7%) 
 
93 (44.1%) 
 
 
67 (39.9%) 
 
58 (48%) 
Mean weight 
(SD) (kg
e
) 
69.7 (12.4) 71.2 (12.3) 71.5 (13.8) 72.4 (13.7) 69.2 (12.2) 70.9 (12.1) 72.3 (15.4) 73.0 (15.4) 
Mean weight 
change (kg
e
), 
(95% CI
e
)  and 
p-value 
 
 
1.50 
(0.62 to 2.37) 
p<0.01
f
 
 
 
0.90 
(0.05 to1.82) 
p=0.04
f
 
 
 
1.70 
(0.83 to 2.52) 
p<0.01
f
 
 
 
0.70 
(-0.36 to 1.81) 
p=0.19
f
 
         a 
Number of participants with available weight records for both diagnosis and the explored evaluation point. 
         b 
Percentage based on the total number of participants available within each follow up period (at 12 months: 226, at 24 months: 211, at 36 months: 168 and at 48 months:121).    
         c 
Diagnosis date -2 months prior diagnosis to 4 months post diagnosis. 
         d 
Period window ±4 months. 
         e 
Kg stands for kilograms, CI stands for confidence interval.      
         f 
Paired t-test p-value. 
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Table 53 Appendix III - Repeated multiple linear regression analysis of participants‘ weight change from breast cancer diagnosis to 24 months post- 
diagnosis, after excluding outliers 
 
Variables included 
 
n 
 
Unstandardised coefficients 
(95% CI
a
), p-value 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Tamoxifen
b 
 
Weight at diagnosis (kg
a
) 
 
94 
 
12.81 (7.42 to 18.20) 
 
-3.67  (-5.52 to -1.81) 
 
-0.09 (-0.16 to -0.03) 
 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.47 
F (2, 91) 
F=12.96 
p<0.01 
      
  
a 
CI stands for confidence interval, kg stands for kilograms, ANOVA stands for analysis of the variance. 
         b 
Categories: 0) users, 1) non – users. 
 
  
 
292 
Table 54 Appendix III - Repeated multiple linear regression analysis of participants‘ weight change from breast cancer diagnosis to 36 months post- 
diagnosis, after excluding outliers  
 
Variables included 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Tamoxifen
b 
 
Weight at diagnosis (kg
a
) 
 
73 
 
13.49 (7.31 to 19.68) 
 
-1.76 (-3.80 to 0.28) 
 
-0.14 (-0.21 to -0.06) 
 
p<0.01 
 
p=0.09 
 
p<0.01 
 
R=0.43 
 F (2, 70) 
F=7.89 
p<0.01 
         a 
CI stands for confidence interval, kg stands for kilograms, ANOVA stands for analysis of the variance.
 
         b 
Categories: 0) users, 1) non – users. 
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Table 55 Appendix III - Multiple linear regression analysis of participants‘ weight change from breast cancer diagnosis to 48 months post- diagnosis, 
including outliers 
 
 Variables included  
 
n 
 
Unstandardised coefficients  
(95% CI
a
) 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
Tamoxifen
b
 
 
57 
 
15.97 (6.96 to 24.98) 
 
-0.09 (-0.18 to -0.002) 
 
-0.09 (-0.21 to 0.03) 
 
2.78 (-5.40 to -0.17) 
 
p<0.01 
 
p=0.04 
 
p=0.14 
 
p=0.04 
 
R=0.64 
F (3, 53) 
F=6.52 
p<0.01 
         a 
CI stands for confidence interval, kg stands for kilograms, ANOVA stands for analysis of the variance. 
      
b 
Categories: 0) users, 1) non – users. 
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Table 56 Appendix III - Repeated multiple linear regression analysis of participants‘ weight change from breast cancer diagnosis to 48 months post- 
diagnosis, after excluding outliers  
 
Variables included 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
Tamoxifen
b 
 
 
56 
 
12.18 (6.96 to 24.98) 
 
-0.04 (-0.18 to -0.002) 
 
-0.10 (-0.21 to 0.03) 
 
-1.98 (-5.40 to 0.17) 
 
p<0.01 
 
p=0.03 
 
p=0.08 
 
p=0.11 
 
R=0.38 
F (3, 52) 
F=2.92 
p=0.04 
         a 
CI stands for confidence interval, kg stands for kilograms, ANOVA stands for analysis of the variance. 
         b 
Categories: 0) users and 1) non-users. 
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APPENDIX IV: SAMPLE RESIDUALS IN THE 
MULTILEVEL MODELS 
 
A visual inspection of the normal quantile-quantile plot (Q-Q Plot) and scatter/dot 
plot for the residuals of the time-invariant model F suggests that they were normally 
distributed and homoscedastic (Figure 5, Appendix IV).   
On the other hand, the normal Q-Q Plot of the residuals in time-varying model 4 
suggested that the residuals were normally distributed.  The scatter/dot plot indicates 
that the residual variability was approximately equal at each tamoxifen and 
anastrozole value (Figure 6, Appendix IV). The variability found in letrozole could 
be due the small number of participants that received that treatment (n=18). 
 
Figure 5 Appendix IV - Normal Q-Q plot and scatter/dot plot of the residuals in 
model F 
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Figure 6 Appendix IV - Normal Q-Q plot and scatter/dot plots of the residuals in model 4 
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APPENDIX V: SENSITIVITY ANALYSIS OF THE 
RESULTS OF BODY ADIPOSITY AND METABOLIC 
PARAMETERS 
 
Appendix V. Introduction 
This appendix provides a rationale for the analytical approach used in Chapter 4 in 
relation to metabolic and adiposity results. It begins by providing a rationale for the 
values chosen to represent insulin levels in participants with initial values of less 
than 13.89 pmol/l. It then presents the distribution of the metabolic and body 
adiposity parameters and continues with an analysis of factors associated with those 
metabolic and body adiposity outcomes using a non-parametric approach. It follows 
by exploring the impact of outliers on the results. The final section is a repeat of the 
multiple regression analyses presented in Chapter 4. 
 
Appendix V.A. Exploring insulin level as a numerical variable 
Thirty-two participants had insulin levels below the limit the assay could detect 
(13.89 pmol/l). Therefore, three parallel analyses were conducted using three 
different presumed values for the insulin levels of these 32 participants. A value of 
13.89 pmol/l was used for the first analysis, 7 pmol/l for the second analysis and a 
value of 1 pmol/l for the third analysis. The results of these three analyses were very 
similar (Tables 57 to 60, Appendix V) (all tables are presented at the end of this 
appendix). Therefore these participants were presumed to have an insulin level of 7 
pmol/l for the main analyses presented in Chapter 4. 
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Appendix V.B. Factors associated with body adiposity and metabolic 
parameters at the end of the follow up, using a non-parametric approach 
Body fat percentage and FM/FFM ratio were the only two normally distributed 
variables (Shapiro-Wilk normality test p-values: 0.25 and 0.22 respectively). The 
distribution of the rest of the outcomes (waist circumference and fasting glucose and 
insulin) is presented in Figure 7 (Appendix V). Nonetheless, in spite of these 
departure from normality, the value of the mean and the median were comparable 
(waist circumference: mean: 92.3cm and median:  91.7 cm, glucose: mean 5.14 
mmol/l and median: 5.2 mmol/l and insulin: mean: 39.31 pmol/l and median: 31.5 
pmol/l). Consequently, the value of these and all metabolic and adiposity parameters 
were summarised in Chapter 4 with the mean and SD.  
A sensitivity analysis was conducted to evaluate the appropriateness of using a 
parametric approach to analyse those non-normally distributed outcomes (waist 
circumference, glucose and insulin levels). The body adiposity and metabolic 
outcome values and p-values resulting from the non-parametric tests were of similar 
magnitude to those from the parametric tests presented in Chapter 4 (tables 61 to 64, 
Appendix V, for waist circumference results and tables 65 to 69, Appendix V for 
metabolic results). Hence, parametric tests were chosen to explore body adiposity 
and metabolic parameters in the sample.  
 
Appendix V.C. Outlier values in body adiposity and metabolic parameters at 
the end of the follow up.  Repeated analysis 
Six participants had higher glucose levels compared to the average in the sample and 
two others had lower glucose levels. In addition, eight participants had higher insulin 
levels than the mean. On the other hand, there was only one participant whose 
FM/FFM ratio and waist circumference values were larger than the mean. All of 
them were considered outliers. 
An inspection of the body adiposity and metabolic outcome values of these 
participants suggested that these were natural values. However, a repeated analysis 
 299 
 
 
was conducted excluding them. The results (data not shown) suggested that 
excluding the outliers did not produce major changes in the results presented in 
Chapter 4, therefore, they were included in the main analysis. 
 
Appendix V.D. Multiple regression analysis of body adiposity and metabolic 
parameters at the end of the follow up.  Repeated analysis 
A sensitivity analysis was conducted as the assumptions of the multiple linear 
regression analysis presented in Chapter 4 were not met due to the presence of 
participants with unusually large (>3) studentized deleted residual values. The 
repeated analysis excluding participants with unusual values showed similar results 
to those presented in Chapter 4, suggesting that the findings of the regression 
analysis were statistically valid (Tables 69 to 71 for body adiposity parameters and 
tables 72 to 74 for metabolic parameters, Appendix V). The only exception was 
when evaluating glucose levels (Tables 72 and 73, Appendix V), as was explained in 
Chapter 4.  
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Table 57 Appendix V - Sensitivity analysis of the association between participants‘ insulin levels at the end of the follow up and breast cancer 
treatment, using three hypothetical values for those insulin levels whose magnitude was below the limit the assay could detect 
 
 
 
Insulin (value: 13.88 pmol/l
a
) 
 
Insulin (value: 7 pmol/l
a
) 
 
Insulin pmol/l (value: 1 pmol/l
a
) 
  
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
Chemotherapy: 
Yes 
 
 
No  
 
 
71 
 
 
76 
 
 
35.86 
(28.60) 
 
45.35 
(31.76) 
 
 
-9.49 
(-19.36 to 0.39) 
p=0.06 
 
 
71 
 
 
76 
 
 
33.92 
(30.23) 
 
44.35 
(32.83) 
 
 
-10.43  
(-20.74 to -12) 
p=0.04 
 
 
71 
 
 
76 
 
 
32.23 
(31.83) 
 
43.48 
(33.89) 
 
 
-11.25  
(-21.99 to 0.51) 
p=0.04 
 
Hormone 
therapy:  
Yes 
 
 
No 
 
 
 
130 
 
 
16 
 
 
 
40.73 
(30.72) 
 
39.22 
(29.95) 
 
 
 
1.51 
(-14.54 to 17.56) 
p=0.85 
 
 
 
130 
 
 
16 
 
 
 
39.35 
(32.04) 
 
37.07 
(32.00) 
 
 
 
2.28  
(-14.49 to 19.06) 
p=0.79 
 
 
 
130 
 
 
16 
 
 
 
38.15 
(33.33) 
 
35.19 
(33.95) 
 
 
 
2.96 
 (-14.53 to 20.44) 
p=0.74 
 
Tamoxifen: 
Yes 
 
 
No  
 
 
83 
 
 
63 
 
 
38.71 
(29.07) 
 
43.01 
(32.47) 
 
 
5.11  
(-14.40 to 5.80) 
p=0.40 
 
 
83 
 
 
63 
 
 
37.13 
(30.54) 
 
41.69 
(33.75) 
 
 
-4.56  
(-15.11 to 5.99) 
p=0.39 
 
 
83 
 
 
63 
 
 
35.76 
(31.98) 
 
40.55 
(35.00) 
 
 
-4.79  
(-15.80 to 6.21) 
p=0.39 
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Aromatase 
inhibitors: 
Yes 
 
 
No 
 
 
 
103 
 
 
43 
 
 
 
40.75 
(29.52) 
 
40.11 
(33.24) 
 
 
 
0.63  
(-10.36 to 11.64) 
p=0.91 
 
 
 
103 
 
 
43 
 
 
 
39.41 
(30.80) 
 
38.35 
(34.77) 
 
 
 
1.06 
 (-10.43 to 12.56) 
p=0.85 
 
 
 
103 
 
 
43 
 
 
 
38.25 
(32.14) 
 
36.82 
(36.25) 
 
 
 
1.43 
 (-10.55 to 13.41) 
p=0.81 
 
Anastrozole: 
Yes 
 
 
No 
 
 
 
66 
 
 
80 
 
 
42.01 
(26.34) 
 
39.37 
(33.75) 
 
 
2.64  
(-7.42 to 12.71) 
p=0.60 
 
 
66 
 
 
80 
 
 
40.97 
(27.56) 
 
37.56 
(35.23) 
 
 
3.40 
 (-7.11 to 13.92) 
p=0.53 
 
 
66 
 
 
80 
 
 
40.06 
(28.76) 
 
35.99 
(36.69) 
 
 
4.07 
 (-6.88 to 15.03) 
p=0.46 
 
Letrozole: 
Yes 
 
 
No 
 
 
11 
 
 
135 
 
 
61.32 
(47.39) 
 
38.87 
(28.36) 
 
 
22.45  
(3.81 to 41.08) 
p=0.02 
 
 
11 
 
 
135 
 
 
61.31 
(47.39) 
 
37.29 
(29.87) 
 
 
24.03  
(4.56 to 43.49) 
p=0.02 
 
 
11 
 
 
135 
 
 
61.32 
(47.39) 
 
35.91 
(31.35) 
 
 
25.40 
 (-5.12 to 45.68) 
p=0.01 
 
Exemestane: 
Yes 
 
 
No 
 
 
37 
 
 
109 
 
 
31.65 
(23.06) 
 
43.59 
(32.24) 
 
 
-11.94  
(-23.30 to -0.57) 
p=0.04 
 
 
37 
 
 
109 
 
 
29.42 
(24.98) 
 
42.39 
(33.39) 
 
 
-12.97  
(-24.82 to -1.10) 
p=0.03 
 
 
37 
 
 
109 
 
 
27.48 
(26.86) 
 
41.34 
(34.61) 
 
 
-13.87  
(-26 to -1.51) 
p=0.03 
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Gonadorelin 
analogues: 
Yes 
 
 
No 
 
 
 
12 
 
 
134 
 
 
 
37.89 
(38.00) 
 
40.80 
(29.96) 
 
 
 
-2.91 
(-21.16 to 15.34) 
p=0.75 
 
 
 
12 
 
 
134 
 
 
 
36.17 
(39.29) 
 
39..36 
(31.36) 
 
 
 
-3.19 
(-22.27 to 15.88) 
p=0.74 
 
 
 
12 
 
 
134 
 
 
 
34.67 
(40.58) 
 
33.11 
(46.91) 
 
 
 
-3.44 
(-23.32 to 16.45) 
p=0.73 
         a
 Pmol/l
 
stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
         b 
Independent sample t-test. Equal variances assumed.
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Table 58 Appendix V - Sensitivity analysis of the association between participants‘ insulin levels at the end of the follow up and 1) menopausal status 
at diagnosis and 2) change in menopausal status after breast cancer diagnosis, using three hypothetical values for insulin levels whose magnitude was 
below the limit the assay could detect 
 
 
 
Insulin (value: 13.88 pmol/l
a
) 
 
Insulin (value: 7 pmol/l
a
) 
 
Insulin (value: 1 pmol/l
a
) 
  
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
Menopausal status at 
diagnosis: 
Pre + peri 
menopausal 
 
 
Postmenopausal 
 
 
 
 
 
36 
 
 
111 
 
 
 
 
37.48 
(30.79) 
 
41.83 
(30.59) 
 
 
 
 
-4.35  
(-15.95 to 7.24) 
p=0.46 
 
 
 
 
36 
 
 
111 
 
 
 
 
37.64 
(32.33) 
 
40.47 
(31.94) 
 
 
 
 
-4.72  
(-16.83 to 7.41) 
p=0.44 
 
 
 
 
36 
 
 
111 
 
 
 
 
34.26 
(33.53) 
 
39.28 
(33.26) 
 
 
 
 
-5.02 
(-17.65 to 7.61) 
p=0.43 
Menopausal status 
change: 
Yes 
 
 
No 
 
 
 
35 
 
 
112 
 
 
 
38.15 
(30.77) 
 
41.58 
(30.56) 
 
 
 
-3.43  
(-15.15 to 8.28) 
p=0.56 
 
 
 
35 
 
 
112 
 
 
 
36.57 
(32.33) 
 
40.16 
(31.94) 
 
 
 
-3.59  
(-15.84 to 8.65) 
p=0.56 
 
 
 
35 
 
 
112 
 
 
 
35.01 
(33.52) 
 
38.94 
(33.31) 
 
 
 
-3.73  
(-16.50 to 9.04) 
p=0.56 
          a
 Pmol/l
 
stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
            b 
Independent sample t-test. Equal variances assumed.  
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Table 59 Appendix V - Sensitivity analysis of the association between participants‘ insulin levels at the end of the follow up and genetic profile, 
using three hypothetical values for insulin levels whose magnitude was below the limit the assay could detect 
 
 
 
Insulin (value: 13.88 pmol/l
a
) 
 
Insulin (value: 7 pmol/l
a
) 
 
Insulin (value: 1 pmol/l
a
) 
  
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference,  
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference,  
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference,  
(95% CI
a
), p-value
b
 
 
FTO: 
AA + AT 
 
 
TT 
 
 
41 
 
19 
 
43.18 
(27.64) 
 
33.80 
(17.50) 
 
9.38  
(-4.47 to 23.24) 
p=0.18 
 
41 
 
19 
 
43.01 
(27.84) 
 
33.07 
(18.48) 
 
9.94  
(-4.12 to 24.00) 
p=0.17 
 
41 
 
19 
 
42.87 
(28.05) 
 
32.32 
(19.49) 
 
10.42  
(-3.85 to 24.77) 
p=0.15 
 
Mc4R:  
CC +CT 
 
 
TT 
 
 
27 
 
 
33 
 
43.05 
(27.54) 
 
37.88 
(23.11) 
 
5.16  
(-7.91 to 18.26) 
p=0.43 
 
27 
 
33 
 
42.80 
(27.85) 
 
37.46 
(23.61) 
 
5.33  
(-7.97 to 18.63) 
p=0.43 
 
27 
 
33 
 
42.58 
(28.17) 
 
37.10 
(24.14) 
 
5.47  
(-8.04 to 18.99) 
p=0.42 
      
 a
 Pmol/l
 
stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval. 
            b 
Independent sample t-test. Equal variances assumed. 
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Table 60 Appendix V - Sensitivity analysis of the association between participants‘ insulin levels at the end of the follow up and biological, 
behavioural and tumour-related variables, using three hypothetical values for insulin levels whose magnitude was below the limit the assay could 
detect 
 
 
 
Insulin (value: 13.88 pmol/l
a
) 
 
Insulin (value: 7 pmol/l
a
) 
 
Insulin (value: 1 pmol/l
a
) 
  
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
 
n 
 
Mean 
(pmol/l
a
) 
(SD
a
) 
 
Mean difference, 
(95% CI
a
), p-value
b
 
Smoking status at 
diagnosis: 
Smoker 
 
Non-smoker 
 
 
 
13 
 
133 
 
 
 
37.65 (30.91) 
 
40.88 (30.64) 
 
 
 
-3.23  
(-20.84 to 14.38) 
p=0.72 
 
 
 
13 
 
133 
 
 
 
35.53 (32.79) 
 
39.48 (31.48) 
 
 
 
-3.95  
(-22.36 to 14.46) 
p=0.67 
 
 
 
13 
 
133 
 
 
 
33.68 (34.61) 
 
38.37 (33.29) 
 
 
 
-4.58  
(-23.77 to 14.61) 
p=0.64 
  
n 
 
Correlation 
coefficient
c
 
 
p-value 
 
n 
 
Correlation 
coefficient
c
 
 
p-value 
 
n 
 
Correlation 
coefficient
c
 
 
p-value 
Time since diagnosis to 
the end of the follow up 
(months) 
 
 
146 
 
 
r=-0.20 
 
 
p=0.01 
 
 
146 
 
 
r=-0.21 
 
 
p=0.01 
 
 
146 
 
 
r=-0.21 
 
 
p=0.01 
Weight at diagnosis 
(kg
a
) 
 
 
133 
 
 
r=0.34 
 
 
p<0.01 
 
 
133 
 
 
r=0.34 
 
 
p<0.01 
 
 
133 
 
 
r=0.34 
 
 
p<0.01 
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Weight at the end of the 
follow up (kg
a
) 
 
 
147 
 
 
r=0.33 
 
 
p<0.01 
 
 
147 
 
 
r=0.33 
 
 
p<0.01 
 
 
147 
 
 
r=0.33 
 
 
p<0.01 
Weight change from 
diagnosis to the end of 
the follow up (kg
a
) 
 
 
133 
 
 
r=-0.06 
 
 
p=0.46 
 
 
133 
 
 
r=-0.07 
 
 
p=0.44 
 
 
133 
 
 
r=-0.07 
 
 
p=0.43 
Age at diagnosis (years) 141 r=0.09 p=0.27 141 r=0.10 p=0.25 141 r=0.10 p=0.25 
Age at the end of the 
follow up (years) 
 
142 
 
r=0.05 
 
p=0.55 
 
142 
 
r=0.05 
 
p=0.54 
 
142 
 
r=0.05 
 
p=0.54 
Tumour size (cm
a
) 143 r=-0.03 p=0.68 143 r=-0.04 p=0.67 143 r=-0.04 p=0.67 
 n Mean 
Weight 
change (kg
a
) 
(SD
a
) 
One-way 
ANOVA
a 
n Mean 
Weight 
change (kg
a
) 
(SD
a
) 
One-way 
ANOVA
a 
n Mean 
Weight 
change (kg
a
) 
(SD
a
) 
One-way 
ANOVaA
 
Stage of disease: 
Stage 1 
Stage 2 
Stage 3 
 
66 
53 
22 
 
43.73 (31.87) 
37.90 (26.73) 
41.28 (36.66) 
   
F(2, 138) 
F=0.52 
p=0.59 
 
66 
53 
22 
 
42.59 (33.06) 
36.35 (28.28) 
39.71 (37.98) 
 
F (2, 138) 
F=0.55 
p=0.56 
 
66 
53 
22 
 
41.59 (34.20) 
34.99 (29.79) 
38.35 (39.28) 
 
  F(2, 138) 
F=0.57 
p=0.56 
             a
 Pmol/l
 
stands for picomole per litre, SD stands for standard deviation, CI stands for confidence interval, kg stands for kilograms, cm stands for centimetres, ANOVA stands for  
         analysis of the variance. 
        
b 
Independent sample t-test. Equal variances assumed. 
            c
 Pearson‘s product moment correlation test.         
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Figure 7 Appendix V - Histograms representing the distribution of waist circumference, glucose and insulin levels at the end of the follow up 
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Table 61 Appendix V - Non-parametric univariable analysis on the association between participants‘ body waist circumference at the end of the 
follow up and breast cancer treatment 
  
Waist circumference   
  
n 
 
Median 
  (cm
b
) 
 
Mann-Whitney U test
 
 
Chemotherapy
a
:
 
Yes 
 
No  
 
 
 
89 
 
91 
 
 
91.00 
 
95.00 
 
 
U=3,406.50 
Z=-1.84 
p=0.07
 
 
Hormone therapy
a
: 
Yes 
 
No 
 
 
157 
 
22 
 
 
92.50 
 
84.50 
 
 
U=1,193.00 
Z=-2.35 
p=0.02
 
 
Tamoxifen
a
: 
Yes 
 
No  
 
 
101 
 
78 
 
 
 
92.00 
 
92.00 
 
 
U=3,749.50 
Z=-0.55 
p=0.58
 
 
Aromatase inhibitors
a
: 
Yes 
 
No 
 
 
123 
 
56 
 
 
 
93.00 
 
90.35 
 
 
 
U=2,827.50 
Z=-1.92 
p=0.055 
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Anastrozole
a
: 
Yes 
 
No 
 
 
82 
 
97 
 
 
94.60 
 
90.70 
 
 
U=3,283.50 
Z=-2.01 
p=0.04 
Letrozole
a
: 
Yes 
 
No 
 
 
 
14 
 
165 
 
 
 
95.00 
 
92.00 
 
 
U=961.50 
Z=-1.04 
p=0.30
 
 
Exemestane
a
: 
Yes 
 
No 
 
 
 
40 
 
139 
 
 
 
92.50 
 
92.00 
 
 
U=2,737.00 
Z=-0.15 
p=0.88
 
 
Gonadorelin analogues
a
: 
Yes 
 
No 
 
 
 
12 
 
167 
 
 
 
92.50 
 
92.00 
 
 
U=960.50 
Z=-0.24 
p=0.81
 
 
        a All participants had surgery and they might have also received other treatments (i.e. radiotherapy, biological therapy).  
          
b
 Cm stands for centimetres.  
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Table 62 Appendix V - Non-parametric univariable analysis on the association between participants‘ waist circumference at the end of the follow up 
and 1) menopausal status at diagnosis and 2) change in menopausal status after breast cancer diagnosis 
  
Waist circumference  
  
n 
 
Median 
(cm
a
)   
 
Mann-Whitney U test
 
 
Menopausal status at diagnosis: 
Pre + perimenopausal 
 
Postmenopausal 
 
 
42 
 
138 
 
 
89.50 
 
93.50 
 
 
U=2,257.00 
Z=-2.17 
p=0.03 
 
Menopausal status change: 
Yes 
 
No 
 
 
39 
 
141 
 
 
90.00 
 
93.00 
 
 
U=2,236.50 
Z=-1.78 
p=0.07 
     
   a
 Cm stands for centimetres. 
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Table 63 Appendix V - Non-parametric univariable analysis on the association between participants‘ waist circumference at the end of the follow up 
and genetic profile 
  
Waist circumference  
  
n 
 
Median 
(cm
a
)  
 
Mann-Whitney U test
 
 
FTO: 
AA + AT 
 
TT 
 
 
45 
 
21 
 
 
92.25 
 
92.00 
 
 
U=396.50 
Z=-1.05 
p=0.29 
Mc4R: 
CC +CT 
 
TT 
 
 
30 
 
36 
 
 
92.25 
 
88.25 
 
 
U=493.00 
Z=-0.60 
p=0.54 
             a
 Cm stands for centimetres. 
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Table 64 Appendix V - Non-parametric univariable analysis on the association between participants‘ waist circumference at the end of the follow up 
and biological, behavioural and tumour-related variables 
  
Waist circumference  
  
n 
 
Median (cm
a
) 
 
Mann-Whitney U test
 
Smoking status at diagnosis: 
Smoker 
 
Non-smoker 
 
 
16 
 
163 
 
 
95.00 
 
92.00 
 
 
U=1,570.00 
Z=-0.66 
p=0.51 
 
n Correlation coefficient
b
 p-value 
Time since diagnosis to the end of the follow up 180 r=-0.03 p=0.70 
Weight at diagnosis (kg
a
) 180 r=0.74 p<0.01 
Weight at the end of follow up (kg
a
) 180 r=0.78 p<0.01 
Weight change from diagnosis to the end of the follow 
up (kg
a
) 
 
180 
 
r=0.17 
 
p=0.03 
Age at diagnosis (years) 180 r=0.19 p=0.01 
Age at the end of the follow up (years) 180 r=0.17 p=0.02 
Tumour size (cm
a
) 180 r=-0.06 p=0.45 
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 n Kruskal Wallis Test p-value 
Stage of disease: 
Stage 1 
Stage 2 
Stage 3
 
 
81 
69 
25 
 
χ 2=2.10 
d.f.
b
=2 
 
 
 
p=0.35 
             a 
Kg stands for kilograms, cm stands for centimetres and d.f. stands for degrees of freedom. 
             b Spearman‘s correlation rho.
  
 
315 
Table 65 Appendix V - Non-parametric univariable analysis on the association between participants‘ glucose and insulin levels at study entry, and 
breast cancer treatment  
   
Glucose  
 
   
Insulin  
 
 
  
n 
 
Median 
(mmol/l
b
) 
 
Mann-Whitney 
U test
 
 
n 
 
Median  
(pmol/l
b
) 
 
 
Mann-Whitney U test
 
 
Chemotherapy
a
: 
Yes 
 
No  
 
82 
 
85 
 
5.00 
 
5.20 
 
U=2,689.50 
Z=-2.55 
p=0.01
 
 
 
71 
 
76 
 
26.60 
 
40.31 
 
U=2,057.00 
Z=-2.49 
p=0.01
 
 
Hormone therapy
a
: 
Yes 
 
No 
 
144 
 
22 
 
5.10 
 
4.90 
 
 
U=1,260.00 
Z=-1.55 
p=0.12
 
 
 
130 
 
16 
 
31.46 
 
27.95 
 
U=976.50 
Z=-0.40 
p=0.69
 
 
Tamoxifen
a
: 
Yes 
No  
 
93 
 
73 
 
5.20 
 
5.10 
 
U=3,037.00 
Z=-1.16 
p=0.24 
 
83 
 
63 
 
27.78 
 
36.25 
 
 
U=2,387.00 
Z=-0.90 
p=0.37
 
 
Aromatase inhibitors
a
: 
Yes 
 
No 
 
112 
 
54 
 
5.10 
 
5.05 
 
U=2,819.00 
Z=-0.708 
p=0.48
 
 
 
103 
 
43 
 
33.82 
 
24.72 
 
U=2,054.00 
Z=-0.69 
p=0.49
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Anastrozole
a
: 
Yes 
 
No 
 
73 
 
93 
 
5.10 
 
5.10 
 
U=3,392.50 
Z=-0.01 
p=0.99
 
 
 
66 
 
80 
 
38.27 
 
26.56 
 
U=2,227.00 
Z=-1.63 
p=0.10
 
 
Letrozole
a
: 
Yes 
 
No 
 
12 
 
154 
 
 
5.20 
 
5.10 
 
U=682.50 
Z=-1.51 
p=0.13
 
 
 
11 
 
135 
 
47.85 
 
29.52 
 
U=469.50 
Z=-2.03 
p=0.04
 
 
Exemestane
a
: 
Yes 
 
No 
 
38 
 
128 
 
5.15 
 
5.10 
 
U=2,156.50 
Z=-1.06 
p=0.29
 
 
 
37 
 
109 
 
21.39 
 
34.86 
 
U=1,500.00 
Z=-2.33 
p=0.02
 
 
Gonadorelin analogues
a
: 
Yes 
 
No 
 
12 
 
154 
 
5.00 
 
5.10 
 
U=679.00 
Z=-1.531 
p=0.13 
 
12 
 
134 
 
21.18 
 
32.36 
 
U=682.50 
Z=-0.87 
p=0.38 
         a
 All participants had surgery and they might have also received other treatments (i.e. radiotherapy, biological therapy).  
         b
 Mmol/l stands for milimol per litre and pmol/l
 
stands for picomole per litre. 
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Table 66 Appendix V - Non-parametric univariable analysis on the association between participants‘ glucose and insulin levels at study entry and 1) 
menopausal status at diagnosis and 2) change in menopausal status after breast cancer diagnosis 
 
Glucose  Insulin  
 
n Median 
(mmol/l
a
) 
Mann-Whitney U test
 
n Median  
(pmol/l
a
) 
Mann-Whitney U test
 
Menopausal status at diagnosis: 
Pre + perimenopausal 
 
Postmenopausal 
 
 
41 
 
126 
 
5.00 
 
5.20 
 
U=1,954.00 
Z=-2.34 
p=0.02 
 
36 
 
111 
 
25.90 
 
34.86 
 
U=1,754.00 
Z=-1.10 
p=0.27 
 
Menopausal status change: 
Yes 
 
No 
 
38 
 
129 
 
5.00 
 
5.10 
 
U=2,019.00 
Z=-1.66 
p=0.09 
 
35 
 
112 
 
26.60 
 
34.48 
 
U=1,774.00 
Z=-0.85 
p=0.39 
         a
 Mmol/l stands for milimol per litre and pmol/l
 
stands for picomole per litre. 
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Table 67 Appendix V - Non-parametric univariable analysis on the association between participants‘ glucose and insulin levels at study entry, and 
genetic profile  
  
Glucose  
 
Insulin  
  
n 
 
Median 
(mmol/l
a
) 
 
Mann-Whitney U test
 
 
n 
 
Median  
(pmol/l
a
) 
 
Mann-Whitney U test
 
FTO: 
AA + AT 
 
TT 
 
 
43 
 
19 
 
 
5.10 
 
5.00 
 
 
U=364.00 
Z=-0.68 
p=0.49 
 
 
41 
 
19 
 
 
35.00 
 
28.75 
 
 
U=328.00 
Z=-0.98 
p=0.33 
 
Mc4R: 
CC +CT 
 
TT 
 
 
29 
 
33 
 
 
5.10 
 
5.00 
 
 
U=446.00 
Z=-0.46 
p=0.65 
 
 
27 
 
33 
 
 
34.10 
 
35.00 
 
 
U=382.00 
Z=-0.94 
p=0.34 
 
         a
 Mmol/l stands for milimol per litre and pmol/l
 
stands for picomole per litre.  
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Table 68 Appendix V - Non-parametric univariable analysis on the association between participants‘ glucose and insulin levels at study entry, and 
biological, behavioural and tumour-related variables 
 
Glucose  Insulin  
  
n 
 
Median  
(mmol/l
a
) 
 
Mann-Whitney U test
 
 
n 
 
Median  
(pmol/l
a
) 
 
Mann-Whitney U test
 
Smoking status at diagnosis: 
Smoker 
 
Non-smoker 
 
 
16 
 
150 
 
 
5.20 
 
5.10 
 
 
U=1,084.00 
Z=-0.64 
p=0.52 
 
 
13 
 
133 
 
 
33.68 
 
31.32 
 
 
U=777.00 
Z=-0.60 
p=0.55 
  
n 
 
Correlation coefficient
a
 
 
p-value 
 
n 
 
Correlation coefficient
b
 
 
p-value 
Time since diagnosis to the end of the 
follow up (months) 
 
166 
 
r=-0.02 
 
p=0.77 
 
146 
 
r=-0.19 
 
p=0.02 
Weight at diagnosis (kg
a
)  153 r=0.29 p<0.01 133 r=0.37 p<0.01 
Weight at the end of follow up (kg
a
) 167 r=0.30 p<0.01 147 r=0.38 p<0.01 
Weight change from diagnosis to the 
end of the follow up (kg
a
) 
 
153 
 
r=0.05 
 
p=0.55 
 
133 
 
r=-0.07 
 
p=0.42 
Age at diagnosis (years) 160 r=0.12 p=0.12 141 r=0.13 p=0.12 
Age at the end of the follow up (years) 161 r=0.13 p=0.12 142 r=0.09 p=0.28 
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Tumour size (cm
a
) 163 r=-0.06 p=0.41 143 r=-0.01 p=0.87 
 
 
n 
 
Kruskal Wallis Test 
 
p-value 
 
n 
 
Kruskal Wallis Test 
 
p-value 
Stage of disease: 
Stage 1 
Stage 2 
Stage 3 
 
 
74 
63 
24 
 
 
χ 2=0.34 
d.f.
b
=2 
 
 
 
p=0.84 
 
 
66 
53 
22 
 
 
χ 2=1.66 
d.f.=2 
 
 
 
p=0.44 
         a
 Mmol/l stands for milimol per litre, pmol/l
 
stands for picomole per litre, kg stands for kilograms, cm stands for centimetres, d.f. stands for degrees of freedom. 
    
   b Spearman‘s correlation rho.
  
 
321 
Table 69 Appendix V - Multiple linear regression analysis of participants‘ body fat percentage at the end of the follow up, after excluding an outlier 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
192 
 
6.87 (2.30 to 11.43) 
 
0.34 (0.30 to 0.39) 
 
0.11 (0.05 to 0.17) 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.75 
F (2, 189) 
F=119.79 
p<0.01 
      
a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
 
 
Table 70 Appendix V - Multiple linear regression analysis of participants‘ fat mass/fat free mass ratio, after excluding two outliers 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Age at diagnosis (years) 
 
184 
 
-0.15 (-0.273 to -0.042) 
 
0.01 (0.008 to 0.013) 
 
0.002 (0.001 to 0.004) 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.76 
  F (2, 181) 
   F=127.92 
p<0.01 
         a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
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Table 71 Appendix V - Multiple linear regression analysis of participants‘ waist circumference at the end of the follow up, after excluding one outlier 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
)  
 
Age at diagnosis (years) 
 
157 
 
31.68 (22.39 to 40.97) 
 
0.70 (0.60 to 0.79)  
 
0.18 (0.07 to 0.30) 
 
 
p<0.01 
 
p<0.01 
 
p<0.01 
 
R=0.77 
F (2, 154) 
F=115.66 
p<0.01 
      
a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
 
Table 72 Appendix V - Multiple linear regression analysis of participants‘ glucose level at the end of the follow up, including outliers 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
Letrozole
b
 
 
153 
 
4.67 (3.54 to 5.87) 
 
0.02 (0.01 to  0.29) 
 
-0.49 (-0.93 to -0.05) 
 
p<0.01 
 
p<0.01 
 
p=0.03 
 
R=0.37 
   F (2, 150) 
 F=12.38 
p<0.01 
     a Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
 
       b 
Categories: 0) users, 1) non-users.
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Table 73 Appendix V - Multiple linear regression analysis of participants‘ glucose level at the end of the follow up, after excluding two outliers 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a) 
 
Letrozole
b
 
 
151 
 
4.22 (3.342 to 5.097) 
 
0.01 (0.008 to  0.022) 
 
-0.10 (-0.456 to 0.249) 
 
p<0.01 
 
p<0.01 
 
p=0.56 
 
R=0.32 
   F (2, 158) 
F=8.54 
p<0.01 
         a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
         b 
Categories: 0) users, 1) non-users. 
 
Table 74 Appendix V - Multiple linear regression analysis of participants‘ insulin level at the end of the follow up, excluding one outlier 
 
Variables included 
 
 
n 
 
Unstandardised coefficients 
(95% CI
a
) 
 
 
p-value 
 
Correlation coefficient 
ANOVA
a
 coefficients 
 
Constant 
 
Weight at diagnosis (kg
a
) 
 
FTO
b
 
 
55 
 
-10.73 (-39.70 to 18.23) 
 
0.94 (0.54 to 1.33) 
 
-12.47 (-23.18 to -1.76) 
 
p=0.46 
 
p<0.01 
 
p=0.02 
 
R=0.57 
F (2, 52) 
F=12.67 
p<0.01 
       
a 
Kg stands for kilograms, CI stands for confidence interval, ANOVA stands for analysis of the variance. 
          b 
Categories: 0) users, 1) non-users.
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APPENDIX VI: PARTICIPANTS INFORMATION SHEET, 
CONSENT FORM AND DECLINE SLIP 
 
Appendix VI. Introduction 
This appendix contains a copy the information letter received by participants, as well as a 
copy of the consent form, and the decline sip. 
 
Appendix VI.A. Participants information sheet 
 
PARTICIPANT INFORMATION SHEET 
LREC Number: 08/H0201/35 
Version 2 
Date: 28
th
 April 2008 
Title of the research project: Excess weight gain among breast cancer patients.  
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve for you. Please take 
the time to read the following information carefully. Talk to others about the study if you 
wish. 
Part 1 tells you the purpose of this study and what will happen to you if you take part. Part 
2 gives you more detailed information about the conduct of the study. Take time to decide 
whether or not you wish to take part. 
 
PART ONE 
What is the purpose of the study? 
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Many women with breast cancer change their weight after the diagnosis. It has been 
suggested that this weight change depends on the type of the tumour, the treatment 
received, and whether or not the woman has gone through her menopause. Furthermore, 
weight change might also be related to the presence of some genes. 
Our study aims to determine weight changes after breast cancer diagnosis. We will also 
investigate whether weight change is related to the tumour, the treatment, the menopausal 
status and some genes.  
This study is being used in part towards a PhD qualification for one member of the team 
(Ana Maria Barberia).  
Why have I been chosen? 
We are interested in breast cancer patients who have been diagnosed more than a year ago.  
Participation in the study is entirely voluntary. You are completely free to decide whether 
you want to participate. Your decision will not determine the quality of care that you are 
receiving.  
What will happen to me if I take part? 
Should you decide to take part, you will be asked to complete and send to us the consent 
form, detailing a contact telephone number. Once we receive it, a member of the research 
team (Ana Maria Barberia) will contact you, at the time and date you indicate us in the 
consent form, to confirm that you want to participate in the study, to answer possible 
questions that you might want to ask us in relation to the study, and to arrange the date and 
time for data collection. 
Data for the study will be collected by phone, with a blood test and from your medical 
notes. Ana Maria Barberia will contact you by phone at an agreed time, and will ask you 
basic relevant questions about your education, ethnic origin, past medical history, 
medication, whether you smoke, and whether you have been through the menopause yet. 
She will also invite you to book an appointment to come to the hospital to give us a blood 
sample, so we can assess the presence of some genes and whether these are related to 
weight change after breast cancer diagnosis.  
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Finally, we will need to obtain further data relevant to this study, such as diagnosis, 
treatment received or weight. We can collect this information directly from your hospital 
medical notes.  However, it is possible that we might need to phone you again to confirm 
or complete some of this information.  
Your normal treatment and/or medication will not be withheld during the study. We will 
refund your travelling expenses when you come to the hospital for this blood sample test.  
If you want, you can contact us to get the results of data that we collect from you, and to 
get a summary of the research findings.   
Are there any risks associated with taking part? 
The only risk from taking part in this study is the risk associated with a normal blood test. 
You might develop an infection in the place where the blood sample is being collected that 
could lead to lymphoedema.  
Lymphoedema is a swelling that occurs when the amount of fluid in an area (e.g. your arm) 
is greater than the capacity of the lymphatic system to transport it away. Lymphoedema 
can occur after surgery, when lymph nodes are removed after treatment for breast cancer, 
and after radiotherapy, as it might cause scar tissue that interrupts the normal activity of the 
lymphatic system. An infection also could damage the lymph vessels leading to 
lymphoedema. 
A study has found that the risk of developing lymphoedema is 2.4 times higher in those 
who have venepuncture than in those who do not have it. This risk should be known by the 
phlebotomist (health professional specialised in taking blood samples), who will be 
requested to collect the blood sample from the arm opposite to the affected breast 
What are the possible benefits of taking part? 
We cannot promise the study will help you but you might find comfort by knowing that the 
information we get from this study will help improve the treatment and care of women 
with breast cancer in the future. 
Will my taking part in the study be kept confidential? 
Yes, all information which is collected about you during the course of this research will be 
kept strictly confidential.  The details are included in Part 2. 
 327 
 
 
This completes Part 1 of the Information Sheet. If the information in part 1 has interested 
you and you are considering participation, please continue to read the additional 
information in Part 2 before making any decision. 
 
PART 2 
What will happen if I do not want to carry on with the study? 
You are free to withdraw at any time, without giving a reason. You will just need to let us 
know. This would not affect the standards of care you receive. If you withdraw from the 
study, we will not collect further data, but we may need to use data collected up to your 
withdrawal, with your permission. 
In addition, we would like to let you know that with your permission, we intend to store 
your blood samples in order for us or other researchers to conduct further medical research 
to look at some genes and proteins that could be related to breast cancer. It is likely that 
results from these further studies will not have a predictive value or clinical implication for 
you, but they will contribute to our understanding of the biological causes of breast cancer. 
Ethical approval and your consent will be sought before conducting any further research 
using your donated blood sample. No test of known clinical value for diagnosis or 
predicting disease on a sample that can be linked to you will be done without your consent. 
It is intended that blood samples collected will be stored in the NHS trust and later 
transferred to a long term research tissue bank, where the samples will be kept anonymous 
but linked to the donor by assigning them a unique code. The samples will be stored for a 
minimum period of five years and while it has a potential use. Afterwards, they will be 
disposed according to existing policy.  
Will my taking part in this study be kept confidential? 
Yes, all information that is collected about you during the course of the research will be 
kept strictly confidential. This information will be safely stored at the hospital and only the 
research team will have access to it. A back up copy of your data will be stored 
anonymously in other computers used for data analysis.  
Our procedures for handling, processing, storing and destroying data relating to your 
participation in the study are compliant with the Data Protection Act 1998. With your 
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consent we will inform your GP of your participation in our study. However, we will not 
share with them data about you that we obtain from your participation in the research. 
In the event that you are unable to confirm that you still wish to participate in this study, 
we will not collect more data from you. Nonetheless, any identifiable data already 
collected will be used for the purpose of this study. 
What will happen to the results of the research study? 
Once the study is completed we intend to publish the results for other researchers to read. 
You will not be identified in any report / publication.  
Who is organising and funding the research? 
The researchers are a group of doctors and a research student from Royal Bournemouth 
Hospital, Poole Hospital and Bournemouth University who have an interest in the topic 
being explored. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people called Research 
Ethics Committee to protect your safety, rights, wellbeing and dignity. This study has been 
reviewed and given a favourable opinion by the Dorset Research Ethics Committee, and by 
the School of Health and Social Care Research Committee at Bournemouth University. A 
Patients‘ Partnership Panel has also provided positive feedback about this study. 
Together with this letter, you will find a consent form, a decline form and a pre-paid 
envelope. If you decide to take part in the study, please tick the boxes in the informed 
consent, sign it and send it to us in the envelope provided.  Once we receive it, we will 
contact you by phone at the time and date you indicate us, to agree a time and date for data 
collection.  
If you do not want to participate, please complete the decline form and send it to us.  
Ask us if there is anything that is not clear or if you would like more information and we 
will be happy to answer your questions. Take time to decide whether or not you wish to 
take part.  
What if something goes wrong?  
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There is only a small risk associated to this study: having a blood test. 
However, if any negligent harm occurs to you because of the management, the design, or 
the conduct of this study, you will be covered by the NHS liability insurance.   
Dr Hickish       Ana Maria Barberia  
Tel. 01202 704789     Tel. 075 074 02595 
Thank you very much for reading this information and considering taking part in 
this study. 
If you need independent information or advice about your rights as a research subject or 
about being involved in this particular research study you can ask other members of the 
Oncology or Surgery team, or you can contact the local NHS Patient Advisory Liaison 
Service (PALS) and the local NHS Research &Development office. 
 
PALS:   
Royal Bournemouth Hospital: tel. 01202 704886 
Poole Hospital: tel. 01202 448499 
 
R&D office: 
 Poole Hospital: tel. 01202 665511 (Ext 8489) 
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Appendix VI.B. Consent form 
 
CONSENT FORM 
LREC Number: 08/H0201/35 
Version 2 
Date: 28
th
 April 2008 
Title of the research project: Excess weight gain among breast cancer patients.  
Research Team: Prof. Hickish, Prof. Kerr, Prof. Thomas, Dr. Begley, Mr. Skene, Mr. 
Perry, Mr. Pain, Miss Evans, Ana M. Barberia 
 
This consent form has two parts. Part 1 refers to the study cited above, detailed in the 
Patient Information Sheet. Part 2 refers to additional research studies that might be 
conducted in the future. Please, read the following lines and initial the box when 
appropriate. If you have any questions, do not hesitate to contact us. 
  
Part 1 
  
1. I confirm that I have read and understand the 
information sheet dated 28
th
 April 2008, version 2, for the 
above study which is part of an educational project. I 
have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.  
 
 
2. I understand that my participation is voluntary and that  
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I am free to withdraw at any time without giving any 
reason, without my medical or legal rights being affected. 
 
3. I understand and consent that relevant sections of my 
medical notes and data collected during the study will be 
stored and kept confidential for the purpose of this study.   
 
 
4. I understand that relevant sections of my medical notes 
and data collected during the study may be looked at by 
individuals from the research team. I give my permission 
for these individuals to have access to my records.  
 
 
 
5. I understand and consent that any identifiable 
data/tissue collected during the study will be retained and 
used for the purpose of this study in the event of me 
loosing capacity to consent. 
 
 
6. I understand and consent that if I decide to withdraw 
from the study, data already collected up to my 
withdrawal might be used for the purpose of this study.  
 
 
7. I agree to my GP being informed of my participation in 
the study. 
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8. I agree to take part in the above study.  
  
Part 2  
9. I confirm that I consent that researchers store my blood 
sample to be used in further medical research projects 
which would have to be approved by a properly 
constituted research ethics committee, and that I will be 
asked for consent before my blood sample will be used.  
 
 
Please, complete the following information and sign the consent 
Telephone number at which we can contact you:  
Most convenient time and dates to contact you at this number 
Days of the week:  
Time: 
Your Name:                            Date:    Your Signature: 
 
Please return these two pages to us in the envelope provided and we will contact you.  
For us to complete:  
Person taking consent : Date:    Signature: 
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DECLINE SLIP 
LREC Number: 08/H0201/35 
Version 1 
Date: 26
th
 January 2008 
 
Title of the research project: Excess weight gain among breast cancer patients  
 
If you don‘t wish to participate in this research project, please complete and return this 
decline slip.  
 
This is to confirm that I do not wish to participate in the study titled ―Excess weight gain 
among breast cancer patients‖. 
 
 
_______________  _______________  _______________ 
 
Name                 Date    Signature 
 
 
To help us plan research projects in the future it would be helpful if you could tell us why 
you do not want to participate.  
 
The reason is (optional): 
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GLOSSARY 
 
 
Term Definition 
 
Abdominal area The area of the body between the thorax and the 
pelvis with the exception of the back—called also 
belly.  
 
Adiponectin A substance secreted by the adipose tissue that 
increases insulin sensitivity, helping cells process 
sugar more effectively. 
  
Adipose tissue Tissue in which fat is stored.  
 
Adjusted R
2
 It indicates how well terms fit a curve or line, but 
adjusts for the number of terms in a model.  
 
Aetiology The cause or causes of a disease or abnormal 
condition. 
 
Agonist A chemical substance (as a drug) capable of 
combining with a receptor on a cell and initiating 
the same reaction or activity typically produced by 
the binding of an endogenous substance.  
 
All-cause mortality 
 
All of the deaths that occur in a population,  
regardless of the cause.  
 
Allele Any of the alternative forms of a gene that may 
occur at a given locus. 
 
Alpha-melanocyte-
stimulating hormone 
A group of polypeptide hormones derived from 
prepro-opiomelanocorticotropin. It stimulates 
production and release of melanin by melanocytes 
in the skin and hair and in the brain; affects the 
appetite and sexual arousal.  
 
Amenorrhea Abnormal absence or suppression of menstruation.  
 
Anaemia A condition in which the blood is deficient in red 
blood cells, in haemoglobin, or in total volume.  
 
Anaesthesia 
 
The branch of medicine concerned with 
administration of anaesthetics (a drug or agent 
used to abolish the sensation of pain, to achieve 
adequate muscle relaxation during surgery, to 
calm fear and allay anxiety, and to produce 
amnesia for the event). 
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Analysis of the 
variance (ANOVA) 
The separation of variance attributable to one 
variable from the variance attributable to others. 
By partitioning the total variance of a set of 
observations into parts due to particular factors, 
for example, sex, treatment group etc., and 
comparing variances (mean squares) by way of F-
tests, differences between means can be assessed. 
The simplest analysis of this type involves a one-
way design, in which n subjects are allocated, 
usually at random, to the k different levels of a 
single factor.  
 
Angiogenesis  The formation and differentiation of blood vessels.  
 
Anorexia nervosa A serious eating disorder that is characterized 
especially by a pathological fear of weight gain 
leading to faulty eating patterns, malnutrition, and 
usually excessive weight loss.  
 
Anthracycline  
 
A class of antineoplastic drugs (as doxorubicin 
and epirubicin) used for inhibiting or preventing 
the growth and spread of neoplasms or malignant 
cells.  
 
Apoptosis  
 
The cessation of all physical and chemical 
processes that invariably occurs in all living 
organisms. 
 
Appetite  The desire to eat.  
  
Area under the receiver 
operating characteristic 
curve (AUC) 
 
Often a useful way of summarizing the 
information from a series of 
measurements made on an individual over time.  
Often a predictor of biological effects such as 
toxicity or efficacy.   
 
Aromatase  An enzyme or complex of enzymes that promotes 
the conversion of an androgen (as testosterone) 
into oestrogens (as oestradiol).  
 
Assays An analysis (as of a drug) to determine the 
presence, absence, or quantity of one or more 
components.  
 
Autocrine Of, relating to, promoted by, or being a substance 
secreted by a cell and acting on surface receptors 
of the same cell.  
 
Automated 
chemiluminescence 
 
Electronic process that produce luminescence (as 
bioluminescence) due to chemical reaction usually 
at low temperatures.   
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Axilla The cavity beneath the junction of the arm or 
anterior appendage and shoulder or shoulder 
girdle.  
 
Basal metabolic rate An expression of the rate at which oxygen is 
utilized in a fasting subject at complete rest as a 
percentage of a value established as normal for 
such a subject. 
 
Bias 
 
Any influence or action at any stage of a study 
that systematically distorts the findings.   
 
Bioactive substances Substances that have an effect on a living 
organism. 
    
Bioelectrical 
Impedance Analysis 
 
 
 
A method that determines the opposition to the 
flow of an electric current through body tissues 
which can then be used to calculate an estimate of 
total body water (TBW). TBW can be used to 
estimate fat-free body mass and, by difference 
with body weight, body fat.  
 
Biopsy The removal and examination of tissue, cells, or 
fluids from the living body. 
  
Bivariate  
 
 
The use of two responses or outcomes per 
observation.  
Body composition 
 
 
The relative proportions of protein, fat, water, and 
mineral components in the body.  
Body Mass Index 
(BMI) 
 
A measure of body fat that is the ratio of the 
weight of the body in kilograms to the square of 
its height in meters.  
 
Bone marrow A soft highly vascular modified connective tissue 
that occupies the cavities and cancellous part of 
most bones.  
 
Bonferroni correction A procedure for guarding against an increase in 
the probability of a type-one error (see below) 
when performing multiple significance tests.  
 
Breast cancer specific 
mortality 
 
 
A term used for death rate, or the number of 
deaths in a certain group of people in a certain 
period of time, attributed to a condition. 
Breast cancer 
progression 
 
 
The course of a disease, such as cancer, as it 
becomes worse or spreads in the body.   
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Breast cancer  
recurrence 
 
Reappearance of a breast tumour after previous 
removal. 
 
Breast cancer survival 
rate 
 
The portion of people with the same type and 
stage of cancer are still alive a certain amount of 
time (usually 5 years) after they were diagnosed.  
 
Breast second primary 
cancer 
 
A term used to describe a new primary cancer that 
occurs in a person who has had cancer in the past.    
Bulimia nervosa A serious eating disorder characterized by 
compulsive overeating usually followed by self-
induced vomiting or laxative or diuretic abuse, 
and is often accompanied by guilt and depression.  
 
Caloric intake  
 
The number of calories received orally and/or 
parenterally into the body.  
 
Cardiology  
 
The study of the heart and its action and diseases.  
Cardiovascular disease 
 
Any abnormal condition characterized by 
dysfunction of the heart and blood vessels.  
 
Carcinogenesis The production of cancer. 
    
Categorical variables Qualitative variables, variables that cannot 
meaningfully be expressed in numbers. i.e. skin 
colour. 
   
Centrifuges 
 
 
A machine using centrifugal force for separating 
substances of different densities, for removing 
moisture, or for simulating gravitational effects.  
   
Cervix The narrow lower or outer end of the uterus. 
   
Chemical ovarian 
ablation 
 
Chemotherapy to block ovarian hormonal activity.   
Cholecystokinin 
 
 
A hormone secreted especially by the duodenal 
mucosa that regulates the emptying of the 
gallbladder and secretion of enzymes by the 
pancreas.   
 
Clinical trial 
 
Medical experiments designed to evaluate which 
(if any) of two or more treatments is the more 
effective.  
  
Coactivators 
 
 
A type of nuclear proteins that participate in the 
potentiation of transcription of genes that are 
responsive to ligand-dependent transcription 
factors.  
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Coefficient of 
determination (R
2
) 
The square of the correlation coefficient between 
two variables. 
Gives the proportion of the variation in one 
variable that is accounted for by the other.   
 
Colorectal cancer Cancer relating to or affecting the colon and the 
rectum.  
 
Comorbid Existing simultaneously with and usually 
independently of another medical condition.  
 
Complete-case data 
analysis 
An analysis that uses only individuals who have a 
complete set of measurements. An individual with 
one or more missing values is not included in the 
analysis.   
 
Computed axial 
tomography (CT) 
A method of producing a three-dimensional image 
of an internal body structure by computerized 
combination of two-dimensional cross-sectional 
X-ray images. 
 
Confidence intervals 
(CI) 
 
A range of values, calculated from the sample 
observations that is believed, with a particular 
probability, to contain the true parameter value. A 
95% confidence interval, for example, implies that 
were the estimation process repeated again and 
again, then 95% of the calculated intervals would 
be expected to contain the true parameter value.   
 
Confounding variable 
 
An extra variable not accounted for. They can ruin 
an experiment and give useless results.   
 
Continuous variables 
 
A measurement not restricted to particular values 
except in so far as this is constrained by the 
accuracy of the measuring instrument.  For such a 
variable equal sized differences on different parts 
of the scale are equivalent.  
 
Convergence 
 
The property or manner of approaching a limit, 
such as a point, line, function, or value. 
 
Cook‘s distance 
 
An influence statistic designed to measure the 
shift in the estimated parameter vector, ^β, from 
fitting a regression model when a particular 
observation is omitted. It is a combined measure 
of the impact of that observation on all regression 
coefficients.  
 
Corepressors A small molecule that activates a particular 
genetic repressor by combining with it.  
 
 
 339 
 
 
Correlation coefficient 
(r) 
An index that quantifies the linear relationship 
between a pair of variables.   
 
Covariance matrix A matrix whose element in the i, j position is the 
covariance between the i 
th
 and j 
th
 elements of a 
random vector. 
 
Cross-sectional data  Data collected by observing many subjects at the 
same point of time, or without regard to 
differences in time. 
 
Cytology The microscopic examination of cells obtained 
from the body for diagnostic purposes.  
 
Cytotoxic Toxic to cells.  
 
Dementia A usually progressive condition (as Alzheimer's 
disease) marked by the development of multiple 
cognitive deficits (as memory impairment, 
aphasia, and inability to plan and initiate complex 
behaviour).    
  
Deoxyribonucleic acid 
(DNA)  
A nucleic acid of complex molecular structure 
occurring in cell nuclei as the basic structure of 
the genes. 
 
Deviance 
 
A measure of the extent to which a particular 
model differs from the saturated model for a data. 
   
Dexamethasone A synthetic glucocorticoid also used in the form of 
its acetate or sodium phosphate especially as an 
anti-inflammatory and antiallergic agent.   
 
Diabetes Type-one diabetes is a diabetes of a form that is 
characterized by a severe deficiency of insulin 
secretion resulting from atrophy of the islets of 
Langerhans and causing hyperglycemia and a 
marked tendency toward ketoacidosis. Type-two 
diabetes is a diabetes of a common form that 
develops especially in adults and most often in 
obese individuals and that is characterized by 
hyperglycemia resulting from impaired insulin 
utilization coupled with the body's inability to 
compensate with increased insulin production. 
     
Dichotonomous 
variable 
 
Observations which occur in one of two possible 
states, these often being labelled 0 and 1.   
Dispersion 
 
The amount by which a set of observations deviate 
from their mean.  
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Ductal carcinoma A type of tumour that primarily presents in the 
ducts of a gland (i.e. mammary gland). 
 
Dummy variable 
 
The variables resulting from recoding categorical 
variables with more than two categories into a 
series of dichotonomous variables.  
 
  
Durbin-Watson test 
 
 
A test that the residuals from a linear regression or 
multiple regression are independent.   
Effect size  A measure of the strength of a phenomenon.   
 
Electrode  
 
Is an electrical conductor used to make contact 
with a non-metallic part of a circuit. 
 
Endocrine  Producing secretions that are distributed in the 
body by way of the bloodstream. 
     
Endogenous Relating to or produced by metabolic synthesis in 
the body.   
 
Fat mass 
 
 
That portion of the human body that is composed 
strictly of fat (as opposed to fat-free mass).  
Fat free mass  
 
 
The lean body mass plus the skeletal mass.  
Fatty acid 
 
 
Any of the saturated or unsaturated organic acids 
that have a single carboxyl group and usually an 
even number of carbon atoms and that occur 
naturally in the form of glycerides in fats and fatty 
oils. 
     
Fenretinide A synthetic vitamin A derivative that exhibits 
apoptotic and anti-invasive properties. 
 
Fixed effects 
 
The effects attributable to a finite set of levels of a 
factor that are of specific interest.   
 
F-test  Test for the equality of the variances of two 
populations having normal distributions, based on 
the ratio of the variances of a sample of 
observations taken from each. Most often 
encountered in the analysis of variance (ANOVA). 
 
Gastro-intestinal 
system 
 
The system that makes food absorbable into the 
body.    
 
Genes A specific sequence of nucleotides in DNA or 
RNA that is located usually on a chromosome and 
that is the functional unit of inheritance 
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controlling the transmission and expression of one 
or more traits by specifying the structure of a 
particular polypeptide and especially a protein or 
controlling the function of other genetic material. 
     
Genotype All or part of the genetic constitution of an 
individual or group.   
 
Ghrelin 
 
A 28-amino-acid peptide hormone that is secreted 
primarily by stomach cells with lesser amounts 
secreted by other cells (as of the pancreas) and 
acts to stimulate appetite and the secretion of 
growth hormone. 
     
Glycosylation 
 
The reaction in which a carbohydrate is attached 
to a hydroxyl or other functional group of another 
molecule 
 
Glucose An optically active sugar C6H12O6 that has an 
aldehydic carbonyl group. 
     
Glucose intolerance 
 
Inability to properly metabolize glucose.   
 
Glucose metabolism 
 
The process by which simple sugars found in 
many foods are processed and used to produce 
energy.   
 
Growth factor 
 
A substance that promotes growth and especially 
cellular growth.   
 
Haemolysed sample 
(Haemolysis) 
 
Alteration, dissolution, or destruction of red blood 
cells in such a manner that haemoglobin is 
liberated into the medium in which the cells are 
suspended.   
 
Hazard ratio (HR) 
 
The ratio of the hazard rates corresponding to the 
conditions described by two levels of an 
explanatory variable.   
 
Histopathology A branch of pathology concerned with the tissue 
changes characteristic of disease. 
 
Holm–Bonferroni 
method 
It is a way to deal with family wise error rates 
(FWER) for multiple hypothesis tests. It is a 
modification of the Bonferroni correction. The 
Holm-Bonferroni method is fairly simple to 
calculate, but it is more powerful than the single-
step Bonferroni.   
 
Homeostasis 
 
The tendency of biological systems to maintain 
relatively constant conditions in the internal 
environment while continuously interacting with 
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and adjusting to changes originating within or 
outside the system. 
 
Homeostasis Model 
Assessment (HOMA) 
It estimates steady state beta cell function (%B), 
and insulin sensitivity (%S), as percentages of a 
normal reference population.  
 
Homoscedasticity 
 
 
A condition when all random variables in the 
sequence or vector have the same finite variance.   
Homozygous Having the two genes at corresponding loci on 
homologous chromosomes identical for one or 
more loci.  
 
Hormone replacement 
therapy 
The administration of oestrogen often along with a 
synthetic progestin especially to ameliorate the 
symptoms of menopause and reduce the risk of 
postmenopausal osteoporosis.  
 
Hot-flushes Waves of sudden widespread relaxation of the 
muscle walls of skin blood vessels so that they 
dilate and cause the skin to become warm. 
 
Hypertriglyceridemia The presence of an excess of triglycerides in the 
blood.   
 
Hypothalamus A basal part of the diencephalon that lies beneath 
the thalamus on each side, forms the floor of the 
third ventricle, and includes vital autonomic 
regulatory centres (as for the control of food 
intake). 
 
Hypothesis testing A general term for the procedure of assessing 
whether sample data is consistent or otherwise 
with statements made about the population.  
 
Hysterectomy 
 
Surgical removal of the uterus. 
Iliac crest The thick curved upper border of the ilium.  
 
Impedance The apparent opposition in an electrical circuit to 
the flow of an alternating current that is analogous 
to the actual electrical resistance to a direct current 
and that is the ratio of effective electromotive 
force to the effective current. 
 
Immunoassay 
 
 
A technique or test (as the enzyme-linked 
immunosorbent assay) used to detect the presence 
or quantity of a substance (as a protein) based on 
its capacity to act as an antigen or antibody. 
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Incidence The rate of occurrence of new cases of a particular 
disease/outcome in a population being studied. 
    
Independent sample t-
test 
 
A student ‗s t tests used  for assessing hypotheses 
about population means when independent 
samples are available from each population. 
 
Inference The process of drawing conclusions about a 
population on the basis of measurements or 
observations made on a sample of units from the 
population.   
 
Inflammatory bowel 
disease 
Either of two inflammatory diseases of the bowel: 
a Crohn‘s disease or Ulcerative colitis.  
 
Insulin A protein hormone that is synthesized in the 
pancreas from proinsulin and secreted by the beta 
cells of the islets of Langerhans, that is essential 
for the metabolism of carbohydrates, lipids, and 
proteins, that regulates blood sugar levels by 
facilitating the uptake of glucose into tissues, by 
promoting its conversion into glycogen, fatty 
acids, and triglycerides, and by reducing the 
release of glucose from the liver, and that when 
produced in insufficient quantities results in 
diabetes mellitus. 
    
Insulin resistance  Reduced sensitivity to insulin by the body's 
insulin-dependent processes (as glucose uptake, 
lipolysis, and inhibition of glucose production by 
the liver) that results in decreased activity of these 
processes or an increase in insulin production or 
both and that is typical of type-two diabetes but 
often occurs in the absence of diabetes.  
 
Insulin sensitivity 
 
The systemic responsiveness to glucose. 
Intercept 
 
 
The parameter in an equation derived from a 
regression analysis corresponding to the expected 
value of the response variable when all the 
explanatory variables are zero.   
 
Internal validity 
 
 
The extent to which the effects detected in a study 
are truly caused by the treatment or exposure in 
the study sample, rather than being due to other 
biasing effects of extraneous variables. 
 
Intra-class correlation A descriptive statistic that describes how strongly 
units in the same group resemble each other.   
 
Invasive carcinoma  A neoplasm in which collections of epithelial cells 
infiltrate or destroy the surrounding tissue. 
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Kruskal Wallis Test 
 
 
 
A distribution free method that is the analogue of 
the analysis of variance of a one-way design. It 
tests whether the groups to be compared have the 
same population median.   
 
Leptin A peptide hormone that is produced by fat cells 
and plays a role in body weight regulation by 
acting on the hypothalamus to suppress appetite 
and burn fat stored in adipose tissue.   
 
Leverage 
 
 
A term used in regression analysis for those 
observations that have an extreme value on one or 
more explanatory variables. The effect of such 
points is to force the fitted model close to the 
observed value of the response leading to a small 
residual.   
 
Ligand A group, ion, or molecule coordinated to a central 
atom or molecule in a complex. 
    
Linear function 
 
A polynomial function of degree zero or one.   
 
Linear  
regression 
The statistical procedure in which a straight line is 
established through a data set that best represents 
a relationship between two subsets or two 
methods. 
 
Linearity 
 
Describing, described by, or related to a straight 
line. 
  
Lipid catabolism 
 
The breakdown processes that generate energy 
and primary metabolites from fatty acids.   
 
Liver A large very vascular glandular organ of 
vertebrates that secretes bile and causes important 
changes in many of the substances contained in 
the blood which passes through it (as by 
converting sugars into glycogen which it stores up 
until required and by forming urea). 
    
Lymph nodes 
 
Small oval or bean-shaped bodies situated in 
groups along the course of the lymph drainage 
vessels. They offer defence against the spread of 
infection by producing antibodies, and become 
involved in the spread of cancer. 
 
Lymphoedema An abnormal excess accumulation of serous fluid 
in connective tissue or in a serous cavity due to 
faulty lymphatic drainage.  
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Malabsorption 
syndrome 
A syndrome resulting from a faulty absorption of 
nutrient materials from the digestive tract that is 
typically characterized by weakness, diarrhoea, 
muscle cramps, oedema, and loss of weight.    
 
Mammary gland 
 
 
An organ in female mammals that produces milk 
to feed young offspring. They are situated in the 
breasts.   
 
Mann-Whitney U test A distribution free test used as an alternative to the 
Student‘s t-test for assessing whether two 
populations have the same median. The test 
statistic U is calculated from comparing each pair 
of values, one from each group, scoring these 
pairs 1 or 0 depending on whether the first group 
observation is higher or lower than that from the 
second group and summing the resulting scores 
over all pairs.   
 
Mastectomy Surgical removal of all or part of the breast and 
sometimes associated lymph nodes and muscles. 
    
Mean 
 
An average; a number that in some sense 
represents the central value of a set of numbers. 
 
Measurement error 
 
The difference between the true value of 
something being measured and the value obtained 
by measurement. Measurement error can be the 
result of one or more of several different factors, 
including random error, and systematic error.   
 
Melanin-concentrating 
hormone  
A cyclic 19-residue orexigenic hypothalamic 
neuropeptide, which plays a key role in regulating 
feeding behaviour, mood, the sleep-wake cycle 
and energy balance.  It also has an autocrine role 
in regulating beta-cell mass dynamics and 
pancreatic islet cell secretion. Overexpression of 
MCH is associated with obesity.   
 
Menopause The cessation of menstruation.  
 
Menstrual period A single cyclic occurrence of menstruation ( a 
discharging of blood, secretions, and tissue debris 
from the uterus that recurs in non-pregnant human 
and other primate females of breeding age at 
approximately monthly intervals and that is 
considered to represent a readjustment of the 
uterus to the non-pregnant state).  
 
Median 
 
The value in a set of ranked observations that 
divides data into two parts of equal size.    
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Meta-analysis Any systematic method that uses statistical 
analysis to integrate data from a number of 
independent studies. 
 
Metabolic syndrome A syndrome marked by the presence of usually 
three or more of a group of factors (as high blood 
pressure, abdominal obesity, high triglyceride 
levels, low HDL levels, and high fasting levels of 
blood sugar) that are linked to an increased risk of 
cardiovascular disease and type-two diabetes.  
 
Metabolism  The sum of the processes by which a particular 
substance is handled in the living body. 
 
Metastasis The spread of a disease-producing agent (as 
cancer cells or bacteria) or disease from the initial 
or primary site of disease to another part of the 
body. 
 
Mitogen-activated 
protein kinase (MAPK) 
A highly conserved family of serine/threonine 
protein kinases involved in a variety of 
fundamental cellular processes such as 
proliferation, differentiation, motility, stress 
response, apoptosis, and survival.  
 
Missing data 
 
Observations missing from a set of data for some 
reason.   
 
Multicollinearity 
 
The condition occurring when two or more of the 
independent variables in a regression equation are 
correlated.   
 
Multilevel model 
 
Regression models for multilevel or clustered data 
where units i are nested in clusters j, for instance a 
cross-sectional study where students are nested in 
schools or longitudinal studies where 
measurement occasions are nested in subjects.   
 
Multiparity 
 
The status of a mother of more than one child.  
 
Multiple linear 
regressions 
A term usually applied to models in which a 
continuous response variable, y, is regressed on a 
number of explanatory variables.  
  
Multivariable analysis Refers to statistical models in which there are 
multiple independent or explanatory variables. 
 
Muscle A body tissue consisting of long cells that contract 
when stimulated and produce motion. 
 
Neutropenia Leukopenia in which the decrease in white blood 
cells is chiefly in neutrophils.  
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Nicotine The chief active principle of tobacco.  
 
Non-melanoma skin 
cancer 
A malignant growth of the external surface or 
epithelial layer of the skin.  
 
Non-parametric tests 
 
A test that does not assume anything about the 
underlying distribution. 
 
Normal distribution 
 
A symmetrical distribution of scores with the 
majority concentrated around the mean. 
 
Normality 
 
A term used to indicate that some variable of 
interest has a normal distribution.   
 
Nuclear receptors 
 
Any of a ―superfamily‖ of soluble (non-
membrane-bound) receptors for a constellation of 
physiologically active compounds (ligands). When 
nuclear receptors are activated by their cognate 
ligand, they form dimers, bind DNA and activate 
transcription of relevant primary target genes. 
 
Null hypothesis 
 
 
It is the commonly accepted fact; it is the opposite 
of the alternate hypothesis.  
Odds ratio (OR) 
 
A measure of association in a case-control study 
which quantifies the relationship between an 
exposure and health outcome from a comparative 
study. 
 
Oesophagus A muscular tube connecting the throat with the 
stomach.  
 
Oestrogens Any of various natural steroids (as oestradiol) that 
are formed from androgen precursors, that are 
secreted chiefly by the ovaries, placenta, adipose 
tissue, and testes, and that stimulate the 
development of female secondary sex 
characteristics and promote the growth and 
maintenance of the female reproductive system.   
 
Oophorectomy The surgical removal of one or both ovaries 
(bilateral). 
 
Oral contraceptives Medicines taken by mouth to help prevent 
pregnancy.   
 
Ordinal variable A variable that allows for rank order by which 
data can be sorted, but still does not allow for 
relative degree of difference between them.   
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Ordinary least squares 
regression 
A method used for estimating parameters by 
minimizing the difference between the observed 
response and the value predicted by the model.  
 
Outlier An observation so distant from the central mass of 
data that it noticeably influences results. 
 
Ovarian ablation Ovarian suppression to block ovarian hormonal 
activity.   
 
Overexpression 
 
Excessive expression of a gene (as that caused by 
increasing the frequency of transcription. 
 
Paired t-tests 
 
A Student‘s t-test for the equality of the means of 
two populations, when the observations arise as 
paired samples.   
 
Pancreas A lobulated gland that in humans lies in front of 
the upper lumbar vertebrae and behind the 
stomach.  It functions in the breakdown of 
proteins, fats, and carbohydrates, and secretes the 
hormones insulin and glucagon.  
 
Paracrine Of, relating to, promoted by, or being a substance 
secreted by a cell and acting on adjacent cells.  
 
Parameter 
 
A numerical characteristic of a population or a 
model.   
 
Parametric tests Procedures for testing hypotheses about 
parameters in a population described by a 
specified distributional form, often, a normal 
distribution.  
 
Pearson‘s product 
moment correlation 
 
Measures of the strength of a linear association 
between two variables.   
Peptides Any of various amides that are derived from two 
or more amino acids by combination of the amino 
group of one acid with the carboxyl group of 
another and are usually obtained by partial 
hydrolysis of proteins. 
    
Pharmacokinetics The characteristic interactions of a drug and the 
body in terms of its absorption, distribution, 
metabolism, and excretion.  
 
Phenotype The observable properties of an organism that are 
produced by the interaction of the genotype and 
the environment.  
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Physiology The organic processes and phenomena of an 
organism or any of its parts or of a particular 
bodily process. 
 
Phosphatidylinosito-3 
kinase (PI3K/atk) 
A signalling pathway that plays a critical role in 
regulating diverse cellular functions including 
metabolism, growth, proliferation, survival, 
transcription and protein synthesis. Dysregulation 
of the PI3K/Akt pathway is implicated in a 
number of human diseases including cancer, 
diabetes, cardiovascular disease and neurological 
diseases.  
 
Phosphorylation  To cause (an organic compound) to take up or 
combine with phosphoric acid or a phosphorus-
containing group.  
 
Pituitary gland 
 
An endocrine gland located at the base of the 
brain. It secretes several hormones which regulate 
the growth, development, and proper functioning 
of other endocrine glands and are of vital 
importance to the growth, maturation, and 
reproduction of the individual.   
  
Polymorphism A variation in a specific sequence of DNA.  
 
Polynomial  Is an expression constructed from variables and 
constants, using only the operations of addition, 
subtraction, multiplication and non-negative 
integer exponents.   
 
Power  
 
 
The probability of rejecting the null hypothesis 
when it is false. Power gives a method of 
discriminating between competing tests of the 
same hypothesis, the test with the higher power 
being preferred. It is also the basis of procedures 
for estimating the sample size needed to detect an 
effect of a particular magnitude.   
 
Precision The extent to which a measurement procedure 
gives the same results each time it is repeated 
under identical conditions. 
 
Prevalence The percentage of a population that is affected 
with a particular disease/factor at a given time.  
  
Prognosis The prospect of survival and recovery from a 
disease as anticipated from the usual course of that 
disease or indicated by special features of the case.  
 
 
Proliferation Rapid and repeated production of new parts or of 
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offspring (as in a mass of cells by a rapid 
succession of cell divisions).  
 
Pseudo-R
2 
statistics 
 
 
An index sometimes used in assessing the fit of 
specific types of models particularly logistic 
regression and those used for modelling survival 
times.   
 
P-value The probability of the observed data (or data 
showing a more extreme departure from the null 
hypothesis) when the null hypothesis is true.   
 
Pyromark 
 
A specially formulated coating for metal surfaces 
intended for high heat exposure. 
 
Pyrosequencing A real-time DNA sequencing technique.  
 
Quadratic function A polynomial function, whose graph is a parabola 
whose axis of symmetry is parallel to the y-axis.   
 
Quantile-quantile plot 
(Q-Q Plot) 
A plot of the points whose coordinates are the 
quantiles for different values of p.   
 
Random effects 
 
The effects attributable to a (usually) infinite set 
of levels of a factor, of which only a random 
sample occur in the data.   
 
Random error Error which occurs due to chance. 
 
Randomised selection 
of the sample (Random 
sample)  
 
A sample of n individuals selected from a 
population in such a way that each sample of the 
same size is equally likely.   
Reagent 
 
 
A substance used (as in detecting or measuring a 
component, in preparing a product, or in 
developing photographs) because of its chemical 
or biological activity.  
 
Receptors A chemical group or molecule (as a protein) on 
the cell surface or in the cell interior that has an 
affinity for a specific chemical group, molecule, or 
virus. 
    
Reliability  The extent to which repeated measurements on 
units (for instance people) yield similar results.  
 
Renal cancer Cancer relating to, involving, affecting, or located 
in the region of the kidneys.  
  
Residual The difference between the observed value of a 
response variable and the value predicted by some 
model of interest.   
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Resting energy 
expenditure (REE) 
Energy expenditure measured under resting, 
although not necessarily basal, conditions.  
 
Resting metabolic rate 
 
A synonymous of resting energy expenditure.  
 
Retrospective study 
 
A general term for studies in which all the events 
of interest occur prior to the onset of the study and 
findings are based on looking backward in time.  
Commonly encountered is the retrospective cohort 
study, in which a past cohort of individuals are 
identified from previous information and their 
subsequent mortality or morbidity determined and 
compared with the corresponding experience of 
some suitable control group.  
 
Rib Any of the paired curved bony or partly 
cartilaginous rods that stiffen the lateral walls of 
the body of most vertebrates and protect the 
viscera, that occur in mammals exclusively or 
almost exclusively in the thoracic region. 
    
Risk ratio (RR) For a disease, death, or other outcome, the ratio of 
the incidence rate among individuals with a given 
risk factor to the incidence rate among those 
without it. 
 
Sarcopenic obesity An increase in body fat mass accompanied by 
decreased or no changes in fat free mass. 
 
Scatter/dot plot 
 
Is a type of mathematical diagram using Cartesian 
coordinates to display values for two variables for 
a set of data. Data is displayed as a collection of 
points, each having the value of one variable 
determining the position on the horizontal axis and 
the value of the other variable determining the 
position on the vertical axis. 
 
Screening programme 
 
 
The systematic offering of a screening test—i.e. , 
faecal occult blood test, cervical cytology, breast 
examination—to a population or a specified 
segment of a population, with the aim of 
identifying a disease at an early and more treatable 
stage. 
 
Shapiro-Wilk normality 
test 
Tests that a set of random variables arise from a 
specified probability distribution. Most commonly 
used to test for departures from the normal 
distribution and the exponential distribution.   
 
 
Serum The clear yellowish fluid that remains from blood 
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plasma after fibrinogen, prothrombin, and other 
clotting factors have been removed.  
 
Šidák correction A variant of Bonferroni which uses a Taylor 
expansion.   
 
Significance level The level of probability at which it is agreed that 
the null hypothesis will be rejected. 
Conventionally set at 0.05.   
 
Single nucleotide  
polymorphism (SNP) 
Although all humans share 99.9 percent of their 
genetic material, single-letter differences in our 
DNA sequences—known as single nucleotide 
polymorphisms—ensure that each individual is 
unique.  
 
Skinfold thickness A measure of the amount of subcutaneous fat, 
obtained by inserting a fold of skin into the jaws 
of a caliper.  The skinfolds are usually measured 
on the upper arm, thigh, or upper abdomen. 
 
 
Slope The gradient of the line or the regression 
coefficient of the relationship. A positive slope 
implies that increasing one variable will increase 
the other. 
 
Social desirability  
bias 
The tendency of respondents to answer questions 
in a manner that will be viewed favourably by 
others. It can take the form of over-reporting 
"good behaviour" or under-reporting "bad," or 
undesirable behaviour. 
 
Spearman‘s  
correlation rho 
A rank correlation coefficient ( a correlation 
coefficients that depend only on the ranks of the 
variables not on their observed values).   
 
Standard deviation   
(SD) 
The difference between a sample value and the 
mean.   
 
Standard error (SE) An estimate of the standard deviation of the means 
of many samples, calculated as the standard 
deviation (s) divided by the square root of the 
number of individuals in a sample. 
 
Steatohepatitis 
 
Liver disease characterized by fatty change of 
hepatocytes, accompanied by intralobular 
inflammation and fibrosis. Most often caused by 
alcohol abuse, diabetes, or obesity but may be 
linked to adverse drug reactions, gastrointestinal 
and pancreatic disorders or total parenteral 
nutrition. 
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Steroids  Substances that are naturally produced in the 
body. They help reduce inflammation and control 
different functions in our bodies such as the 
immune system or the way the body uses food.  
Steroids can also be man-made and used as part of 
cancer treatment.   
 
Studentized deleted 
residual 
An alternative criterion for identifying outliers. 
The basic idea is to delete the observations one at 
a time, each time refitting the regression model on 
the remaining n–1 observations. Then, we 
compare the observed response values to their 
fitted values based on the models with the ith 
observation deleted. This produces 
(unstandardised) deleted residuals. Standardizing 
the deleted residuals produces studentized deleted 
residuals.    
 
Subcutaneous adipose  
Tissue 
 
Fat deposits beneath the skin. 
Survey 
 
A study that collects planned information from a 
sample of individuals about their history, habits, 
knowledge, attitudes or behaviour in order to 
estimate particular population characteristics.  
  
Synthesise To produce by synthesis (the formation of a 
chemical compound by the union of its elements 
or from other suitable components.    
 
Systematic error A non-random statistical error that affects the 
mean of a population of data and defines the bias 
between the means of two populations.  
 
Systematic review A review of a clearly formulated question which 
uses systematic and explicit methods to identify, 
select and critically appraise relevant research, and 
collect and analyse data from the studies that are 
included in the review. Statistical methods (e.g., 
meta-analysis), may or may not be used to analyse 
and summarise the results of the included studies.  
 
Systemic Pertaining to or affecting the body as a whole.  
 
Taxane Any of various tricyclic compounds (as docetaxel 
and paclitaxel) with anticancer activity that are 
obtained from yew trees or are made synthetically. 
    
 
Thermogenesis The production of heat especially in the body (as 
by oxidation).  
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Thyroid gland  
 
The largest of the endocrine glands. It is located in 
the front and sides of the neck just below the 
thyroid cartilage and produces hormones that are 
vital in maintaining normal growth and 
metabolism. 
 
Transcriptional activity 
 
The synthesis of RNA using a DNA template 
catalyzed by an RNA polymerase. 
 
Type-one error 
 
The error that results when the null hypothesis is 
falsely rejected.   
 
Type-two error The error that results when the null hypothesis is 
falsely accepted.   
 
Tyrosine kinase 
receptors 
 
Single-pass, transmembrane proteins that bind 
extracellular polypeptide ligands and cytoplasmic 
effector and adaptor proteins to regulate biological 
processes.   
 
Umbilical level Of or relating to the central abdominal region that 
is situated between the right and left lumbar 
regions and between the epigastric region above 
and the hypogastric region below. 
    
Unbalance design 
 
A design which has an unequal number of 
observations.  
 
Univariable analysis 
 
 
The statistical procedures that involve the use of 
one explanatory variable.    
 
Univariate The use of one response variable or outcome per 
observation. 
 
Unstandardised 
coefficient 
 
It represents the amount by which dependent 
variable changes if we change independent 
variable by one unit keeping other independent 
variables constant.   
 
Urinary bladder A distensible membranous sac that serves for the 
temporary retention of the urine.  
 
Validity  
 
It means that a test or instrument is accurately 
measuring what it‘s supposed to. 
 
Variance components Variances of random effects terms in multilevel 
models.   
 
Venepuncture Entry into a vein, usually with a hollow needle so 
as to gain access to the bloodstream for the 
purpose of obtaining a sample of blood.  
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Waist The part of the body between the thorax and hips. 
    
Wilcoxon signed-rank 
test 
A distribution free method for testing the 
difference between two populations using matched 
samples. The test is based on the absolute 
differences of the pairs of observations in the two 
samples, ranked according to size, with each rank 
being given the sign of the original difference. The 
test statistic is the sum of the positive ranks. 
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